

Genature version 5.1.3
Copyright (c) 1993-2002 CompuGen Ltd.

OM protein: protein search, using sw model

Run on: November 6, 2002, 14:04:59 : Search time 10.451 Seconds
(without alignments)
312.880 Million cell updates/sec

Title: US 09 834-409-4

Perfect score: 751

Sequence: 1 G1SGSPPTTNGRISYST ANMMWPTPLPTGVSEFLE 134

Scoring table: BLOSUM62

Gapop 10.0 / Gapext 0.5

Searched: 246,000 seqs, 244,000 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

- Database: Issued patents AA**
- 1: /seq2/6/p/odata/1/iaa/5A_0MBR pep**
 - 2: /seq2/6/p/odata/1/iaa/5B_0MBR pep**
 - 3: /seq2/6/p/odata/1/iaa/6A_0MBR pep**
 - 4: /seq2/6/p/odata/1/iaa/6B_0MBR pep**
 - 5: /seq2/6/p/odata/1/iaa/6C_0MBR pep**
 - 6: /seq2/6/p/odata/1/iaa/6D_0MBR pep**

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB ID	Description
1	219	29.2	1466	6	5256642 6 Patent No. 5256642
2	219	29.2	1466	6	5472939 6 Patent No. 5472939
3	219	29.2	1537	6	5256642 5 Patent No. 5256642
4	219	29.2	1537	6	5472939 5 Patent No. 5472939
5	219	29.2	1847	6	5256642 10 Patent No. 5256642
6	219	29.2	1847	6	5472939 10 Patent No. 5472939
7	219	29.2	2039	6	5256642 2 Patent No. 5256642
8	219	29.2	2039	6	5472939 2 Patent No. 5472939
9	214	28.5	264	1	05 07-905 983 2 Sequence 2, Appl
10	198	26.4	133	2	US 08-769-967A-31 Sequence 31, Appl
11	198	26.4	133	2	US 08-769-967A-31 Sequence 31, Appl
12	198	26.4	253	3	US 08-367-463 29 Sequence 29, Appl
13	198	26.4	254	2	US 08-769-967A-29 Sequence 29, Appl
14	195	26.0	254	2	US 08-356-361-30 Sequence 30, Appl
15	195	26.0	254	2	US 08-769-967A-30 Sequence 30, Appl
16	190	25.3	464	4	US 08-981-234B-2 Sequence 2, Appl
17	160	21.3	484	4	US 08-139-195-2 Sequence 2, Appl
18	159	21.2	169	1	US 08-410-416A-18 Sequence 18, Appl
19	159	21.2	169	1	US 08-888-171-18 Sequence 18, Appl
20	159	21.2	254	1	US 08-310-416A-13 Sequence 13, Appl
21	159	21.2	254	2	US 08-888-171-13 Sequence 13, Appl
22	159	21.2	254	2	US 08-435-149-1 Sequence 1, Appl
23	159	21.2	293	1	US 08-310-416A-16 Sequence 16, Appl
24	159	21.2	293	2	US 08-888-171-16 Sequence 16, Appl
25	159	21.2	470	2	US 08-528-057 42 Sequence 42, Appl
26	159	21.2	474	2	US 08-528-057 44 Sequence 44, Appl
27	159	21.2	477	2	US 08-528-057 2 Sequence 2, Appl

23	159	21.2	384	6	5514787 2	Patent No. 5514787
24	159	21.2	577	2	US 08-435-149-3	Sequence 3, Appl
25	159	21.2	611	4	US 09-475-60A 32	Sequence 42, Appl
26	158.5	21.1	323	3	US 08-435-149-2	Sequence 2, Appl
27	158.5	21.1	324	1	US 08-310-416A 14	Sequence 14, Appl
28	158.5	21.1	324	2	US 08-808-171-14	Sequence 14, Appl
29	155	20.6	324	2	US 08-508-157-46	Sequence 46, Appl
30	153.5	20.4	197	2	US 08-356-361-22	Sequence 22, Appl
31	153.5	20.4	197	2	US 08-769-957A 27	Sequence 27, Appl
32	147	19.6	196	3	US 08-824-692-42	Sequence 42, Appl
33	147	19.6	229	3	US 08-824-692-41	Sequence 41, Appl
34	147	19.6	290	3	US 08-824-692-29	Sequence 29, Appl
35	144	19.2	126	6	5514582 43	Patent No. 5514582
36	144	19.2	1019	1	US 08-356-361-14A-4	Sequence 4, Appl
37	144	19.2	1019	2	US 08-506-405-4	Sequence 4, Appl
38	144	19.2	1019	2	US 08-496-114A-2	Sequence 2, Appl
39	144	19.2	1083	2	US 08-296-019A-2	Sequence 2, Appl
40	144	19.2	1083	2	US 08-506-405-2	Sequence 2, Appl
41	144	19.2	1083	2	US 08-477-629-2	Sequence 2, Appl
42	144	19.2	1083	2	US 08-477-629-2	Sequence 2, Appl
43	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
44	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
45	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
46	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
47	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
48	140	18.6	274	2	US 08-356-361-22	Sequence 2, Appl
49	137	17.7	46	6	5514582 41	Patent No. 5514582
50	133	17.7	124	6	5514582 43	Patent No. 5514582
51	133	17.7	265	2	US 08-177-109A 33	Sequence 33, Appl
52	133	17.7	265	2	US 08-177-109A 33	Sequence 33, Appl
53	133	17.7	764	2	US 08-177-109A 2	Sequence 2, Appl
54	133	17.7	764	2	US 08-177-109A 2	Sequence 2, Appl
55	129	17.2	177	3	US 08-624-692-36	Sequence 36, Appl
56	127	16.9	248	2	US 08-440-977-2	Sequence 2, Appl
57	127	16.9	266	2	US 08-440-977-4	Sequence 4, Appl
58	127	16.9	326	2	US 08-440-977-1	Sequence 1, Appl
59	126	16.8	128	6	5514582 43	Patent No. 5514582
60	126	16.8	128	6	5514582 43	Patent No. 5514582
61	125	16.7	76	2	US 08-356-361-28	Sequence 28, Appl
62	125	16.7	76	2	US 08-356-361-28	Sequence 28, Appl
63	124	16.6	181	2	US 08-356-361-28	Sequence 28, Appl
64	123	16.4	574	6	5478464 33	Patent No. 5478464
65	120	16.0	610	1	US 08-485-470-3	Sequence 3, Appl
66	120	16.0	610	3	US 09-209-668-19	Sequence 19, Appl
67	120	16.0	610	4	US 09-039-490A-89	Sequence 89, Appl
68	120	16.0	610	6	5217870 2	Patent No. 5217870
69	118	15.7	484	2	US 08-452-490C-4	Sequence 4, Appl
70	118	15.7	484	3	US 09-275-197-9	Sequence 9, Appl
71	115	15.3	126	6	5514582 43	Patent No. 5514582
72	114	15.2	830	1	US 08-111-158-4	Sequence 4, Appl
73	114	15.2	830	5	PCI-US91-05059-2	Sequence 2, Appl
74	112	15.0	830	6	5378464 2	Patent No. 5378464
75	111	14.8	242	3	US 08-624-692-23	Sequence 23, Appl
76	110	14.7	216	3	US 08-624-692-24	Sequence 24, Appl
77	110	14.6	123	3	US 08-824-692-37	Sequence 37, Appl
78	110	14.6	123	3	US 08-824-692-38	Sequence 38, Appl
79	109	14.5	127	6	5514582 42	Patent No. 5514582
80	108	14.4	128	6	5514582 42	Patent No. 5514582
81	106	14.1	62	1	US 08-356-361-22	Sequence 2, Appl
82	106	14.1	62	1	US 08-356-361-22	Sequence 2, Appl
83	106	14.1	62	1	US 08-356-361-22	Sequence 2, Appl
84	106	14.1	62	1	US 08-356-361-22	Sequence 2, Appl
85	103	13.8	127	6	5514582 42	Patent No. 5514582
86	103	13.8	127	6	5514582 42	Patent No. 5514582
87	101	13.4	62	1	US 08-356-361-22	Sequence 2, Appl
88	101	13.4	62	1	US 08-356-361-22	Sequence 2, Appl
89	101	13.4	62	1	US 08-356-361-22	Sequence 2, Appl
90	97	13.0	177	3	US 08-477-8607-13	Sequence 13, Appl
91	97	13.0	207	2	US 08-824-692-40	Sequence 40, Appl
92	84	11.3	145	2	US 08-640-977-5	Sequence 5, Appl
93	83	11.1	385	1	US 08-340-539A-2	Sequence 2, Appl
94	83	11.1	385	2	US 08-340-539A-2	Sequence 2, Appl
95	83	11.1	385	2	US 08-340-539A-2	Sequence 2, Appl
96	83	11.1	385	2	US 08-340-539A-2	Sequence 2, Appl
97	82	11.0	339	1	US 08-356-361-22	Sequence 2, Appl
98	82	11.0	339	1	US 08-356-361-22	Sequence 2, Appl
99	82	11.0	339	1	US 08-356-361-22	Sequence 2, Appl
100	82	11.0	339	1	US 08-356-361-22	Sequence 2, Appl


```

: APPLICATION NUMBER: 432,865
: FILING DATE: 03 APR 1989
: APPLICATION NUMBER: 176,542
: FILING DATE: 01 APR 1988
: SEQ ID NO: 5
: LENGTH: 1547
5472939-5

Query Match
Best Local Similarity 29.2% Score 219; DB 6; Length 1547;
Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;

QY 2 ISCGSEPPILNCRISYS--TPIAVHIVYS-----SGIFLIGESLICTIKSV 52
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1015 ISCEPPTISNG--DFYSNNRTSFHNGTIVVYQCHTGCHQHFELVGRSIVCTSKDDQ 1072
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 53 DGTWDPAPKCYENKYSSTPEPIVPGYKIPGTP-YRIGDSVTFACKTNFMSNKNKV 111
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1074 VGVWSSPPPRISLNK---CTAPEVENAIVPGNKRSPESITETIRFCQGFVWVGSHTV 1129
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 112 WQANNMGPTRLPICVSV 130
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1140 QQTNRWGP-KLPICSRV 1147
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111

RESULT 5
5256642 10
: Patent No. 5256642
: APPLICANT: FEARON, DOUGLAS T.; KLIKSTEIN, LLOYD B.; WING,
: WINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
: H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
: TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
: RECEPTOR 1 (CRL) AND A THROMBOTIC AGENT, AND THE METHODS OF
: USE THEREOF
: NUMBER OF SEQUENCES: 40
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/588,128
: FILING DATE: 24 SEP 1990
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 412,745
: FILING DATE: 26 SEP 1989
: APPLICATION NUMBER: 432,865
: FILING DATE: 03 APR 1989
: APPLICATION NUMBER: 176,542
: FILING DATE: 01 APR 1988
: SEQ ID NO: 10
: LENGTH: 1847
5256642 10

Query Match
Best Local Similarity 29.2% Score 219; DB 6; Length 1847;
Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;

QY 2 ISCGSEPPILNCRISYS--TPIAVHIVYS-----SGIFLIGESLICTIKSV 52
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1522 ISCEPPTISNG--DFYSNNRTSFHNGTIVVYQCHTGCHQHFELVGRSIVCTSKDDQ 1579
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 53 DGTWDPAPKCYENKYSSTPEPIVPGYKIPGTP-YRIGDSVTFACKTNFMSNKNKV 111
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1580 VGVWSSPPPRISLNK---CTAPEVENAIVPGNKRSPESITETIRFCQGFVWVGSHTV 1646
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 112 WQANNMGPTRLPICVSV 130
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1647 QQTNRWGP-KLPICSRV 1654
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111

RESULT 6
5472939 10
: Patent No. 5472939
: APPLICANT: FEARON, DOUGLAS T.; KLIKSTEIN, LLOYD B.; WING,
: WINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
: H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
: TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT

```

```

: MEDIATED DISORDERS
: NUMBER OF SEQUENCES: 30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/138,823
: FILING DATE: 19-OCT-1993
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 588,128
: FILING DATE: 24-SEP-1990
: APPLICATION NUMBER: 412,745
: FILING DATE: 26-SEP-1989
: APPLICATION NUMBER: 332,865
: FILING DATE: 03-APR-1989
: APPLICATION NUMBER: 176,532
: FILING DATE: 01-APR-1988
: SEQ ID NO: 10
: LENGTH: 2006
5472939-10

Query Match
Best Local Similarity 29.2% Score 219; DB 6; Length 1847;
Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;

QY 2 ISCGSEPPILNCRISYS--TPIAVHIVYS-----SGIFLIGESLICTIKSV 52
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1522 ISCEPPTISNG--DFYSNNRTSFHNGTIVVYQCHTGCHQHFELVGRSIVCTSKDDQ 1579
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 53 DGTWDPAPKCYENKYSSTPEPIVPGYKIPGTP-YRIGDSVTFACKTNFMSNKNKV 111
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1580 VGVWSSPPPRISLNK---CTAPEVENAIVPGNKRSPESITETIRFCQGFVWVGSHTV 1646
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 112 WQANNMGPTRLPICVSV 130
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1637 QQTNRWGP-KLPICSRV 1654
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111

RESULT 7
5256642-2
: Patent No. 5256642
: APPLICANT: FEARON, DOUGLAS T.; KLIKSTEIN, LLOYD B.; WING,
: WINNIE W.; CARSON, GERALD R.; CONCINO, MICHAEL F.; IP, STEPHEN
: H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
: TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
: RECEPTOR 1 (CRL) AND A THROMBOTIC AGENT, AND THE METHODS OF
: USE THEREOF
: NUMBER OF SEQUENCES: 30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/588,128
: FILING DATE: 24-SEP-1990
: PRIOR APPLICATION DATA:
: APPLICATION NUMBER: 412,745
: FILING DATE: 26-SEP-1989
: APPLICATION NUMBER: 332,865
: FILING DATE: 03-APR-1989
: APPLICATION NUMBER: 176,532
: FILING DATE: 01-APR-1988
: SEQ ID NO: 2
: LENGTH: 2039
5256642-2

Query Match
Best Local Similarity 29.2% Score 219; DB 6; Length 2039;
Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;

QY 2 ISCGSEPPILNCRISYS--TPIAVHIVYS-----SGIFLIGESLICTIKSV 52
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1517 ISCEPPTISNG--DFYSNNRTSFHNGTIVVYQCHTGCHQHFELVGRSIVCTSKDDQ 1574
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 53 DGTWDPAPKCYENKYSSTPEPIVPGYKIPGTP-YRIGDSVTFACKTNFMSNKNKV 111
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
DB 1575 VGVWSSPPPRISLNK---CTAPEVENAIVPGNKRSPESITETIRFCQGFVWVGSHTV 1641
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
QY 112 WQANNMGPTRLPICVSV 130
   111 111 111 111 111 111 111 111 111 111 111 111 111 111 111

```



```
? FILING DATE: 15-May-1995
? ATTORNEY/AGENT INFORMATION:
? NAME: Kind, William T.
? REGISTRATION NUMBER: 30,954
? REFERENCE/DOCKET INFORMATION: P4042402
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (610) 270-5464
? TELEFAX: (610) 270-5090
? INFORMATION FOR SEQ ID NO: 30:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 254 amino acids
? TYPE: amino acid
? TOPOLOGY: linear
? MOLECULE TYPE: peptide
? FRAGMENT TYPE: N-terminal
US 08 981 234B 40

Query Match 25.04; Score 195; DB 2; Length 254;
Best Local Similarity 48.16; Pred. No. 9,68-14;
Matches 51; Conservative 13; Mismatches 58; Indels 12; Gaps 6;

QY 2 ISGSPPPILNGR-LSYYSSTPIAVGTIVRYSQ- -SG- - - - -TERLIGKSLICITIKKVDG 54
DB 124 ITCGLPTTIGDFTSTNFFNHYGVVTVYCPNPGSGGPKVFELVGPSTYTSNDNQVG 183
QY 55 TWKPAKQVEYENKYSCEPEPIVPGYKIRG-STYRHKLSVTFACRTNFSMNGNKSVWC 113
DB 184 IWSGLAPQVLIHNK- - -CTFNVRNGHIVASNRSLSFNEVVEPRCOIGFVWKGPDRHVKC 240
QY 114 QANNMGPHRLPTCV 127
DB 241 QALNKWEP ELPSQ 253

RESULT 16
US 08 981 234B 2
? Sequence 2, Application US/08081234B
? Patent No. 6,270,997
? GENERAL INFORMATION:
? APPLICANT: TOYOMURA, KOJI
? APPLICANT: MURAKAMI, HIROSHI
? APPLICANT: SHIGEMURA, TAMOTSU
? TITLE OF INVENTION: DNA ENCODING A PORCINE COMPLEMENT
? TITLE OF INVENTION: INHIBITOR
? NUMBER OF SEQUENCES: 2
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: BIRCH, STEWART, KOLASCH & BIRCH
? STREET: PO BOX 747
? CITY: FALLS CHURCH
? STATE: VA
? COUNTRY: USA
? ZIP: 22040-0747
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC DOS/MS DOS
? SOFTWARE: Patent In Release #1.0, Version #1.30
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/981,234B
? FILING DATE: 12-DEC-1997
? CLASSIFICATION:
? ATTORNEY/AGENT INFORMATION:
? NAME: MURPHY JR, GERALD M.
? REGISTRATION NUMBER: 28,477
? REFERENCE/DOCKET NUMBER: 2520-111P
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: 703 205 8000
? TELEFAX: 703 205 8050
? INFORMATION FOR SEQ ID NO: 2:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 463 amino acids
? TYPE: amino acid
? TOPOLOGY: linear

? FILING DATE: 15-May-1995
? ATTORNEY/AGENT INFORMATION:
? NAME: Kind, William T.
? REGISTRATION NUMBER: 30,954
? REFERENCE/DOCKET INFORMATION: P4042402
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (610) 270-5464
? TELEFAX: (610) 270-5090
? INFORMATION FOR SEQ ID NO: 30:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 254 amino acids
? TYPE: amino acid
? TOPOLOGY: linear
? MOLECULE TYPE: peptide
? FRAGMENT TYPE: N-terminal
US 08 981 234B 40

Query Match 25.38; Score 193; DB 4; Length 463;
Best Local Similarity 33.68; Pred. No. 3,40-14;
Matches 45; Conservative 20; Mismatches 53; Indels 16; Gaps 7;

? FILING DATE: 15-May-1995
? ATTORNEY/AGENT INFORMATION:
? NAME: Kind, William T.
? REGISTRATION NUMBER: 30,954
? REFERENCE/DOCKET INFORMATION: P4042402
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (610) 270-5464
? TELEFAX: (610) 270-5090
? INFORMATION FOR SEQ ID NO: 30:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 254 amino acids
? TYPE: amino acid
? TOPOLOGY: linear
? MOLECULE TYPE: peptide
? FRAGMENT TYPE: N-terminal
US 08 981 234B 2

RESULT 17
US 08 139 195 2
? Sequence 2, Application US/08139195
? Patent No. 6,218,420
? GENERAL INFORMATION:
? APPLICANT: Atkinson, John P.
? TITLE OF INVENTION: RECOMBINANTLY PRODUCED HUMAN MEMBRANE
? TITLE OF INVENTION: COFACTOR PROTEIN (MCP)
? NUMBER OF SEQUENCES: 2
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Patrea L. Pabst
? STREET: 1100 Peachtree Street, SW # 2800
? CITY: Atlanta
? STATE: Georgia
? COUNTRY: USA
? ZIP: 30309-4530
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC-DOS/MS-DOS
? SOFTWARE: Patent In Release #1.0, Version #1.25
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/139,195
? FILING DATE: 20-OCT-1993
? CLASSIFICATION: 435
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 07/948,350
? FILING DATE: 21-SEP-1992
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: US 07/384,211
? FILING DATE: 21-JUL-1989
? ATTORNEY/AGENT INFORMATION:
? NAME: Pabst, Patrea L.
? REGISTRATION NUMBER: 31,284
? REFERENCE/DOCKET NUMBER: W010070N
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (404)-815-6508
? TELEFAX: (404)-815-6555
? INFORMATION FOR SEQ ID NO: 2:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 384 amino acids
? TYPE: amino acid
? STRANDEDNESS: single
? TOPOLOGY: linear
? MOLECULE TYPE: protein
? HYPOTHETICAL: NO
? ANTI-SENSE: NO
? FRAGMENT TYPE: N-terminal
? ORIGINAL SOURCE: Human Membrane CoFactor Protein (MCP)
US 08 139 195 2

Query Match 21.38; Score 160; DB 4; Length 384;
```

RESULT 19
US-GB 888 171 18
Sequence 18, Application US/0888171
Patent No. 5853528
GENERAL INFORMATION:
APPLICANT: JEAN LEROY, RO
APPLICANT: HIGUINS, Paul J.
APPLICANT: Yeh, C. Grace
TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT
NUMBER OF INVENTIONS: 1
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FASTSEQ For Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATIION NUMBER: 35/08/888, 171
FILING DATE: 03 JUL 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/310, 416
FILING DATE: 22 SEP 1994
ATTORNEY/AGENT INFORMATION:
NAME: Freeman, John W.
REGISTRATION NUMBER: 29, 066
ALTERED SEQUENCE NUMBER: 5616, 005,002
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542 507
TELEFAX: 617/542 890
TELEX: 200154
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 169 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
S 08 888 171 18

[illegible]

RESULT 20
 US 08-310-416A 13
 ; Sequence 13; Application 03/08410416A
 ; Patent No. 5,679,546
 ; GENERAL INFORMATION:
 ; APPLICANT: JUNG LUNG KO et al.
 ; TITLE OF INVENTION: CHIMERIC PROTEINS WHICH BLOCK
 ; TITLE OF INVENTION: COMPLEMENT ACTIVATION
 ; NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: Massachusetts
 COUNTRY: U.S.A.
 ZIP: 02110 2804
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 COMPUTER: IBM PS/2 Model 50Z or 55SX
 OPERATING SYSTEM: MS DOS (Version 5.0)
 SOFTWARE: WordPerfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/410,416A
 FILING DATE: 22 SEP 1994
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Paul T. Clark
 REGISTRATION NUMBER: 40,162
 REFERENCE/DOCKET NUMBER: 06180/005001
 TELEPHONE: (617) 542-5070
 TELEFAX: (617) 542-8906
 TELEX: 200154
 INFORMATION FOR SEQ ID NO: 13:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 254 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-09-410-416A-13

Query Match 21.2%; Score 159; DB 1; length 254;
 Best Local Similarity 27.9%; Pred. No. 8,66-10;
 Matches 48; Conservative 25; Mismatches 57; Indels 16; Gaps 6;

QY 2 ISGSPHPLNGRISYSYSTPI AVCTVIRYSCS-----GTERLIGERSLLCTTKDKVVG 55
 DB 126 VICTPIPKIKCKHTFSEVVEFYLDVITYSCDAPGDDPFLICESTIYC-----GINSV 181
 QY 56 WDKFAKCEYENKYSCEPIVGGYKIRG STYRHCDSYTFACKTNFSMNCNKSVWQ 114
 DB 182 WSKAAEC---KVKCRFPVVENCKQISGFGKFFYKATVMEFCDKGYLDGSDITVCD 237
 QY 115 ANNMWCPRLPTCVSV 130
 DB 238 SNSTWUPP VPKCLV 252

RESULT 21
 US-09-888-171-13
 Sequence 13, Application US/0888171
 Patent No. 5851528
 GENERAL INFORMATION:
 APPLICANT: Zome Labs, Co
 APPLICANT: Higgins, Paul J.
 APPLICANT: Yeh, C. Grace
 TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT
 TITLE OF INVENTION: ACTIVATION
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson, P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: MA
 COUNTRY: US
 ZIP: 02110 2804
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM compatible
 OPERATING SYSTEM: Windows
 SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/888,171
 FILING DATE: 03-JUL-1997
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/310,416
 FILING DATE: 22-SEP-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Freeman, John W.
 REGISTRATION NUMBER: 29,066
 REFERENCE/DOCKET NUMBER: 06180/0,5012
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617/542-507
 TELEFAX: 617/542-890
 TELEX: 200154
 INFORMATION FOR SEQ ID NO: 13:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 254 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-888-171-13

Query Match 21.2%; Score 159; DB 2; length 254;
 Best Local Similarity 27.9%; Pred. No. 8,66-10;
 Matches 38; Conservative 25; Mismatches 57; Indels 16; Gaps 6;

QY 2 ISGSPHPLNGRISYSYSTPI AVCTVIRYSCS-----GTERLIGERSLLCTTKDKVVG 55
 DB 126 VICTPIPKIKCKHTFSEVVEFYLDVITYSCDAPGDDPFLICESTIYC-----GINSV 161
 QY 56 WDKFAKCEYENKYSCEPIVGGYKIRG STYRHCDSYTFACKTNFSMNCNKSVWQ 114
 DB 182 WSKAAEC---KVKCRFPVVENCKQISGFGKFFYKATVMEFCDKGYLDGSDITVCD 247
 QY 115 ANNMWCPRLPTCVSV 130
 DB 238 SNSTWUPP VPKCLV 252

RESULT 22
 US-08-435-149-1
 Sequence 1, Application US/08435149
 Patent No. 5856402
 GENERAL INFORMATION:
 APPLICANT: INNIS, MICHAEL A.
 APPLICANT: ZAKOR, ISABEL
 APPLICANT: CREASEY, ABRA A.
 TITLE OF INVENTION: CHIMERIC MCP AND DAF PROTEINS WITH CELL
 TITLE OF INVENTION: SURFACE LOCALIZING DOMAIN
 NUMBER OF SEQUENCES: 26
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: CHIRON CORPORATION
 STREET: INTELLECTUAL PROPERTY - 8440, P.O. BOX 8097
 CITY: EMERYVILLE
 STATE: CALIFORNIA
 COUNTRY: U.S.A.
 ZIP: 94662-8097
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/435,149
 FILING DATE: 05-MAY-1995
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:
 NAME: SAVERIDE, PAUL B.
 REGISTRATION NUMBER: 36,914
 REFERENCE/DOCKET NUMBER: 0989,101
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (510) 602-2585
 TELEFAX: (510) 655-3542

TELEX: N/A
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 294 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US 09 834 309 4

Query Match 21.2% Score 159; DB 2; length 294;
 Best local similarity 27.9% Pred. No. 16 09;
 Matches 48; Conservative 25; Mismatches 67; Indels 16; Gaps 67

QY 2 ISGSGPPTLNGKSYSTPLAVGVIVSYNS -GIFRLGKSLGSLGKVKVMT 55
 DB 126 VLTPTPKTKRKHTESEVEVEVEVLLAVVYSQTPAHPGPSTLQSTLYC GNSV 181
 QY 56 WPKAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 DB 182 WSPAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 QY 115 ANMMWGTPRLPCVSV 140
 DB 238 SNSTWPPVPKCLKV 252

RESULT 24
 US 09 834 309 4
 Sequence 16, Application US/090808171
 Patent No. 6951528

GENERAL INFORMATION:
 APPLICANT: Jomo-Lord, Ko
 APPLICANT: Hioquins, Paul J.
 APPLICANT: Yoh, C. Grace
 TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: Massachusetts
 COUNTRY: U.S.A.
 ZIP: 02110-2804

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 MB
 COMPUTER: IBM PS/2 Model 55, 386
 OPERATING SYSTEM: MS DOS (Version 5.0)
 SOFTWARE: WordPerfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/410,416A
 FILING DATE: 22 SEP 1994
 CLASSIFICATION: 4.05
 ATTORNEY/AGENT INFORMATION:
 NAME: Paul J. Clark
 REGISTRATION NUMBER: 40,162
 REFERENCE/REGISTER NUMBER: 05,180,200-001
 TELEPHONE: (617) 542-5000
 TELEFAX: (617) 542-5000
 TELEX: 200154

INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 294 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US 09 834 309 4

Query Match 21.2% Score 159; DB 2; length 294;
 Best local similarity 27.9% Pred. No. 16 09;
 Matches 48; Conservative 25; Mismatches 67; Indels 16; Gaps 67

QY 2 ISGSGPPTLNGKSYSTPLAVGVIVSYNS -GIFRLGKSLGSLGKVKVMT 55
 DB 126 VLTPTPKTKRKHTESEVEVEVEVLLAVVYSQTPAHPGPSTLQSTLYC GNSV 181
 QY 56 WPKAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 DB 182 WSPAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 QY 115 ANMMWGTPRLPCVSV 140
 DB 238 SNSTWPPVPKCLKV 252

RESULT 24

US 09 834 309 4
 Sequence 16, Application US/090808171
 Patent No. 6951528

GENERAL INFORMATION:
 APPLICANT: Jomo-Lord, Ko
 APPLICANT: Hioquins, Paul J.
 APPLICANT: Yoh, C. Grace
 TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: MA
 COUNTRY: US
 ZIP: 02110-2804

COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: Windows95
 SOFTWARE: FastSeq for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/888,171
 FILING DATE: 03-JUL-1997
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/410,416
 FILING DATE: 22 SEP-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Freeman, John W.
 REGISTRATION NUMBER: 29,066
 REFERENCE/REGISTER NUMBER: 05,180,000-002
 TELEPHONE: 617/542-5007
 TELEFAX: 617/542-890
 TELEX: 200154

INFORMATION FOR SEQ ID NO: 16:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 294 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US 09 888 171 16

Query Match 21.2% Score 159; DB 2; length 294;
 Best local similarity 27.9% Pred. No. 16 09;
 Matches 48; Conservative 25; Mismatches 67; Indels 16; Gaps 67

QY 2 ISGSGPPTLNGKSYSTPLAVGVIVSYNS -GIFRLGKSLGSLGKVKVMT 55
 DB 126 VLTPTPKTKRKHTESEVEVEVEVLLAVVYSQTPAHPGPSTLQSTLYC GNSV 181
 QY 56 WPKAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 DB 182 WSPAFKTYEYKSYSTPLAVGVIVSYNS STPLRUGLSVIFA'KINSMGNKNSVWQ 114
 QY 115 ANMMWGTPRLPCVSV 140
 DB 238 SNSTWPPVPKCLKV 252

RESULT 25

US 08 528 057-42
Sequence 42, Application US/08528057
Patent No. 5846715

GENERAL INFORMATION:

APPLICANT: PURCELL, Damian F. J.
APPLICANT: RUSSELL, Sarah M.
APPLICANT: MCKENZIE, Ian F. C.
TITLE OF INVENTION: CD46 VARIANTS
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Policy & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08528057

FILING DATE: CONCURRENTLY HERewith

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/961,686

FILING DATE: 11-JAN-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/A091/00199

FILING DATE: 10-MAY-1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: AU 860133/90

FILING DATE: 11-MAY-1990

ATTORNEY/AGENT INFORMATION:

NAME: HENI, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/DOCKET NUMBER: 17227/112 DACO

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399

TELEX: 604136

INFORMATION FOR SEQ ID NO: 42:

SEQUENCE CHARACTERISTICS:

LENGTH: 373 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US 08 528 057 42

Query Match 21.2%; Score 159; DB 2; Length 370;

Best Local Similarity 27.9%; Pred. No. 1.4e-09;

Matches 48; Conservative 25; Mismatches 57; Indels 16; Gaps 6;

QY 2 ISGSGPFFILNGRISYSTPI AVGVTVIRYSGS-----GTFELIGEKSLLCITTKKVDST 55

DB 160 VLCTPPPKTKNGKHITSEVEFEYLIAVTYSQDPAPGDPFSLIGESTIYC-----GDNSV 215

QY 56 WDKPAKCEYFNKYSSTPEFVIGGYKIKG-SUPYRHGDSVTFACKTFNSMNGKNSVWQ 114

DB 216 WSRAAPEG---KVKCRFFVWENGKQISGFGKKFYKATVMFECDKGYLGSSTIYCD 271

QY 115 ANNMWGPTRLPCTCVSV 130

DB 272 SNTWDDPP-VPKCIKV 286

RESULT 26

US 08 528 057 44
Sequence 44, Application US/08528057
Patent No. 5846715

GENERAL INFORMATION:

APPLICANT: PURCELL, Damian F. J.
APPLICANT: RUSSELL, Sarah M.
APPLICANT: MCKENZIE, Ian F. C.
TITLE OF INVENTION: CD46 VARIANTS
NUMBER OF SEQUENCES: 46
CORRESPONDENCE ADDRESS:
ADDRESSEE: Policy & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08528057

FILING DATE: CONCURRENTLY HERewith

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/961,686

FILING DATE: 11-JAN-1993

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/A091/00199

FILING DATE: 10-MAY-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: AU 860133/90

FILING DATE: 11-MAY-1990

ATTORNEY/AGENT INFORMATION:

NAME: HENI, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/DOCKET NUMBER: 17227/112 DACO

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399

TELEX: 604136

INFORMATION FOR SEQ ID NO: 44:

SEQUENCE CHARACTERISTICS:

LENGTH: 373 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US 08 528 057 44

Query Match 21.2%; Score 159; DB 2; Length 373;

Best Local Similarity 27.9%; Pred. No. 1.4e-09;

Matches 48; Conservative 25; Mismatches 57; Indels 16; Gaps 6;

QY 2 ISGSGPFFILNGRISYSTPI AVGVTVIRYSGS-----GTFELIGEKSLLCITTKKVDST 55

DB 160 VLCTPPPKTKNGKHITSEVEFEYLIAVTYSQDPAPGDPFSLIGESTIYC-----GDNSV 215

QY 56 WDKPAKCEYFNKYSSTPEFVIGGYKIKG-SUPYRHGDSVTFACKTFNSMNGKNSVWQ 114

DB 216 WSRAAPEG---KVKCRFFVWENGKQISGFGKKFYKATVMFECDKGYLGSSTIYCD 271

QY 115 ANNMWGPTRLPCTCVSV 130

DB 272 SNTWDDPP-VPKCIKV 286

RESULT 27

US 08 528 057-2

Sequence 2, Application US/08528057

Patent No. 5846715

GENERAL INFORMATION:

APPLICANT: PURCELL, Damian F. J.

APPLICANT: RUSSELL, Sarah M.

APPLICANT: MCKENZIE, Ian F. C.

TITLE OF INVENTION: CD46 VARIANTS

NUMBER OF SEQUENCES: 46


```

QY 117 N MW GPTRLEPC 127
DB 491 NDEGEWSCP--PDC 503

RESULT 40
US 09 475 460A 42
: Sequence 42, Application US/09475460A
: Patent No. 6416253
: GENERAL INFORMATION:
: APPLICANT: Scott, Elizabeth
: TITLE OF INVENTION: EXPRESSION VECTORS, TRANSECTION SYSTEMS, AND METHOD OF
: FILE REFERENCE: 1527 004
: CURRENT APPLICATION NUMBER: US/09475,460A
: CURRENT FILING DATE: 1999-12-40
: NUMBER OF SEQ ID NOS: 42
: SOFTWARE: Patent In Ver. 2.0
: SEQ ID NO 42
: LENGTH: 611
: TYPE: PRT
: ORGANISM: CAB2
US 09 475 460A 42

Query Match 21.2% Score 159; DB 4; Length 611;
Best Local Similarity 44.4% Prod. No. 2.76-09;
Matches 45; Conservative 17; Mismatches 50; Indels 23; Gaps 9;

QY 4 SCGSPPLINGRISYYSTP--IAVTVIRYSCGTFRLIGKSLLCITKDKVDGT---WD 57
DB 416 SCPNNGEIRNGQJ---DWPGGLEGATLISEAN YALPGNISSEFCI-----ISGSSVQWS 468
QY 58 KIPAKCEYFNKYSSCPDPIVPGGYKIRGSDP-YRHGDSVTFACKTNEMNKNKSVWCOAN 116
DB 469 DPLPEC---REIYCPAPPQIDNGIIQGER-HYGRQSVIVACNKGFTMIGHSIYCTVN 524

QY 117 N MW GPTRLEPC 127
DB 525 NDEGEWSCP--PDC 547

RESULT 41
US 08 445 149-2
: Sequence 2, Application US/08445149
: Patent No. 5866402
: GENERAL INFORMATION:
: APPLICANT: INNIS, MICHAEL A.
: APPLICANT: ZAROB, ISABEL
: TITLE OF INVENTION: CHIMERIC MCP AND DAF PROTEINS WITH CELL
: FILE REFERENCE: CREASEY, ABLA A.
: TITLE OF INVENTION: SURFACE LOCALIZING DOMAIN
: NUMBER OF SEQUENCES: 26
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: CHIRON CORPORATION 4440, P.O. BOX 8097
: STREET: INTELLECTUAL PROPERTY
: CITY: EMERYVILLE
: STATE: CALIFORNIA
: COUNTRY: U.S.A.
: ZIP: 94662 8097
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent In Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/445,149
: FILING DATE: 05 MAY 1995
: CLASSIFICATION: 530
: ATTORNEY/AGENT INFORMATION:
: NAME: SAVERIDE, PAUL B.
: REGISTRATION NUMBER: 46,914

QY 117 N MW GPTRLEPC 127
DB 525 NDEGEWSCP--PDC 547

Query Match 21.1% Score 158; DB 2; Length 423;
Best Local Similarity 33.3% Prod. No. 36-077;
Matches 45; Conservative 17; Mismatches 60; Indels 24; Gaps 9;

QY 3 SCGSPPLINGRISYYSTP--IAVTVIRYSCGTFRLIGKSLLCITKDKVDGT WD 57
DB 128 SCPNNGEIRNGQJ---DWPGGLEGATLISEAN YALPGNISSEFCI-----ISGSSVQWS 180
QY 58 KIPAKCEYFNKYSSCPDPIVPGGYKIRGSDP-YRHGDSVTFACKTNEMNKNKSVWCOAN 116
DB 161 DPLPEC---REIYCPAPPQIDNGIIQGER-HYGRQSVIVACNKGFTMIGHSIYCTVN 246
QY 117 N MW GPTRLEPC 127
DB 237 NDEGEWSCP--PDC 249

RESULT 42
US 08 310 416A 11
: Sequence 14, Application US/08310416A
: Patent No. 5673546
: GENERAL INFORMATION:
: APPLICANT: Jone-Long Ko et al.
: TITLE OF INVENTION: CHIMERIC PROTEINS WHICH BLOCK
: TITLE OF INVENTION: COMPLEMENT ACTIVATION
: NUMBER OF SEQUENCES: 19
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Fish & Richardson P.C.
: STREET: 225 Franklin Street
: CITY: Boston
: STATE: Massachusetts
: COUNTRY: U.S.A.
: ZIP: 02110 2404
: COMPUTER READABLE FORM:
: MEDIUM TYPE: 3.5" Diskette, 1.44 MB
: COMPUTER: IBM PS/2 Model 502 or 505
: OPERATING SYSTEM: MS-DOS (Version 5.0)
: SOFTWARE: WordPerfect (Version 5.1)
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/310,416A
: FILING DATE: 22-SEP-1994
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Paul T. Clark
: REGISTRATION NUMBER: 30,162
: REFERENCE/Docket NUMBER: 06180/035001
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (617) 542-5070
: TELEFAX: (617) 542-8906
: TELEX: 200154
: INFORMATION FOR SEQ ID NO: 14:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 324 amino acids
: TYPE: amino acid
: STRANDEDNESS: not relevant
: TOPOLOGY: linear
: MOLECULE TYPE: protein
US 08 310 416A 11

```


RESULT 45
 US-08-456-461-27
 : Sequence 27, Application US/08456461
 : Patent No. 583484
 : GENERAL INFORMATION:
 : APPLICANT: Smith, Richard A.G.
 : APPLICANT: Dodd, Ian
 : APPLICANT: Freeman Mary A.
 : APPLICANT: Mossakowska, Janeta E.L.
 : TITLE OF INVENTION: No. 583484ol Compounds
 : NUMBER OF SEQUENCES: 41
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: SmithKline Beecham Corporate Intellectual Property
 : STREET: P.O. Box 1549
 : CITY: King of Prussia
 : STATE: Pennsylvania
 : COUNTRY: USA
 : ZIP: 19406
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.25
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/456,461
 : FILING DATE: 03 Jul 1995
 : CLASSIFICATION: 445
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Jervis, Herbert H.
 : REGISTRATION NUMBER: 43,171
 : REFERENCE/DOCKET NUMBER: P40424
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: (610) 270-5019
 : TELEFAX: (610) 270-5090
 : INFORMATION FOR SEQ ID NO: 27:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 197 amino acids
 : TYPE: amino acid
 : TOPOLOGY: linear
 : MOLECULE TYPE: peptide
 : FRAGMENT TYPE: N-terminal
 US-08-456-461-27

Query Match 20.4%; Score 153.5; DB 2; Length 197;
 Best Local Similarity 30.4%; Pred. No. 2.5e-09;
 Matches 42; Conservative 21; Mismatches 56; Indels 19; Gaps 8;
 QY 3 SCGSPPEPLNGRISYSYTPIAVGIVIRYSGSTFRLGKSLLC-ITKDKVGGTWKRPAP 61
 DB 63 SCRNPDVNGMV-HVIRKIGFGSQIKYSCTKGYRLGSSSATCIIISGDIV--IWDNETP 119
 QY 62 KCEYFNKYSCEPIVPGYKIRGSTIYRHGDSVTFACKTN-----FSMNGKNSVMCOA 115
 DB 120 ICDRIIP--CGLPPTITNGFISTNPFNFHYGVSATYFCTNAGSGGKVELVGEFSYCTS 177
 QY 116 NN---MW-GPTRLPTCV 128
 DB 178 NDDQVCWISGPA--PQCI 193

RESULT 46
 US-08-769-967A-27
 : Sequence 27, Application US/08769967A
 : Patent No. 5859224
 : GENERAL INFORMATION:
 : APPLICANT: Mossakowska, Janeta E.L.
 : APPLICANT: Smith, Richard A.G.
 : APPLICANT: Dodd, Ian
 : APPLICANT: Freeman, Anne Mary
 : TITLE OF INVENTION: Soluble Cx1 Derivatives
 : NUMBER OF SEQUENCES: 33
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: SmithKline Beecham Corporate Intellectual Property

: STREET: P.O. Box 1539
 : CITY: King of Prussia
 : STATE: Pennsylvania
 : COUNTRY: USA
 : ZIP: 19406
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.25
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/769,967A
 : FILING DATE: 15-May-1995
 : CLASSIFICATION: 536
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: 08/440,564
 : ATTORNEY/AGENT INFORMATION:
 : NAME: King, William T.
 : REGISTRATION NUMBER: 30,954
 : REFERENCE/DOCKET NUMBER: P30423C2
 : TELECOMMUNICATION INFORMATION:
 : TELEPHONE: (610) 270-5364
 : TELEFAX: (610) 270-5090
 : INFORMATION FOR SEQ ID NO: 27:
 : SEQUENCE CHARACTERISTICS:
 : LENGTH: 197 amino acids
 : TYPE: amino acid
 : TOPOLOGY: linear
 : MOLECULE TYPE: peptide
 : FRAGMENT TYPE: N-terminal
 US-08-769-967A-27

Query Match 20.4%; Score 153.5; DB 2; Length 197;
 Best Local Similarity 30.4%; Pred. No. 2.5e-09;
 Matches 42; Conservative 21; Mismatches 56; Indels 19; Gaps 8;
 QY 3 SCGSPPEPLNGRISYSYTPIAVGIVIRYSGSTFRLGKSLLC-ITKDKVGGTWKRPAP 61
 DB 63 SCRNPDVNGMV-HVIRKIGFGSQIKYSCTKGYRLGSSSATCIIISGDIV--IWDNETP 119
 QY 62 KCEYFNKYSCEPIVPGYKIRGSTIYRHGDSVTFACKTN-----FSMNGKNSVMCOA 115
 DB 120 ICDRIIP--CGLPPTITNGFISTNPFNFHYGVSATYFCTNAGSGGKVELVGEFSYCTS 177
 QY 116 NN---MW-GPTRLPTCV 128
 DB 178 NDDQVCWISGPA--PQCI 193

RESULT 47
 US-08-824-692-3;
 : Sequence 32, Application US/08824692
 : Patent No. 60,7703
 : GENERAL INFORMATION:
 : APPLICANT: Kinders, Robert J.
 : APPLICANT: Enfield, David L.
 : APPLICANT: Bass, G. Michael
 : TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR SCREENING
 : OPERATING SYSTEM: FOR OR MODULATING A TUMOR ASSOCIATED ANTI-EN
 : NUMBER OF SEQUENCES: 38
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: SEED and HERRY LLP
 : STREET: 600 Columbia Center, 701 - 11th Avenue
 : CITY: Seattle
 : STATE: Washington
 : COUNTRY: USA
 : ZIP: 98104
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.40

US 08 596 405 2
? Sequence 2: Application US/08596405
? Patent No. 5858706
? GENERAL INFORMATION:
? APPLICANT: Ding, Jack Ling
? TITLE OF INVENTION: the Cloned Factor C cDNA of the
? TITLE OF INVENTION: Singapore Horseshoe Crab, Carcinoscorpius
? TITLE OF INVENTION: rotundicauda and Purification of Factor C Proenzyme
? NUMBER OF SEQUENCES: 4
? CORRESPONDENCE ADDRESS:
? ADDRESSEE: Birch, Stewart, Kolasch & Birch
? STREET: 8110 Gatehouse Road, Suite 500 East
? CITY: Falls Church
? STATE: Virginia
? COUNTRY: USA
? ZIP: 22042
? COMPUTER READABLE FORM:
? MEDIUM TYPE: Floppy disk
? COMPUTER: IBM PC compatible
? OPERATING SYSTEM: PC DOS/MS DOS
? SOFTWARE: Patent In Release #1.0, Version #1.25
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/596,405
? FILING DATE:
? CLASSIFICATION: 435
? ATTORNEY/AGENT INFORMATION:
? NAME: Murphy, J. Gerald M.
? REGISTRATION NUMBER: 28,977
? REFERENCE/DOCKET NUMBER: 1781 1050
? TELECOMMUNICATION INFORMATION:
? TELEPHONE: (703) 205-8000
? TELEFAX: (703) 205-8050
? TELEX: 248445
? INFORMATION FOR SEQ ID NO: 2:
? SEQUENCE CHARACTERISTICS:
? LENGTH: 1083 amino acids
? TYPE: amine acid
? TOPOLOGY: Linear
? MOLECULE TYPE: protein
US 08 596 405 2

Query Match 19.2%; Score 144; DH 2; Length 1083;
Best Local Similarity 24.5%; Prod. No. 2.5e-07;
Matches 48; Conservative 41; Mismatches 50; Indels 36; Gaps 8;
QY 2 ISG----GSPPPIL---NCRISYVSTPIAVGTIVIRYSCSGTFLRIGKSL 44
DB 244 ISCLNGCWSNPPKCIWECAMVSSPEKCVNAISGDMTEGATLRFSCDSPPYLLIGQFTL 303
QY 45 LKTKKVGWTKVAPKCEYENKYSSTP--EPVPGGYKTR-----GSTPYRHGDSV 95
DB 404 TC--QNGGWN--QIPQCK--NLVFGPDLFPVNHAEHKVIGVEQKYGQFP--QGTEV 354
QY 96 TEAKNFSMNGKSNVWCQANNMGPIRLPICVSV 140
DB 455 TTTCSNTPLMGFUTLKNPDSNSGSG PSCVKV 488

Search completed: November 6, 2002, 16:06:53
Job time: 13.461 secs

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

85 159 21.2 377 17 AAR93941
 86 159 21.2 377 18 AAW27484
 87 159 21.2 378 17 AAR93940
 88 159 21.2 384 12 AAR10924
 89 159 21.2 384 16 AAR86316
 90 159 21.2 421 21 AAR38394
 91 159 21.2 421 22 AAG75528
 92 159 21.2 577 17 AAW06882
 93 159 21.2 611 22 AAL12569
 94 159 21.2 611 22 AAE03762
 95 158.5 21.1 299 17 AAW06881
 96 158.5 21.1 420 22 AAG68150
 97 158.5 21.1 476 20 AAY50035
 98 158.5 21.1 481 18 AAF70048
 99 158.5 21.1 481 20 AAF94774
 100 158.5 21.1 481 16 AAR66683

ALIGNMENTS

RESULT 1
 AAR11982
 ID AAR11982 standard; Protein: 1587 AA.
 XX AAR11982
 DE 25 MAY 1991 (first entry)
 XX
 DE B lymphocyte membrane glycoprotein CR2
 XX
 DE CR2; B lymphocyte membrane receptor protein; Epstein Barr virus;
 KW extracellular domain;
 CC
 CC Homo Sapiens.
 XX
 XX Key Location/Qualifiers
 FH Region 20...300
 FT Znote= "1"
 FT 20...154
 FT Znote= "2"
 FT 20...276
 FT Znote= "4"
 FT 20...652
 FT Znote= "4"
 FT 20...776
 FT Znote= "6"
 FT 20...1026
 FT Znote= "9"
 FT Peptide 1...20
 FT Protein 21...1087
 FT Zlabel= sig peptide
 FT Zlabel= mat protein

XX W69102566 A.
 XX
 XX 07 MAR 1991.
 XX
 XX 27 AUG 1990: 90W0105047.
 XX
 XX 27 AUG 1989: R0051001224.
 XX
 XX (90W1) 3081PES-CLINIC & R01.
 XX
 XX Moore MB, Cooper ND, Nemerow GR.
 XX WPE 1991 06/109/12.
 XX N ESDB: AAG10989.
 XX
 XX synthetic polypeptide(s) of extracellular domain. Treat
 P1 Epstein Barr virus infections and diagnose same by formation of
 P1 complex between CR2 and EBV
 XX

PS
 XX
 CC The six indicated fragments encode claimed and disclosed
 CC polypeptides, which are synthesized by recombinant expression, prod.
 CC in a baculovirus expression system in which a DNA plasmid, contg. a
 CC cDNA encoding this sequence, is truncated to encode a CR2 polypeptide
 CC that comprises a region of the extracellular domain of CR2. The
 CC construct is then inserted downstream of an appropriate promoter in
 CC a transfer vector and integrated into a baculovirus which is then
 CC used to infect host insect cells for expression.
 CC The polypeptides correspond to B lymphocyte membrane receptor
 CC protein for Epstein Barr Virus (EBV) and give specific binding.
 CC Protein number 3 is used to inhibit infection of mammalian cells in
 CC contact with an aq. medium, (esp. mammalian blood) and of human
 CC B lymphocytes, by EBV. The peptides are used to detect the presence
 CC of EBV in an aq. sample and to detect antibodies directed against CR2.
 CC The peptides are used in a pharmacological compsn. as active
 CC ingredient with a carrier to treat immune disorders.

XX Sequence 1687 AA:

Query Match 100.0% Score 751; 106 12; Length 1087;
 Host Local Similarity 100.0%; Prod. No. 586 67;
 Matches 154; Conservative 0; Mismatches 0; Indels 0; Gaps 6;
 QY 1 GTSNSPPPTINSPISYSPTIAYSTIVKYSSTIEFTPEESTITTFITVWTFEPA 60
 ID 1 GTSNSPPPTINSPISYSPTIAYSTIVKYSSTIEFTPEESTITTFITVWTFEPA 60
 DB 20 GTSNSPPPTINSPISYSPTIAYSTIVKYSSTIEFTPEESTITTFITVWTFEPA 79
 QY 51 PREFTNYSSTPEFTVPEPTPESTVPESTVPESTVPESTVPESTVPESTVPESTV 120
 DE 80 PREFTNYSSTPEFTVPEPTPESTVPESTVPESTVPESTVPESTVPESTVPESTV 159
 QY 121 PTHPTCVSVFPLE 134
 DB 140 PTHPTCVSVFPLE 153

RESULT 2
 AAR11982
 ID AAR11982 standard; Protein: 1587 AA.
 XX AAR11982
 XX 25 JUN 1991 (first entry)
 XX Partial human complement type 1 receptor.
 XX
 XX Capillary system, CR2/CR3 receptor, CR2 allelic variants;
 KW immune response; long homologous repeat; LRR.
 XX
 XX Homo Sapiens.
 XX
 XX Key Location/Qualifiers
 FH Region 1...48
 FT Zlabel= LRR B
 FT 48...891
 FT Zlabel= LRR C
 FT 892...1441
 FT Zlabel= LRR D
 FT 1495...1498
 FT Znote= "positively-charged; preceded by hydrophobic
 FT sequence"
 FT 1521...1526
 FT Znote= "has 67 per cent homology to site of protein
 FT kinase C phosphorylation in the EGF
 FT receptor"
 XX W69105047 A.
 XX
 XX 18 APR 1991.
 XX 25 SEP 1990: 90W010505454.

XX 26 SEP 1989; HQUS 0412745.
 XX 26 SEP 1990; HQUS 0912449.
 XX (CCEL) T CELL SCI INC.
 PA (CJJD) JOHNS HOPKINS UNIVERSITY.
 PA (HRC) BRIGHAM AND WOMEN'S HOSPITAL.
 XX
 PT Featon DT, Klieckstein LB, Wood WW, Carson GR, Boh M, Concino MF;
 PT Makrides SC, Marsh RC;
 XX WPI: 2001-633362/73.
 DR N-PSDB: AAQ11643.
 PS
 XX Human complement receptor type 1 gene, encoded proteins and
 PT fragments for treatment of immune disorders, myocardial infarct,
 PT damage due to inflammation and in treatment of thrombosis
 XX Disclosure: Fig 5; 24pp; English.
 PS
 XX This sequence comprises three of the four tandem, direct, long
 CC homologous repeats of the full-length F allozyme of CRI. LIR-A is
 CC absent. Each LIR might represent a single C3b/C4b binding domain,
 CC making the receptor multivalent. The LIRs are composed of 7 short
 CC consensus repeats of 60-70 residues resembling the SCR's of other
 CC C3/C4 binding proteins. The protein and fragments of it having C3b
 CC and/or C4b binding activity can be used to treat immune disorders
 CC or disorders involving inappropriate complement activity.
 CC See also AAQ11642.
 XX
 XX Sequence 1547 AA;
 SQ
 Query Match 29.2%; Score 219; DB 12; Length 1537;
 Best Local Similarity 36.7%; Pred. No. 3.7e-13;
 Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;
 QY 2 ISCGSPPPLNGRISSYS---TPVAGVIVRYSC-----SGTFRIGKSLGCTTKDKV 52
 DB 1015 ISCEPPTISNG--DFYNNRPTSFHNTVVYQHTGPGKEQLFELVGFSTVYTSKDDQ 1072
 QY 53 DGTWDKPAKCEYFNKYSKCPPIVPGGYEIMGTPYRIGDSVTFACKTNFSMGNKSV 111
 DB 1073 VGVWSSPPPHCTSNK---CTAFVEVENAIVPNRHSFFSLTEITRPGQPGVWVGSHTV 1129
 QY 112 WQANNMW:PTRLPTCVSV 130
 DB 1130 QVOTNRWGP-KLPKCSRV 1147
 RESULT 4
 ID AAG00104
 XX AAG00104 standard; protein; 1929 AA.
 XX AAG00104;
 XX
 DE 14 FEB 2002 (first entry)
 DE
 XX Novel human diagnostic protein #94.
 XX
 XX Human: chromosome mapping; gene mapping; gene therapy; forensic;
 XX food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 XX W0200175067 A2.
 XX
 XX 11 OCT 2001.
 XX
 XX 30 MAR 2001; 2001WO 0508631.
 XX
 XX 31 MAR 2000; 2000US 0540217.
 XX
 XX 24 AUG 2000; 2000US 0649767.
 XX

PA (HYSE-) HYSEQ INC.
 PI Drmanac RT, Liu C, Tanq YT;
 XX
 DR WPI: 2001-633362/73.
 DR N-PSDB: AAS64290.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity
 XX
 PS Claim 20; SEQ ID No 30462; 10pp; English.
 XX
 XX The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detection of
 CC quantitation a polypeptide in tissue, at molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. AHC00010-AHC00047 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPo,
 CC at http://wipo.int/pub/published_pat_sequences.
 XX
 XX Sequence 1929 AA;
 SQ
 Query Match 29.2%; Score 219; DB 22; Length 1929;
 Best Local Similarity 36.7%; Pred. No. 4.8e-14;
 Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;
 QY 2 ISCGSPPPLNGRISSYS---TPVAGVIVRYSC-----SGTFRIGKSLGCTTKDKV 52
 DB 1407 ISCEPPTISNG--DFYNNRPTSFHNTVVYQHTGPGKEQLFELVGFSTVYTSKDDQ 1464
 QY 53 DGTWDKPAKCEYFNKYSKCPPIVPGGYEIMGTPYRIGDSVTFACKTNFSMGNKSV 111
 DB 1465 VGVWSSPPPHCTSNK---CTAFVEVENAIVPNRHSFFSLTEITRPGQPGVWVGSHTV 1521
 QY 112 WQANNMW:PTRLPTCVSV 130
 DB 1522 QVOTNRWGP-KLPKCSRV 1539
 RESULT 4
 ID AAW45899
 XX AAW45899 standard; peptide; 1930 AA
 XX AAW45899;
 XX
 DE 30-JUN-1998 (first entry)
 DE
 XX Human complement receptor 1 (residues 1-1929).
 XX
 XX Membrane binding element; thrombotic disease; soluble proteins;
 XX complement related disease; integral membrane proteins; inflammation;
 XX short consensus repeat; SCR 1-3; CRI; complement receptor type 1.
 XX
 OS Homo sapiens.
 XX
 XX Key location/Qualifiers
 XX Cross-links 1930
 FT

AA0017612
 11 JAN 2001 (first entry)
 Human CK1 protein homologue, SEQ ID NO:2192.
 human cytokine; cell proliferation; cell differentiation; growth factor;
 hematopoiesis regulation; tissue growth; immunomodulator; activating
 inhibiting chemotaxis; chemokinesis; thrombolysis; oncogenesis;
 proliferation; metastasis; cancer; tumor; hematopoietic disorder;
 myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;
 chronic inflammatory condition; proliferative retinopathy;
 atherosclerosis; coronary heart disease; arterial ischemia;
 bone disorder; osteoporosis; vascular growth disorder;
 tissue regeneration; wound healing; infection; immune disorder;
 cell culture; cell activation; gene therapy; autoimmunology;
 antihistamine; antithrombin; hemostatic; antileukosclerotic;
 cytoprotective; self-protection; cardiac; fibrosis; antidiabetic;
 osteoporosis; pulmonary; and nuclear.
 Homo sapiens
 WC00192180 A2
 20 JAN 2001
 20 FEB 2001; 2001WO050690
 23 FEB 2000; 2000US 0406014
 27 APR 2000; 2000US 0506016
 (0030)) HY:60 INC
 Tang YL, Liu J, Linman JF;
 WO/2001/45740/49
 N 1300; AA000626
 Human proteins and DNA encoding sequences useful for prevention,
 treatment or ameliorating a medical condition in a mammalian subject
 e.g., arthritis and cancer;
 C. num 20; Page 24; 246; 20-APP; English.
 Sequences AA010941 AB014400 represent 150 novel human polypeptides, and
 sequences AA06225 AA06574 represent nucleic acids encoding them. The
 invention also relates to vectors and recombinant host cells comprising a
 nucleotide of the invention, methods of producing the novel polypeptides,
 antibodies against the polypeptides, methods of detecting the nucleotides
 or polypeptides in a sample, and methods of identifying compounds which
 bind to polypeptides of the invention. Although novel, many of the
 polypeptides of the invention have homology to known proteins, thereby
 giving an insight into their probable biological activities, and hence
 potential therapeutic applications. The polypeptides of the invention may
 have various properties, including cytokine, cell proliferation or cell
 differentiation activities, stem cell growth factor activity;
 hematopoietic regulatory activity; tissue growth activity;
 immunomodulatory activity; cellin or inhibin related activities;
 chemokine or chemokine receptor activities; hemostatic; thrombolytic or
 fibrinolytic activities; receptor or ligand activities; or may be
 involved in oncogenesis, cancer, cell proliferation or metastasis,
 depending on their biological activities, polypeptides and nucleotides of
 the invention are useful for prevention, treatment or ameliorating medical
 conditions, e.g., by protein or gene therapy. Such conditions include
 cancers; hematopoietic disorders (e.g., myeloid or lymphoid cell
 disorders); chronic inflammatory conditions (e.g., asthma or arthritis),
 proliferative retinopathy; atherosclerosis; coronary heart disease,
 arterial ischemia; bone disorders (e.g., osteoporosis); and abnormal
 vascular growth. Polypeptides involved with tissue regeneration and
 repair (or nucleic acids encoding them) may be used to promote wound
 healing (e.g., of burns, incisions and ulcers), while those with
 immunomodulatory activities may be used in the treatment of viral,
 bacterial and fungal infections in addition to immune disorders.

CC Polypeptides with growth factor activity may be used in cell cultures to
 promote cell growth. For example, such polypeptides may be used to
 manipulate stem cells in culture to give rise to neuroepithelial cells
 that can be used to augment or replace cells damaged by illness,
 autoimmune disease or accidental damage. The polypeptides and nucleotides
 may also be used in the diagnosis of the above conditions, and in drug
 screening techniques. The present sequence represents a novel human
 CC polypeptide of the invention.
 XX
 SQ Sequence 2044 AA;

Query Match 29.2%; Score 219; DB 22; Length 2044
 Best local Similarity 36.7%; Pred. No. 5,26 14;
 Matches 51; Conservative 17; Mismatches 55; Indels 16; Gaps 6;
 QY 2 2SCSGFFRLLRPLSYYS TP2AVGLVLYSS - SGLHLLFMRKLLLEKPRV 52
 11
 DB 1522 1SLTLLTSLG GYS66KLSFNGIVVYQALGPDQKQKLVKESLYFSDQD 1579
 QY 53 3PTW3QAAQFVYRYSNGLFVYR1953TP Y992PVLAF787P992R9SV 111
 11
 DB 1580 VGWSSPPHCTSNK CTAPVENAIRVGNISFSLTEIFRQGPCFVWVNSHTV 1636
 QY 112 WQANRHW3PRKPTCVSV 130
 11 11 11 11 11 11
 DB 1637 QGQNGHW3P KLPHC3RV 1654

RESULT 9
 AAM49224
 ID AAM49224 Standard; Proteins; 2044 AA.
 XX
 AC AAM49224;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polypeptide SEQ ID NO 2469.
 XX
 KW Human; modulator; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; hemostatic;
 KW amyotrophic lateral sclerosis; Shy drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX
 OS Homo sapiens.
 XX
 PN WC000154312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26 JAN 2000; 2000WO 0534264.
 XX
 PR 21 JAN 2000; 2000US 0488725.
 PR 25 APR 2000; 2000US 0552317.
 PR 09 JUL 2000; 2000US 0598042.
 PR 19 JUL 2000; 2000US 0620422.
 PR 03 AUG 2000; 2000US 0653450.
 PR 14 SEP 2000; 2000US 0662191.
 PR 19 OCT 2000; 2000US 0694036.
 PR 29 NOV 2000; 2000US 0727344.
 XX
 PA (HYSEQ) HYSEQ INC.
 XX
 PI Tang YT, Liu J, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
 PI Wang J, Wang J, Wehrman L, Xu C, Xie AL, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Brimacombe R;
 XX
 DR WFJ, 2001 44:253-47.
 DR N-PSDB; AA058480.
 XX
 PI Novel nucleic acids and polypeptides, useful for treating disorders
 PI such as central nervous system injuries

FI Duplication /note- "See note a in comments below."
 FT 202 /note- "See note a in comments below."
 XX
 PN DSN729208 N.
 XX
 PD 14 MAR 1989.
 XX
 PE 20 AUG 1988; 88US 0249208.
 XX
 PR 20 AUG 1988; 88US 0249208.
 XX
 PA (ORSH) NAT INST OF HEALTH.
 XX
 PI Kowal G.
 XX
 PR 1989 165451/22.
 DR N-PSDB; AAN90113.
 XX
 PT New protein with anti-complement activity
 PT encoded by Vaccinia virus 35K gene
 XX
 PS Disclosure; Figure 2A; 20pp; English.
 XX
 CC 340 binding protein which specifically blocks human complement cascades.
 CC It is the deduced sequence of a 35kDa protein encoded by sequence 52-840
 CC of the 35K gene of vaccinia virus strain WR. Note a - these sites
 CC indicate the start of 60 amino acid tandem repeating units which have a
 CC consensus sequence. The signal peptide sequence is not found in purified
 CC 35K protein recovered from the medium of cells infected with vaccinia
 CC virus strain WR. A suggested use is to treat diseases due to abnormally
 CC high complement activity.
 CC (Note: Revised entry submitted to correct the patent number format of
 CC US government owned NTIS applications to prevent clashes with ongoing US
 CC granted patent numbers. For further information please visit the Derwent
 CC web site at www.derwent.com/derp/updates/ntis_us.html.)
 XX
 SQ Sequence 263 AA;
 Query Match 28.6%; Score 215; DB 10; Length 263;
 Best Local Similarity 35.9%; Pred. No. 1,1e-13;
 Matches 46; Conservative 15; Mismatches 55; Indels 12; Gaps 5;
 QY 2 ISGSSPPPIINRISYSTPIAVITVIVYS:SGIFRLIGKSLIITKDKVETWKPAP 61
 DB 146 VKQSPPSISNGRHNGYETHTDGSVVTYS:NSGYSLIGSGVL:---SGGEWSDP-p 199
 QY 62 KCEYENKYSSTPEPIVPGYKIRG-STPYRGRD-VTEACKINFSMNGKSVWQANNMWG 120
 DB 200 TQIV -KCHPTISNGYLSGGRKRSYNDVDFCKYKLSGSSSTCSPGNTWK 255
 QY 121 PTRLPTCV 128
 DB 256 P-ELPKCV 262
 RESULT 14
 AAY29859
 ID AAY29859 standard; protein: 263 AA.
 XX
 AC AAY29859;
 DT 16 NOV 1999 (first entry)
 XX
 DE Vaccinia complement control protein sequence.
 KW Vaccinia virus; smallpox inhibitor of complement enzyme; SPIKE;
 KW fusion protein; hyperacute rejection; xenograft; inflammation;
 KW post ischemic reperfusion injury; malignancy; autoimmune disease;
 KW immune system disorder; neurodegeneration; infection; gene therapy;
 KW blood additive; extracorporeal circulation system.
 XX
 OS Vaccinia virus.

OS Synthetic.
 XX
 PN W09544625-A1.
 XX
 PD 10-SEP-1999.
 XX
 PF 02-MAR-1999; 99WO-US04635.
 XX
 PR 13-MAR-1998; 98US-0076821.
 XX
 PA (UYJO) UNIV CHINS HOPKINS.
 PA (UYPI-) UNIV PITTSBURGH.
 XX
 PI Rosengard AM, Abcarin JM;
 XX
 DR WPI. 1999-550681/46.
 DR N-PSDB; AAZ21091.
 XX
 PT New smallpox inhibitor of complement enzyme protein, used to treat
 PT complement-mediated disease, particularly γ hyperacute rejection
 XX
 PS Claim 15; F.g 1; 88pp; English.
 XX
 CC The present invention describes the Vaccinia virus smallpox inhibitor of
 CC complement enzymes (SPIKE) protein. SPIKE is an inhibitor of complement
 CC activation, and so can be used to treat or prevent complement-mediated
 CC disorders, especially hyperacute rejection, inflammation or post
 CC ischemic reperfusion injury, malignancies, autoimmune diseases,
 CC immune system disorders, neurodegeneration and infections. Hyperacute
 CC rejection may also be prevented by treating the graft with SPIKE before
 CC transplanting it or by using a xenograft that has been transfected to
 CC express SPIKE from a gene therapy vector. SPIKE is also useful as
 CC additive to blood, e.g. in an extra-corporeal circulation system (created
 CC on tubing) or in storage, also for studying complement activation.
 CC Transgenic animals that express SPIKE are used as sources of xenografts.
 CC The present sequence represents a vaccinia complement control protein
 CC (VCP) encoded by the specifically cloned mutated VCP nucleotide
 CC sequence, having a silent T to A transversion at nucleotide position
 CC number 267.
 XX
 SQ Sequence 263 AA;
 Query Match 28.6%; Score 215; DB 20; Length 263;
 Best Local Similarity 35.9%; Pred. No. 1,1e-13;
 Matches 46; Conservative 15; Mismatches 55; Indels 12; Gaps 5;
 QY 2 ISGSSPPPIINRISYSTPIAVITVIVYS:SGIFRLIGKSLIITKDKVETWKPAP 61
 DB 146 VKQSPPSISNGRHNGYETHTDGSVVTYS:NSGYSLIGSGVL:---SGGEWSDP-p 199
 QY 62 KCEYENKYSSTPEPIVPGYKIRG-STPYRGRD-VTEACKINFSMNGKSVWQANNMWG 120
 DB 200 TQIV -KCHPTISNGYLSGGRKRSYNDVDFCKYKLSGSSSTCSPGNTWK 255
 QY 121 PTRLPTCV 128
 DB 256 P-ELPKCV 262
 RESULT 15
 AAB13014
 ID AAB13014 standard; protein: 263 AA.
 XX
 AC AAB13014;
 DT 11-DEC-2000 (first entry)
 XX
 DE Complement inhibitory protein, VCP amino acid sequence.
 KW Alzheimer's disease; Vaccinia virus VCP; complement pathway inhibitor;
 KW treatment; diagnosis; amyloid plaque.
 XX
 OS Vaccinia virus.

XX Sequence 2049 AA;
 Query Match 28.2%; Score 212; DB 14; Length 2039;
 Best Local Similarity 36.0%; Pred. No. 2.6e 12;
 Matches 50; Conservative 19; Mismatches 54; Indels 16; Gaps 7;
 QY 2 ISGTSPPDILNGRISVYS--TPIAVGIVIRYS-----SGPRLLGKSLGCTKDKV 52
 DB 1517 ISC EPPTISNR DFYSNNKTSFNGIVTYQCHTGPDEQLQVGRSIVYCTSKDDQ 1574
 QY 53 LGTWKRPAPKTEYFNKYSSTPEPIVPGAYKIRGSLP-YRHQDSVTFACKINFSMNKNKV 111
 DB 1675 VGVWSSPPRCISTNK--CTAPEVQNAIRVPGNRKSFSEITETIRPRCHICFVWVGSHTV 1631
 QY 112 WQANNMNGPTPLPTCVSV 130
 DB 1632 QCQTNIRWGF-KLPICSRV 1649
 RESULT 17
 AAY55755
 ID AAY55755 standard; Protein: 450 AA;
 XX AAY55755;
 XX 22 FEB 2000 (first entry)
 DE Human CR1 protein LHR D SCR fragment.
 XX C3b/C4b receptor; CR1 protein; cell surface protein; erythrocyte; human;
 KW complement regulatory activity; complement pathway enzyme; tissue damage;
 KW reperfusion injury; Arthus reaction; myocardial infarct; inflammation;
 KW heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;
 KW short consensus repeat.
 XX Homo sapiens.
 XX US'981481 A.
 XX 09 NOV 1999.
 XX 06 JUN 1995; 9505-0470652.
 XX 03 APR 1989; 8905-0332865.
 XX 06 DEC 1974; 7405-0350248.
 XX 24 FEB 1993; 9305-0026144.
 XX 01 APR 1988; 8805-0176542.
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX (BIDM) BRIGHAM & WOMENS HOSPITAL.
 XX (AVAN) AVANT IMMUNOTHERAPEUTICS INC.
 P Concino MF, Wong KW, Makrides SC, Klickstein LB, Fearon DF, Ip SH;
 P Marsh HC, Carlson GR;
 XX WPI: 1999-633357/54.
 PT A human C3b/C4b receptor (CR1) protein having antiinflammatory and
 PT cardiant activity.
 PS Disclosure; Fig 10; 87pp; English.
 XX The invention relates to a human C3b/C4b receptor (CR1) protein. The CR1
 protein or fragment is expressed as a cell surface protein on the surface
 of a non human cell and exhibits a complement regulatory activity of full
 length human CR1 as expressed on erythrocytes. The CR1 function in vivo
 may be mediated through the inhibition of complement pathway enzymes. The
 soluble CR1 protein exhibits a complement regulatory activity, and thus
 may be used to prevent reperfusion injury, inhibit Arthus reaction, and
 neutrophil mediated tissue damage, and reduce myocardial infarct size,
 and inflammation. The CR1 protein and its fragments can also be used in
 the treatment of conditions which involve unwanted complement activity.

CC e.g., shock lung, tissue damage due to burn, or ischemic heart conditions,
 CC and autoimmune disorders. CR1 proteins, analogues, derivatives, and anti-
 CC -CR1 antibodies are used in assays, and diagnostics. The present sequence
 CC represents the short consensus repeat (SCR) fragments of human CR1
 CC protein long homologous repeat (LHR) sequence.
 XX Sequence 450 AA;
 Query Match 28.1%; Score 211; DB 10; Length 450;
 Best Local Similarity 36.0%; Pred. No. 5.2e 13;
 Matches 50; Conservative 17; Mismatches 56; Indels 16; Gaps 6;
 QY 2 ISGTSPPDILNGRISVYS--TPIAVGIVIRYS-----SGPRLLGKSLGCTKDKV 52
 DB 124 ISCEPPTISNG--DFYSNNKTSFNGIVTYQYHGRDEQLQVGRSIVYCTSKDDQ 191
 QY 53 LGTWKRPAPKTEYFNKYSSTPEPIVPGAYKIRGSLP-YRHQDSVTFACKINFSMNKNKV 111
 DB 182 VGVWSSPPRCISTNK--CTAPEVQNAIRVPGNRKSFSEITETIRPRCHICFVWVGSHTV 248
 QY 112 WQANNMNGPTPLPTCVSV 130
 DB 239 QCQTNIRWGF-KLPICSRV 256
 RESULT 18
 AAY29858
 ID AAY29858 standard; Protein: 263 AA;
 XX AAY29858;
 XX 15 NOV 1999 (first entry)
 DE Vaccinia virus SPICE protein.
 XX Vaccinia virus.
 KW Vaccinia virus, smallpox inhibitor of complement enzyme; SPICE;
 KW fusion protein; hyperacute rejection; xenotraft; inflammation;
 KW post-ischemic reperfusion injury; ne injury; autoimmune disease;
 KW immune system disorder; neurodegeneration; infection; gene therapy;
 KW blood additive; extracorporeal circulation system.
 OS Vaccinia virus.
 XX Key location/Qualific's
 FT Misc-difference 13
 XX /note- "encoded by cDNA"
 XX W09944625 A1.
 XX 10-SEP-1999.
 XX 02-MAR-1999; 99WO-0504635.
 XX 03-MAR-1998; 98US-0076821.
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX (UYPI-) UNIV PITTSBURGH.
 XX Rosenquard AM, Ahearn JM;
 XX WPI: 1999-550981/46.
 XX N-PSDB; AAZ21690.
 PT New smallpox inhibitor of complement enzyme protein, used to treat
 FT complement-mediated disease, particularly hyperacute rejection
 XX Claim 1; Fig 2; 88pp; English.
 XX The present sequence represents Vaccinia virus smallpox inhibitor of
 CC complement enzymes (SPICE) protein. SPICE is an inhibitor of complemen-
 CC activation, and so can be used to treat or prevent complement mediated
 CC disorders, especially hyperacute rejection, inflammation or fest,
 CC ischaemic reperfusion injury, malformities, autoimmune diseases.

immune system disorders; neurodegeneration and infections. Hyperacute rejection may also be prevented by treating the graft with SPICE before transplanting it or by using a xenograft that has been transformed to express SPICE from a gene therapy vector. SPICE is also useful as additive to blood, e.g. in an extracorporeal circulation system (coated on tubing) or in storage, also for studying complement activation. Transgenic animals that express SPICE are used as sources of xenografts.

XX The present sequence represents the protein encoded by a specifically cloned mutated vaccinia complement control protein (VCP) encoding SPICE, in which position 5 of the protein is occupied by Ser (from VCP) rather than Arg.

Query Match 28.0% Score 210; DB 20; Length 264;

Best local similarity 45.2% Pred. No. 4.4e 13;

Matches 45; Conservative 16; Mismatches 55; Indels 12; Gaps 5;

QY 2 ISGSGPPLHNGISVYSTPLAGVIRYSSTETPLTCKRSIICTTRKVTWKEAP 61

DB 146 VKQLPESTNGRNGYNYHETDGSVVIVSNQSYSLTNSGVLC--- SQGWSNP P 199

QY 62 KTYENKYSCTPEVPGYKIRG SIYKRDHVFPAKINQSNKVKVQANNMKG 120

DB 200 TQGVV KTHPTTINQVLSSTKPKSYNWVDFPKYKYSLSSSSSLSGNTWQ 256

QY 121 PTRKPTCV 128

DB 256 P ELPKCV 262

RESULT 19

AAV57598

DB AAV57598 standard; Protein: 263 AA.

XX AAV57598;

QY 1 NOV 1999 (first entry)

DE Mutated VCP giving SPICE protein sequence.

XX Vaccinia virus: smallpox inhibitor of complement enzyme; SPICE;

XX fusion protein; hyperacute rejection; xenograft; inflammation;

XX post ischemic reperfusion injury; malignancy; autoimmune disease;

XX immune system disorder; neurodegeneration; infection; gene therapy;

XX blood additive; extracorporeal circulation system.

XX Vaccinia virus.

XX Synthesized.

XX W099446Z AL.

XX 10 SEP 1999.

XX 02 MAR 1999; 9906050450.

XX 03 MAR 1999; 9803007002.

XX (OYJO) UNIV JOHNS HOPKINS.

XX (OYF1) UNIV PITTSBURGH.

XX Rosenzweig AM. Abcart JM.

XX W11 1999 500041/46.

XX N PSL00; AAZ21092.

XX New smallpox inhibitor of complement enzyme protein, used to treat

XX complement mediated disease, particularly hyperacute rejection .

XX Disclosure: Fig 3; 88pp; English.

XX The present invention describes the Vaccinia virus smallpox inhibitor of

XX complement enzymes (SPICE) protein. SPICE is an inhibitor of complement

XX activation, and so can be used to treat or prevent complement mediated

XX disorders, especially hyperacute rejection, inflammation or post

XX ischemic reperfusion injury, malignancies, autoimmune diseases,

XX immune system disorders, neurodegeneration and infections. Hyperacute

CC rejection may also be prevented by treating the graft with SPICE before transplanting it or by using a xenograft that has been transformed to express SPICE from a gene therapy vector. SPICE is also useful as additive to blood, e.g. in an extracorporeal circulation system (coated on tubing) or in storage, also for studying complement activation. Transgenic animals that express SPICE are used as sources of xenografts. The present sequence represents the protein encoded by a specifically cloned mutated vaccinia complement control protein (VCP) encoding SPICE, in which position 5 of the protein is occupied by Ser (from VCP) rather than Arg.

Query Match 28.0% Score 210; DB 20; Length 264;

Best local similarity 45.2% Pred. No. 4.4e 13;

Matches 45; Conservative 16; Mismatches 55; Indels 12; Gaps 5;

QY 2 ISGSGPPLHNGISVYSTPLAGVIRYSSTETPLTCKRSIICTTRKVTWKEAP 61

DB 146 VKQLPESTNGRNGYNYHETDGSVVIVSNQSYSLTNSGVLC--- SQGWSNP P 199

QY 62 KTYENKYSCTPEVPGYKIRG SIYKRDHVFPAKINQSNKVKVQANNMKG 120

DB 200 TQGVV KTHPTTINQVLSSTKPKSYNWVDFPKYKYSLSSSSSLSGNTWQ 256

QY 121 PTRKPTCV 128

DB 256 P ELPKCV 262

RESULT 20

AAV57598

DB AAV57598 standard; Protein: 263 AA.

XX AAV57598;

QY 22-FEB-2000 (first entry)

XX Human CRI protein LHR-3 fragment.

XX C3b/C4b receptor; CRI protein; cell surface protein; erythrocyte; human;

XX complement regulatory activity; complement pathway; enzyme; disease;

XX reperfusion injury; Arthus reaction; myocardial infarct; inflammation;

XX heart condition; autoimmune disorder; lung hemolysis repeat; LHR.

XX Homo Sapiens.

XX US5981481 A.

XX 09-NOV-1999.

XX 06-JUN-1999; 9505-0470652.

XX 03-APR-1999; 8905-0432865.

XX 06-DEC-1974; 7405-0350248.

XX 24-FEB-1994; 9405-0026144.

XX 01-APR-1988; 8805-0176532.

XX (OYJO) UNIV JOHNS HOPKINS.

XX (RGIM) BRIGHAM & WOMENS HOSPITAL.

XX (AVAN-) AVANT IMMUNOTHERAPEUTICS INC.

XX Conelino MF, Wang WW, Markides SC, Klierstein LB, Forston BL, Ip SH,

XX Marsh HC, Carlson GR;

XX WPI; 1999-643457/54.

XX A human C3b/C4b receptor (CRI) protein having antiinflammatory and

XX cardiant activity

XX disclosure: Fig 5a; 87pp; English.

XX The invention relates to a human C3b/C4b receptor (CRI) protein. The CRI


```

DE Human CRI protein LHR A SCR fragment.
XX
XX C4b/C4b receptor; CRI protein; cell-surface protein; erythrocyte; human;
KW complement regulatory activity; complement pathway enzyme; tissue damage;
KW reperfusion injury; Arthus reaction; myocardial infarct; inflammation;
KW heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;
KW short consensus repeat.
XX
XX Homo sapiens.
XX
XX US981481 A.
XX
XX 09 NOV 1999.
XX
XX 06 JUN 1995; 9505 0470652.
XX
XX 03 APR 1989; 8905 0332865.
XX
XX 06 DEC 1974; 7405 0450248.
XX
XX 24 FEB 1993; 9405 0026144.
XX
XX 01 APR 1988; 8805 0176542.
XX
XX (UNIV.) UNIV. JOHNS HOPKINS.
XX
XX (BCHM.) BRICHAM & WOMENS HOSPITAL.
XX
XX (AVAN.) AVANT IMMUNOTHERAPEUTICS INC.
XX
XX Concino ME, Wood WM, Makrides SC, Klickstein LB, Pearson DT, Ip SH;
PI Marsh BC, Carson GK;
XX
XX WPI; 1999 6435754.
XX
XX A human C4b/C4b receptor (CRI) protein having antiinflammatory and
PI cardiac activity.
XX
XX Disclosure; Fig 10; 87pp; English.
XX
XX The invention relates to a human C4b/C4b receptor (CRI) protein. The CRI
XX protein or fragment is expressed as a cell-surface protein on the surface
XX of a non-human cell and exhibits a complement regulatory activity of full
XX length human CRI as expressed on erythrocytes. The CRI function in vivo
XX may be mediated through the inhibition of complement pathway enzymes. The
XX soluble CRI protein exhibits a complement regulatory activity, and this
XX may be used to prevent reperfusion injury, inhibit Arthus reaction, and
XX neutrophil mediated tissue damage, and reduce myocardial infarct size,
XX and inflammation. The CRI protein and its fragments can also be used in
XX the treatment of conditions which involve unwanted complement activity,
XX e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,
XX and autoimmune disorders. CRI proteins, analogues, derivatives, and anti
XX CRI antibodies are used in assays, and diagnostics. The present sequence
XX represents the short consensus repeat (SCR) fragments of human CRI
XX protein long homologous repeat (LHR)-A sequence.
XX
XX Query Match 26.5%; Score 199; DB 20; Length 496;
XX Best Local Similarity 86.0%; Pred. No. 9, 6e-12;
XX Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps 5;
XX
XX QY 2 ISCGSDPPHNR LSYSDIAWVLPYSGSC---SG---TPRLCKSLCITKQKVDG 54
XX ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
XX 170 IFCGLPPTITNGDFISTNRENFHVSVVTVGNCPSGSRKVFELVGEPSLYCTSDQVG 229
XX
XX QY 55 TWDFAPKCEYFNKYSCPDPVIGYKIRGS-TPYRIGDSVTFN-KTNFSMNKNSVWC 113
XX ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
XX 240 IWSFAVAGVDFPNK-CTPTNVTNCTTIVLNNKLSFNSVDFKCFQGVMAKGRVRKC 286
XX
XX QY 114 GANNMWSPTRIETAVSV 146
XX ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
XX 287 QALNKKWEP ELPSVSRV 302
XX
XX RESULT 25
XX AAR1490
XX AAR1490 standard; Protein; 581 AA.

```

```

XX AAR13490;
XX
XX 30-OCT-1991 (first entry)
XX
XX Human C4 binding protein.
XX
XX C4bp; monomer; complement protein; FcL-C4bp.4; SCR;
XX short consensus repeat.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..32 /label= signal_peptide
XX Protein 33..581 /label= C4bp
XX Region 33..93 /label= SCR8
XX Region 94..155 /label= SCR7
XX Region 156..219 /label= SCR6
XX Region 220..279 /label= SCR5
XX Region 280..345 /label= SCR4
XX Region 346..406 /label= SCR3
XX Region 407..464 /label= SCR2
XX Region 465..523 /label= SCR1
XX Domain 524..581 /label= C4bp_core
XX Disulfide-bond 34..80 /note= "responsible for multimer assembly"
XX Disulfide-bond 65..92 /note= "intradomain"
XX W09111461-A. /note= "intradomain"
XX 08-AUG-1991.
XX 28-JAN-1991; 91WO-US00567.
XX 26-JAN-1990; 90NS-0470888.
XX (BIOG-) BIOGEN INC.
XX Vasok MP, Wirklter G, Liu TR;
XX
XX PFI: 1991-252613/34.
XX N-PSDB: AAQ13242.
XX
XX New C4 binding protein fusion proteins and DNA encoding them
XX comprise assemblies of C4bp monomers linked to functional moiety,
XX e.g. A2U, useful as delivery vehicles in diagnosis and therapy
XX
XX Example 1; Fig 1: 105pp; English.
XX
XX This sequence was deduced from human hepatocyte (Hep G2) cDNA
XX obtained following PCR amplification. The protein is a monomer
XX containing 8 SCRs. Each SCR forms a looped domain due to the
XX presence of two intradomain disulphide bonds (only the disulphide
XX bonds of SCR8 are labelled in the Figures Table). Within each SCR,
XX the first cysteine residue bonds with the third and the second
XX cysteine residue bonds with the fourth. This secondary structure is
XX responsible for the conformational stability of the C4bp monomer.
XX The invention covers fusion proteins in which the monomer sequence,
XX or a specified subfragment of it, e.g. having 5, 4, 3 or 1 SCR(s)
XX is fused to the C-terminal of a protein such as a viral receptor.

```

CC Cell bound, a bacterial, viral or parasitic immunogen, enzyme,
 CC cytokine, toxin, etc. See also AAL14243-51.

XX epidermis bullous or Hashimoto's disease.

XX Sequence 581 AA.

Query Match 26.5%, Score 199; DB 12; Length 581;
 Best local similarity 32.0%; Pred. No. 1,25 11;
 Matches 432; Conservative 20; Mismatches 60; Indels 6; Gaps 61

QY 2 LAGSGPPPIINR-LSYVSTPFAVGTIVDYS-SS TPTTTPSLLPTTKKVLG 61
 DB 157 VKKPTDPIKNGRSGEENYAGDSVYSDFRSLGASHSTVENELGVWRSPD 216
 QY 62 KLVKPVGSGDPTGVESDFRSDVAGGCVTA-KTSE-MKRRKSVW-CARRPWC 120
 DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 DB 217 DPKI 4CRKPDVSGEMVSGDPTGVKTLIVFK-QKGFVLGGSSVITRADSKN 272
 QY 121 DPKLPD 127
 DB 13 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 DB 230 CSP PAC 278

RESULT 27

AAW 1447

ID AAW1447 Standard; protein: 778 AA.

XX AAW1447

XX 29 JAN 1999 (first entry)

XX Amino acid sequence of the soluble complement receptor 1 (SCR1).

XX Human soluble complement receptor 1; SCR1; T cell; B cell;
 KW mediated immune response: inhibition; tissue rejection; gene therapy;
 KW erysipelas; inflammatory response; interferon gamma secretory response;
 KW autoimmune response; neurological response; Alzheimer's disease;
 KW Parkinson's disease; multiple sclerosis; systemic lupus erythematosus;
 KW rheumatoid arthritis; myasthenia gravis; epidermis bullous;
 KW Hashimoto's disease.

XX B-cell receptor.

XX W 045440 A1.

XX 15 JUL 1998

XX 06 APR 1998 9806 GR01012.

XX 05 APR 1997 9738 000650.

XX (ANNEX) ANNEX V A.

XX (CHIK) CHIKNAJOSKY Y.

XX Annex V A. Chiknajasovsky Y.

XX W 11 1998 60850/48.

XX Treatment of soluble human complement receptor 1 useful for
 treating T cell or B cell mediated immune responses e.g.
 inflammatory responses such as rheumatoid arthritis

XX (abstract: Fig 1; 50pp; English.

XX This is an amino acid sequence of the human soluble complement
 receptor 1 (SCR1), useful in the treatment of T cell or B cell
 mediated immune responses. It is used to inhibit a T cell or
 B cell mediated immune response to prevent immune response mediated
 tissue rejection and destruction or clearance or inactivation of an
 expressed protein especially from cells that have been treated by gene
 therapy to express the protein, e.g. dystrophin. The protein can also
 be used to inhibit a T cell or B cell mediated inflammatory response,
 e.g. interferon gamma secretory response, autoimmune response or
 neurological response, e.g. Alzheimer's or Parkinson's disease or

CC multiple sclerosis. Also the protein can be used to treat systemic
 CC lupus erythematosus, rheumatoid arthritis, myasthenia gravis,
 CC epidermis bullous or Hashimoto's disease.

XX Sequence 778 AA.

Query Match 26.5%, Score 199; DB 19; Length 778;
 Best local similarity 38.0%; Pred. No. 1,76 11;
 Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps 62

QY 2 LAGSGPPPIINR-LSYVSTPFAVGTIVDYS-SS TPTTTPSLLPTTKKVLG 64
 DB 619 IPGLDPTLANGDFISTNREHYGVSVLYRONPSGGRKKFELVDFISYVTSNDAQVG 678

QY 55 TWKPAFPGFYENKYSSTPEPTVPGCYKIDPS TTYKDH-SVITA-KTNE-SNN-NKSVWC 114
 DB 1 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 679 IWSGPAQGLIPNK---CTPPVNGILVSDNLSLENNVEFRQLPTWKQHPKVK 745

QY 114 QANNMWDPIRLPQSV 140
 DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 746 QALNKKEP ELPSCKV 761

RESULT 27

AAW 156

ID AAW156 Standard; protein: 133 AA.

XX AAW156

XX 18 JUL 1994 (first entry)

XX Sequence of soluble complement receptor type 1 (CR1) derivative
 which comprises internal fragment MD122-5253 of CR1.

XX Complement receptor type 1; CR1; short consensus repeat;
 KW long homologous repeat; domain; inflammation; therapy.

XX Synthetic.

XX W 09400571 A.

XX 06 JAN 1994.

XX 16 JUN 1994 9406 GR01282.

XX 24 JUN 1992 9206 0014376.

XX 01 MAR 1993 9303 0004057.

XX (SMK) SMITHKLINE BEECHAM PLC.

XX Dodd L, Freeman AM, Mossakowska DEL, Smith RAC;

XX W 11 1994 026208/03.

XX New soluble complement receptor type 1 derivative, used for
 treating disease or disorder associated with inflammation or
 inappropriate complement activation

XX Claim 13; Page 54 55; 65pp; English.

XX CR1 is composed of 40 short consensus repeats (SCRs) that each
 contain around 60-70 AAs. It is further arranged as 4 long
 homologous repeats (LHRs) of 7 SCRs each. Following a leader
 sequence, the CR1 molecule consists of the N-terminal LHR A, the
 next two repeats, LHR B and LHR C, and the most C-terminal LHR D,
 followed by 2 additional SCRs, a 25 residue putative transmembrane
 region and a 43 residue cytoplasmic tail. Based on the mature CR1
 molecule, having a predicted N-terminal clip, designated residue 1,
 the first four SCR domains of LHR A are 2 98, 63 129, 129 191 and
 197-252 of mature CR1. Soluble fragments of CR1 which corresp. to
 part of CR1 possess functional complement inhibitory, including
 anti haemolytic, activity.

50	Sequence	133 AA;	Matches	51;	Conservative	14;	Mismatches	57;	Indels	12;	Gaps	6;
Query Match												
Best Local Similarity 46.1%; Score 198; DB 15; Length 133;												
Matches 51; Conservative 14; Mismatches 57; Indels 12; Gaps 6;												
QY	2	ISCSPPPLNGR ISYSTPIAGVIVIRSC--SQ--TFELIGKSLILTIKKVIG 54	QY	2	ISCSPPPLNGR ISYSTPIAGVIVIRSC--SQ--TFELIGKSLILTIKKVIG 54							
DB	3	IPCLPTITNGDITSTNRENTHYSSVITVAFKGSSEKVELLVSEFSTVTSKNGV 184	DB	3	IPCLPTITNGDITSTNRENTHYSSVITVAFKGSSEKVELLVSEFSTVTSKNGV 184							
QY	5	IMKFAIKQVAFKRYSSCPPIVIGQVKKIPDS--QYPRKISVITAFKINFSMNKNSVW 114	QY	5	IMKFAIKQVAFKRYSSCPPIVIGQVKKIPDS--QYPRKISVITAFKINFSMNKNSVW 114							
DB	154	IMSPAPPA ² ILPNK---CTTPNVENGILV--NLSLAFVVEFPQ ² QFVMSGPPPVGC 240	DB	154	IMSPAPPA ² ILPNK---CTTPNVENGILV--NLSLAFVVEFPQ ² QFVMSGPPPVGC 240							
QY	114	QANNMKGTPLTC 127	QY	114	QANNMKGTPLTC 127							
DB	241	QALNKWEP-ELPSC 253	DB	241	QALNKWEP-ELPSC 253							
RESULT 29												
DB	AAV5754	standard; Protein: 450 AA	DB	AAV5754	standard; Protein: 450 AA							
XX	AC	AAV5754;	XX	AC	AAV5754;							
XX	ET	22-FEB-2000 (first entry)	XX	ET	22-FEB-2000 (first entry)							
XX	DE	Human CRI protein LHR-C SCR fragment.	XX	DE	Human CRI protein LHR-C SCR fragment.							
XX	KW	C3H/CAH receptor; CRI protein; cell surface protein; erythrocyte; tomato;	XX	KW	C3H/CAH receptor; CRI protein; cell surface protein; erythrocyte; tomato;							
XX	KW	complement regulatory activity; complement pathway enzyme; tissue damage;	XX	KW	complement regulatory activity; complement pathway enzyme; tissue damage;							
XX	KW	reperfusion injury; Arthus reaction; myocardial infarct; inflammation;	XX	KW	reperfusion injury; Arthus reaction; myocardial infarct; inflammation;							
XX	KW	heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;	XX	KW	heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;							
XX	OS	short consensus repeat.	XX	OS	short consensus repeat.							
XX	OS	Homo sapiens.	XX	OS	Homo sapiens.							
XX	PN	U55981481-A.	XX	PN	U55981481-A.							
XX	PD	09-NOV-1993.	XX	PD	09-NOV-1993.							
XX	PF	06-JUN-1993; 95US-0470652.	XX	PF	06-JUN-1993; 95US-0470652.							
XX	PR	03-APR-1983; 89US-0332865.	XX	PR	03-APR-1983; 89US-0332865.							
XX	PR	06-DEC-1974; 74US-0450248.	XX	PR	06-DEC-1974; 74US-0450248.							
XX	PR	24-FEB-1993; 93US-0026134.	XX	PR	24-FEB-1993; 93US-0026134.							
XX	PR	01-APR-1983; 88US-0176532.	XX	PR	01-APR-1983; 88US-0176532.							
XX	PA	(UYJO) UNIV JOHNS HOPKINS.	XX	PA	(UYJO) UNIV JOHNS HOPKINS.							
XX	PA	(BGIM) BRIGHAM & WOMENS HOSPITAL.	XX	PA	(BGIM) BRIGHAM & WOMENS HOSPITAL.							
XX	PA	(AVAN) AVANT IMMUNOTHERAPEUTICS INC.	XX	PA	(AVAN) AVANT IMMUNOTHERAPEUTICS INC.							
XX	PI	Cencino MP, Wong WW, Makrides SC. Flickstein LB. Pearson GL. J Biol	XX	PI	Cencino MP, Wong WW, Makrides SC. Flickstein LB. Pearson GL. J Biol							
XX	PI	Marsh HC, Carson GR;	XX	PI	Marsh HC, Carson GR;							
XX	DR	WFI: 1999-633357/54.	XX	DR	WFI: 1999-633357/54.							
XX	PT	A human C3H/CAH receptor (CRI) protein having anti-inflammatory and	XX	PT	A human C3H/CAH receptor (CRI) protein having anti-inflammatory and							
XX	PT	cardiant activity -	XX	PT	cardiant activity -							
XX	PS	Disclosure: Fig 10; 87pp; English.	XX	PS	Disclosure: Fig 10; 87pp; English.							
XX	CC	The invention relates to a human C3H/CAH receptor (CRI) protein. The CRI	XX	CC	The invention relates to a human C3H/CAH receptor (CRI) protein. The CRI							
XX	CC	protein of fragment is expressed as a cell surface protein on the surface	XX	CC	protein of fragment is expressed as a cell surface protein on the surface							
XX	CC	of a non-human cell and exhibits a complement regulatory activity of full	XX	CC	of a non-human cell and exhibits a complement regulatory activity of full							
XX	CC	length human CRI as expressed on erythrocytes. The CRI function in vivo	XX	CC	length human CRI as expressed on erythrocytes. The CRI function in vivo							
XX	CC	may be mediated through the inhibition of complement pathway enzymes. The	XX	CC	may be mediated through the inhibition of complement pathway enzymes. The							
XX	CC	soluble CRI protein exhibits a complement regulatory activity, and this	XX	CC	soluble CRI protein exhibits a complement regulatory activity, and this							
XX	CC	may be used to prevent reperfusion injury, inhibit Arthus reaction, and	XX	CC	may be used to prevent reperfusion injury, inhibit Arthus reaction, and							
XX	CC	neutrophil mediated tissue damage, and reduce myocardial infarct size,	XX	CC	neutrophil mediated tissue damage, and reduce myocardial infarct size,							
XX	CC	and inflammation. The CRI protein and its fragments can also be used in	XX	CC	and inflammation. The CRI protein and its fragments can also be used in							
XX	CC	the treatment of conditions which involve unwanted complement activity,	XX	CC	the treatment of conditions which involve unwanted complement activity,							
XX	CC	e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,	XX	CC	e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,							
XX	CC	and autoimmune disorders. CRI protein, analogues, derivatives, and anti	XX	CC	and autoimmune disorders. CRI protein, analogues, derivatives, and anti							
XX	CC	-CRI antibodies are used in assays and diagnostics. The present sequence	XX	CC	-CRI antibodies are used in assays and diagnostics. The present sequence							
XX	CC	represents the short consensus repeat (SCR) fragments of human CRI	XX	CC	represents the short consensus repeat (SCR) fragments of human CRI							
XX	CC	protein long homologous repeat (LHR) sequence.	XX	CC	protein long homologous repeat (LHR) sequence.							

50	Sequence	133 AA;	Matches	51;	Conservative	14;	Mismatches	57;	Indels	12;	Gaps	6;
Query Match												
Best Local Similarity 46.1%; Score 198; DB 15; Length 133;												
Matches 51; Conservative 14; Mismatches 57; Indels 12; Gaps 6;												
QY	2	ISCSPPPLNGR ISYSTPIAGVIVIRSC--SQ--TFELIGKSLILTIKKVIG 54	QY	2	ISCSPPPLNGR ISYSTPIAGVIVIRSC--SQ--TFELIGKSLILTIKKVIG 54							
DB	3	IPCLPTITNGDITSTNRENTHYSSVITVAFKGSSEKVELLVSEFSTVTSKNGV 184	DB	3	IPCLPTITNGDITSTNRENTHYSSVITVAFKGSSEKVELLVSEFSTVTSKNGV 184							
QY	5	IMKFAIKQVAFKRYSSCPPIVIGQVKKIPDS--QYPRKISVITAFKINFSMNKNSVW 114	QY	5	IMKFAIKQVAFKRYSSCPPIVIGQVKKIPDS--QYPRKISVITAFKINFSMNKNSVW 114							
DB	154	IMSPAPPA ² ILPNK---CTTPNVENGILV--NLSLAFVVEFPQ ² QFVMSGPPPVGC 240	DB	154	IMSPAPPA ² ILPNK---CTTPNVENGILV--NLSLAFVVEFPQ ² QFVMSGPPPVGC 240							
QY	114	QANNMKGTPLTC 127	QY	114	QANNMKGTPLTC 127							
DB	241	QALNKWEP-ELPSC 253	DB	241	QALNKWEP-ELPSC 253							
RESULT 29												
DB	AAV5754	standard; Protein: 450 AA	DB	AAV5754	standard; Protein: 450 AA							
XX	AC	AAV5754;	XX	AC	AAV5754;							
XX	ET	22-FEB-2000 (first entry)	XX	ET	22-FEB-2000 (first entry)							
XX	DE	Human CRI protein LHR-C SCR fragment.	XX	DE	Human CRI protein LHR-C SCR fragment.							
XX	KW	C3H/CAH receptor; CRI protein; cell surface protein; erythrocyte; tomato;	XX	KW	C3H/CAH receptor; CRI protein; cell surface protein; erythrocyte; tomato;							
XX	KW	complement regulatory activity; complement pathway enzyme; tissue damage;	XX	KW	complement regulatory activity; complement pathway enzyme; tissue damage;							
XX	KW	reperfusion injury; Arthus reaction; myocardial infarct; inflammation;	XX	KW	reperfusion injury; Arthus reaction; myocardial infarct; inflammation;							
XX	KW	heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;	XX	KW	heart condition; autoimmune disorder; long homologous repeat; LHR; SCR;							
XX	OS	short consensus repeat.	XX	OS	short consensus repeat.							
XX	OS	Homo sapiens.	XX	OS	Homo sapiens.							
XX	PN	U55981481-A.	XX	PN	U55981481-A.							
XX	PD	09-NOV-1993.	XX	PD	09-NOV-1993.							
XX	PF	06-JUN-1993; 95US-0470652.	XX	PF	06-JUN-1993; 95US-0470652.							
XX	PR	03-APR-1983; 89US-0332865.	XX	PR	03-APR-1983; 89US-0332865.							
XX	PR	06-DEC-1974; 74US-0450248.	XX	PR	06-DEC-1974; 74US-0450248.							
XX	PR	24-FEB-1993; 93US-0026134.	XX	PR	24-FEB-1993; 93US-0026134.							
XX	PR	01-APR-1983; 88US-0176532.	XX	PR	01-APR-1983; 88US-0176532.							
XX	PA	(UYJO) UNIV JOHNS HOPKINS.	XX	PA	(UYJO) UNIV JOHNS HOPKINS.							
XX	PA	(BGIM) BRIGHAM & WOMENS HOSPITAL.	XX	PA	(BGIM) BRIGHAM & WOMENS HOSPITAL.							
XX	PA	(AVAN) AVANT IMMUNOTHERAPEUTICS INC.	XX	PA	(AVAN) AVANT IMMUNOTHERAPEUTICS INC.							
XX	PI	Cencino MP, Wong WW, Makrides SC. Flickstein LB. Pearson GL. J Biol	XX	PI	Cencino MP, Wong WW, Makrides SC. Flickstein LB. Pearson GL. J Biol							
XX	PI	Marsh HC, Carson GR;	XX	PI	Marsh HC, Carson GR;							
XX	DR	WFI: 1999-633357/54.	XX	DR	WFI: 1999-633357/54.							
XX	PT	A human C3H/CAH receptor (CRI) protein having anti-inflammatory and	XX	PT	A human C3H/CAH receptor (CRI) protein having anti-inflammatory and							
XX	PT	cardiant activity -	XX	PT	cardiant activity -							
XX	PS	Disclosure: Fig 10; 87pp; English.	XX	PS	Disclosure: Fig 10; 87pp; English.							
XX	CC	The invention relates to a human C3H/CAH receptor (CRI) protein. The CRI	XX	CC	The invention relates to a human C3H/CAH receptor (CRI) protein. The CRI							
XX	CC	protein of fragment is expressed as a cell surface protein on the surface	XX	CC	protein of fragment is expressed as a cell surface protein on the surface							
XX	CC	of a non-human cell and exhibits a complement regulatory activity of full	XX	CC	of a non-human cell and exhibits a complement regulatory activity of full							
XX	CC	length human CRI as expressed on erythrocytes. The CRI function in vivo	XX	CC	length human CRI as expressed on erythrocytes. The CRI function in vivo							
XX	CC	may be mediated through the inhibition of complement pathway enzymes. The	XX	CC	may be mediated through the inhibition of complement pathway enzymes. The							
XX	CC	soluble CRI protein exhibits a complement regulatory activity, and this	XX	CC	soluble CRI protein exhibits a complement regulatory activity, and this							
XX	CC	may be used to prevent reperfusion injury, inhibit Arthus reaction, and	XX	CC	may be used to prevent reperfusion injury, inhibit Arthus reaction, and							
XX	CC	neutrophil mediated tissue damage, and reduce myocardial infarct size,	XX	CC	neutrophil mediated tissue damage, and reduce myocardial infarct size,							
XX	CC	and inflammation. The CRI protein and its fragments can also be used in	XX	CC	and inflammation. The CRI protein and its fragments can also be used in							
XX	CC	the treatment of conditions which involve unwanted complement activity,	XX	CC	the treatment of conditions which involve unwanted complement activity,							
XX	CC	e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,	XX	CC	e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,							
XX	CC	and autoimmune disorders. CRI protein, analogues, derivatives, and anti	XX	CC	and autoimmune disorders. CRI protein, analogues, derivatives, and anti							
XX	CC	-CRI antibodies are used in assays and diagnostics. The present sequence	XX	CC	-CRI antibodies are used in assays and diagnostics. The present sequence							
XX	CC	represents the short consensus repeat (SCR) fragments of human CRI	XX	CC	represents the short consensus repeat (SCR) fragments of human CRI							
XX	CC	protein long homologous repeat (LHR) sequence.	XX	CC	protein long homologous repeat (LHR) sequence.							

Query Match

Best Local Similarity 46.1%; Score 198; DB 15; Length 254;

Matches 51; Conservative 14; Mismatches 57; Indels 12; Gaps 6;


```

PF 28 APR 1992; 92EP-0304826.
XX
PR 03 MAY-1991; 91US-0695514
XX
XX (UNIW ) UNIV WASHINGTON.
PA Atkinson JP, Bourcade D, Krych M;
XX WPI; 1992-375009/46.
XX
XX Complement activity regulator protein analogues - useful for
XX treating autoimmune diseases, to suppress transplant rejection,
XX for diagnosis etc.
XX
XX Claim 11; Fig 2 and R11810; 23pp; English.
XX
XX The cDNA clone designated CRI-4 was described in J.Exp.Med.(1988)
XX 168:1255-1270. It encodes the first 8 and a half amino terminal
XX SCR's of CRI. The invention concerns analogues of "regulator of
XX complement activation" proteins or truncated, hybrid or recombinant
XX forms of them. CRI-4 is a preferred truncated form and a number of
XX specified substitution variants of it are claimed. Positions 35 and
XX 47 of SCR 1 and the corresponding positions in SCR-8 have been
XX identified as important in C4b binding. The specification does not
XX contain the CRI 4 sequence; the sequence given here was constructed
XX from the full length CRI amino acid sequence having GENESEQ
XX accession number AAR11810 and descriptions in the disclosure.
XX
XX Sequence 543 AA;

Query Match 26.1%; Score 196; DB 13; Length 543;
Best Local Similarity 38.0%; Pred. No. 2.2e-11;
Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps 6;

QY 2 ISGSPPTPLNGR-LSYVSTPIAVGVIRVSC -SG- TFRIGCKSLITIKKVDG 54
DB 123 IPGCLPPTITNGDFISTNPNENFHYGSVVTWVWNSGSPWVFEIWDGSLYTSNLTQWG 182
QY 55 TWKPAKPKTEYFNKYSKCPPEPIVPGYKIPGSS PYRHHGSVTFACKTNFSMNGKSVWC 113
DB 183 IWSGAPAQCTIPNK---CTPPNVENGILVSDNKSLEFNEVFERCQVWVMKGRKVKC 239
QY 114 QANNMWGPTRLPTCVSV 130
DB 240 QALNKWEP-ELFSCSRV 255

RESULT 46
AAR28546
XX AAR28546 standard; peptide; 543 AA.
XX
XX AAR28546;
XX
XX 19 MAR 1993 (first entry)
XX
XX CRI 4 (44T, 47D, 49L) analogue.
XX
XX short consensus repeat; regulator of complement activation;
XX C4b binding; C4b binding; human complement type 1 receptor.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Region 1..60
XX /label= SCR 1
XX Region 61..122
XX /label= SCR 2
XX Region 451..510
XX /label= SCR 8
XX Region 511..543
XX /label= SCR 9
XX /note= "TRUNCATED"
XX
XX Misc difference 44

```

```

FT Misc-difference 47 /note= "Ile substituted by Thr (SCR-8)"
FT
FT Misc-difference 49 /note= "Lys substituted by Asp (SCR-8)"
FT
FT Misc-difference 49 /note= "Ser substituted by Leu (SCR-8)"
XX
XX EP5:2733-A.
XX
XX 11-NOV-1992.
XX
XX 28-APR-1992; 92EP-0304826.
XX
XX 03-MAY-1991. 91US-0695514.
XX
XX (UNIW ) UNIV WASHINGTON.
XX
XX Atkinson JP, Bourcade D, Krych M;
XX WPI; 1992-375009/46.
XX
XX Complement activity regulator protein analogues - useful for
XX treating autoimmune diseases, to suppress transplant rejection,
XX for diagnosis etc.
XX
XX Claim 11; Fig 2 and R11810; 23pp; English.
XX
XX The cDNA clone designated CRI-4 was described in J.Exp.Med.(1988)
XX 168:1255-1270. It encodes the first 8 and a half amino terminal
XX SCR's of CRI. The invention concerns analogues of "regulator of
XX complement activation" proteins or truncated, hybrid or recombinant
XX forms of them. CRI-4 is a preferred truncated form and a number of
XX specified substitution variants of it are claimed in which certain
XX positions in SCR 1 which have been identified as important for the
XX degree of C3b and C4b-binding are substituted by amino acids from
XX the corresponding positions in SCR-8. The specification does not
XX contain the CRI-4 sequence; the sequence given here was constructed
XX from the full length CRI amino acid sequence having GENESEQ
XX accession number AAR11810 and descriptions in the disclosure.
XX
XX Sequence 543 AA;

Query Match 26.1%; Score 196; DB 13; Length 543;
Best Local Similarity 38.0%; Pred. No. 2.2e-11;
Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps 6;

QY 2 ISGSPPTPLNGR-LSYVSTPIAVGVIRVSC -SG- TFRIGCKSLITIKKVDG 54
DB 123 IPGCLPPTITNGDFISTNPNENFHYGSVVTWVWNSGSPWVFEIWDGSLYTSNLTQWG 182
QY 55 TWKPAKPKTEYFNKYSKCPPEPIVPGYKIPGSS PYRHHGSVTFACKTNFSMNGKSVWC 113
DB 183 IWSGAPAQCTIPNK---CTPPNVENGILVSDNKSLEFNEVFERCQVWVMKGRKVKC 239
QY 114 QANNMWGPTRLPTCVSV 130
DB 240 QALNKWEP-ELFSCSRV 255

RESULT 37
AAR28547
XX AAR28547 standard; peptide; 543 AA.
XX
XX AAR28547;
XX
XX 19-MAR-1993 (first entry)
XX
XX CRI-4 (52S, 53S, 54P) analogue.
XX
XX short consensus repeat; regulator of complement activation;
XX C3b binding; C4b binding; human complement type 1 receptor.
XX
XX Homo sapiens
XX
XX Misc difference 44

```


QY	114 QANNMGHPTLPCTVSV 140	114 QANNMGHPTLPCTVSV 140	114 QANNMGHPTLPCTVSV 140
DB	240 QALNKWEP-ELPSCSRV 255	240 QALNKWEP-ELPSCSRV 255	240 QALNKWEP-ELPSCSRV 255
QY	55 TWDKADPKCFYFNKYSSCPPIVGGCYKIDKES-TPYRHCUSVTFAC-KINFSNNKNSVW 114	55 TWDKADPKCFYFNKYSSCPPIVGGCYKIDKES-TPYRHCUSVTFAC-KINFSNNKNSVW 114	55 TWDKADPKCFYFNKYSSCPPIVGGCYKIDKES-TPYRHCUSVTFAC-KINFSNNKNSVW 114
DB	183 TWSGAPQCIIPNK--CTPPNVFNCILVSVNLSFSLNEVVFRCQPVFVKMGHPRVK 244	183 TWSGAPQCIIPNK--CTPPNVFNCILVSVNLSFSLNEVVFRCQPVFVKMGHPRVK 244	183 TWSGAPQCIIPNK--CTPPNVFNCILVSVNLSFSLNEVVFRCQPVFVKMGHPRVK 244
QY	114 QANNMGHPTLPCTVSV 130	114 QANNMGHPTLPCTVSV 130	114 QANNMGHPTLPCTVSV 130
DB	240 QALNKWEP-ELPSCSRV 255	240 QALNKWEP-ELPSCSRV 255	240 QALNKWEP-ELPSCSRV 255
RESULT 40			
ID	AAR28550 standard; peptide: 543 AA.	AAR28550 standard; peptide: 543 AA.	AAR28550 standard; peptide: 543 AA.
XX	AAR28550;	AAR28550;	AAR28550;
XX	19-MAR-1993 (first entry)	19-MAR-1993 (first entry)	19-MAR-1993 (first entry)
DE	CRI-4 (64K) analogue.	CRI-4 (64K) analogue.	CRI-4 (64K) analogue.
KW	short consensus repeat; regulator of complement activation;	short consensus repeat; regulator of complement activation;	short consensus repeat; regulator of complement activation;
OS	C3b binding; C4b binding; human complement type 1 receptor	C3b binding; C4b binding; human complement type 1 receptor	C3b binding; C4b binding; human complement type 1 receptor
XX	Homo sapiens.	Homo sapiens.	Homo sapiens.
FT	Key	Location/Qualifiers	Key
FT	Region	1..60	Region
FT	Region	/label= SCR-1	Region
FT	Region	61..122	Region
FT	Region	/label= SCR-2	Region
FT	Region	451..510	Region
FT	Region	/label= SCR-8	Region
FT	Region	511..543	Region
FT	Region	/label= SCR-9	Region
FT	Misc difference 64	/note= "TRUNCATED"	Misc difference 64
FT	Misc difference 64	/note= "Arq substituted by Lys (SCR-9)"	Misc difference 64
PN	EP512733-A.	EP512733-A.	EP512733-A.
XX	11 NOV-1992.	11 NOV-1992.	11 NOV-1992.
XX	28 APR-1992; 92EP-040826.	28 APR-1992; 92EP-040826.	28 APR-1992; 92EP-040826.
XX	03 MAY-1991; 91US-0695514.	03 MAY-1991; 91US-0695514.	03 MAY-1991; 91US-0695514.
XX	(UNIV) UNIV WASHINGTON.	(UNIV) UNIV WASHINGTON.	(UNIV) UNIV WASHINGTON.
XX	Atkinson JP, Hourcade D, Krych M.	Atkinson JP, Hourcade D, Krych M.	Atkinson JP, Hourcade D, Krych M.
XX	WPI; 1992-375009/46.	WPI; 1992-375009/46.	WPI; 1992-375009/46.
XX	Complement activity regulator protein analogues - useful for	Complement activity regulator protein analogues - useful for	Complement activity regulator protein analogues - useful for
XX	treating autoimmune diseases, to suppress transplant rejection,	treating autoimmune diseases, to suppress transplant rejection,	treating autoimmune diseases, to suppress transplant rejection,
XX	for diagnosis etc.	for diagnosis etc.	for diagnosis etc.
XX	Claim 11; Fig 2 and R11810; 2pp; English.	Claim 11; Fig 2 and R11810; 2pp; English.	Claim 11; Fig 2 and R11810; 2pp; English.
XX	The cDNA clone designated CRI-4 was described in J.Exp.Med.(1988)	The cDNA clone designated CRI-4 was described in J.Exp.Med.(1988)	The cDNA clone designated CRI-4 was described in J.Exp.Med.(1988)
XX	168:125-1270. It encodes the first 8 and a half amino terminal	168:125-1270. It encodes the first 8 and a half amino terminal	168:125-1270. It encodes the first 8 and a half amino terminal
XX	SCRs of CRI. The invention concerns analogues of "regulator of	SCRs of CRI. The invention concerns analogues of "regulator of	SCRs of CRI. The invention concerns analogues of "regulator of
XX	complement activation" proteins or truncated, hybrid or recombinant	complement activation" proteins or truncated, hybrid or recombinant	complement activation" proteins or truncated, hybrid or recombinant
XX	forms of them. CRI-4 is a preferred truncated form and a number of	forms of them. CRI-4 is a preferred truncated form and a number of	forms of them. CRI-4 is a preferred truncated form and a number of
XX	specified substitution variants of it are claimed in which certain	specified substitution variants of it are claimed in which certain	specified substitution variants of it are claimed in which certain
XX	positions in SCR-2 which have been identified as important for the	positions in SCR-2 which have been identified as important for the	positions in SCR-2 which have been identified as important for the
XX	degree of C3b- and C4b-binding are substituted by amino acids from	degree of C3b- and C4b-binding are substituted by amino acids from	degree of C3b- and C4b-binding are substituted by amino acids from
XX	the corresponding positions in SCR-9. The specification does not	the corresponding positions in SCR-9. The specification does not	the corresponding positions in SCR-9. The specification does not
XX	contain the CRI-4 sequence; the sequence given here was constructed	contain the CRI-4 sequence; the sequence given here was constructed	contain the CRI-4 sequence; the sequence given here was constructed
XX	from the full-length CRI amino acid sequence having GENESFO	from the full-length CRI amino acid sequence having GENESFO	from the full-length CRI amino acid sequence having GENESFO
XX	accession number AAR11810 and descriptions in the disclosure.	accession number AAR11810 and descriptions in the disclosure.	accession number AAR11810 and descriptions in the disclosure.
XX	Sequence: 543 AA.	Sequence: 543 AA.	Sequence: 543 AA.
XX	Query Match.	Query Match.	Query Match.
XX	Best Local Similarity 48.0%; Prob. No. 2.2e-11;	Best Local Similarity 48.0%; Prob. No. 2.2e-11;	Best Local Similarity 48.0%; Prob. No. 2.2e-11;
XX	Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps	Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps	Matches 52; Conservative 14; Mismatches 59; Indels 12; Gaps

Accession number: AAR11810 and descriptions in the disclosure.

XX Sequence: 543 AA;

Query Match: 26.1%; Score 196; DB 14; Length 543;
Best Local Similarity: 38.0%; Pred. No. 2.2e-11;
Matches: 92; Conservative: 14; Mismatches: 59; Indels: 12; Gaps: 6;

CV 2 LKSGPPTLNGEFTSNKRNHYGVYKQKRS LG TPLDGEKSLTITKDKVWG 54
DB 123 LKSGPPTLNGEFTSNKRNHYGVYKQKRS LG TPLDGEKSLTITKDKVWG 54
CV 55 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
DB 113 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
DB 183 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
CV 114 QANNMWPRLDPCVSV 140
DB 240 QANNMWPRLDPCVSV 140

RESULT 41
AAR28552
XX AAR28552 standard; peptide: 543 AA;

XX AAR28552
XX 19-MAR-1993 (first entry)
XX CR1-4 (787, 793) analogue.

XX short consensus repeat; regulator of complement activation;
XX c4b binding; c4b binding; human complement type 1 receptor;
XX Homo sapiens.

XX Key: Location/Qualifiers
XX Region: 1..60
XX /Label= SCR 1
XX Region: 61..122
XX /Label= SCR 2
XX Region: 451..510
XX /Label= SCR 8
XX Region: 511..543
XX /Label= SCR 9
XX /Label= "TRUNCATED"
XX Misc-difference 64
XX /note= "Asp substituted by Lys (SCR 9)"
XX Misc-difference 65
XX /note= "Asp substituted by Thr (SCR 9)"

XX EF512733 A.
XX 11 NOV 1992;
XX 28 APR 1992; 92EP-0404826
XX 04 MAY 1991; 91US-0695514
XX (UNIV) UNIV WASHINGTON;
XX Atkinson DP, Bourcade D, Krych M;
XX W01: 1992 475009/46;

XX Complement activity regulator protein analogues useful for
XX treating autoimmune diseases, to suppress transplant rejection,
XX for diagnosis etc.
XX Claim 11: Fig 2 and R101C; 2pp; English.
XX The cDNA clone designated CR1-4 was described in J. Exp. Med. (1988)
XX 168:1265-1270. It encodes the first 8 and a half amino terminal

CC SCRs of CR1, the invention concerns analogues of "regulation of
CC complement activation" proteins or truncated, hybrid or recombinant
CC forms of them. CR1-4 is a preferred truncated form and a number of
CC specified substitution variants of it are claimed in which certain
CC positions in SCR-2 which have been identified as important for the
CC degree of c4b- and c4b binding are substituted by amino acids from
CC the corresponding positions in SCR 9. The specification does not
CC contain the CR1-4 sequence; the sequence given here was constructed
CC from the full length CR1 amino acid sequence having GENESEQ
CC accession number AAR11810 and descriptions in the disclosure.

XX Sequence: 543 AA;

Query Match: 26.1%; Score 196; DB 14; Length 543;
Best Local Similarity: 38.0%; Pred. No. 2.2e-11;
Matches: 92; Conservative: 14; Mismatches: 59; Indels: 12; Gaps: 6;

CV 2 LKSGPPTLNGEFTSNKRNHYGVYKQKRS LG TPLDGEKSLTITKDKVWG 54
DB 123 LKSGPPTLNGEFTSNKRNHYGVYKQKRS LG TPLDGEKSLTITKDKVWG 54
CV 55 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
DB 113 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
DB 183 TWKKAQKVEYKNSKSTPEYVGGYKQKRS LPRHGGSYTRACKNFSMNGKNSVWC 113
CV 114 QANNMWPRLDPCVSV 140
DB 240 QANNMWPRLDPCVSV 140

RESULT 42
AAR28552
XX AAR28552 standard; peptide: 543 AA;

XX AAR28552
XX 19-MAR-1993 (first entry)
XX CR1-4 (787, 793) analogue.

XX short consensus repeat; regulator of complement activation;
XX c4b binding; c4b binding; human complement type 1 receptor;
XX Homo sapiens.

XX Key: Location/Qualifiers
XX Region: 1..60
XX /Label= SCR 1
XX Region: 61..122
XX /Label= SCR 2
XX Region: 451..510
XX /Label= SCR 8
XX Region: 511..543
XX /Label= SCR 9
XX /Label= "TRUNCATED"
XX Misc-difference 78
XX /note= "Lys substituted by Thr (SCR 9)"
XX Misc-difference 79
XX /note= "Gly substituted by Asp (SCR 9)"

XX EF512733 A.
XX 11 NOV 1992;
XX 28 APR 1992; 92EP-0404826
XX 04 MAY 1991; 91US-0695514
XX (UNIV) UNIV WASHINGTON;
XX Atkinson DP, Bourcade D, Krych M;
XX W01: 1992 475009/46;

GenCore version 5.1.1.3
Copyright (c) 1993-2002 CompuGen Ltd.

om protein protein search, using sw model

Run on: November 6, 2002, 16:04:59 : Search time 14.4461 Seconds
(without alignments)
891.311 Million cell updates/sec

Title: US 09 834 009 4

Perfect score: 751

Sequence: 1 G1SGVSPPTIIN:PIFSYST

ANNMW:PTPLETCVSFPLE 134

Scoring table: BLASTM62

Gapop 10.0 , Gapext 0.5

Searched: 283148 seqs, 968044 residues

Total number of hits satisfying chosen parameters: 283148

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database: PIR 71:*

1: pir1:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	751	100.0	1091	1 P10009	complement C3d/Eps
2	466.5	62.1	363	2 B45900	complement C3d/Eps
3	466.5	62.1	676	2 A45900	complement C3d/Eps
4	466.5	62.1	1025	1 A45926	complement C3d/Eps
5	420	29.3	2489	2 I36012	complement C3b/C4b
6	218	29.0	2014	2 I36936	complement receptor
7	215	28.6	263	1 WW223P	apolipoprotein H h
8	210	28.0	263	1 C36848	complement control
9	210	29.0	263	2 I28450	hypothetical prote
10	208	27.7	263	2 B22152	B18L protein var
11	203.5	27.1	579	2 A56740	sperm egg recogniti
12	202.5	27.0	597	1 S53711	CARF alpha chain p
13	201	26.8	482	2 A44924	complement C3b/C4b
14	199	26.5	597	1 NH0054	C4b-binding protei
15	197.5	26.3	610	1 I46001	C4b-binding protei
16	184	24.5	497	2 J62054	complement regulat
17	182	24.2	558	2 S57953	C4BP protein alpha
18	180.5	24.0	440	2 A43519	complement recepto
19	180.5	24.0	1241	1 NH0004	complement factor
20	178.5	23.8	469	1 NH0054	C4b-binding protei
21	178.5	23.8	1234	1 NH0054	complement factor
22	165.5	22.0	808	2 D45069	complement factor
23	165	22.0	661	1 KPI013	coagulation factor
24	164	21.8	2043	2 T18524	scavenger receptor
25	162	21.6	343	2 G35070	apolipoprotein H :
26	160	21.3	362	2 J65194	membrane cofactor
27	160	21.3	369	2 J65148	membrane cofactor
28	159	21.2	377	2 I54479	membrane cofactor
29	159	21.2	484	2 S01896	membrane cofactor

30	158.5	21.1	340	2	I56274	decay-acceleration
31	158.5	21.1	381	1	B26359	decay-acceleration
32	158.5	21.1	440	2	A26359	decay-acceleration
33	155	20.6	349	2	G02913	Sperm C4b - human
34	155	20.6	369	2	I57998	membrane cofactor
35	150	20.0	302	1	WMBE1E	secretory compleme
36	150	20.0	360	1	WMBE2E	membrane bound com
37	149	19.8	668	2	A46013	coagulation factor
38	148	19.7	768	2	A42755	p-selectin precurs
39	147	19.6	330	2	I56100	complement factor
40	146.5	19.5	768	2	I53821	p-selectin - rat
41	142	18.9	1019	2	A48748	coagulation factor
42	141	18.8	252	2	A44877	C4b-binding protei
43	140	18.6	152	2	A53274	complement factor
44	140	18.6	258	2	S57960	C4BP protein beta
45	140	18.6	752	1	C28U	complement C2 prec
46	137	18.2	345	1	NH005	apolipoprotein H p
47	135	18.0	360	2	T42921	complement control
48	134.5	17.9	270	2	I37278	complement factor
49	134	17.8	297	1	NHRT	apolipoprotein H p
50	134	17.8	763	2	I50807	complement factor
51	133	17.7	764	1	BH0U	complement factor
52	132	17.6	345	1	JN0465	apolipoprotein H p
53	131	17.4	202	2	A44247	C4b binding protei
54	131	17.4	669	2	S65551	factor II - bovine
55	129.5	17.2	702	2	T16842	hypothetical prote
56	128	17.0	560	2	I16843	hypothetical prote
57	127	16.9	345	1	NH0U	apolipoprotein H p
58	127	16.9	345	1	NH0U	apolipoprotein H p
59	127	16.9	646	2	JN0473	p-selectin precurs
60	125	16.6	868	2	T0249	hypothetical prote
61	125	16.6	1827	2	T34288	hypothetical prote
62	124.5	16.6	977	2	I52657	structure-related pr
63	123.5	16.4	612	2	B42755	p-selectin precurs
64	123	16.4	934	1	A44372	complement C6 prec
65	122	16.2	761	1	BH0S	complement factor
66	120.5	16.0	551	2	I46739	cadherin-like
67	120.5	16.0	760	1	C2MS	classical compleme
68	120	16.0	330	2	I55975	X/Y protein - mous
69	120	16.0	610	2	A50316	p-selectin precurs
70	118	15.7	331	2	A45232	complement factor
71	118	15.7	482	2	J65092	E-selectin - pig
72	116.5	15.5	1797	2	T21899	hypothetical prote
73	116.5	15.5	1805	2	T21898	hypothetical prote
74	116	15.4	303	2	A35068	apolipoprotein H :
75	114	15.2	452	2	A35068	complement factor
76	113	15.0	830	2	A30359	p-selectin precurs
77	113	15.0	570	2	T46261	hypothetical prote
78	111.5	14.8	449	1	NH0H5	complement factor
79	111.5	14.8	1506	2	I30886	integrin alpha muc
80	111	14.8	747	2	I51579	complement factor
81	110.5	14.7	843	1	A27340	complement C7 prec
82	110	14.6	485	2	I36772	E-selectin - bovin
83	106.5	14.2	1053	2	S46199	probable complemen
84	102.5	13.6	317	2	A84933	ps/alpha protein - va
85	101.5	13.5	686	1	A59271	Ra reactive factor
86	98.5	13.3	317	2	I47412	trypsinogen
87	97.5	13.0	317	2	T28605	hypothetical prote
88	94.5	12.6	317	2	J61799	p66 protein precur
89	93	12.4	347	1	BHRT	apolipoprotein prec
90	91.5	12.2	317	2	F72172	p78 protein - vari
91	91.5	12.2	317	2	G36855	p78 protein - vari
92	90.5	12.1	317	2	I42526	p66 protein - vari
93	86	11.5	699	1	I54763	Ra-reactive factor
94	85.5	11.4	926	1	OPPGIT	iodide peroxidase
95	85	11.3	198	2	I46002	C4BP beta chain
96	85	11.3	347	1	HPMS	apolipoprotein prec
97	85	11.3	633	2	T24898	hypothetical prote
98	84	11.2	370	2	S22124	p-selectin precurs
99	83.5	11.1	406	1	HPH02	haptoglobin precur
100	83	11.1	933	1	OPH01T	iodide peroxidase

QY 111 VWCANNKGGPTKPTC 127
111 VWCANNKGGPTKPTC 127
Db 244 THCADKSWSP-VPC 258
244 THCADKSWSP-VPC 258

RESULT 18
A43519
complement receptor CR1 precursor - mouse
C:Species: Mus musculus (house mouse)
C:Date: 28 Oct 1992 #sequence_revision: 30 Jan 1993 #text_change: 17 Nov 2000
C:Accession: A43519; A30550
R:Paul, M.S.; Acquerio, M.; Copek, K.; Miller, M.D.; Weiss, J.H.
J. Immunol. 144, 1988 1996, 1990
A:Title: The murine complement receptor gene family. The genomic and transcriptional com
A:Reference number: A43519; MUID:90171600
A:Accession: A43519
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-440 <PAU>
A:Cross references: GB:M41464
A:Note: The authors translated the codon GGC for residue 21 as Ala, and CAG for residue
R:Paul, M.S.; Acquerio, M.; O'Brien, S.E.; Kurtz, C.B.; Weiss, J.H.
J. Immunol. 142, 582-589, 1989
A:Title: The murine complement receptor gene family. Analysis of mCR1 gene products and
A:Reference number: A30550; MUID:89094944
A:Accession: A30550
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-20, A', 22-120, 122-474 <PAU>
C:Superfamily: C4b-binding protein alpha chain; complement factor H repeat homology
F:42-56/Domain: complement factor H repeat homology <FHL>
F:103-160/Domain: complement factor H repeat homology <FH2>
F:165-231/Domain: complement factor H repeat homology <FH3>
F:237-293/Domain: complement factor H repeat homology <FH4>
F:299-355/Domain: complement factor H repeat homology <FH5>

Query Match 24.0%; Score 180.5; DB 2; Length 440;
Best Local Similarity 34.0%; Prod. No. 1:1e-09;
Matches 47; Conservative 34; Mismatches 60; Indels 15; Gaps 5;

QY 2 ISGSGPPPLNCRISYVST--PIAVTIVIRYSCS-----GTFRIIGKSLICLUKDV 52
163 IPCEIPPIPNQ--DFSSSTREDFHYGMVYTYRNTDARKKALENLVGLPSLYCTNDGE 220
163 IPCEIPPIPNQ--DFSSSTREDFHYGMVYTYRNTDARKKALENLVGLPSLYCTNDGE 220

QY 53 DCTWIKIPAKPEYFNKYSSCEPIVPGYKI-RGSTYRHCUSVIFACKTFNSMGNKSV 111
111 DCTWIKIPAKPEYFNKYSSCEPIVPGYKI-RGSTYRHCUSVIFACKTFNSMGNKSV 111
Db 221 LGWSGPPPGQIEFNKCT--PEYVAVNAVMSLRSLRDLIVERKCHPGFIMKCASSV 278
221 LGWSGPPPGQIEFNKCT--PEYVAVNAVMSLRSLRDLIVERKCHPGFIMKCASSV 278

QY 112 WCCANNKGGPTKPTC 127
112 WCCANNKGGPTKPTC 127
Db 279 HCQSLNKWEP ELPSG 293
279 HCQSLNKWEP ELPSG 293

RESULT 19
NH0018
complement factor H precursor, long splice form [validated] - human
C:Species: Homo sapiens (man)
C:Date: 31 Dec 1993 #sequence_revision: 31 Dec 1993 #text_change: 08 Dec 2000
C:Accession: S00254; A60238; A54726; A61565; A26505; 172654; S66298
R:Ripoche, J.; Day, A.J.; Harris, T.J.P.; Sim, P.B.
Biochem. J. 249, 593-602, 1988
A:Title: The complete amino acid sequence of human complement factor H.
A:Reference number: S00254; MUID:88140059
A:Accession: S00254
A:Molecule type: mRNA
A:Residues: 1-1241 <RBP>
A:Cross references: EMBL:Y00716; MUI:q31964; PIDN:CAA68704.1; PID:q31965
A:Note: 402 Tyr was also found
A:Note: parts of this sequence, including the amino and carboxyl ends of the mature pro
R:Stallier, C.; Schwachble, W.; Dietrich, M.; Weiss, E.H.
Eur. J. Immunol. 21, 799-802, 1991
A:Title: Human complement factor H: two factor H proteins are derived from alternatively
A:Reference number: A60238; MUID:91184292

A:Accession: A60248
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-56; 177-1231 <EST>
A:Note: only portions of this 4.3 kilobase mRNA were sequenced
R:Day, A.J.; Ripoche, J.; Lyons, A.; McIntosh, E.; Harris, T.J.P.; Sim, P.B.
Biosci. Rep. 7, 201-207, 1987
A:Title: Sequence analysis of a cDNA clone encoding the C-terminal end of human comp
A:Reference number: A54726; MUID:88025472
A:Accession: A54726
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: 1-56; 177-1231 <DAY>
A:Cross references: GB:M17517; MUI:q180495; PID:q180496
A:Note: parts of this sequence were determined by protein sequencing
R:Ripoche, J.; Day, A.J.; Willis, A.C.; Holt, K.T.; Campbell, R.D.; Sim, P.B.
Biosci. Rep. 6, 65-72, 1986
A:Title: Partial characterization of human complement factor H by protein and cDNA se
A:Reference number: A61565; MUID:86188234
A:Accession: A61565
A:Status: not compared with conceptual translation
A:Molecule type: mRNA
A:Residues: M17517; MUI:q180495; 12 <M12>
R:Sim, P.B.; DiScipio, R.G.
Biochem. J. 205, 285-293, 1982
A:Title: Purification and structural studies on the complement-system control protei
A:Reference number: A26505; MUID:83648213
A:Accession: A26505
A:Molecule type: protein
A:Residues: 1-28, 32, 22-26, 31-33, 36-45 <SIM>
R:Barlow, P.N.; Norman, D.G.; Steinkasserer, A.; Horne, T.J.; Pearce, J.; Driscoll, P.
Biochemistry 3, 3626-3634, 1992
A:Title: Solution structure of the third repeat of factor H: A second example of the
A:Reference number: A44551; MUI:q232549
A:Contents: annotation, NMR structure determination, residues 264-292
R:Norman, D.G.; Barlow, P.N.; Day, A.J.; Sim, P.B.; Campbell, I.D.
J. Mol. Biol. 219, 717-725, 1991
A:Title: Three dimensional structure of a complement control protein module in soluti
A:Reference number: A49244; MUI:q1278097
A:Contents: annotation, NMR structure determination, residues 927-985
R:Stallier, C.; Koistinen, V.; Schwachble, E.; Dietrich, M.P.; Weiss, E.H.
J. Immunol. 146, 3190-3196, 1991
A:Title: Cloning of the 1.4-kb mRNA species of human complement factor H reveals a ho
A:Reference number: 156100; MUID:91201892
A:Accession: 172754
A:Status: translated from GB/EMBL/JDBJ
A:Molecule type: mRNA
A:Residues: 1017-1231 <RES>
A:Cross references: GB:M65294; MUI:q180765; PIDN:AAA5948.1; PID:q180767
R:Carroll, J.A.; Bates, R.C.; Smith, A.; Tetzlaff, L.; Arellano, A.; Gordon, D.L.; Burn
Biochim. Biophys. Acta 1289, 305-311, 1994
A:Title: Factor H co-purifies with thrombospondin isolated from platelet secretate
A:Reference number: S66298; MUID:9620565
A:Accession: S66298
A:Status: preliminary
A:Molecule type: protein
A:Residues: 411-419; 574-578; 580-582 <CAK>
C:Comment: Factor H has also been found bound to cell membranes in an unknown manner.
C:Comment: Alternative transcripts of 4.3, 1.8, and 1.4 kilobases are expressed in liv
C:Genetics: <HFI>
A:Gene: GDB:HFI; HP
A:Cross references: GDB:120041; OMIM:134350
A:Map position: q12-q13
C:Genetics: <HFI>
A:Gene: GDB:HFI; HP
A:Cross references: GDB:129095
A:Map position: q12-q13
A:Note: the correspondence between the two loci and the sequences indicated is unclear
C:Function:
A:Description: a cofactor in the inactivation of C3b by serine protease 1; also the
he alternative complement pathway
A:Pathway: complement alternate pathway

A:Molecule type: mRNA
 A:Residues: 1-369 <MUR>
 A:Cross references: DDBJ:p64811; NID:q1777315; PID:q1777315
 C:Comment: This protein is a complement regulator and measles virus receptor. It protects
 C:Superfamily: herpesvirus complement control protein; complement factor H repeat homolo
 F:1-34/Domain: signal sequence #status predicted <SIG>
 F:35-469/Product: membrane cofactor protein (MCP, CD46)
 F:35-94/Domain: complement factor H repeat homology <PH02>
 F:99-157/Domain: complement factor H repeat homology <PH01>
 F:162-223/Domain: complement factor H repeat homology <PH03>
 F:228-283/Domain: complement factor H repeat homology <PH04>
 F:315-346/Domain: transmembrane #status predicted <TM>
 F:347-369/Domain: intracellular #status predicted <IM>
 Query Match 21.2% Score 160; DB 2; Length 369;
 Best Local Similarity 27.9% Pred. No. 1.1e-07;
 Matches 48; Conservative 25; Mismatches 57; Indels 16; Gaps 6;
 QY 2 ISGSGPPPLNGRISYSSTPI-AGTVIVFYSCS-----GTFRLGKSLJLCTKDKVDGT 55
 DB 160 ILCTPPPKIKNGKHTESEVEVEYLDVAVYSCHDAPGPDPESLIGESMIVGN-----NST 215
 QY 56 WDKPAKKEEYFNKYSSTPEIVPGGYKTRG-STPYRHGDSVTFACKTNFSGNKNKSVWQ 114
 DB 216 WSHAAPEG----KVKKRPFPVVGNGKQISGPGKKFYKNAIVMFEDKSGYFLNGSKIVCE 271
 QY 115 ANNMGGPTRLPTGV 128
 DB 272 SNSTWDP-VPKCLKV 286
 RESULT 28
 154479
 membrane cofactor protein precursor, splice form p64.1 human
 N:Alternate names: lymphocyte surface glycoprotein CD46
 C:Species: Homo sapiens (man)
 C:Date: 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change 31-Mar-2000
 C:Accession: 154479
 Immunoblot: 33, 35-44, 1991
 A:Title: Alternatively spliced mRNAs encode several isoforms of CD46 (MCP), a regulator o
 A:Reference number: 154479; MUID:91267562
 A:Accession: 154479
 A:Status: translated from GH/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-377 <RES>
 A:Cross references: GDB:M58050; NID:q180136; PID:AAA62833.1; FID:q180137
 C:Genetics:
 A:Gene: GDB:MCP
 A:Cross references: GDB:120169; OMIM:120929
 A:Map position: 1q42-1q52
 C:Function:
 A:Description: for the factor I mediated cleavage of the complement convertases
 C:Superfamily: herpesvirus complement control protein; complement factor H repeat homolo
 C:Keywords: alternative splicing; glycoprotein; transmembrane protein
 F:35-94/Domain: complement factor H repeat homology <PH01>
 F:99-157/Domain: complement factor H repeat homology <PH02>
 F:162-223/Domain: complement factor H repeat homology <PH03>
 F:228-283/Domain: complement factor H repeat homology <PH04>
 F:329-351/Domain: transmembrane #status predicted <TM>
 Query Match 21.2% Score 159; DB 2; Length 377;
 Best Local Similarity 27.9% Pred. No. 1.1e-07;
 Matches 48; Conservative 25; Mismatches 57; Indels 16; Gaps 6;
 QY 2 ISGSGPPPLNGRISYSSTPI-AGTVIVFYSCS-----GTFRLGKSLJLCTKDKVDGT 55
 DB 160 ILCTPPPKIKNGKHTESEVEVEYLDVAVYSCHDAPGPDPESLIGESMIVGN-----NST 215
 QY 56 WDKPAKKEEYFNKYSSTPEIVPGGYKTRG-STPYRHGDSVTFACKTNFSGNKNKSVWQ 114
 DB 216 WSHAAPEG----KVKKRPFPVVGNGKQISGPGKKFYKNAIVMFEDKSGYFLNGSKIVCE 271

QY 115 ANNMGGPTRLPTGVSV 130
 DB 272 SNSTWDP-VPKCLKV 286
 RESULT 29
 S01896
 membrane cofactor protein precursor - human
 N:Alternate names: lymphocyte surface glycoprotein CD46
 C:Species: Homo sapiens (man)
 C:Date: 30-Sep-1995 #sequence_revision 30-Sep-1998 #text_change 21-Jul-2000
 C:Accession: S01896; A60765; 156188
 R:Lablin, D.M.; Liszewski, M.K.; Post, J.W.; Aruffo, A.; Le Beau, M.M.; Kobayashi, M.
 J.; Exp. Med. 164, 181-194, 1988
 A:Title: Molecular cloning and chromosomal localization of human membrane cofactor pr
 A:Reference number: S01896; MUID:88266080
 A:Accession: S01896
 A:Molecule type: mRNA
 A:Residues: 1-384 <LUR>
 A:Cross references: EMBL:Y00651; NID:q34501; PID:CAA6875.1; FID:q34505
 A:Note: part of this sequence, including the amino end of the mature protein, was con
 R:Parcell, D.F.; Deacon, N.J.; Andrew, S.A.; McKenzie, I.F.C.
 Immunogenetics 31, 21-28, 1990
 A:Title: Human non lineage antigen, CD41 (TLY-m5): purification and partial sequenc
 A:Reference number: A60765; MUID:90129152
 A:Accession: A60765
 A:Molecule type: protein
 A:Residues: 'X' 36-39, 'X' 41-58 <PUR>
 R:Call, W.; Boucade, D.; Post, T.; Greenhalgh, A.C.; Atkinson, T.P.; Kumar, V.
 J. Immunol. 151, 4137-4146, 1993
 A:Title: Characterization of the promoter region of the membrane cofactor protein (CD
 A:Reference number: 156188; MUID:94014356
 A:Accession: 156188
 A:Status: preliminary; translated from GH/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-34 <RES>
 A:Cross references: GDB:S65879; NID:q425633; PID:AAI1968.1; FID:q425634
 C:Genetics:
 A:Gene: GDB:MCP
 A:Cross references: GDB:120169; OMIM:120929
 A:Map position: 1q42-1q52
 C:Function:
 A:Description: membrane cofactor protein for the factor I mediated cleavage of the co
 C:Superfamily: herpesvirus complement control protein; complement factor H repeat hom
 C:Keywords: alternative splicing; glycoprotein; transmembrane protein
 F:1-34/Domain: signal sequence #status predicted <SIG>
 F:35-384/Product: membrane cofactor #status experimental <MAT>
 F:35-94/Domain: complement factor H repeat homology <PH01>
 F:99-157/Domain: complement factor H repeat homology <PH02>
 F:162-223/Domain: complement factor H repeat homology <PH03>
 F:228-283/Domain: complement factor H repeat homology <PH04>
 F:329-351/Domain: transmembrane #status predicted <TM>
 Query Match 21.2% Score 159; DB 2; Length 384;
 Best Local Similarity 27.9% Pred. No. 1.1e-07;
 Matches 38; Conservative 25; Mismatches 57; Indels 16; Gaps 6;
 QY 2 ISGSGPPPLNGRISYSSTPI-AGTVIVFYSCS-----GTFRLGKSLJLCTKDKVDGT 55
 DB 160 ILCTPPPKIKNGKHTESEVEVEYLDVAVYSCHDAPGPDPESLIGESMIVGN-----NST 215
 QY 56 WDKPAKKEEYFNKYSSTPEIVPGGYKTRG-STPYRHGDSVTFACKTNFSGNKNKSVWQ 114
 DB 216 WSHAAPEG----KVKKRPFPVVGNGKQISGPGKKFYKNAIVMFEDKSGYFLNGSKIVCE 271
 QY 115 ANNMGGPTRLPTGVSV 130
 DB 272 SNSTWDP-VPKCLKV 286
 RESULT 30
 156234
 decay accelerating factor - orangutan (fragment)

A:Cross references: GR:M22432; NID:q149565; PIDN:AAA3712.1; PID:q149566
 A:Note: sequence extracted from NBI backbone (NBIIP:109900)
 C:Superfamily: unassigned EGF-related proteins; complement factor H repeat homology; ECH
 C:Keywords: cell adhesion; glycoprotein; phosphatidyl; phosphoprotein, transmembrane
 F:1.41/Domain: signal sequence #status predicted <SIG>
 F:4.2.76/Product: P-selectin #status predicted <MAT>
 F:16.3.194/Domain: EGF homology - EGF
 F:249.257/Domain: complement factor H repeat homology <PH01>
 F:262.319/Domain: complement factor H repeat homology <PH02>
 F:324.381/Domain: complement factor H repeat homology <PH03>
 F:386.443/Domain: complement factor H repeat homology <PH04>
 F:448.505/Domain: complement factor H repeat homology <PH05>
 F:510.567/Domain: complement factor H repeat homology <PH06>
 F:580.647/Domain: complement factor H repeat homology <PH07>
 F:642.699/Domain: complement factor H repeat homology <PH08>
 F:710.733/Domain: transmembrane #status predicted <TM>
 F:734.768/Domain: intracellular #status predicted <INT>
 F:45.54.107.212.347.398.456.467.603.654.661.679/Binding site: carbohydrate (Asn) (covalent)
 Query Match 19.7%; Score 148; DB 2; Length 768;
 Best Local Similarity 28.6%; Pred. No. 2.6e-06;
 Matches 36; Conservative 21; Mismatches 49; Indels 20; Gaps 5;
 QY 16 SYSTPIAVGTVIPYSSCTETLIGFESKSLITLTKKVCWTKDPAPKCEYENKYS----- 71
 DB 5.4 SHVHGFVGSILHRSQNEDELIGSERVQ-----TVSGWSAPPPTCKITSLPAPAVR 576
 QY 72 CPEPTVPGYKIRGSPYKRRH-----GGSVLFACIKNFNMGNKSVWCQANNMNGPTRL 124
 DB 580 GVALTPG---GRTMSGHHIGSPDNTCTYFVKTGTFLRGANSICPACSGQWTA-V 634
 QY 125 PTCVSV 140
 DB 6.6 PMRAV 640
 RESULT 49
 156100
 A:Accession: 156100
 A:Status: preliminary; translated from GH/EMBL/DBD
 A:Molecule type: mRNA
 A:Residues: 1-340 <EST>
 A:Cross references: GH:M65292; NID:q183742; PIDN:AAA35946.1; PID:q183763
 A:Superfamily: 172653
 A:Status: preliminary; translated from GH/EMBL/DBD
 A:Molecule type: mRNA
 A:Residues: 1-156/H, 158-176/160-174/E, 176-340 <EST>
 A:Cross references: GH:M65293; NID:q183764; PIDN:AAA35947.1; PID:q183765
 F:Skorka, C.; Horstmann, F.D.; Zipfel, P.F.
 J. Biol. Chem. 266, 12015-12020, 1991
 A:Title: Molecular cloning of a human serum protein structurally related to complement
 A:Reference number: A40455; MUID:91268081
 A:Accession: A40455
 A:Molecule type: mRNA
 A:Residues: 4-70, N, 72-340 <SKI>
 A:Cross references: EMBL:X6209; NID:q43190; PIDN:CAA49666.1; PID:q388519
 C:Genetics:
 A:Gene: GDB:BFL1; H36.1; FBR1
 A:Cross references: GDB:128809; OMIM:144471
 C:Superfamily: apolipoprotein H; complement factor H repeat homology
 C:Keywords: duplication; extracellular protein; glycoprotein; tandem repeat
 F:1.18/Domain: signal sequence #status predicted <SIG>
 F:2.4 H/Domain: complement factor H repeat homology <PH1>

F:87-140/Domain: complement factor H repeat homology <PH2>
 F:147-201/Domain: complement factor H repeat homology <PH3>
 F:208-265/Domain: complement factor H repeat homology <PH4>
 F:266-327/Domain: complement factor H repeat homology <PH5>
 Query Match 19.6%; Score 147; DB 2; Length 336;
 Best Local Similarity 27.9%; Pred. No. 1.3e-06;
 Matches 36; Conservative 22; Mismatches 41; Indels 10; Gaps 5;
 QY 3 SCGSPPTTNGRI--SYSTPIAVGTVIPYSSCTETLIGFESKSLITLTKKVCWTKDPAP 61
 DB 145 SCVNPTVQNAVIVSRQMSKYPSEYVYQYRSYCEMGDFEVMCL---NKNWTEP P 159
 QY 62 KCEYENKYSQPEPTVPGYKIRGSPYKRRH-----GGSVLFACIKNFNMGNKSVWCQANNMNG 120
 DB 200 QCKDSTGKCGTTPPDNGHILFSLSYVAPASSVYQYQNYQLKGRKIFCRNGQWSE 218
 QY 121 -PTRLPTCV 128
 DB 259 PKCLHCV 257
 RESULT 40
 153821
 P-selectin - rat
 C:Species: Rattus norvegicus (Norway rat)
 C:Date: 29-May-1998 #sequence_revision 26-May-1998 #text_change 19-May-2000
 C:Accession: 153821
 R:Auchampach, J.A.; Oliver, M.G.; Anderson, D.C.; Manning, A.M.
 Gene 145, 251-255, 1994
 A:Title: Cloning, sequence comparison and in vivo expression of the gene encoding rat
 A:Reference number: 153821; MUID:94333817
 A:Accession: 153821
 A:Status: preliminary; translated from GH/EMBL/DBD
 A:Molecule type: mRNA
 A:Residues: 1-768 <RES>
 A:Cross references: GDB:L23088; NID:q349552; PIDN:AAA60325.1; PID:q449554
 C:Superfamily: unassigned EGF-related proteins; C-type lectin homology; complement 1a
 F:12-158/Domain: 2-type lectin homology <LCH>
 F:163-194/Domain: EGF homology <EGF>
 F:262-319/Domain: complement factor H repeat homology <PH>
 F:510-567/Domain: complement factor H repeat homology <PH06>
 F:580-637/Domain: complement factor H repeat homology <PH07>
 F:642-694/Domain: complement factor H repeat homology <PH08>
 Query Match 19.5%; Score 146.5; DB 2; Length 768;
 Best Local Similarity 28.7%; Pred. No. 3.6e-06;
 Matches 43; Conservative 20; Mismatches 54; Indels 33; Gaps 9;
 QY 5 GSPP-----PIL-----NGRI--SYSTPIAVGTVIPYSSCTETLIGFESKSLITLTK 51
 DB 500 GSPPMCEAIKCPETAPPEGSDCSHVHCRFSV33CHFSNNEEFELGSHNVH-----1 558
 QY 52 VQGTMEKAPKCEYENKYS-----SCPEPTVPGYKIRGSPYKRRH-----GGSVLFACIK 100
 DB 556 VSGPWSNPPTKGVTSLEFVSVECFALITP---QGLMSKHILSESPNTHYFQK 611
 QY 101 TNFSMGNKSVWCQANNMNGPTRLPTCVSV 131
 DB 612 TGPTLRGNSIPGASGQWTA-VTPVAV 640
 RESULT 41
 A38738
 coagulation factor C precursor - horseshoe crab (Tachyplesus tridentatus)
 N:Alternate names: coagulation-complement factor C; Limulus factor C
 N:Contains: coagulation factor C heavy chain; coagulation factor C light chain pep-13
 C:Species: Tachyplesus tridentatus
 C:Date: 04-Oct-1991 #sequence_revision 04-Oct-1991 #text_change 08-Dec-2000
 C:Accession: A38738; M18738; S00105
 R:Muta, T.; Miyata, T.; Misumi, Y.; Tokunaga, F.; Nakamura, T.; Itoh, Y.; Ikohata, Y.
 J. Biol. Chem. 266, 6554-6561, 1991
 A:Title: Limulus factor C. An endotoxin-sensitive serine protease zymogen with a mos

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd

OM protein protein search, using sw model

Run on: November 6, 2002, 16:04:58 : Search time 8.4684 Seconds
(without alignments)
612.680 Million cell updates/sec

Title: US 09-834-309-4

Perfect score: 761

Sequence: 1 G1SGSGPPPTLNGP1SVYST ANNMWPTGCTPTVSVFPLE 134

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 105224 seqs, 4871950 residues

Total number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database : SwissProt_40.*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Length	DB ID	Description
1	751	100.0	1033	1	CR2_HUMAN
2	466.5	62.1	1025	1	CR2_MOUSE
3	219	29.2	2039	1	CR1_HUMAN
4	215	28.6	263	1	VCP_VACCV
5	199	26.5	547	1	C4BP_HUMAN
6	197.5	26.3	610	1	C4BP_BOVIN
7	182	24.2	558	1	C4BP_RAT
8	180.5	24.0	1231	1	CFAB_HUMAN
9	178.5	23.8	469	1	C4BP_MOUSE
10	178.5	23.8	1234	1	CFAB_MOUSE
11	167.5	22.3	390	1	DAF1_MOUSE
12	165	22.0	661	1	F13H_HUMAN
13	161	21.4	407	1	DAF2_MOUSE
14	159	21.2	377	1	MCP_HUMAN
15	158.5	21.1	440	1	DAF_PONY
16	158.5	21.1	481	1	DAF_HUMAN
17	150	20.0	360	1	C13H_RSVSA
18	149	19.8	668	1	F13H_MOUSE
19	148	19.7	768	1	LEM3_MOUSE
20	147	19.6	330	1	PER1_HUMAN
21	146.5	19.5	708	1	LEM3_RAT
22	144	19.2	3019	1	LEP_CANEC
23	142	18.9	1019	1	LEP_ACHIR
24	141.5	18.8	507	1	DAF_CAVIO
25	141	18.8	252	1	C4HR_HUMAN
26	140	18.6	151	1	CFAB_PIG
27	140	18.6	258	1	C4BP_RAT
28	140	18.6	752	1	C02_HUMAN
29	137	18.2	345	1	APDH_MOUSE
30	136.5	18.2	958	1	HIG_MOUSE
31	134.5	17.9	297	1	PHR2_HUMAN
32	134	17.8	52	1	APR_RAT
33	133	17.7	764	1	CFAB_HUMAN

34	132	17.6	345	1	APOLCANFA
35	131	17.4	202	1	APAR_PIG
36	131	17.4	685	1	CFAB_BOVIN
37	131	17.4	769	1	LEM3_SPER
38	129.5	17.2	549	1	LEM2_RAT
39	127	16.9	345	1	APOLBOVIN
40	127	16.9	345	1	APOLHUMAN
41	127	16.9	646	1	LEM3_BOVIN
42	123.5	16.4	612	1	LEM2_MOUSE
43	123	16.4	934	1	C06_HUMAN
44	122	16.2	611	1	LEM2CANFA
45	122	16.2	761	1	CFAB_MOUSE
46	120.5	16.0	760	1	C02_MOUSE
47	120	16.0	610	1	LEM2_HUMAN
48	119	15.8	331	1	PHR4_HUMAN
49	118	15.7	330	1	PHR3_HUMAN
50	118	15.7	484	1	LEM2_PIG
51	117.5	15.6	551	1	LEM2_RHAT
52	114	15.2	830	1	LEM3_HUMAN
53	110.5	14.7	843	1	C07_HUMAN
54	110	14.6	485	1	LEM2_BOVIN
55	102.5	13.6	317	1	VR05_VACCV
56	102	13.6	464	1	SRPX_RAT
57	101.5	13.5	686	1	MAS2_HUMAN
58	99.5	13.2	317	1	VR05_VACCV
59	94.5	12.6	317	1	VR05_VACCV
60	94	12.5	464	1	SRPX_HUMAN
61	93	12.4	347	1	HPT_RAT
62	90.5	12.1	317	1	VR05_VACCV
63	86	11.5	699	1	GRAC_HUMAN
64	85.5	11.4	926	1	PERT_F13
65	85	11.3	198	1	C4BB_BOVIN
66	85	11.3	347	1	HPT_MOUSE
67	84	11.2	370	1	LEM1_BOVIN
68	83.5	11.1	406	1	HPT2_HUMAN
69	83	11.1	250	1	CFAB_HUMAN
70	83	11.1	933	1	PERT_HUMAN
71	82.5	11.0	810	1	PLMN_MOUSE
72	81	10.8	372	1	LEM1_MOUSE
73	81	10.8	372	1	LEM1_HUMAN
74	80	10.7	372	1	LEM1_PANIR
75	80	10.7	372	1	LEM1_PANIR
76	79	10.5	704	1	CRAR_MOUSE
77	78.5	10.5	1627	1	PAPA_HUMAN
78	78.5	10.5	3562	1	PCOV_CHICK
79	77	10.3	372	1	LEM1_PONY
80	74	9.9	347	1	HPT_PIG
81	73.5	9.8	470	1	NRAM_RAT
82	73.5	9.8	662	1	NR02_MOUSE
83	73.5	9.8	662	1	NR02_RAT
84	73.5	9.8	684	1	XYNA_RAT
85	73.5	9.8	812	1	PLMN_BOVIN
86	72.5	9.7	378	1	CXAL_XENLA
87	72.5	9.7	470	1	NRAM_HUMAN
88	72.5	9.7	470	1	FCGB_BOVIN
89	71.5	9.5	912	1	NRAM_HUMAN
90	71.5	9.5	628	1	ILU_HUMAN
91	71.5	9.5	688	1	C15_HUMAN
92	71.5	9.5	705	1	C1R_HUMAN
93	71.5	9.5	883	1	FCGB_MOUSE
94	71.5	9.5	883	1	FCGB_RAT
95	71	9.5	812	1	FCMB_MOUSE
96	71	9.5	1700	1	HAR3_MOUSE
97	71	9.5	2738	1	PCOV_RAT
98	70.5	9.4	335	1	G4RH_MOUSE
99	70.5	9.4	662	1	MM02_RHAT
100	69.5	9.3	262	1	MUR1_HUMAN

ALL SUMMARIES

RESULT 1


```

FT SIGNAL 1 56
FT CHAIN 57 469
FT D-MAIN 57 116
FT D-MAIN 119 177
FT D-MAIN 180 241
FT D-MAIN 244 400
FT D-MAIN 402 456
FT D-MAIN 458 414
FT D-SULFID 58 103
FT D-SULFID 88 115
FT D-SULFID 120 160
FT D-SULFID 146 176
FT D-SULFID 181 223
FT D-SULFID 239 240
FT D-SULFID 245 287
FT D-SULFID 273 299
FT D-SULFID 303 343
FT D-SULFID 329 355
FT D-SULFID 359 400
FT D-SULFID 486 413
FT CARBOHYD 74 74
FT CARBOHYD 227 227
FT CARBOHYD 275 275
FT CARBOHYD 292 292
FT CARBOHYD 366 366
FT CARBOHYD 381 381
FT CARBOHYD 428 428
SQ SEQUENCE 469 AA; 51551 MW; 41E137C8B0DC6321 CRC64;

Query Match 23.89; Score 178.5; DB 1; Length 469;
Best Local Similarity 33.49; Pred. No. 1e-10;
Matches 45; Conservative 14; Mismatches 54; Indels 23; Gaps 7;

QY 2 LSGSPDPTLNGRIS---YKSLPIAGVIVIVYSSTPRTIQPKSLCTCTKIKVGTWTD 57
DB 179 VKCGPPDPSNKKNSITELFY--FYNGG--ISYEDGDFRLVGSFFGSLVWNKIVFVWS 234
QY 58 KPAKCFENKYSQTFP---IVPGYKTRGTPPTPHPSVTFKATKTFSMKNGKSVW 112
DB 245 NSDPTCEK 1GSGPNTLHGIVSGYK---ATYTHRDSVRLACINGTVLGRHIV 286
QY 113 QANNMKGPTRLPCT 127
DB 287 QACNINW--SSLPTC 299

RESULT 10
CFAR MOISE
AC P06009; STANDARD; PRT: 1234 AA.
DI 01 JAN 1988 (rel. 06, Created)
DI 01 JAN 1988 (rel. 06, last sequence update)
DI 01 MAR 2002 (rel. 41, last annotation update)
DE Complement factor H precursor (Protein beta-1-H).
GN HFI OR CFH
OS Mus musculus (Mouse)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognatha; Muridae; Mus;
OX NCBI TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=6624354; PubMed=2940596;
RA Kristensen F., Lack H.F.;
RI "Murine protein H is comprised of 20 repeating units, 61 amino acids
RI in length.*"
RL Proc. Natl. Acad. Sci. U.S.A. 84:3963-3967(1986).
RN [2]
RP SEQUENCE OF 119 FROM N.A.
RX STRAIN=BAUR/C;
RX MEDLINE=90148945; PubMed=2533512;
RA Minor Canaves P., Lack H.F., Vik D.P.;
RT "Analysis of complement factor H mRNA expression: dexamethasone and
RT IFN-gamma increase the level of H in L cells.*"

```

```

RL Biochemistry 28:9891-9897(1989).
RN [3]
RP SEQUENCE OF 116 FROM N.A.
RX MEDLINE=9011034; PubMed=2136885;
RA Natsume-Sakai S., Nonaka M., Harada Y.N., Shroffler D.C.,
RA Moriwaki K.;
RT "Demonstration of an unusual allelic variation of mouse factor H by
RT the complete cDNA sequence of the H 2 J101y1e.*"
RL J. Immunol. 144:358-362(1990).
CC 1- FUNCTION: FACTOR H FUNCTIONS AS A COFACTOR IN THE INACTIVATION +
CC C3B BY FACTOR I AND ALSO INCREASES THE RATE OF DISSOCIATION OF THE
CC C3BBB COMPLEX (C3 CONVERTASE) AND THE (C4B)NBS COMPLEX (C5
CC CONVERTASE) IN THE ALTERNATIVE COMPLEMENT PATHWAY.
CC 2- POLYMORPHISM: TWO CODOMINANT ALLELES OF FACTOR H ARE PRESENT IN
CC MICE.
CC 3- SIMILARITY: CONTAINS 20 SUSHI (S-CR) DOMAINS.
CC
CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch) or
CC or send an email to license@sib-sib.ch).
CC
DR EMBL: M12660; AAA37759.1; ;
DR EMBL: J02891; AAA37795.1; ;
DR EMBL: M31979; AAA37762.1; ;
DR F1R; A26154 NMESH.
DR HSSP; P08604; IHLI.
DR MGD; MGI:88485; Cih.
DR InterPro; IPR000436; Sushi_SCR_CCP.
DR Pfam; PF00084; sushi; 20.
DR SMART; SM00042; CCP; 20.
KW Complement alternate pathway; Plasma; Glycoprotein; Repeat; Sushi;
KW SIGNAL.
FT SIGNAL 1 18
FT CHAIN 19 1234
FT DOMAIN 20 81
FT DOMAIN 84 142
FT DOMAIN 145 206
FT DOMAIN 209 263
FT DOMAIN 266 321
FT DOMAIN 324 386
FT DOMAIN 388 443
FT DOMAIN 447 506
FT DOMAIN 508 565
FT DOMAIN 568 623
FT DOMAIN 628 684
FT DOMAIN 689 744
FT DOMAIN 751 803
FT DOMAIN 807 862
FT DOMAIN 866 932
FT DOMAIN 935 990
FT DOMAIN 993 1049
FT DOMAIN 1052 1108
FT DOMAIN 1113 1169
FT DOMAIN 1171 1234
FT D1SULFID 21 66
FT D1SULFID 52 80
FT D1SULFID 85 129
FT D1SULFID 114 141
FT D1SULFID 145 192
FT D1SULFID 173 205
FT D1SULFID 213 251
FT D1SULFID 257 262
FT D1SULFID 267 309
FT D1SULFID 294 320
FT D1SULFID 325 374
FT D1SULFID 357 385
FT D1SULFID 389 431
FT D1SULFID 415 442
FT D1SULFID 443 494

```


QY 62 KCEYENKYSOPEPIVPGYKIRG-STYYPBQTSVTFACKTNESMNKNKSWVQAN-----116
 DB 216 VTFTH---CDEPFNNIMRGESGYYSOVVTSYDCKCFILVGNASYTGVSKSDV 274
 QY 117 NMWG-----PTRLPT 126
 DL 275 GWSSEPPRGCTEKSVPTRKPT 296

RESULT 12
 F14B_HUMAN STANDARD: PRT: 661 AA.
 AC P05160;
 DI 13 AUG 1987 (rel. 05, Created)
 DI 16 AUG 1990 (rel. 15, last sequence update)
 DI 16 OCT 2001 (rel. 40, last annotation update)
 DE Coagulation factor XIII B chain precursor (EC 2.3.2.13) (Protein-
 DE glutamine gamma-glutamyltransferase B chain) (Transglutaminase B
 DE chain).
 GN F14b.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=91105054; PubMed=2271707;
 RA Rottenberg E., Ichinose A., Davie E.W.;
 RT "Nucleotide sequence of the gene for the b subunit of human factor
 RT XIII.";
 RL Biochemistry 29:11195-11209(1990).
 RP [2]
 RP SEQUENCE OF 2 661 FROM N.A.
 RX MEDLINE=87026535; PubMed=4021194;
 RA Ichinose A., McMillen B.A., Fujikawa K., Davie E.W.;
 RT "Amino acid sequence of the b subunit of human factor XIII, a protein
 RT composed of ten repetitive segments.";
 RL Biochemistry 25:4634-4648(1986).
 RP [3]
 RP REVISIONS.
 RA Ichinose A.;
 RL Submitted (FEB 1987) to the EMBL/GenBank/DBJ databases.
 RP [4]
 RP SEQUENCE OF 1-20 FROM N.A.
 RX ISSUES=11wet;
 RX MEDLINE=90251467; PubMed=2439067;
 RA Grundmann U., Neillich C., Rein T., Zettilmeissl G.;
 RT "Complete cDNA sequence encoding the B subunit of human factor XIII.";
 RL Nucleic Acids Res. 18:2817-2817(1990).
 RP [5]
 RP VARIANT PHE 450.
 RX MEDLINE=94314189; PubMed=8424218;
 RA Bashirzadeh T., Saito M., Morishita E., Matsuda T., Ichinose A.;
 RT "Two genetic defects in a patient with complete deficiency of the b-
 RT subunit for coagulation factor XIII.";
 RL Blood 82:145-150(1993).
 CC 1. FUNCTION: THE B CHAIN OF FACTOR XIII IS NOT CATALYTICALLY ACTIVE,
 CC BUT IS THOUGHT TO STABILIZE THE A SUBUNITS AND REGULATE THE RATE
 CC OF TRANSGLUTAMINASE FORMATION BY THROMBIN.
 CC 2. SUBUNIT: TETRAMER OF TWO A CHAINS AND TWO B CHAINS
 CC 3. DISEASE: A DEFICIENCY IN F14B CAN RESULT IN A LIFELONG BLEEDING
 CC TENDENCY, DEFECTIVE WOUND HEALING, AND HABITUAL ABORTION.
 CC 4. SIMILARITY: CONTAINS 10 SUSHI (SCR) DOMAINS.

This SWISS-Prot entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed, usage by and for commercial
 entities requires a license agreement (See <http://www.isb.ch/announce/>
 or send an email to license@isb-sib.ch).

EMBL: M64554 AAA51821.1; ALT_SEQ.
 EMBL: M14057 AAA88042.1;
 EMBL: X51823 CAA36123.1;
 PIR: A23830; A23830.
 PIR: A36397; A36397.
 PIR: S09980; S09980.
 HSP: P08603; IUPI.
 MCM: 134580;
 InterPro: IP0000436; Sushi_SCR_CCP.
 Pfam: PF0084; Sushi_8.
 SMART: SM0032; CCP; 8.
 Transferrase; Plasma; Blood coagulation; Repeat; Glycoprotein; Signal;
 Sushi; Disease mutation.
 FT SIGNAL 1 20
 FT CHAIN 21 661 COAGULATION FACTOR XIII B CHAIN.
 FT DOMAIN 24 88 SUSHI 1
 FT DOMAIN 90 147 SUSHI 2
 FT DOMAIN 152 209 SUSHI 3
 FT DOMAIN 212 268 SUSHI 4
 FT DOMAIN 273 328 SUSHI 5
 FT DOMAIN 335 390 SUSHI 6
 FT DOMAIN 395 451 SUSHI 7
 FT DOMAIN 453 516 SUSHI 8
 FT DOMAIN 523 579 SUSHI 9
 FT DOMAIN 581 647 SUSHI 10
 FT DISULFID 25 76 BY SIMILARITY.
 FT DISULFID 59 87 BY SIMILARITY.
 FT DISULFID 91 135 BY SIMILARITY.
 FT DISULFID 118 146 BY SIMILARITY.
 FT DISULFID 153 197 BY SIMILARITY.
 FT DISULFID 180 208 BY SIMILARITY.
 FT DISULFID 213 255 BY SIMILARITY.
 FT DISULFID 241 267 BY SIMILARITY.
 FT DISULFID 274 316 BY SIMILARITY.
 FT DISULFID 302 327 BY SIMILARITY.
 FT DISULFID 346 378 BY SIMILARITY.
 FT DISULFID 364 389 BY SIMILARITY.
 FT DISULFID 396 439 BY SIMILARITY.
 FT DISULFID 425 450 BY SIMILARITY.
 FT DISULFID 454 505 BY SIMILARITY.
 FT DISULFID 486 515 BY SIMILARITY.
 FT DISULFID 524 567 BY SIMILARITY.
 FT DISULFID 553 578 BY SIMILARITY.
 FT DISULFID 582 636 BY SIMILARITY.
 FT DISULFID 616 646 BY SIMILARITY.
 FT CARBOHYD 162 162 N-1 NKED (GLCNAC...) (POTENTIAL)
 FT CARBOHYD 545 545 N-1 NKED (GLCNAC...) (POTENTIAL).
 FT SITE 617 619 CELL ATTACHMENT SITE.
 FT VARIANT 450 450 C>S; F IN F.B DEFICIENCY.
 FT SEQUENCE 661 AA; 75491 MW; 5742134656057F2 CRC64;
 FT13-VAR.009475.
 Quality Match 22.0%; Score 95; Pos 1; Length 661;
 Res: Local Similarity 31.0%; Pos 3.5e-09;
 Matches 3%; Conservative 19; Mismatches 58; Indels 10; Gaps 5;
 QY 4 CSDPPLNGRISSYSPPIAVGVTVVYSCGTFPIQPKSLQITKIKVIQTIKFAPEK 64
 DE 274 CSDPPLPINSKIQTHSTYRHCIVHICE NPTGHSABIRG----EICKWTEP PK 427
 QY 64 EYENKYSOPEPIVPGYKIRGSTPYIHGSGVTTAKTNESMNKNKSWVQANRSGGT 122
 DE 328 IEGQKVCERPPPTENGAAHRSKIYNGKVTVAKSGYLIGSGNELCN RGRW-- 484
 QY 123 RLPTCV 128
 DB 385 LPEPCV 590
 RESULT 13
 ID DAF2_MOUSE
 AC Q61476; STANDARD: PRT: 407 AA.

1 DOMAIN: THE FIRST SUSHI DOMAIN (SCR1) IS NOT NECESSARY FOR
 FUNCTION. SCR2 AND SCR4 PROVIDE THE PROPER CONFORMATION FOR THE
 ACTIVE SITE ON SCR3 (BY SIMILARITY).
 2 PIM: THE SER/TUR RICH DOMAIN IS HEAVILY O-GLYCOSYLATED.
 3 POLYMORPHISM: DAF IS RESPONSIBLE FOR THE CROMER BLOOD GROUP
 SYSTEM. IT CONSISTS OF AT LEAST SEVEN HIGH-INCIDENCE (CR(A),
 TC(A), DR(A), ES(A), WES(R), OM* AND IF*) AND LOW INCIDENCE
 (TC(B), TC(C), AND WES(A)) ANTIGENS THAT RESIDE ON DAF. IN THE
 CROMER PHENOTYPES DR(A) AND INAH THERE IS REDUCED OR ABSENT
 EXPRESSION OF DAF, RESPECTIVELY. IN THE CASE OF THE DR(A-)
 PHENOTYPE, A SINGLE NUCLEOTIDE SUBSTITUTION WITHIN EXON 5 ACCOUNTS
 FOR TWO CHANGES: A SIMPLE AMINO ACID SUBSTITUTION THAT IS THE
 BASIS OF THE ANTIGENIC VARIATION, AND AN ALTERNATIVE SPLICING
 EVENT THAT UNDERLIES THE DECREASED EXPRESSION OF DAF IN THIS
 PHENOTYPE.
 4 SIMILARITY: CONTAINS 4 SUSHI (SCR) DOMAINS.
 5 SIMILARITY: BELONGS TO THE RECEPTORS OF COMPLEMENT ACTIVATION
 (RCA) FAMILY.
 6 DATABASE: NAME: PROW; NOTE: CD guide CD55 entry:
 WWW-<http://www.ncbi.nlm.nih.gov/prov/cd/cd55.htm>.
 7 THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL Outstation.
 8 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 or send an email to license@sib-sib.ch).
 9 EMBL: M49516; AAA52169.1;
 10 EMBL: M40142; AAA52168.1;
 11 EMBL: BC001288; AA001288.1;
 12 EMBL: M15799; AAA52167.1;
 13 EMBL: U88576; AA48622.1;
 14 EMBL: M64653; AAA52170.1;
 15 EMBL: M64456; AAA52170.1; JOINED.
 16 EMBL: S72858; AAC60633.1;
 17 PIR: B26459; B26459.
 18 PIR: A26459; A26459.
 19 PIR: S16187; S16187.
 20 PIR: A19101; A19101.
 21 PIR: S24148; S24148.
 22 BSSP: P08603; IHCC.
 23 MIM: 125240;
 24 InterPro: IPR000446; Sush1_SCR_CCP.
 25 Pfam: PF00084; Sush1; 4.
 26 SMART: SM00042; CCP; 4.
 27 Complement pathway: Plasma; glycoprotein; Membrane; Repeat;
 28 Alternative splicing; GPI anchor; Signal; Sush1; Polymorphism;
 29 Blood group antigen.
 30 SIGNAL: 1 44
 31 CHAIN: 45 453
 32 PROPEP: 454 481
 33 DOMAIN: 45 95
 34 SUSHI 1.
 35 SUSHI 2.
 36 SUSHI 3.
 37 SUSHI 4.
 38 SUSHI 4.
 39 SER/THR-RICH.
 40 COMPLEMENT DECAY ACCELERATING FACTOR.
 41 REMOVED IN MATURE FORM.
 42 SUSHI 1.
 43 SUSHI 2.
 44 SUSHI 3.
 45 SUSHI 4.
 46 SUSHI 4.
 47 SER/THR-RICH.
 48 DISULFID: 36 81
 49 DISULFID: 65 94
 50 DISULFID: 98 145
 51 DISULFID: 129 158
 52 DISULFID: 163 204
 53 DISULFID: 190 220
 54 DISULFID: 225 267
 55 DISULFID: 253 284
 56 CARDIOPHYD: 95 96
 57 LIPID: 453 454
 58 VARSPLIC: 362 381
 59 N-LINKED (GLCNAC...) (POTENTIAL).
 60 GPI ANCHOR.
 61 HIGH-TO-LOW INCIDENCE -> SRPVTUAGMKWCRSL.
 62 CSRTDPRKSPHSLSSWYRAHVFVDFPANDSNHCL
 63 DLAKELRRKRYTOYRIKFIYS (IN ISOFORM 1).
 64 R -> L (IN TC(B) ANTIGEN).
 65 /FTid-VAR_001997.
 66 VARIANT 52 52

FT VARIANT 52 52 R -> P (IN TC(C) ANTIGEN).
 FT /FTid-VAR_001998.
 FT VARIANT 82 82 L -> R (N WES(A) ANTIGEN).
 FT /FTid-VAR_001999.
 FT VARIANT 199 199 S -> L (N DR(A) ANTIGEN).
 FT /FTid-VAR_002000.
 FT VARIANT 227 227 A -> P (N CR(A) ANTIGEN).
 FT /FTid-VAR_002001.
 FT CONFLICT 80 80 T -> I (N REF 1, 2 AND 4).
 FT CONFLICT 85 85 S -> M (N REF 3).
 FT CONFLICT 187 187 S -> I (N REF 4).
 FT CONFLICT 297 297 Q -> H (IN REF 4).
 SQ SEQUENCE 381 AA: 41388 MW: 291483 DB4365E (CR64);
 Query Match 21.18; Score 103.5; DB 1; Length 481;
 Best Local Similarity 33.38; Pred. No. 8.8; 09;
 Matches 45; Conservative 17; Mismatches 50; Indels 24; Gaps 9;
 QY 3 SCGS-PEELINGISYSTP--IAVTVIVYS-SGTFLIGKSLNITIKVIRT--WD 57
 DB 162 SCNPGEIENCOI---DWPGGILFCATIPESINIGYKLPSTSTSECI---ISCSWWS 214
 QY 58 KIAPACIEFNKYSSCPPIVPGGYKIECHIP-YHIGSVIFACIKINSMKNSVWQAN 116
 DB 215 DLPET---PELYCPAEPQIDNHIGKEELIYGYRQSVTYA-NKQFTMIGESHTIVN 270
 QY 117 N---MW-GPTRIPTIC 127
 DB 271 NDECEKSGDP--PDC 284
 RESULT 17
 CQPH_HSVSA
 ID CQPH_HSVSA STANDARD; PR: 360 AA.
 AC Q01016;
 DT 01-APR-1994 (Rel. 25, Created)
 DT 01-APR-1994 (Rel. 25, Last sequence update)
 DT 15-JUL-1998 (Rel. 36, Last annotation update)
 DE Complement control protein homolog precursor (CQPH).
 GN 4 OR CQPH.
 OS Herpesvirus saimiri (strain 11).
 OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
 CC Gammaherpesvirinae; Rhadinovirus
 CC NCBI TaxID: 10383;
 RN 111
 RP SEQUENCE FROM N.A.
 PX MEDLINE-92:33688; pubmed-1321287
 RA Albrecht J.-C., Nicholas J., Biller D., Cameron K.R., Biesinger R.,
 FA Newman C., Wittmann S., Craxton M.A., Coleman H., Fleckenstein R.,
 RA Honess R.W.
 R* "Primary structure of the herpesvirus saimiri genome."
 RL J. Virol. 66:5047-5058(1992).
 RN 121
 RP SIMILARITY TO CCP.
 RX MEDLINE-92260674; Pubmed-1316492;
 RA Albrecht J.-C., Fleckenstein B.;
 RT "New member of the multigene family of complement control proteins in
 herpesvirus saimiri.";
 RL J. Virol. 66:3937-3940(1992).
 CC -|- ALTERNATIVE PRODUCTS: A MEMBRANE-BOUND FORM AND A SECRETED FORM
 CC ARE PRODUCED BY ALTERNATIVE SPLICING OF THE SAME GENE.
 CC -|- SIMILARITY: BELONGS TO THE SUPERFAMILY OF THE REGULATORS OF
 CC COMPLEMENT ACTIVATION (RCA).
 CC -|- SIMILARITY: CONTAINS 3 SUSHI (SCR) DOMAINS.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL Outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC

CC this SWISS prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC EMBL: L11244; AAA5615.1;
 CC EMBL: L11245; AAA5616.1;
 CC EMBL: M29664; AAB59520.1;
 CC PIR: A44877; A44877;
 CC PIR: A47107; A47107;
 CC HSP: P19998; IVD;
 CC MIM: 120841;
 CC InterPro: IPR000406; Sushi SCR CCP;
 CC Pfam: PF00084; Sushi; 3;
 CC SMART: SM00042; CCP; 3;
 CC Complement pathway; Plasma; Glycoprotein; Repeat; Sushi; Signal;
 CC Polymorphism;
 CC SIGNAL 1 17
 CC CHAIN 18 252 C4B BINDING PROTEIN BETA CHAIN.
 CC DOMAIN 22 77 SUSHI 1;
 CC DOMAIN 80 135 SUSHI 2;
 CC DOMAIN 138 192 SUSHI 3;
 CC DISULFID 23 63 HY SIMILARITY;
 CC DISULFID 49 76 HY SIMILARITY;
 CC DISULFID 81 121 HY SIMILARITY;
 CC DISULFID 107 134 HY SIMILARITY;
 CC DISULFID 139 179 HY SIMILARITY;
 CC DISULFID 165 191 HY SIMILARITY;
 CC DISULFID 202 202 INTERCHAIN (WITH ALPHA CHAIN)
 CC DISULFID 216 216 INTERCHAIN (WITH ALPHA CHAIN)
 CC DISULFID 64 64 N LINKED (GLNAC. . .) (POTENTIAL);
 CC CARBOHYD 71 71 N LINKED (GLNAC. . .) (POTENTIAL);
 CC CARBOHYD 98 98 N LINKED (GLNAC. . .) (POTENTIAL);
 CC CARBOHYD 117 117 N LINKED (GLNAC. . .) (POTENTIAL);
 CC CARBOHYD 154 154 N LINKED (GLNAC. . .) (POTENTIAL);
 CC VARIANT 198 198 P. 3 S (UN DESN:1804226).
 CC SEQUENCE 252 AA; 28457 MW; 0F6C6436765E2E7 CRC64;
 CC

Query Match 18.6% Score 141; DB 1; Length 252;
 Best Local Similarity 26.0%; Pred. No. 3.4e-07;
 Matches 43; Conservative 21; Mismatches 59; Indels 14; Gaps 6;
 QY 4 GSDPPPLING---RISYYSITIAVGVIRYSNGSGLFELDERKSLIC IKKVGGLW 67
 DB 23 CPELPVDN--STFAKEVRQIDGYVGTGKYLGVKKTLF---NASKEDNTTE 75
 QY 63 CEYENKYSCEPEIVPGYKIRGSLTFRHGLSVIFA/KTNFSMNGKNSVWCVANNWGP 122
 DB 76 C RICHCPDVLVNG--DESSSCVNVSVLKTFPMCMNDHYILKGSNRSQCLEDHWAP 130
 QY 123 MLPTCVS 129
 DB 141 FPICKS 146

RESULT 26
 ID CTAB PIG STANDARD; PRT; 151 AA.
 AC Q04710;
 DT 15 DEC 1998 (Rel. 37, Created)
 DT 15 DEC 1998 (Rel. 47, Last sequence update)
 DT 16 OCT 2001 (Rel. 40, Last annotation update)
 DE Complement factor B (E034.4.21.47) (C3/C5 convertase) (Properdin
 DE factor B) (Fragment).
 GN BF.
 OS Sus scrofa (Pig)

CC Fukuyota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus;
 CC NCBI_TaxID=9823;
 CC [1]
 CC RP SEQUENCE FROM N.A.
 CC MEDLINE=9 372866; PubMed=1680099;
 CC Igelman L J., van de Weghe A.R., Coppinckers W.R., van Zeytzen A.J.
 CC Bouquet Y.H.;
 CC "Cloning and sequencing of the porcine complement factor B";
 CC Immunogenetics 34:192-195(1991).
 CC -1- FUNCTION: FACTOR B WHICH IS PART OF THE ALTERNATE PATHWAY OF THE
 CC COMPLEMENT SYSTEM IS CLEAVED BY FACTOR D INTO 2 FRAGMENTS: BA AND
 CC BB. BA, A SERINE PROTEASE, THEN COMBINES WITH COMPLEMENT FACTOR D
 CC TO GENERATE THE C3 OR C5 CONVERTASE.
 CC -1- CATALYTIC ACTIVITY: Cleaves C3 in the alpha chain to yield C3a and
 CC C3b. Cleaves C5 in the alpha chain to yield C5a and C5b. Both
 CC cleavages take place at the C-terminal of an arginine residue.
 CC -1- SUBUNIT: MONOMER.
 CC -1- MISCELLANEOUS: FACTOR B IS A MAJOR HISTOCOMPATIBILITY COMPLEX
 CC CLASS-III PROTEIN.
 CC -1- SIMILARITY: WITH COMPLEMENT C3.
 CC -1- SIMILARITY: CONTAINS 3 SUSHI (SCF) DOMAINS (BY SIMILARITY).
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY.
 CC -----
 CC this SWISS-prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC EMBL: M5624; AAA31021.1;
 CC HSP: P07743; LOUB
 CC InterPro: IPR000436; Sushi SCR CCP;
 CC Pfam: PF00084; Sushi; 2;
 CC SMART: SM00042; CCP; 2;
 CC PROSITE: PS50240; TRYPSIN_DOM; PART AL;
 CC PROSITE: PS00134; TRYPSIN_HIS; PART AL;
 CC PROSITE: PS00135; TRYPSIN_SER; PART AL;
 CC Complement alternate pathway; Plasma; Hydrolase; Serine protease;
 CC Glycoprotein; Repeat; Sushi;
 CC NON_TER 1 1
 CC DOMAIN 1 58 SUS 1 1;
 CC DOMAIN 63 118 SUS 1 1;
 CC DISULFID 4 46 HY SIM. ACTIVITY
 CC DISULFID 32 59 HY SIM. ACTIVITY
 CC DISULFID 66 106 HY SIM. ACTIVITY
 CC DISULFID 92 119 HY SIM. ACTIVITY
 CC CARBOHYD 23 23 N-LINKED (GLNAC. . .) (POTENTIAL);
 CC CARBOHYD 43 43 N-LINKED (GLNAC. . .) (POTENTIAL);
 CC NON_TER 151 151
 CC SEQUENCE 151 AA; 16765 MW; H0247E5047E517F CRC64;
 CC

Query Match 18.6% Score 140; DB 1; Length 151;
 Best Local Similarity 30.6%; Pred. No. 2.4e-07;
 Matches 41; Conservative 15; Mismatches 62; Indels 16; Gaps 4;
 QY 2 ISCSPPLING---RISYYSITIAVGVIRYSNGSGLFELDERKSLIC IKKVGGLW 67
 DB 2 IRCPRHILFENGSEWPRAPYNN---LSEISFIDYDITLRGSKRIG--QVGRWD 64
 QY 58 KPAKCEYENKYSCEPEIVPGYKIRGSLTFRHGLSVIFA/KTNFSMNGKNSVWCVANN 117
 DB 54 GOTA(CD)GAGY--CPNPGIPICGPKWV--CYPLEISVITYCTEILRSQRRCQED 110
 QY 118 MWGPTRLPTCVSVF 131
 DB 111 SWSQTE-PSQDSF 123

FT DOMAIN 893 952 SUSLI 4.
 FT SITE 418 420 CELL ATTACHMENT SITE.
 FT DISULFID 714 755 BY SIMILARITY.
 FT DISULFID 741 768 BY SIMILARITY.
 FT DISULFID 773 814 BY SIMILARITY.
 FT DISULFID 860 827 BY SIMILARITY.
 FT DISULFID 842 877 BY SIMILARITY.
 FT DISULFID 863 890 BY SIMILARITY.
 FT DISULFID 894 949 BY SIMILARITY.
 FT DISULFID 922 952 BY SIMILARITY.
 FT CARBOHYD 476 476 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 525 525 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 605 605 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 620 620 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 752 752 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 789 789 N-LINKED (GLCNAC...) (POTENTIAL).
 FT VARSPLIC 529 553 MISSING (IN ISOFORM 2 AND ISOFORM 4).
 FT VARSPLIC 892 958 MISSING (IN ISOFORM 1 AND ISOFORM 2).
 SQ SEQUENCE 958 AA: 107027 MW: 416125885 ABC764 CRC64;
 Query Match 18.2% Score 136.5; DB 1; Length 958;
 Best Local Similarity 31.6%; Pred. No. 4e-06;
 Matches 43; Conservative 16; Mismatches 58; Indels 19; Gaps 8;
 QY 2 ISGSPPLINGRI---SYSTPIAVGVIVRYKSGFRLIGESKSLCTKDKVDGTDWK 58
 DB 840 IQCVMPVAPLNGITSGRLTVALVTSCNDHISLGESSLICTE-----NGQWSH 885
 QY 59 IAFKYEYKYSYSCPEP-IVDSYKIPGSTVPHCPVSTFACKTF---SNNG-NKSVWVQ 114
 DB 886 SPPFK---SCTVYEDHPNGLLIADLKFNADAGVLSVQCRCFVSGEPPFPRKQ 940
 QY 115 ANNMW GTRLPITVS 129
 DB 941 PGRWSGP- MPKCKS 954
 RESULT 41
 FHR2 HUMAN
 AC P46980; Q14310;
 D1 31 JUN 1994 (Ref. 29, Created)
 D1 16 OCT 2001 (Ref. 40, last sequence update)
 DE Complement factor H-related protein 2 precursor (FHR-2) (H factor-like protein 2) (H factor-like 3) (FESK59).
 GN FHR2 OR HFL3.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC ISSUES-1199;
 RA Skerka C., Timman C., Horstmann K.D., Zipfel P.R.;
 RI "Two additional human serum proteins structurally related to complement factor H: Evidence for a family of factor H-related genes.";
 RI J. Immunol. 148:3313-3318(1992).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=95402981; PubMed=7672821;
 RA Skerka C., Moulds J.M., Tailon-Miller P., Hourcade D., Zipfel P.F.;
 RI "The human factor H-related gene 2 (FHR2): structure and linkage to the coagulation factor XIIIb gene.";
 RI Immunogenetics 42:268-274(1995).
 RN [3]
 RP REVIEW
 RX MEDLINE=94226679; PubMed=8172644;
 RA Zipfel P.F., Skerka C.;
 RI "Complement factor H and related proteins: an expanding family of complement regulatory proteins?";
 RI

Immunol. Today 15:121-126(1994).
 - FUNCTION: MIGHT BE INVOLVED IN CYTLEMENT REGULATION. CAN ASSOCIATE WITH LIPOPROTEINS AND MAY PLAY A ROLE IN LIPID METABOLISM.
 - SUBCELLULAR LOCATION: Extracellular.
 - ALTERNATIVE PRODUCTS: 2 ISOFORMS; A LONG FORM (SHOWN HERE) AND A TRUNCATED FORM; MAY BE PRODUCED BY ALTERNATIVE SPLICING.
 - PTM: N-GLYCOSYLATED. TWO FORMS ARE OBSERVED; ONE WITH A SINGLE SIDE CHAIN, THE OTHER IS NOT GLYCOSYLATED.
 - SIMILARITY: CONTAINS 4 SUSHI (S'R) DOMAINS.
 - SIMILARITY: STRONG. TO FACTOR H.
 THIS SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement. See <http://www.isb-sib.ch/announcement/> or send an email to license@isb-sib.ch.
 EMBL: X64877; CAA60375.1;
 EMBL: X86504; CAA60375.1; JOINED.
 EMBL: X86505; CAA60375.1; JOINED.
 EMBL: X86506; CAA60375.1; JOINED.
 EMBL: X86507; CAA60375.1; JOINED.
 P R: S24564; S24564.
 DR HSP: P08673; IHEF.
 MIM: 600883;
 TrpPro: IP0600436; Sushi_SCP_CCP.
 TrpPro: P00384; sushi; 4.
 SMART: SMO3042; CCP; 4.
 KW Repeat; Glycoprotein; Sushi; Signal; Alternative splicing.
 FT SIGNAL 1 18 POTENTIAL.
 FT CHAIN 19 270 COMPLEMENT FA-1 OR H-RELATED PROTEIN 2.
 FT DOMAIN 19 85 SUSHI 1.
 FT DOMAIN 86 127 SUSHI 2.
 FT DOMAIN 128 205 SUSHI 3.
 FT DOMAIN 206 270 SUSHI 4.
 FT CARBOHYD 126 126 N-LINKED (GLCNAC...).
 FT VARSPLIC 144 171 ISAEKGGPPIDNEDITSELLSYVAL3--S (IN TRUNCATED ISOFORM).
 FT CONFLICT 85 85 K->K (N REF. 2).
 SQ SEQUENCE 270 AA: 30651 MW: 31280-13942.7AB CRC64;
 Query Match 17.9% Score 134.5; DB 1; Length 270;
 Best Local Similarity 28.5%; Pred. No. 1.6e-06;
 Matches 39; Conservative 17; Mismatches 50; Indels 31; Gaps 7;
 QY 4 CGSPPLINGRI-SYSTPIAVGVIVRYKSGFRLIGESKSLCTKDKVDGTDWK 62
 DB 149 CGPP-PIDNGDITSLSVYAPGSSVEYQVQVQLEINNGITC-----RNGQWSEP EK 202
 QY 63 G-----EYENKYSYSCPEP-IVDSYKIPGSTVPHCPVSTFACKTF---SNNGSVTFACKTFESMNKKS 110
 DB 203 GPPVYV-SCTIMEAYN-----IKLWIKKSLKSLIGIVHVSASCTHPRKSHS 252
 QY 111 VMCQANNMGGPTRLPTC 127
 DB 253 FRAMQN--GKLVPESC 267
 RESULT 32
 APOH RAT
 ID APOH_RAT STANDARD: PRT: 297 AA.
 AC P26644;
 DT 01-AUG-1992 (Ref. 23, Created)
 DT 01-FEB-1996 (Ref. 33, last sequence update).
 DT 16-OCT-2001 (Ref. 40, last annotation update).
 DE Beta-2-glycoprotein I precursor (Apo lipoprotein H) (Apo H) (h2GPI);
 DE (Beta(2)GPI).
 GN APOH.
 OS Rattus norvegicus (Rat).
 OC Chordata; Vertebrata; Euteleostomi;
 OC Eukaryota; Metazoa; Chordata; Cranioa; Vertebrata; Euteleostomi;

Sequence of the major cytosolic bromide-cleavage peptide (CR-11) and completion of the sequence of the BB fragment.";

RI Biochem. J. 209:61-70(1984).

RN [10]

SEQUENCE OF 44-764 FROM N.A.

RX MEDLINE-B4274541; PubMed-6308626;

RA Campbell R.D., Porter R.R.

RI "Molecular cloning and characterization of the gene coding for human

complement protein factor B";

RL Proc. Natl. Acad. Sci. U.S.A. 80:4464-4468(1983).

RN [11]

SEQUENCE OF 467-595 AND 752-764 FROM N.A.

RX MEDLINE-B439428; PubMed-6957884;

RA Woods D.F., Markham A.F., Ricker A.T., Goldberger G., Golten H.R.

RI "Isolation of cDNA clones for the human complement protein factor B,

a class III major histocompatibility complex gene product";

RL Proc. Natl. Acad. Sci. U.S.A. 79:5661-5665(1982).

RN [12]

SEQUENCE OF 16-259 FROM N.A.

RX MEDLINE-B4158524; PubMed-6424161;

RA Morley R.D., Campbell R.D.

RI "Internal homologues of the BB fragment from human complement

protein factor B, a class III MHC antigen";

RL EMBO J. 3:153-157(1984).

RN [13]

SEQUENCE OF 1-99 FROM N.A.

RX TISSUE-Blood;

RA MEDLINE-B7102880; PubMed-4044061;

RA Wu L.C., Morley R.D., Campbell R.D.

RI "Cell specific expression of the human complement protein factor B

gene: evidence for the role of two distinct 5'-flanking elements";

RL Cell 48:341-342(1987).

RN [14]

GLYCATION IN POSITION 291.

RX MEDLINE-91174758; PubMed-2006911;

RA Nicomano M.A., Brown A.S., Miller E.J.

RI "The principal site of glycation of human complement factor B";

RL Biochem. J. 274:473-480(1991).

CC 1 FUNCTION FACTOR B WHICH IS PART OF THE ALTERNATE PATHWAY OF THE

COMPLEMENT SYSTEM IS CLEAVED BY FACTOR D INTO 2 FRAGMENTS: BA AND

BB. BB, A SERINE PROTEASE, THEN COMBINES WITH COMPLEMENT FACTOR 3B

TO GENERATE THE C3 OR C5 CONVERTASE. IT HAS ALSO BEEN IMPLICATED

IN PROLIFERATION AND DIFFERENTIATION OF PREACTIVATED B

LYMPHOCYTES, RAPID SPREADING OF PERIPHERAL BLOOD MONOCYTES,

STIMULATION OF LYMPHOCYTE BLASTOGENESIS AND LYSIS OF ERYTHROCYTES.

BA INHIBITS THE PROLIFERATION OF PREACTIVATED B LYMPHOCYTES.

1 CATALYTIC ACTIVITY: Cleaves C3 in the alpha-chain to yield C3a and

C3b. Cleaves C5 in the alpha-chain to yield C5a and C5b. Both

cleavages take place at the C-terminal of an arginine residue.

1 SUBUNIT: MONOMER.

1 ALTERNATIVE PRODUCTS: 2 isoforms: 1 (shown here) and 2: are

produced by alternative splicing.

1 POLYMORPHISM: TWO MAJOR VARIANTS, F AND S, AND 2 MINOR VARIANTS,

AS WELL AS AT LEAST 14 VERY RARE VARIANTS, HAVE BEEN IDENTIFIED.

1 MISCELLANEOUS: FACTOR B IS A MAJOR HISTOCOMPATIBILITY COMPLEX

CLASS III PROTEIN.

1 SIMILARITY: WITH COMPLEMENT C2.

1 SIMILARITY: CONTAINS 3 SUSHI (SCR) DOMAINS.

1 SIMILARITY: CONTAINS 1 VWFA DOMAIN.

1 SIMILARITY: BELONGS TO DEPTIDASE FAMILY S1; ALSO KNOWN AS THE

TRYPSIN FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

between the Swiss Institute of Bioinformatics and the EMBL outstation -

the European Bioinformatics Institute. There are no restrictions on its

use by non-profit institutions as long as its content is in no way

modified and this statement is not removed. Usage by and for commercial

entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/)

or send an email to license@isb-sib.ch).

CC

EMBL: X72875; CAA51489.1;

EMBL: S67410; A001989.1;

EMBL: L15702; AAA16820.1;

DR EMBL: X00284; CAA25077.1;

DR EMBL: AF019414; AA867977.1;

DR EMBL: BC004.43; AA004143.1;

DR EMBL: AF349679; AA30167.1;

DR EMBL: J00156; AA36225.2;

DR EMBL: J00125; NOT_ANNOTATED_CHS.

DR EMBL: J00126; AA36226.1;

DR EMBL: J00185; AA36219.1; ALT_SEQ.

DR EMBL: J00186; AA36220.1;

DR EMBL: M15082; AA59625.1;

DR PIR: A00944; BBDD.

DR PIR: S14339; S14339.

DR PIR: S34075; S34075.

DR 4SSP: P00734; 2HNT.

DR MEROPS: S01.195;

DR SWISS-2DPAGE: P00751; HUMAN.

DR Pfam: 2DPAGE; P00751;

DR MIM: 138470;

DR InterPro: I1R001314; Chymotrypsin.

DR InterPro: I1R00436; Sushi_SCR_CCP.

DR InterPro: IERC01254; Trypsin.

DR InterPro: IERC02035; VWFA.

DR Pfam: PF00084; Sushi; 3.

DR Pfam: PF00089; trypsin; 1.

DR PRINTS: PR00092; vwa; 1.

DR PRINTS: PR00722; CHYMOTRYPSIN.

DR PRINTS: PR00453; VWFADOMAIN.

DR SMART: SM00032; CCP; 3.

DR SMART: SM00020; TRYP-SPC; 1.

DR SMART: SM00327; VWA; 1.

DR PROSITE: PS02040; TRYPSIN_DOM; 1.

DR PROSITE: PS00134; TRYPSIN_HIS; 1.

DR PROSITE: PS00135; TRYPSIN_SER; 1.

DR PROSITE: PS0214; VWFA; 1.

KW Complement alternate pathway; Plasma hydrolase; Serine protease;

KW Glycoprotein; Repeat; Sushi; Signal; Polymorphism; Zymogen

KW Alternative splicing; 25

FT CHAIN 26 764 COMPLEMENT FACTOR B.

FT CHAIN 26 259 BA FRAGMENT.

FT CHAIN 260 764 BB FRAGMENT.

FT DOMAIN 36 99 SUSHI 1

FT DOMAIN 104 159 SUSHI 2

FT DOMAIN 161 219 SUSHI 3

FT DOMAIN 27 469 VWFA.

FT DOMAIN 484 764 SERINE PROTEASE.

FT ACT_SITE 326 526 CHARGE RELAY SYSTEM.

FT ACT_SITE 376 576 CHARGE RELAY SYSTEM.

FT ACT_SITE 693 699 CHARGE RELAY SYSTEM.

FT DISULFID 37 76 HY SIMILARITY.

FT DISULFID 62 98 BY SIMILARITY.

FT DISULFID 104 145 BY SIMILARITY.

FT DISULFID 131 158 BY SIMILARITY.

FT DISULFID 165 205 HY SIMILARITY.

Query Match 17.7%; Score 153; DB 1; Length 764;

Best Local Similarity 29.9%; Pred. No. 7; Le-05;

Matches 40; Conservative 15; Mismatches 53; Indels 16; Gaps 6;

QY 2 ISCGSPPHHNG---RISYSTPIAVGVY-YSP-GRFR-GRKSLGTTIKKVGCTMD 57

DB 101 HCPHPRHDFENGFWPRSPYYN---VSDEISFRCDCYI-KGSANKD---GVNQRWS 192

QY 56 KVAPKLEIFNRYSSPEPIVPGYKIRGTSPTFRHDSVTFV-KTNFNMNKNKSVWQANN 117

DB 153 CQTALDQ-NCA3YCSNDCIPGTPKVS-GVP-PVSVTHCSWGIHFGSQHPHFGFSS 209

QY 118 MNGPRLHFCVSVF 131

DB 210 SWSGTE-FSCQSPF 222

RESULT 34


```

FT DISULFID 163 163 INTERCHAIN (BY SIMILARITY)
FT CONFLICT 44 44 1 - V (IN REF. 1; AA SEQUENCE)
FT CONFLICT 46 46 1 - A (IN REF. 1; AA SEQUENCE)
SQ SEQUENCE 202 AA: 22724 MW: EABC951B06A0D80C GRC64;

Query Match 17.4% Score 131; DB 1; Length 202;
Host Local Similarity 25.2%; Pred. No. 2,7e-06;
Matches 34; Conservative 24; Mismatches 56; Indels 22; Gaps 6;

QY 4 GUSPPILNGRLSYSTPIACTV-----IRYSCTGFLIGELKSLITKDKVDGTWD 57
DB 30 CNTPVAVARG---HTTQI-IGLEFMKKDEVVYKCDGYTLVGHDRLSCKS-----SRWS 79
QY 58 KVAPEYENKYSCTPEIVAGCKNIRGSTYPRHGSVTFACKTNFNMCKNSKSWCCANN 117
DB 80 PAAPQK-----ALGPKPIQDGLSLVQIQDEYIESENVIVGCSGSGYGLVGPRLITCTEDG 134
QY 118 MWGPTRLTNCVSVP 132
DB 135 TMHP RVKCEWEXP 148

RESULT 46
ID CFAB_BOVIN STANDARD; PRI: 685 AA.
AC Q28085;
DT 01 MAR 2002 (Rel. 41, Created)
DT 01 MAR 2002 (Rel. 41, Last sequence update)
DI 01 MAR 2002 (Rel. 41, Last annotation update)
DE Complement factor H (H factor 1) (Fragments).
GN HFI.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN 111
RP TISSUE=Liver;
RX MEDLINE=96202005; PubMed=8615824;
RA Soares G.J., Day A.J., Sim R.B.;
RI "Prediction from sequence comparisons of residues of factor H involved
RI in the interaction with complement component C3b.";
RL Biochem. J. 315:523-531(1996).
CC 1- FUNCTION: Factor H functions as a cofactor in the inactivation of
CC C3b by factor I and also increases the rate of dissociation of the
CC C3bB complex (C3 convertase) and the (C3b)BB complex (C5
CC convertase) in the alternative complement pathway (By similarity).
CC 1- SIMILARITY: CONTAINS AT LEAST 13 SUSHI (SCK) DOMAINS.
CC
CC This SWISS Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed, usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL: X98697; CAA67257.1;
DR RSSP: P10998; IYVD.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR Pfam: PF00084; sushi; 11.
DR SMART: SM00042; CCP; 11.
KW Complement alternate pathway; Plasma; Repeat; Sushi.
FT NON_TER 1 1
FT NON_CONS 16 17
FT DOMAIN 17 67 SUSHI 2.
FT DOMAIN 68 131 SUSHI 3.
FT DOMAIN 132 148 SUSHI 4.
FT DOMAIN 149 246 SUSHI 5.
FT DOMAIN 247 409 SUSHI 6.
FT DOMAIN 410 466 SUSHI 7.
FT DOMAIN 467 470 SUSHI 8.

```

```

FT DOMAIN 431 488
FT DOMAIN 491 547
FT DOMAIN 553 609
FT DOMAIN 614 668
FT DOMAIN 675 >685
FT DISULFID 39 66
FT DISULFID 71 117
FT DISULFID 103 130
FT DISULFID 135 176
FT DISULFID 162 187
FT DISULFID 192 234
FT DISULFID 219 245
FT DISULFID 250 297
FT DISULFID 280 308
FT DISULFID 312 354
FT DISULFID 339 365
FT DISULFID 371 417
FT DISULFID 400 428
FT DISULFID 432 476
FT DISULFID 459 487
FT DISULFID 492 534
FT DISULFID 520 546
FT DISULFID 554 597
FT DISULFID 583 608
FT DISULFID 615 656
FT DISULFID 642 667
FT NON_TER 685
SQ SEQUENCE 685 AA: 77536 MW: 69FC9_C8D53CEB72 GRC64;

Query Match 17.4% Score 131; DB 1; Length 685;
Host Local Similarity 28.5%; Pred. N. 1e-05;
Matches 39; Conservative 19; Mismatches 49; Indels 40; Gaps 8;

QY 3 SNGSPPIING-RISVYSPIAVGIVIPYSSTGTFELI EKSLITKDKVDGTWDIKPAP 61
DB 553 SCALPPLNGRLKKEIKHEEYAHNEVYVYACNPKPLKGSCHKIQC---VDRP-SIALP 606
QY 52 KQYENKYSCTPEIVAGCKNIRGSTYPRHGSVTFACKTNFNMCKNSKSWCCANN 112
DB 607 VC TEERTCEISLDGDKVKSVP-----PIHDSVSESKREAFIMAGRFII 655
QY 113 QVANNWGWPTRLTNCVS 129
DB 656 C-1SPW---TQPPQCTA 669

RESULT 37
ID LEM3_SHEEP STANDARD; PRI: 769 AA.
AC P98109;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE P-selectin precursor (Granule membrane protein 140) (GMP-140) (PAK3DM)
DE (CD62P) (Leukocyte endothelial cell adhesion molecule 4) (LECAM4).
GN SELP.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN 111
RP SEQUENCE FROM N.A.
RC TISSUE=Heart;
RA Burns S.A., Neufeld E.J., Donady J.;
RL Submitted (JUL-1994) to the EMBL/GenBank/DBJ databases.
CC 1- FUNCTION: CA(24)-DEPENDENT RECEPTOR FOR WYELOID CELLS THAT BINDS
CC TO CARBOHYDRATES ON NEUTROPHILS AND MONOCYTES. MEDIATES THE
CC INTERACTION OF ACTIVATED ENDOTHELIAL CELLS OR PLATELETS WITH
CC LEUKOCYTES. THE LIGAND RECOGNIZED IS SIALYL LEWIS X.
CC 1- SUBCELLULAR LOCATION: TYPE I membrane protein.
CC 1- SIMILARITY: TO OTHER SLEPTINS/LXAMS
CC 1- SIMILARITY: CONTAINS 1 C-TYPE 3-LEU-TIN FAMILY DOMAIN.

```


1 CC ? SIMILARITY: CONTAINS 6 SUSHI (SUS) DOMAINS; BOVINE P-LESTIN LACKS
2 THE HUMAN SUSHI 3, 4 AND 7 EQUIVALENTS.
3
4 CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration
5 between the Swiss Institute of Bioinformatics and the EMBL outstation
6 at the European Bioinformatics Institute. There are no restrictions on its
7 use by non-profit institutions as long as its content is in no way
8 modified and this statement is not removed. Usage by and for commercial
9 entities requires a license agreement (See <http://www.ebi.ac.uk/submit/faq.html>
10 or send an email to license@ebi.ac.uk).
11
12 DB EMBL: U22041; AAA02434.1;
13 RESPI: P16109; LF58
14 InterPro: IPR000561; EGF-like.
15 InterPro: IPR002496; Selectin.
16 InterPro: IPR000446; SUSHI SUS CDP.
17 InterPro: IPR001404; Lectin C.
18 Pfam: PF00006; EGF-1.
19 Pfam: PF00059; Lectin C. 1.
20 Pfam: PF00064; SUSHI 6.
21 PRINTS: PR00044; SELECTIN.
22 SMART: SM00042; CYP. 6.
23 SMART: SM00044; CLECT. 1.
24 SMART: SM00181; EGF. 1.
25 PROSITE: PS00022; EGF. 1.
26 PROSITE: PS00166; EGF. 2.
27 PROSITE: PS00616; C-TYPE LECTIN 1.
28 PROSITE: PS00617; C-TYPE LECTIN 2.
29 PROSITE: PS00618; C-TYPE LECTIN 3.
30 Cell adhesion; Transmembrane; glycoprotein; EGF-like domain; Lectin;
31 Selectin; SUSHI; Repeat.
32
33 FT SIGNAL 1 41 BY SIMILARITY.
34 FT CHAIN 1 41 P-SELECTIN.
35 FT DOMAIN 42 64 EXTRACELLULAR (POTENTIAL).
36 FT TRANSMEM 42 64 POTENTIAL.
37 FT DOMAIN 612 646 CYTOPLASMIC (POTENTIAL).
38 FT DOMAIN 612 646 C-TYPE LECTIN (SHORT FORM).
39 FT DOMAIN 199 199 EGF-LIKE.
40 FT DOMAIN 199 268 SUSHI 1.
41 FT DOMAIN 261 320 SUSHI 2.
42 FT DOMAIN 324 382 SUSHI 3.
43 FT DOMAIN 385 443 SUSHI 4.
44 FT DOMAIN 457 511 SUSHI 5.
45 FT DOMAIN 519 576 SUSHI 6.
46 FT DISULFID 60 198 BY SIMILARITY.
47 FT DISULFID 141 198 BY SIMILARITY.
48 FT DISULFID 163 174 BY SIMILARITY.
49 FT DISULFID 188 183 BY SIMILARITY.
50 FT DISULFID 188 194 BY SIMILARITY.
51 FT DISULFID 200 243 BY SIMILARITY.
52 FT DISULFID 240 257 BY SIMILARITY.
53 FT DISULFID 262 306 BY SIMILARITY.
54 FT DISULFID 292 319 BY SIMILARITY.
55 FT DISULFID 324 368 BY SIMILARITY.
56 FT DISULFID 354 381 BY SIMILARITY.
57 FT DISULFID 386 430 BY SIMILARITY.
58 FT DISULFID 416 418 BY SIMILARITY.
59 FT DISULFID 436 502 BY SIMILARITY.
60 FT DISULFID 488 515 BY SIMILARITY.
61 FT DISULFID 520 544 BY SIMILARITY.
62 FT DISULFID 550 577 BY SIMILARITY.
63 FT CARBOHYD 48 48 N LINKED (GLYCAN...) (POTENTIAL).
64 FT CARBOHYD 54 54 N LINKED (GLYCAN...) (POTENTIAL).
65 FT CARBOHYD 80 80 N LINKED (GLYCAN...) (POTENTIAL).
66 FT CARBOHYD 180 180 N LINKED (GLYCAN...) (POTENTIAL).
67 FT CARBOHYD 212 212 N LINKED (GLYCAN...) (POTENTIAL).
68 FT CARBOHYD 219 219 N LINKED (GLYCAN...) (POTENTIAL).
69 FT CARBOHYD 336 336 N LINKED (GLYCAN...) (POTENTIAL).
70 FT CARBOHYD 481 481 N LINKED (GLYCAN...) (POTENTIAL).
71 FT CARBOHYD 542 542 N LINKED (GLYCAN...) (POTENTIAL).
72 FT CARBOHYD 549 549 N LINKED (GLYCAN...) (POTENTIAL).
73 FT CARBOHYD 567 567 N LINKED (GLYCAN...) (POTENTIAL).
74 SITE 634 634 ENZYME ACTIVE SITE (PROBABLE).
75 SEQUENCE 646 AA: 71229 MW: 57491.240.2/ALATA CR664;

Query Match 16.9%; Score 127; DB 1; Length 646;
Best Local Similarity 26.9%; Pred. No. 2.4e 06;
Matches 46; Conservative 21; Mismatches 99; Indels 18; Gaps 7;
QY 1 G1SGSDPPPLINPIS VYTFIVAVGVYVSSEIFEGKSEKLEIKKVIWIK 96
DB 455 GVQVFLIAKQCTMSQHVNFQINTFCRKRAGETLLDSDALQV RESROWIA 510
QY 59 FAKKLEVFYFSSQVPEIVVGVYFISFVEERQVILAVETNEVDRKRWV 114
DB 511 AADICRAV KCAKLPVTFIV - MNVSNVWGFVSQVSTSFHQPRQVINSRIV 564
QY 114 GANNMMPRLPIC 127
DB 565 QENQDWS-TIMPTC 577
RESULT 42
LEM2_MOUSE
ID LEM2_MOUSE STANDARD: PRI: 612 AA
AC Q00690;
DT 01-APR-1994 (Rel. 25, Created)
DT 01-APR-1994 (Rel. 25, Last sequence update)
DT 01-FEB-1996 (Rel. 53, Last annotation update)
DE E-selectin precursor (endothelial leukocyte adhesion molecule 1)
DE (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2)
DE (5962E).
GN SELE OR ELAM-1.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus;
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE:92283265; PubMed:1375914;
RA Hockett Andre M.; van Halbeek H.; Leshetzer C.; Whelan J.;
RA Delamarier J.F.;
RT "Marine endothelial leukocyte adhesion molecule 1 is a close
RT structural and functional homologue of the human protein.";
RL Eur. J. Biochem. 206:401-411(1992).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE:92440571; PubMed:1378846;
RA Weller A.; Isenmann S.; Vestweber D.;
RT "Cloning of the mouse endothelial selectins. Expression of both E
RT and P-selectin is inducible by tumor necrosis factor alpha.";
RL J. Biol. Chem. 267:15176-15183(1992).
CC 1- FUNCTION: EXPRESSED ON CYCLOKINE INDUCED ENDOTHELIAL CELLS AND
CC MEDIATES THEIR BINDING TO LEUKOCYTES. THE LIGAND RECOGNIZED BY
CC ELAM-1 IS STALYL LEWIS X (ALPHA(1-3)FUCOSYLATED DERIVATIVES OF
CC POLYLACTOSAMINE THAT ARE FOUND AT THE N-TERMINUS TERMINI OF
CC GLYCOPOLYIDS).
CC 1- SUBCELLULAR LOCATION: Type 1 membrane protein.
CC 1- SIMILARITY: TO OTHER SELECTINS/LECAMs.
CC 1- SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
CC 1- SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
CC 1- SIMILARITY: CONTAINS 6 SUSHI (SUS) DOMAINS.
CC
CC This SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC at the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.ebi.ac.uk/submit/faq.html>
CC or send an email to license@ebi.ac.uk).
CC
CC EMBL: M80778; AAA37547.1; -
CC EMBL: M87862; AAA37577.1; ALT_INIT.
CC ISSP: P16581; IKIA.
CC MGD: MGI:98278; Sele.
CC InterPro: IPR000561; EGF-like.
CC InterPro: IPR002496; Selectin.


```

106 EMIL: AF109906: AAC84146.12
107 EMIL: K01496: AAA69549.12
108 EMIL: K01497: AAA69550.12
109 EMIL: K01498: AAA69551.12
110 EMIL: M57690: AAA64293.12
111 PIR: A08757: RMS
112 RSP: P00744: 20N1
113 M6P0R: S01.196
114 MG1: MG1:105979: 02 B1
115 InterPro: IPR001414: Chemotaxis
116 InterPro: IPR000466: Sushi SR CCP
117 InterPro: IPR001254: LYPSTIN
118 InterPro: IPR002039: VWFA
119 Pfam: PF000847: sushi: 1
120 Pfam: PF00089: trypsin: 2
121 Pfam: PF00092: vwa: 1
122 PRINTS: PR00722: CHYMOTRYPSIN
123 PKINSE: PR00453: VWFA/MAIN
124 SMART: SM00042: CCP: 3
125 SMART: SM00020: Typ Src: 1
126 SMART: SM00427: VWA: 1
127 PROSITE: PS0240: TRYPSIN Dom: 1
128 PROSITE: PS00144: TRYPSIN HIS: 1
129 PROSITE: PS00145: TRYPSIN SER: 1
130 PROSITE: PS0244: VWFA: 1
131 KW Complement alternative pathway: Plasma: Hydrolase: Serine protease:
132 Glycoprotein: Repeat: Sushi:
133 STONAL 1 22
134 CHAIN 24 761
135 CHAIN 24 256
136 CHAIN 257 761
137 DOMAIN 34 96
138 DOMAIN 99 156
139 DOMAIN 161 216
140 DOMAIN 267 466
141 DOMAIN 479 761
142 AC1 SITE 523 523
143 AC1 SITE 574 574
144 AC1 SITE 696 696
145 DISULFID 34 74
146 DISULFID 59 96
147 DISULFID 100 142
148 DISULFID 128 155
149 DISULFID 162 202
150 DISULFID 188 215
151 CARBOHYD 119 119
152 CARBOHYD 139 139
153 CARBOHYD 282 284
154 CARBOHYD 476 476
155 CONFLICT 730 730
156 CONFLICT 745 745
157 SEQUENCE 761 AA: 8004 MW: 9901544861020E CR64
158
159 Match 16.4% Score 122: DR 1: Length 761:
160 Local Similarity 28.4% Pred. No. 9.2e 05:
161 Matches 40: conservative 16: Mismatches 64: Indels 16: Gaps 6:
162
163 2 ISCSPPPLNG KISTYSTPLAVGVIVRYNSGTRFLGKSLDITTKVVGTD 67
164 98 TRCRQDFQDFQDFWSPSPYN ISQISQYVGVVLRGSAIRDT -QENGRWD 149
165
166 58 KPAIKKVEYKNSGDFIVMGVYKTRGSTFYRGRGVTFACKTFNSMNGKNSVWQANN 117
167 150 GQTALCTGKAY CTRNGVPTGRKVGVS QYKLEIVIVTRSRGLVLRGSKRKQREG 206
168
169 118 MWGTRLEPTVSVVF 141
170 207 SWSGGLE PSCQDSF 214

```


Genome version 5.1.3
Copyright (c) 1994 - 2002 Computer IId

protein protein search, using sw model

run on: November 6, 2002, 16:05:00 : Search time 21.4201 Seconds
(without alignments)
1082.224 Million cell updates/sec

title: US 09-834 309-4

perfect score: 751

sequence: 1 G1SGSGSPPLINGRISYSY.....ANNWGTPLPVCVSVPFLE 134

scoring table: BIASUM62

Gapop 10.0 , Gapext 0.5

searched: 562222 seqs, 17299429 residues

total number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

database: SPTREMBL 19:*

1: sp_archaea:*

2: sp_bacteria:*

3: sp_fungi:*

4: sp_human:*

5: sp_invertebrate:*

6: sp_mammal:*

7: sp_mice:*

8: sp_ornithello:*

9: sp_phage:*

10: sp_plant:*

11: sp_rodent:*

12: sp_virus:*

13: sp_vertebrate:*

14: sp_unclassified:*

15: sp_virus:*

16: sp_bacteriap:*

17: sp_archaeap:*

Prod. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	751	100.0	1032	4	Q14666 homo sapien
2	751	100.0	1037	4	Q14212 homo sapien
3	466.5	62.1	679	11	Q99254 mus musculus
4	466.5	62.1	1032	11	Q99254 mus musculus
5	466.5	61.9	1045	6	Q46545 mus musculus
6	246	41.4	1911	6	Q29528 papio hamad
7	220	29.3	2039	4	Q16745 mus musculus
8	220	29.3	2489	4	Q16744 homo sapien
9	218	29.0	132	4	Q99B99 homo sapien
10	218	29.0	132	4	Q99B98 homo sapien
11	218	29.0	2014	6	Q29530 pan troglod
12	215	28.6	132	4	Q99C55 homo sapien
13	215	28.6	259	12	P87616 cowpox virus
14	211	28.1	132	4	Q99C54 homo sapien
15	210	28.0	263	12	Q98B59 variola vir
16	210	28.0	263	12	Q07033 variola vir

17	208	27.7	263	12	Q89076
18	208	27.7	263	12	Q89076
19	203.5	27.1	395	12	Q92206
20	203.5	27.1	579	11	Q28736
21	203	27.0	522	6	Q28769
22	199	26.5	559	4	Q92QV2
23	198.5	26.4	533	11	Q08569
24	198	26.4	522	6	Q28797
25	196	26.1	661	6	Q29531
26	194	25.8	315	6	Q28770
27	194	25.8	645	12	Q9WE92
28	191.5	25.5	555	11	Q99Q41
29	190	25.3	363	6	Q02839
30	188.5	25.1	451	13	Q9D850
31	184	24.5	417	11	Q35520
32	184	24.5	497	11	Q63612
33	184	24.5	559	11	Q63135
34	180.5	24.0	483	11	Q64735
35	180.5	24.0	657	4	Q14006
36	178.5	23.8	469	11	Q91X48
37	176	23.4	337	11	Q97263
38	175.5	23.4	1172	4	Q9N087
39	172	22.9	300	11	Q9R0K9
40	171	22.8	267	11	Q97939
41	171	22.8	339	11	Q97261
42	171	22.8	379	11	Q70105
43	169.5	22.6	268	12	Q9QAX6
44	169.5	22.6	550	12	Q88933
45	168.5	22.4	550	12	Q49912
46	168	22.4	365	11	Q88174
47	168	22.4	481	4	Q9H284
48	167.5	22.3	390	11	Q92100
49	167.5	22.3	699	11	Q91W00
50	167.5	22.3	1236	11	Q91Y86
51	167.5	22.3	3567	11	Q9ES77
52	166.5	22.2	569	4	Q9HXR6
53	165.5	22.0	808	11	Q61408
54	165	22.0	225	12	Q91M43
55	164	21.8	2043	5	Q96943
56	163	21.7	285	6	Q19121
57	162	21.6	343	11	Q61406
58	161.5	21.5	305	6	Q9MYJ5
59	161.5	21.5	347	6	Q9MYJ6
60	160.5	21.4	347	6	Q9MYJ7
61	160	21.3	285	6	Q19126
62	160	21.3	285	6	Q19127
63	160	21.3	369	6	Q79138
64	160	21.3	754	13	Q98006
65	159	21.2	389	4	Q96Q09
66	159	21.2	3508	4	Q96RMA
67	158	21.0	336	6	Q62834
68	157	20.9	372	11	Q9QV39
69	157	20.9	378	6	Q62847
70	157	20.9	382	11	Q9Q013
71	157	20.9	399	11	Q9Q016
72	157	20.9	399	11	Q9Z0M0
73	157	20.9	466	11	Q9Z0L9
74	156	20.8	1001	4	Q9Y2E1
75	155	20.6	349	4	Q15429
76	154.5	20.6	3564	11	Q92313
77	154	20.5	222	6	Q19128
78	153	20.4	222	6	Q19128
79	153	20.4	314	6	Q62835
80	153	20.4	377	6	Q62836
81	153	20.4	377	13	Q90422
82	153	20.3	1061	5	Q9VXX7
83	152.5	20.3	343	6	Q9MYJ4
84	152.5	20.3	946	4	Q96Q04
85	152	20.2	762	13	Q9Y106
86	151	20.1	1653	5	Q9V109
87	149	19.8	809	4	Q9BW82
88	149	19.8	840	4	Q9UJ45
89	149	19.8	853	4	Q9UJ47

Q89076 variola vir	Q89061 variola vir	Q91406 mus musculus	Q28769 papio cynae	Q99342 homo sapien	Q08569 cavia porce	Q28797 pan troglod	Q29531 pan troglod	Q28770 papio cynae	Q9WE92 macaca mola	Q99Q41 cavia porce	Q02839 sus scrofa	Q9D850 gallus gall	Q35520 rattus norv	Q63612 rattus norv	Q63135 rattus norv	Q64735 mus musculus	Q14006 homo sapien	Q91X48 mus musculus	Q97263 cavia porce	Q9N087 homo sapien	Q9R0K9 mus musculus	Q97939 cavia porce	Q97261 cavia porce	Q70105 cavia porce	Q9QAX6 yaba monkey	Q88933 kapos's sa	Q49912 kapos's sa	Q88174 mus musculus	Q9H284 homo sapien	Q92100 mus musculus	Q91W00 rattus norv	Q91Y86 rattus norv	Q9ES77 mus musculus	Q9HXR6 homo sapien	Q61408 mus musculus	Q91M43 lumpy skin	Q96943 quodia cydo	Q19121 papio hamad	Q61406 mus musculus	Q9MYJ5 pan troglod	Q9MYJ6 pan troglod	Q9MYJ7 papio cynae	Q19126 macaca mola	Q19127 macaca mola	Q79138 cercopithec	Q98006 cyrtinus ca	Q96Q09 homo sapien	Q96RMA homo sapien	Q62834 saquinus oe	Q9QV39 rattus norv	Q62847 saquinus oe	Q9Q013 rattus norv	Q9Q016 rattus norv	Q9Z0M0 rattus norv	Q9Z0L9 rattus norv	Q9Y2E1 homo sapien	Q15429 homo sapien	Q92313 mus musculus	Q19128 pithecia pl	Q19128 saquinus oe	Q62835 saquinus oe	Q62836 saquinus oe	Q90422 brachyodonto	Q9VXX7 drosophila	Q9MYJ4 papio hamad	Q96Q04 homo sapien	Q9Y106 cyrtinus ca	Q9V109 drosophila	Q9BW82 homo sapien	Q9UJ45 homo sapien	Q9UJ47 homo sapien
--------------------	--------------------	---------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	-------------------	--------------------	--------------------	--------------------	--------------------	---------------------	--------------------	---------------------	--------------------	--------------------	---------------------	--------------------	--------------------	--------------------	--------------------	-------------------	-------------------	---------------------	--------------------	---------------------	--------------------	--------------------	---------------------	--------------------	---------------------	-------------------	--------------------	--------------------	---------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	--------------------	---------------------	--------------------	--------------------	--------------------	--------------------	---------------------	-------------------	--------------------	--------------------	--------------------	-------------------	--------------------	--------------------	--------------------


```

11 Q992W PRELIMINARY: PRI: 1911 AA.
12 Q992W
13 01 NOV 1996 (TREMBLrel, 01, Created)
14 01 NOV 1996 (TREMBLrel, 01, Last sequence update)
15 01 DEC 2001 (TREMBLrel, 19, Last annotation update)
16 COMPLEMENT COMPONENT RECEPTOR TYPE 1 (FRAGMENT).
17
18 Papio hamadryas (Hamadryas baboon).
19 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
20 Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
21 Cercopithecinae; Papio.
22 NCBI TaxID:9557.
23
24 SEQUENCE FROM N.A.
25 Q16744
26 Q16744: Submanian B.V., Nickells M.W., Bourcade D.E.,
27 A'kinson J.P.
28 "Primary sequence of the baboon 200 kDa C4b/C4d receptor (CRL).";
29 Submitted (MAR 1995) to the EMBL/GenBank/Tran databases.
30 EMBL: L17417; AAA62170.1;
31
32 HSSP: P08603; 1HE1.
33 InterPro: IPR001424; S0LCE_ZN.
34 InterPro: IPR000436; Sushi_SCR_CCP.
35 InterPro: IPR000844; Zn_carbopept.
36 Pfam: PF00084; Sushi: 29.
37 SMART: SM00942; CCP: 29.
38 PROSITE: PS00134; CARBOXYPEPT_ZN_2: UNKNWN_2.
39 PROSITE: PS00087; S0LCE_ZN_1: UNKNWN_1.
40 KW Receptor.
41 NITER 1911 1911
42 SEQUENCE 1911 AA: 216/174 MW: 53544000AAASZID CRC64;
43
44 Query Match 41.4%; Score 245; DB 6; Length 1911;
45 Best Local Similarity 46.8%; Pred. No. 5,26 17;
46 Matches 94; Conservative 16; Mismatches 54; Indels 16; Gaps 6;
47
48 QY 2 ISGSGPPTINGKISYYS---IPVAVGVIRYSC SUPERLIGKSLGKSLTKKVV 52
49 III III III III III III III III III III III III III III
50 1304 ISGKPPPTISNG DYSNNKISFENGIVVYQCHGQHQKQFELVGVKRSYVLSKDDQ 1461
51 III III III III III III III III III III III III III III
52 QY 53 DGTWVFATVGFYTPYYS*FEIVFVGFVPEVETFEYHETVVA*FVNEPDRPVS 111
53 III III III III III III III III III III III III III III
54 1462 VGVSSPPPTISNK---CTAEVFNATRVNKRSEFSEFIVKRGQGVGVVMSHTV 1518
55 III III III III III III III III III III III III III III
56 QY 112 WCCANNMWGPTRLPICVSV 140
57 III III III III III III III III III III III III III III
58 1519 QVTTNRWGP-KLPICSRV 1646
59 III III III III III III III III III III III III III III
60
61 RESULT 7
62 Q16744 PRELIMINARY: PRI: 2039 AA.
63 AC Q16744
64 01 NOV 1996 (TREMBLrel, 01, Created)
65 01 NOV 1996 (TREMBLrel, 01, Last sequence update)
66 01 DEC 2001 (TREMBLrel, 19, Last annotation update)
67 COMPLEMENT RECEPTOR 1.
68 Homo sapiens (Human).
69 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
70 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
71 NCBI TaxID:9606.
72
73 SEQUENCE FROM N.A.
74 Q16744
75 Q16744: Submanian B.V., Nickells M.W., Bourcade D.E.,
76 A'kinson J.P.
77 "Structure of the gene for the F allele of complement receptor type 1
78 and sequence of the coding region unique to the S allele.";
79 Submitted (MAR 1995) to the EMBL/GenBank/Tran databases.
80 EMBL: L17417; AAA60694.1;
81 EMBL: L17400; AAA60694.1; JOINED.

```

```

DR EMBL: L17499; AAA60694.1; JOINED.
DR EMBL: L17499; AAA60694.1; JOINED.
DR EMBL: L17419; AAA60694.1; JOINED.
DR EMBL: L17420; AAA60694.1; JOINED.
DR EMBL: L17421; AAA60694.1; JOINED.
DR EMBL: L17422; AAA60694.1; JOINED.
DR EMBL: L17423; AAA60694.1; JOINED.
DR EMBL: L17424; AAA60694.1; JOINED.
DR EMBL: L17425; AAA60694.1; JOINED.
DR EMBL: L17426; AAA60694.1; JOINED.
DR EMBL: L17427; AAA60694.1; JOINED.
DR EMBL: L17428; AAA60694.1; JOINED.
DR EMBL: L17429; AAA60694.1; JOINED.
DR EMBL: L17430; AAA60694.1; JOINED.
DR EMBL: L17431; AAA60694.1; JOINED.
DR EMBL: L17432; AAA60694.1; JOINED.
DR EMBL: L17433; AAA60694.1; JOINED.
DR EMBL: L17434; AAA60694.1; JOINED.
DR EMBL: L17435; AAA60694.1; JOINED.
DR EMBL: L17436; AAA60694.1; JOINED.
DR EMBL: L17437; AAA60694.1; JOINED.
DR HSSP: P08603; 1HE1.
DR InterPro: IPR001424; S0LCE_ZN.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR InterPro: IPR000844; Zn_carbopept.
DR Pfam: PF00084; Sushi: 30.
DR SMART: SM00942; CCP: 30.
DR PROSITE: PS00134; CARBOXYPEPT_ZN_2: UNKNWN_2.
DR PROSITE: PS00087; S0LCE_ZN_1: UNKNWN_1.
DR KW Receptor.
DR SEQUENCE 2039 AA: 2236/1616 MW: 68267116H16635 CRC64;
49
50 Query Match 29.4%; Score 220; DB 4; Length 2039;
51 Best Local Similarity 47.4%; Pred. No. 2,64 15;
52 Matches 52; Conservative 16; Mismatches 55; Indels 16; Gaps 6;
53
54 QY 2 ISGSGPPTINGKISYYS---IPVAVGVIRYSC SUPERLIGKSLGKSLTKKVV 52
55 III III III III III III III III III III III III III III
56 1517 ISGKPPPTISNG DYSNNKISFENGIVVYQCHGQHQKQFELVGVKRSYVLSKDDQ 1574
57 III III III III III III III III III III III III III III
58 QY 53 DGTWVFATVGFYTPYYS*FEIVFVGFVPEVETFEYHETVVA*FVNEPDRPVS 111
59 III III III III III III III III III III III III III III
60 1575 VGVSSPPPTISNK---CTAEVFNATRVNKRSEFSEFIVKRGQGVGVVMSHTV 1641
61 III III III III III III III III III III III III III III
62 QY 112 WCCANNMWGPTRLPICVSV 140
63 III III III III III III III III III III III III III III
64 1632 QVTTNRWGP-KLPICSRV 1649
65 III III III III III III III III III III III III III III
66
67 RESULT 8
68 Q16744 PRELIMINARY: PRI: 2489 AA.
69 AC Q16744
70 01 NOV 1996 (TREMBLrel, 01, Created)
71 01 NOV 1996 (TREMBLrel, 01, Last sequence update)
72 01 DEC 2001 (TREMBLrel, 19, Last annotation update)
73 COMPLEMENT RECEPTOR 1.
74 Homo sapiens (Human).
75 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
76 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
77 NCBI TaxID:9606.
78
79 SEQUENCE FROM N.A.
80 Q16744
81 Q16744: Submanian B.V., Nickells M.W., Bourcade D.E.,
82 A'kinson J.P.
83 "Structure of the gene for the F allele of complement receptor type 1
84 and sequence of the coding region unique to the S allele.";
85 Submitted (MAR 1995) to the EMBL/GenBank/Tran databases.
86 EMBL: L17417; AAA60694.1;
87 EMBL: L17400; AAA60694.1; JOINED.

```


RA Ryazankina O.L., Gutorov V.V., Kotwal G.J.;
 RT *The genomic sequence analysis of the left and right species-specific
 RC terminal region of a coxpos virus strain reveals unique sequences and
 RL a cluster of intact ORFs for immunomodulatory and host range
 RT proteins.*

RE Virology 24:432-460(1998).
 DR EMBL: X94355; CAA64102.1;
 DR EMBL: Y11842; CAA72567.1;
 DR HSP: P10998; LVVD.
 DR InterPro: IPR000436; Sushi_SRF_CCP.
 DR Pfam: PF00084; sushi; 4.
 DR SMART: SM00042; CCP; 4.
 SQ SEQUENCE 259 AA: 28193 MW: 901AAEF6894BR59A CRC64;

Query Match 28.6%; Score 215; DR 12; Length 259;
 Best Local Similarity 35.9%; Pred. No. 7.7e-16;
 Matches 46; Conservative 15; Mismatches 55; Indels 12; Gaps 5;

QY 2 ISGSPPTILNGISYSTPIAVGVTVIRKYSSTGERLIGKSLITPKDKVDFWIKPAP 61
 1 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
 DB 142 VKQSPHSISNGKHCNGEDFYIDNSVYVYSCNSGVLSIGNSCVLC-----SGGHSNP-P 195

QY 62 KTEYENKYSSTPEPTIVPGYKIRG STYPIHDSVTFAKTNFMMNGKNSVWYVANNMW 120
 1
 DB 196 TCGIV ---KCPPTISNGKHCNGEDFYIDNSVYVYSCNSGVLSIGNSCVLC-----SGGHSNP-P 195

QY 121 PTERLPTCV 128
 1 11 11
 DB 252 P-ELPCV 258

RESULT 14
 QYHC54
 ID QYHC54 PRELIMINARY; PRT; 132 AA.
 AC QYHC54;
 DT 01-MAR-2001 (TREMHLrel, 16, Created)
 DT 01-MAR-2001 (TREMHLrel, 16, Last sequence update)
 DT 01-DEC-2001 (TREMHLrel, 19, Last annotation update)
 DE COMPLEMENT RECEPTOR 1 (FRAGMENT).
 GN CR1.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 OX NCBI_TaxID:9606;
 RN 111
 PP SEQUENCE FROM N.A.
 RA Zimmerman P.A., McNamara D.J., Birmingham D., Atkinson J.P.,
 FA Miller L., Doubo O., Moulds J.,
 RL Submitted (JUL-1999) to the EMBL/GenBank/DBJ databases.
 DR EMBL: AF169970; AAC09140.1;
 DR HSP: P10998; LVVD.
 DR InterPro: IPR000436; Sushi_SRF_CCP.
 DR Pfam: PF00084; sushi; 2.
 DR SMART: SM00042; CCP; 2.
 KW Receptor.
 FT NON_TER 1 1
 FT VARIANT 74 74 E -> K.
 FT VARIANT 85 85 G -> R.
 FT NON_TER 142 132
 SQ SEQUENCE 132 AA: 14554 MW: 1AD1159EF598FCB CRC64;

Query Match 28.1%; Score 211; DB 4; Length 132;
 Best Local Similarity 36.8%; Pred. No. 9.5e-16;
 Matches 50; Conservative 16; Mismatches 54; Indels 16; Gaps 6;

QY 2 ISGSPPTILNGISYSTPIAVGVTVIRKYSSTGERLIGKSLITPKDKVDFWIKPAP 52
 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
 DB 1 ISCEPPTISNG -DFSNKRSSTPIAVGVTVIRKYSSTGERLIGKSLITPKDKVDFWIKPAP 58
 1
 QY 53 DETWIKPAIKYKPNKYSSTPEPTIVPGYKIRG STYPIHDSVTFAKTNFMMNGKNSV 111
 1
 DB 59 VAVWSSPPKCSINP -CTAPFVNAIGVGNKRSSTPEPTIVPGYKIRG STYPIHDSVTFAKTNFMMNGKNSV 115

QY 112 WCQANNMNGPTRELPTC 127
 1 1 111 111 1
 DB 116 QCQTNCWGP-KLPWC 130

RESULT 15
 QYHC59
 ID QYHC59 PRELIMINARY; PRT; 263 AA.
 AC QYHC59;
 DT 01-NOV-1996 (TREMHLrel, 01, Created)
 DT 01-NOV-1996 (TREMHLrel, 01, Last sequence update)
 DT 01-JUN-2001 (TREMHLrel, 17, Last annotation update)
 DE FORMING OF VA-INTA VIRUS CDS C31
 GN D15L.
 OS Variola virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 OX NCBI_TaxID:10255;
 RN 111
 PP SEQUENCE FROM N.A.
 RA STRAIN-BANGLADESH-1975;
 RX MEDLINE-94088747; PubMed-8264798;
 RA Wassung F.F., Esposito J.J., Liu H.L., Qi L., Griebank L.K.,
 RA Knight J.C., Aubin L., Yuran T.E., Parsons J.M., Loparev V.N.;
 RT *Potential virulence determinants in terminal regions of variola
 RT smallpox virus genome.*
 RL Nature 366:748-751(1993).
 RN 121
 RP SEQUENCE FROM N.A.
 RC STRAIN-SOMALIA-1977;
 RA Massung F.F., Loparev V.N., Knight J.C., Chizhikov V.E., Parsons J.M.,
 RA Totmenin A.V., Shchelkunov S.N., Esposito J.J.;
 RL Submitted (JUL-1995) to the EMBL/GenBank/DBJ databases.
 DR EMBL: 122573; AAA60760.1;
 DR EMBL: U18343; AA669423.1;
 DR HSP: P10998; LVVD.
 DR InterPro: IPR000436; Sushi_SRF_CCP.
 DR Pfam: PF00084; sushi; 4.
 DR SMART: SM00042; CCP; 4.
 SQ SEQUENCE 263 AA: 28816 MW: 046597800294220 CRC64;

Query Match 28.0%; Score 210; DR 12; Length 263;
 Best Local Similarity 35.2%; Pred. No. 2.8e-15;
 Matches 41; Conservative 16; Mismatches 55; Indels 12; Gaps 5;

QY 2 ISGSPPTILNGISYSTPIAVGVTVIRKYSSTGERLIGKSLITPKDKVDFWIKPAP 61
 1 1 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111
 DB 146 VKQSPHSISNGKHCNGEDFYIDNSVYVYSCNSGVLSIGNSCVLC-----SGGHSNP-P 199

QY 62 KTEYENKYSSTPEPTIVPGYKIRG STYPIHDSVTFAKTNFMMNGKNSVWYVANNMW 120
 1
 DB 200 TCGIV ---KCPPTISNGKHCNGEDFYIDNSVYVYSCNSGVLSIGNSCVLC-----SGGHSNP-P 199

QY 121 PTERLPTCV 128
 1 11 11
 DB 256 P-ELPCV 262

RESULT 16
 QYHC59
 ID QYHC59 PRELIMINARY; PRT; 263 AA.
 AC QYHC59;
 DT 01-NOV-1996 (TREMHLrel, 01, Created)
 DT 01-NOV-1996 (TREMHLrel, 01, Last sequence update)
 DT 01-JUN-2001 (TREMHLrel, 17, Last annotation update)
 DE D12L PROTEIN.
 GN D12L.
 OS Variola virus.
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 OX NCBI_TaxID:10255;
 RN 111
 PP SEQUENCE FROM N.A.

RESULT 4

Q64765

ID Q64765 PRELIMINARY: PRI: 483 AA.

AC Q64765

DT 01-NOV-1996 (TrEMBLrel. 01, created)

DT 01-NOV-1996 (TrEMBLrel. 01, last sequence update)

DT 01-JUN-2001 (TrEMBLrel. 17, last annotation update)

DE COMPLEMENT 1 RECEPTOR RELATED PROTEIN.

GN CRRY

OS Mus musculus (Mouse)

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN 1

RC SLAIN DATA

RX MEDLINE 6011000; PubMed 6010480;

RA FALC M S. Ascorbic acid receptor. Shaw M, Copok K, Miller M D., Weiss J H. J

RT "The murine complement receptor gene family. II. The genomic and

R1 cross-species complexity of the Crry and Crry ps genes."

R1 J. Immunol. 144:1998-1999(1990).

DR EMBL: M44174, AAA/4408.11

DR EMBL: M44164, AAA/4408.11 JOINED.

DR EMBL: M44165, AAA/4408.11 JOINED.

DR EMBL: M44166, AAA/4408.11 JOINED.

DR EMBL: M44167, AAA/4408.11 JOINED.

DR EMBL: M44168, AAA/4408.11 JOINED.

DR EMBL: M44169, AAA/4408.11 JOINED.

DR EMBL: M44170, AAA/4408.11 JOINED.

DR EMBL: M44171, AAA/4408.11 JOINED.

DR EMBL: M44172, AAA/4408.11 JOINED.

DR EMBL: M44173, AAA/4408.11 JOINED.

DR EMBL: M44164, AAA/4407.11

DR EMBL: M44170, AAA/4407.11 JOINED.

DR EMBL: M44171, AAA/4407.11 JOINED.

DR EMBL: M44172, AAA/4407.11 JOINED.

DR EMBL: M44165, AAA/4407.11 JOINED.

DR EMBL: M44166, AAA/4407.11 JOINED.

DR EMBL: M44167, AAA/4407.11 JOINED.

DR EMBL: M44168, AAA/4407.11 JOINED.

DR EMBL: M44169, AAA/4407.11 JOINED.

DR EMBL: P08603, IHHI

DR M30, M31, M32, C, C1Y

DR InterPro: IPR001005; Myb DNA bind.

DR InterPro: IPR000466; Sushi SR exp.

DR Pfam: PF00084; sushi_5.

DR SMART: SM00042; CYP_5.

DR PROSITE: PS00047; MYR 1; UNRES-W2 1.

FT VARIANT 41 RC MISSING (IN LIVER ISOFORM).

SQ SEQUENCE 483 AA: 53762 MW: 25096Da-E6547C1 CR664;

Query Match 24.0% Score 180.5; DB 11; Length 483;

Best Local Similarity 34.6% Pred. No. 1, 1e 11;

Matches 47; Conservative 14; Mismatches 60; Indels 1%; Gaps 6;

QY 2 LSGSPPTILNGSYST PLACIVRYS - GPRLEKSLCTIKRV 52

DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 206 LVEEDPLGNG DESSGDEPHYGMVYRNCNDARKALFNAGPSGYCTSNDE 263

QY 53 LGLTWKALRQ EENAYSSGQFVVGAKK1 KGSIFVGGISVYFAKINFSMNINRNV 111

DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 264 LKVRGSGPTQWDELNCT PHYVINAVMLSENRSLSRLDIVPRHPCFMKCAHSV 421

QY 117 WQANNMGPTPTPT 127

DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 422 RQSLKWEPELESC 436

RESULT 5

Q14006

ID Q14006 PRELIMINARY: PRI: 657 AA.

AC Q14006

DT 01-NOV-1996 (TrEMBLrel. 01, created)

DT 01-NOV-1996 (TrEMBLrel. 01, last sequence update)

DT 01-JUN-2001 (TrEMBLrel. 17, last annotation update)

DE COMPLEMENT 1 RECEPTOR RELATED PROTEIN.

GN CRRY

OS Mus musculus (Mouse)

OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Muridae; Murinae; Mus.

OX NCBI_TaxID=10090;

RN 1

RC SLAIN DATA

RX MEDLINE 6011000; PubMed 6010480;

RA FALC M S. Ascorbic acid receptor. Shaw M, Copok K, Miller M D., Weiss J H. J

RT "The murine complement receptor gene family. II. The genomic and

R1 cross-species complexity of the Crry and Crry ps genes."

R1 J. Immunol. 144:1998-1999(1990).

DR EMBL: M44174, AAA/4408.11

DR EMBL: M44164, AAA/4408.11 JOINED.

DR EMBL: M44165, AAA/4408.11 JOINED.

DR EMBL: M44166, AAA/4408.11 JOINED.

DR EMBL: M44167, AAA/4408.11 JOINED.

DR EMBL: M44168, AAA/4408.11 JOINED.

DR EMBL: M44169, AAA/4408.11 JOINED.

DR EMBL: M44170, AAA/4408.11 JOINED.

DR EMBL: M44171, AAA/4408.11 JOINED.

DR EMBL: M44172, AAA/4408.11 JOINED.

DR EMBL: M44173, AAA/4408.11 JOINED.

DR EMBL: M44164, AAA/4407.11

DR EMBL: M44170, AAA/4407.11 JOINED.

DR EMBL: M44171, AAA/4407.11 JOINED.

DR EMBL: M44172, AAA/4407.11 JOINED.

DR EMBL: M44165, AAA/4407.11 JOINED.

DR EMBL: M44166, AAA/4407.11 JOINED.

DR EMBL: M44167, AAA/4407.11 JOINED.

DR EMBL: M44168, AAA/4407.11 JOINED.

DR EMBL: M44169, AAA/4407.11 JOINED.

DR EMBL: P08603, IHHI

DR M30, M31, M32, C, C1Y

DR InterPro: IPR001005; Myb DNA bind.

DR InterPro: IPR000466; Sushi SR exp.

DR Pfam: PF00084; sushi_5.

DR SMART: SM00042; CYP_5.

DR PROSITE: PS00047; MYR 1; UNRES-W2 1.

FT VARIANT 41 RC MISSING (IN LIVER ISOFORM).

SQ SEQUENCE 657 AA: 74247 MW: 68620Da-E20P1213 CR664;

Query Match 24.0% Score 178.5; DB 11; Length 469;

Best Local Similarity 34.3% Pred. No. 1, 1e 11;

Matches 45; Conservative 14; Mismatches 54; Indels 2%; Gaps 7;

QY 2 LSGSPPTILNGSYST PLACIVRYS - GPRLEKSLCTIKRV 52

DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

DB 179 VKGCPDPLSNCKSGTHDFY - PYNHG 15YICDPCFRLVGSDFGCTVVNKKIVLWS 234

QY 58 FFAIPFQYENFYSSSTEEF 1VPGVYZLPGG1PVPF4SVVIAKTNISMMNRKSVW 112

DB 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11

```

DE 245 SSPTCKEKT---TQSQNILLRWIVSYGK-----ATVTHRSVPLA*LN:TVLMGRHIVIE 286
QY 113 CQANNWGPTRLPIC 127
DE 287 CQCGNWN---SSLPIC 299
RESULT 47
ID 1997264 PRELIMINARY: PRT: 337 AA.
AC 1997264;
DT 01 MAY 1997 (Tremblrel. 03, Created)
DT 01 MAY 1997 (Tremblrel. 04, Last sequence update)
DT 01 DEC 2001 (Tremblrel. 19, Last annotation update)
DE MEMBRANE COFACTOR PROTEIN PRECURSOR.
OS Cavia porcellus (Guinea pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Hystriocomnathi; Caviidae; Cavia.
NCBI_TaxID=10141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=HARTLEY; TISSUE=TESTIS;
RA Hosokawa M., Nonaka M., Okada N., Nonaka M., Okada H.;
RT "Molecular cloning of guinea pig membrane cofactor
RT protein: preferential expression in testis.*"
RL J. Immunol. 157:4946-4952(1996).
DR EMBL: 084142; BAA12234.1;
DR HSSP: P10998; LVVD.
DR InterPro: IPR000436; Sushi_SCR_CYP.
IR PLAM: PF00084; sushi; 4.
IR SMART: SM00042; CCP; 4.
KW SIGNAL.
FT SIGNAL. 1 44 POTENTIAL.
FT CHAIN 45 437 MEMBRANE COFACTOR PROTEIN (GM3).
SQ SEQUENCE 337 AA: 37377 MW: 40644DFCC4D1FDBB CRC64;
Query Match 23.4%; Score 176; DB 11; Length 337;
Best Local Similarity 30.2%; Pred. No. 2,20-11;
Matches 42; Conservative 21; Mismatches 60; Indels 16; Gaps 6.
QY 2 ISCGSPPTLNGRISYSSTPI-ANGTVIRYSCSGT FRLIGKSLLCITKDKYDGT 55
DB 160 VLSGPPPTLNGKTYTSVQVFEVYSCDAVQGHDKLSLVGNVVIYCACHQK----- 215
QY 56 WIKPAKPKYFNKYSCHPEPIVGGYKIRG-STPYRHGDSVTFACKTFNFMGNKNSVMCO 114
DB 216 WSSAAPEQ----KVKVKPLPVVKNKKGISGLGQTFFVYQNTVTFQCLGFGYNGSSTVCG 271
QY 115 ANNMWGPTRLPICSVFPL 133
DB 272 SNTWKPS IPRCKVVGGL 289
RESULT 48
QY0087
ID QY0087 PRELIMINARY: PRT: 1172 AA.
AC QY0087;
DT 01 OCT 2000 (Tremblrel. 15, Created)
DT 01 OCT 2000 (Tremblrel. 16, Last sequence update)
DT 01 DEC 2001 (Tremblrel. 19, Last annotation update)
DE h177p10.1.1 (H FACTOR 1 (COMPLEMENT) ISOFORM 1).
GN HFL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```

```

OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Hird C.;
RL Submitted (JAN-2000) to the EMBL/Genbank/DBJ databases.
DR EMBL: AL049744; CAB70597.1;
DR HSSP: P08603; IUPH.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR Pfam: PF00084; sushi; 19.
DR SMART: SM00042; CCP; 19.
SQ SEQUENCE 1172 AA: 142087 MW: 154954C44FA454 CRC64;
Query Match 23.4%; Score 173.5; DB 4; Length 1172;
Best Local Similarity 35.7%; Pred. No. 1,1-10;
Matches 46; Conservative 20; Mismatches 48; Indels 15; Gaps 8;
QY 3 SCGSPPPIINGRISYSSTPIAVG--TVIRYS--SGTFRIGKSKSLCITKDKYVAGIDWIKPA 60
DB 629 SCSPPEPINVNR-EKTKEEYGHSEVVEYV--NPFLMKGFNKTQC--V--VGEW-TIL 661
QY 61 PKCEYFNKYSCHPE-PIVGGYKIRG-STPYRHGDSVTFACKTFNFMGNKNSVMCOANNMW 119
DB 682 PWC--IVRSTCCDIDLEHGWQAQLSSIPYVYGVSVFNTSSTFIMICRSTIC IREVV 748
QY 120 GPTRLPTVY 128
DB 739 --TQLPQCV 745
RESULT 39
QY0087
ID QY0087 PRELIMINARY: PRT: 400 AA.
AC QY0087;
DT 01-MAY-2000 (Tremblrel. 13, Created);
DT 01-MAY-2000 (Tremblrel. 13, Last sequence update);
DT 01-DEC-2001 (Tremblrel. 19, Last annotation update);
DE SOLUBLE FORM OF MEMBRANE COFACTOR PROTEIN CD46.
GN MCP.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciuroinath; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=70094984; PubMed=10630287;
RA Nomura M., Tsujimura A., Shida K., Matsumoto M., Matsuda Y.,
RA Toyoshima K., Seya T.;
RT "Membrane and secretory forms of mouse membrane cofactor protein
RT (CD46) generated from a single gene through alternative splicing.*"
RL Immunogenetics 50:245-254(1999).
DR EMBL: AB122600; BAA86056.1;
DR HSSP: P13998; LVVD.
DR MGD: MGI:1203290; MCP.
DR InterPro: IPR000436; Sushi_SCR_CYP.
DR Pfam: PF00084; sushi; 4.
DR SMART: SM00042; CCP; 4.
SQ SEQUENCE 300 AA: 33658 MW: 1457FA1655FA1F14 CRC64;
Query Match 22.9%; Score 172; DB 11; Length 400;
Best Local Similarity 32.6%; Pred. No. 5,4-11;
Matches 45; Conservative 17; Mismatches 56; Indels 20; Gaps 7;
QY 2 ISCGSPPTLNGRISYSSTPIAV CTVIRYSCSGT-----FRLIGKSLCITKDKYV 54
DB 171 IYCLPPPKIKNG--THTLTIDINVKYHCAVSYSCDIDLEHGWQAQLSSIPYVYGVSVFNTSSTFIMICRSTIC IREVV 225
QY 54 GTWKDPKPKYFNKYSCHPEPIVGGYKIRG-STPYRHGDSVTFACKTFNFMGNKNSVMCO 112
DB 226 --WSSNPPPEQ----KVKVKPLPVVKNKKGISGLGQTFFVYQNTVTFQCLGFGYNGSSTVCG 271
QY 113 CQANNWGPTRLPICSV 130
DB 281 CSANNWSPS-IPKCLV 297

```



```

106 EMBO: D98872: AAR2602.1 (1)
106 R580: P10998: LVVH
106 InterPro: IPR00436: Sushi_SCR_CSP
106 Pfam: PF00084: sushi; 4
106 SMART: SM0042: SH1; 4
106 SEQUENCE: 550 AA: 60648 MW: 3476010079666 CRC64
Query Match: 2248; Score 168.5; DB 12; Length 550;
Best local similarity: 33.9%; Pred. No. 2.7e 10;
Matches 4; Conservative 14; Mismatches 51; Indels 19; Gaps 7;
CY H PPTINDRI SYSTPTAVGLIVIRKYSNGTFRIGERSLLTLEKDKVGLHWKPAKQ 63
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
106 156 PKINDKFKDKYFE YNDVHFENEGYTLVGPHSIAVAVNNIWLNNMPTG 207
CY 64 FYENKYSSTPEPTAVGCKIRG STIYRIGDSVTACKTNEFMGNKSNWQANNMNGPT 122
106 208 1 LAGKFFSVLRKSYTLGGSLIYKIKQSVTFACNDFEVRSPITITNVLEWDDP 262
CY 123 RLPDLY 128
11 11
106 263 LKRY 267

```

Search completed: November 6, 2002, 16:08:22
 Job time: 27.4201 secs

genCore version 5.1.3
Copyright (c) 1994 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2002, 16:04:59 : Search time 27.1004 seconds

(without alignments)

553,312 Million cell updates/sec

File: US-09-834-309-6

Perfect score: 752

Sequence: 1 ELS-DPPPEVKKARPPYSL.....ANEMGPTALPVCSDFPLE 135

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 747574 seqs, 11107096 residues

Total number of hits satisfying chosen parameters: 747574

Minimum db seq length: 0

Maximum db seq length: 2000000000

Post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database: A_GenSeq 0428022*

1: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1980.DAT*

2: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1981.DAT*

3: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1982.DAT*

4: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1983.DAT*

5: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1984.DAT*

6: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1985.DAT*

7: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1986.DAT*

8: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1987.DAT*

9: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1988.DAT*

10: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1989.DAT*

11: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1990.DAT*

12: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1991.DAT*

13: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1992.DAT*

14: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1993.DAT*

15: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1994.DAT*

16: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1995.DAT*

17: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1996.DAT*

18: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1997.DAT*

19: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1998.DAT*

20: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA1999.DAT*

21: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA2000.DAT*

22: /SIDSI/qqqdat/a/genseq/geneseq-emb1/AA2001.DAT*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	466.5	62.0	1047	AAE11149	B lymphocyte membr
2	425.5	30.0	581	AAE13490	Human C4 binding p
3	421.5	29.5	2049	AAE16743	CRI- Homo sapiens
4	420.5	29.4	1540	AAE11982	Partial human comp
5	420.5	29.4	1926	AAE00183	Rezel human diagno
6	420.5	29.4	1916	AAE45899	Human complement r
7	420.5	29.4	2014	AAE11810	Human complement t
8	420.5	29.4	2049	AAE55751	Human C3b/C4b rece
9	420.5	29.4	2049	AAE55751	Human C3b/C4b rece
10	420.5	29.4	2044	AAE11782	Rezel human diagno
11	420.5	29.4	2044	AAE11782	Human CRI protein
					Human polypeptide

12	220.5	23.3	2044	22	AAE41010	Human polypeptide
13	220.5	23.3	2317	19	AAE92219	CRI protein, Homo
14	215	23.6	579	19	AAE92224	Amino acid sequen
15	212.5	23.3	450	20	AAE55755	Human CRI protein
16	204.5	27.2	646	20	AAE55758	Human CRI protein
17	199.5	25.5	363	18	AAE12414	Porcine complement
18	199.5	25.5	363	20	AAE30918	MCV protein, build
19	197.5	23.2	263	26	AAE29858	Va-inia virus SPI
20	197.5	23.3	263	20	AAE29860	Mutated VCP giving
21	195.5	23.6	263	22	AAE48846	Cowpox virus infla
22	193.5	23.7	263	10	AAE92033	Induced sequence o
23	193.5	23.7	263	20	AAE29859	Vaccinia complement
24	193.5	23.7	263	21	AAE14014	Vaccinia complement
25	189.5	25.2	324	12	AAE15233	C146, from clone pm
26	189.5	25.2	336	12	AAE15232	C146, from clone pm
27	189.5	25.2	350	12	AAE15231	C146, from clone pm
28	189.5	25.2	357	12	AAE1927	Human membrane cof
29	189.5	25.2	373	12	AAE15230	C146, from clone pm
30	189.5	25.2	377	12	AAE15229	C146, from clone pm
31	188.5	25.1	251	14	AAE41361	Membrane cofactor
32	188.5	25.1	254	17	AAE06880	Membrane cofactor
33	188.5	25.1	279	14	AAE41360	Membrane cofactor
34	188.5	25.1	279	19	AAE69523	rsM1 protein seq
35	188.5	25.1	476	17	AAE94939	C146, wild type, H
36	188.5	25.1	377	17	AAE94942	C146 construct sub
37	188.5	25.1	377	17	AAE94941	C146 construct sub
38	188.5	25.1	377	18	AAE27484	Human MCP, Homo S
39	188.5	25.1	378	17	AAE94940	C146, construct sub
40	188.5	25.1	384	12	AAE10924	Human membrane cof
41	188.5	25.1	384	16	AAE86516	Human C146, Homo
42	188.5	25.1	421	21	AAE5494	Local capact assoc
43	188.5	25.1	421	22	AAE37528	Human C146, carrier
44	188.5	25.1	577	17	AAE06882	Membrane cofactor
45	188.5	25.1	611	22	AAE15669	CAR2 protein, Uni
46	188.5	25.1	611	22	AAE03762	CAR2, chimeric pro
47	187.5	24.9	314	17	AAE94943	C146 construct del
48	185.5	24.7	645	21	AAE53125	Macaca mulatta rha
49	178.5	23.7	133	15	AAE47156	Sequence of solubl
50	178.5	23.7	254	15	AAE47154	Sequence of solubl
51	178.5	23.7	438	20	AAE55756	Human CRI protein
52	178.5	23.7	450	20	AAE55753	Human CRI protein
53	178.5	23.7	476	20	AAE55752	Human CRI protein
54	178.5	23.7	778	19	AAE73147	Amino acid sequen
55	175.5	23.3	254	15	AAE47155	Sequence of solubl
56	175.5	23.3	481	13	AAE20992	CRI-4 (amino acids
57	175.5	23.3	483	13	AAE20991	CRI-4 (amino acids
58	175.5	23.3	543	13	AAE28543	CRI-4 (45E, 37Y) a
59	175.5	23.3	543	13	AAE28544	CRI-4 (45E) analog
60	175.5	23.3	543	13	AAE28545	CRI-4 (37Y) analog
61	175.5	23.3	543	13	AAE28546	CRI-4 (44T, 47T, 4
62	175.5	23.3	543	13	AAE28547	CRI-4 (52S, 54S, 5
63	175.5	23.3	543	13	AAE28548	CRI-4 (57V, 59K) a
64	175.5	23.3	543	13	AAE28549	CRI-4 (64K, 65I) a
65	175.5	23.3	543	13	AAE28550	CRI-4 (64K) analog
66	175.5	23.3	543	13	AAE28551	CRI-4 (65T) analog
67	175.5	23.3	543	13	AAE28552	CRI-4 (78T, 79T) a
68	175.5	23.3	543	13	AAE28553	CRI-4 (84R, 87N) a
69	175.5	23.3	543	13	AAE28554	CRI-4 (92I, 94H) a
70	175.5	23.3	543	13	AAE28555	CRI-4 (92I) analog
71	175.5	23.3	543	13	AAE28556	CRI-4 (94H) analog
72	175.5	23.3	543	13	AAE28557	CRI-4 (99I, 103E)
73	175.5	23.3	543	13	AAE28558	CRI-4 (109N, 113A,
74	175.5	23.3	543	13	AAE28559	CRI-4 (114, 117S)KP
75	175.5	23.3	543	13	AAE28560	CRI-4 (114I) analog
76	175.5	23.3	543	13	AAE28561	CRI-4 (115I) analog
77	175.5	23.3	543	13	AAE28562	CRI-4 (116K) analog
78	175.5	23.3	543	13	AAE28563	CRI-4 (117I) analog
79	175.5	23.3	543	13	AAE28564	CRI-4 (116K, 117P)
80	175.5	23.3	543	13	AAE28565	CRI-4 (121C) analog
81	175.5	23.3	543	13	AAE28566	CRI-4 (118R, 119N)
82	175.5	23.3	543	13	AAE28567	CRI-4 (118I, 121R)
83	175.5	23.3	543	13	AAE28568	CRI-4 (147I, 149Y)
84	175.5	23.3	543	13	AAE28569	CRI-4 (149, 176) STK

86 176 5 23.3 543 1 AAR28570
87 176 5 23.3 543 1 AAR28571
88 169 22.5 667 15 AAR50087
89 168 5 22.4 450 20 AAY55754
90 168 5 22.4 453 20 AAY55757
91 164 5 21.9 1653 22 AAB11860
92 163 5 21.7 764 20 AAW94376
93 162 5 21.6 600 22 AAB61858
94 162 5 21.6 764 20 AAW94380
95 162 21.5 920 22 AAG55921
96 161 21.4 920 22 AAG22404
97 161 21.4 982 22 AAG301221
98 161 21.4 990 22 AAG50922
99 161 21.4 990 22 AAG22405
100 161 21.4 996 22 AAG50925

ALIGNMENTS

RESULT 1
AAR11159
10 AAR11159 standard; Protein 1087 AA.

AC AAR11159:

XX 23 MAY 1991 (first entry)

DE B lymphocyte membrane glycoprotein CR2.

KW CR2, B lymphocyte membrane receptor protein, Epstein Barr virus,

CC extracellular domain.

CS Homo sapiens.

XX Key Location/Qualifiers

FT Region 20..90

FT Znoter "1"

FT Znoter "2"

FT Znoter "3"

FT Znoter "4"

FT Znoter "5"

FT Znoter "6"

FT Znoter "7"

FT Znoter "8"

FT Znoter "9"

FT Znoter "10"

FT Znoter "11"

FT Znoter "12"

FT Znoter "13"

FT Znoter "14"

FT Znoter "15"

FT Znoter "16"

FT Znoter "17"

FT Znoter "18"

FT Znoter "19"

FT Znoter "20"

CR1 4 (266-274 KIK
CR1 4 (464-467 NAA
MCP-DAF fusion pro
Human CR1 protein
Human CR1 protein
Protophila melanog
Human Factor B and
Myxoma Virus human
Human Factor B and
Novel human diagra
Novel human diagra
Human OREF ORF2489
Novel human diagra
Novel human diagra
Novel human diagra
Novel human diagra

PS Disclosure: Fig 9.1-9.9; 60pp; English.

XX The six indicated fragments encode claimed and disclosed polypeptides, which are synthesised by recombinant expression, pref. in a baculovirus expression system in which a DNA plasmid, conf. a cDNA encoding this sequence, is truncated to encode a CR2 polypeptide that comprises a region of the extracellular domain of CR2. The construct is then inserted downstream of an appropriate promoter in a transfer vector and integrated into a baculovirus which is then used to infect host insect cells for expression.

CC The polypeptides correspond to B-lymphocyte membrane receptor protein for Epstein-Barr Virus (EBV) and give specific binding. Protein number 3 is used to inhibit infection of mammalian cells in contact with an aq. medium, (esp. mammalian blood) and of human B-lymphocytes, by EBV. The peptides are used to detect the presence of EBV in an aq. sample and to detect antibodies directed against CR2. The peptides are used in a pharmacological compsh. as active ingredient with a carrier to treat immune disorders.

SQ Sequence 1087 AA;

Query Match 62.0%; Score 466.5; 108 12; Length 1087;

Best Local Similarity 61.2%; Pred. No. 6; 76 46;

Matches 82; Conservative 18; Mismatches 44; Gaps 1;

QY 2 ISGPPPPVNRAPFYYSPTVEHIVYI-SQSYRIGGKATPQSPNVAHAWRAP 61

DE III I

DE 21 ISGSPPPPIINRISYSSPTIAVIVIVYSSTIERIIEKESLIETIKKVIETWKPAP 80

QY 62 IESVNETISSEPTVEDEENRSEFAIEETVYIIEKATMEAKVWQZEMWG 121

DE III I

DE 81 KCEFNKYSSEPTVPAQYKIGS IYRHSVITIA KINSNNKESVWQANRWG 149

QY 122 PTALVPSDEPPE 135

DE III I I I

DE 140 PTKLPTVSVFELE 154

RESULT 2

AAR13490

10 AAR13490 standard; Protein: 581 AA.

AC AAR13490;

XX 30 OCT 1991 (first entry)

DE Human C4 binding protein.

KW C4bp, monomer; complement protein; polypeptide; SCR;

XX short consensus repeat.

CS Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..32

FT /label= signal_peptide

FT Protein 43..581

FT /label= C4bp

FT Region 43..94

FT /label= SCR8

FT Region 94..165

FT /label= SCR7

FT Region 156..219

FT /label= SCR6

FT Region 220..274

FT /label= SCR5

FT Region 280..345

FT /label= SCR4

FT Region 346..406

FT /label= SCR3

FT Region 407..464

FT /label= SCR2

FT Region 465..523

FT Synthesised polypeptide(s) of extracellular domain. Treat

FT Epstein Barr virus infections and diagnose same by formation of

FT complex between CR2 and EBV

XX

CC represent differences in the polypeptide chain of CR1, rather than
 CC phosphorylation state because they are not abolished by treatment of
 CC purified receptor protein with endoglycosidase F; the CR1 gene has
 CC been shown to have repetitive intervening sequences which may have
 CC been duplicated in the formation of the larger allotypes.

XX
 SQ Sequence 2049 AA;
 Query Match 29.5%; Score 221.5; ID 14; Length 2039;
 Best local similarity 46.0%; Pred. No. 4; 56-143;
 Matches 49; Conservative 19; Mismatches 54; Indels 15; Gaps 5;
 QY 2 ISCTPEFEVKNAPKPYYS--LPTVGVVLPYTPSPS-----YVLGSEKALDITSENCV 52
 DB 1015 ISCEPPTISN--DEYSNNRPSFNGTIVVYQCHAGDNGEQLFOLVGRSTYCLSKDQ 1574
 QY 53 HATWKAAPDCTSVNKLISLSLIVGGHMNKGSKAPRKHDSVDFCTKANEIRKGSKV 112
 DB 1073 VGVWSSEPPKCLSTNK-CTAPEVNAIRVGNKSPFSLTEIFERQVSEVWVGSHTV 1129
 QY 113 WQANEMWSPITALPVC 128
 DB 1130 QCTNGRWGP KLPHC 1144

RESULT 4
 AAR11982
 ID AAR11982 standard; Protein: 1547 AA;
 XX
 AC AAR11982;
 XX
 UT 25 JUN 1991 (first entry)
 XX
 DE Critical human complement type 1 receptor;
 XX
 KW complement system; C3b/C4b receptor; CR1; allelic reduction;
 KW immune response; long homologous repeat; LHR;
 XX
 CG Homo sapiens

XX
 FH Key Location/Qualifiers
 FT Residues 1-1438
 FT /Label: LHR R
 FT Residues 406-891
 FT /Label: LHR C
 FT Residues 892-1144
 FT /Label: LHR D
 FT Residues 1495-1498
 FT /note "positively charged; preceded by hydrophobic
 FT sequence"
 FT Residues 1521-1526
 FT /note "has 67 per cent homology to site of protein
 FT kinase C phosphorylation in the EGF
 FT receptor"
 XX
 W0105047 A
 XX
 DE ABR 1991
 XX
 PE 26 SEP 1990 9060 0505454
 XX
 PR 26 SEP 1989 8405 0412745
 XX
 PR 26 SEP 1990 9005 0912546
 XX
 (CCL) 1 CCL, SCL, INC
 PA (CCL) 1 JOHNS HOPKINS UNIVERSITY,
 PA (CCL) 1 BRIGHAM AND WOMEN'S HOSPITAL,
 XX
 PR 1990 10, Kluksstein LB, Wood WW, Carlson GR, Bob M, Cuelmo MF;
 PR Marsh SC, Marsh SC;
 XX
 PR WFL 1991 142654/18,
 PR N PSDB, AAQ11643.

XX Human complement receptor type 1 gene, encoded proteins and
 PT fragments for treatment of immune disorders, myocardial infarct,
 PT damage due to inflammation and in treatment of thrombosis
 XX
 PS Disclosure: Fig 5; 234pp; English;
 XX
 CC This sequence comprises three of the four tandem, direct, long
 CC homologous repeats of the full length polypeptide of CR1. LHR A is
 CC absent. Each LHR might represent a single C3b/C4b binding domain,
 CC making the receptor multivalent. The LHRs are compared at 7 short
 CC consensus repeats of 60-70 residues resembling the SCRs of other
 CC C3/C4 binding proteins. The protein and fragments of it having C3b
 CC or C4b binding activity can be used to treat immune disorders
 CC or disorders involving inappropriate complement activity.
 CC See also AAQ11642.

XX
 SQ Sequence 1537 AA;
 Query Match 29.3%; Score 220.5; ID 12; Length 1537;
 Best local similarity 46.0%; Pred. No. 4; 13;
 Matches 49; Conservative 18; Mismatches 54; Indels 15; Gaps 5;
 QY 2 ISCTPEFEVKNAPKPYYS--LPTVGVVLPYTPSPS-----YVLGSEKALDITSENCV 52
 DB 1015 ISCEPPTISN--DEYSNNRPSFNGTIVVYQCHAGDNGEQLFOLVGRSTYCLSKDQ 1072
 QY 53 HATWKAAPDCTSVNKLISLSLIVGGHMNKGSKAPRKHDSVDFCTKANEIRKGSKV 112
 DB 1073 VGVWSSEPPKCLSTNK-CTAPEVNAIRVGNKSPFSLTEIFERQVSEVWVGSHTV 1129
 QY 113 WQANEMWSPITALPVC 128
 DB 1130 QCTNGRWGP KLPHC 1144

RESULT 5
 ARG00104
 ID ARG00104 standard; Protein: 1929 AA;
 XX
 AC ARG00104;
 XX
 UT 14 FEB 2002 (first entry)
 XX
 DE Novel human diagnostic protein #94.
 XX
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder;
 XX
 QS Homo sapiens.
 XX
 FN W0200175067 A2,
 XX
 PD 11-OCT-2001.
 XX
 PE 30-MAR-2001; 2001WO-0508631.
 XX
 PR 31 MAR 2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US 0649167.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Brimacombe RI, Liu C, Tamm YL;
 XX
 DR WPI; 2001 53462773,
 DR N PSDB; AAS64290.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity.
 XX
 PS claim 20; SEQ ID No 30462; 103pp; English.

XX the invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC the polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. A630010 A630177 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at http://wipo.int/pub/published_pat_sequences.
 XX
 SQ Sequence 1929 AA;
 Query Match 29.14; Score 220.5; DB 22; Length 1929;
 Best Local Similarity 36.04; Pred. No. 5,3e-13;
 Matches 49; Conservative 18; Mismatches 54; Indels 15; Gaps 5;
 QY 2 ISGDPPEVKNAPKPYVS--LPIVPCIVLPIYCSPS-----YELTCEKATFCISNQV 52
 DB 1407 ISGDPPTISNG--DFTSNNTSHNGGVVYQGRHGGGRQGFEDWGRSFGCSKDDQ 1404
 QY 53 HATWKAFFPCISVNKTISGDPVTPGTFMNGSKAPFPRHDSVTEFKANFTKFSKTV 112
 DB 1465 VGVWSSPPPRCISTNK--CTAPEVENATKYPONRSPFSSTETLFRRCQPCFVWGSHTV 1521
 QY 113 WCOANEMKGPITALPVC 128
 DB 1522 QCOINRWGFLKPHC 1546
 RESULT 6
 AAW45899
 ID AAW45899 standard; peptide; 1930 AA;
 AC AAW45899;
 DE 30-JUN-1998 (first entry)
 XX Human complement receptor 1 (residues 1-1929).
 XX
 XX Membrane binding element; thrombotic disease; soluble protein;
 KW complement related disease; integral membrane protein; inflammation;
 KW short consensus repeat; SRK 1-3; CR1; complement receptor type 1.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH Cross-Links 1930
 FT /note= "disulphide linked to Cys in peptide given
 FT in AAW45889"
 XX
 XX W9902454 A2.
 FN 22 JAN 1998.
 PD 68 JUL 1997; 97W0-EP04715.
 XX
 XX 15 JUL 1996; 96GB-0014871.
 XX
 XX (ADPR) ALBROTECH PLC.
 XX

PI Todd I, Mossakowska DEL, Smith KAG;
 XX WPI: 1998-110524/10.
 XX Derivatives of soluble poly:peptide(s) bonded to low affinity
 PT membrane binding groups - useful for treating complement related and
 PT thrombotic diseases, providing improved localisation at cellular
 PT membranes
 XX
 XX Claim 22; Pages 60-61; 75pp; English.
 XX This sequence represents human complement receptor 1 (CR1, Cl. 45)
 CC N-terminal fragment. The invention relates to a soluble derivative (A)
 CC of a soluble polypeptide (I), which comprises at least 2 heterologous
 CC membrane-binding elements (MBE) of low membrane affinity covalently
 CC associated with (I). MBE interact, independently and with thermodynamic
 CC additivity, with components of cellular or artificial membranes exposed
 CC to extracellular fluids. (A) are used to treat disorders treatable with
 CC (I) itself, specifically inflammation or any other complement related
 CC disorder (e.g. thrombotic disease, graft rejection, myocardial
 CC infarction, sepsis, rheumatoid arthritis and many others; including
 CC application to indwelling devices) and thrombotic disease, but also to
 CC treat allergy induce weight loss, to treat ischaemia or asthma and as
 CC immuno-modulators for treating multiple sclerosis. (A) are administered
 CC orally, topically, by injection or inhalation at 0.01-10 (preferably
 CC 0.1-10) mg/kg/day.
 XX
 SQ Sequence 1530 AA;
 Query Match 29.38; Score 220.5; DB 19; Length 1930;
 Best Local Similarity 36.04; Pred. No. 5,3e-13;
 Matches 49; Conservative 18; Mismatches 54; Indels 15; Gaps 5;
 QY 2 ISGDPPEVKNAPKPYVS--LPIVPCIVLPIYCSPS--YELTCEKATFCISNQV 52
 DB 1476 ISGDPPTISNG--DFTSNNTSHNGGVVYQGRHGGGRQGFEDWGRSFGCSKDDQ 1534
 QY 53 HATWKAFFPCISVNKTISGDPVTPGTFMNGSKAPFPRHDSVTEFKANFTKFSKTV 112
 DB 1534 VGVWSSPPPRCISTNK--CTAPEVENATKYPONRSPFSSTETLFRRCQPCFVWGSHTV 1590
 QY 113 WCOANEMKGPITALPVC 128
 DB 1591 QCOINRWGFLKPHC 1605
 RESULT 7
 AAW11810
 ID AAW11810 standard; Protein: 2039 AA
 AC AAW11810;
 DE 25-JUN-1991 (first entry)
 XX Human complement type 1 receptor.
 XX
 XX complement system; C3b/iC4b receptor; CR1; allergic reaction;
 KW immune response; clone lambda T109.1
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH Peptide 1..41
 FT /label= putative signal peptide
 FT Protein 42..2039
 FT /label= CR1
 XX
 XX W09105047 A.
 XX 19-APR-1991.
 XX
 XX 25-SEP-1990; 90W0-US05454.
 XX

[illegible]

Query Match 28.0%; Score 215; DB 19; Length 579;
Best local Similarity 40.0%; Pred. No. 4, 4e 13;
Matches 40; Conservative 27 Mismatches 51; Indels 14; Gaps 4;

Q6	A SCHUPPEVANKAR	KAYSTLVLNGLWRYUYSNYRLGKATPCISENVJHRTWD	57
		I I	
Q6	LCTEPTTFTCKRGSRGRDRIYF	GSSVLYNDPOTETELGNASTVCIVVNHTCVGVWR	212
		I I	
Q7	R KAPTESANKEIENSDPVITADGE	MNGSKRPFREHGVSIFVTKANETMKSGKLVMGCAN	117
		I I	
Q8	FHDFAFYOK	VCHRPQTFRGYLAHFQRVAHYRALETRCKKGTELRGGSVTHCEAN	268
		I I	
Q9	TMMOCPALAVETE		129
		I I	
Q9	CWEPSSEDE		279
		I I	

[illegible]

XX	Homo sapiens.
XX	
OS	
PN	US5981481-A.
XX	
PN	09 NOV 1999.
XX	
PD	
XX	
PD	06 JUN 1995; 9505-0470652.
XX	
XX	
PR	03 APR 1969; 800S 0432865.
XX	
PR	06 DEC 1974; 740S 0450248.
XX	
PR	24 FEB 1993; 940S 0026144.
XX	
PR	01 APR 1988; 880S 0176542.
XX	
XX	(OYU) UNIV JOHNS HOPKINS.
XX	(BGIM) BRIGHAM & WOMEN HOSPITAL.
PA	(AVAN-) AVANT IMMUNOTHERAPEUTICS INC.
XX	
PA	
XX	
PL	Cancino MF, Wond WW, Makrides SC, Klinkstein LR, Pordon DL, Ip SH.
XX	Marsh HC, Carlson GR.
XX	
XX	WPI: 1999-63357/54.
XX	
PT	A human CD46/49 receptor (CR1) protein having anti-inflammatory and
PT	cardiac activity
XX	
PT	
XX	
PS	Disclosure: Fig 10; 87pp; English.
XX	
CC	The invention relates to a human CD46/49 receptor (CR1) protein. The CR1
CC	protein or fragment is expressed as a cell surface protein on the surface
CC	of a non-human cell and exhibits a complement regulatory activity of full
CC	length human CR1 as expressed on erythrocytes. The CR1 function in vivo
CC	may be mediated through the inhibition of complement pathway enzymes. The
CC	soluble CR1 protein exhibits a complement regulatory activity, and this
CC	may be used to prevent reperfusion injury, inhibit Arthus reaction, and
CC	neutrophil mediated tissue damage, and reduce myocardial infarct size,
CC	and inflammation. The CR1 protein and its fragments can also be used in
CC	the treatment of conditions which involve unwanted complement activity,
CC	e.g. shock lung, tissue damage due to burn, or ischemic heart conditions,
CC	and autoimmune disorders. CR1 proteins, polypeptides, derivatives, and anti-
CC	-CR1 antibodies are used in assays, and diagnostics. The present sequence
CC	represents the short consensus repeat (SCR) fragments of human CR1
CC	protein long homologous repeat (LHR) D sequence.

[illegible]

QY	2	1SCTHTEVFNKAPFVYS--	LPVPLVIVVYVYS	YQVLEKRAVTEVSEVAV	62
DB	124	1SCTHTEVFNKAPFVYS--	LPVPLVIVVYVYS	YQVLEKRAVTEVSEVAV	101
QY	53	HAIWQKAPDCEVSNKLTST	SNPLVCGVGNKRS	AAVPHGVAVVGVANV	112
DB	182	VAVWSEPTGVSTNK--	GVTAENVKAVVGNKLTST	LVVGVVWVSHIV	248
QY	113	WQANEMKCEVLPVC	128		
DB	239	OCQVNCWCP	KLDHC	254	

RESULT 16	
AAV55758	
1D	AAV55758 standard; Protein; 646. AA.
XX	
XX	AAV55758
XX	AC
XX	AAV55758;
XX	
XX	22-FEB-2000 (first entry)
XX	
XX	Human CR1 protein LHR-D fragment.
DE	

XX 26 SEP 1998; 083P 029155.0;
 XX
 XX 26 SEP 1997; 92JP 0279547;
 XX
 XX (NHIA) NIPPON HAM KK;
 XX
 XX WPI; 1999-486 02/41;
 XX N P300; AAZ09145;
 XX
 XX New reporter gene useful for distinguishing extracellularly the
 XX presence and/or extent of expression of gene
 XX
 XX Bioscience; Page 13 14; 18pp; Japanese;
 XX
 XX this invention describes a novel reporter gene, MCP, consisting of a
 XX gene of complement inhibitor; the invention also describes a method for
 XX the measurement of expression of MCP in which a gene containing the above
 XX MCP gene (reporter gene) is introduced to a cell derived from an animal
 XX species other than the animal species derived from the above MCP gene to
 XX prepare a transmutant and then an antibody recognizing MCP is reacted to
 XX measure MCP; the invention also describes a monoclonal antibody of IgG1
 XX type recognizing pig complement inhibitor MCP (pMCP); The method can
 XX distinguish extracellularly the presence and/or the extent of expression
 XX of a gene; This sequence represents the MCP protein of the invention;
 XX
 XX Sequence 463 AA;
 XX
 XX Query MCP
 XX Best Local Similarity 31.9%; Score 199.5; ID 20; Length 463;
 XX Matches 4%; Conservative 21; Mismatches 52; Indels 25; Gaps 4;
 XX
 XX QY 1 ELSDDPPVKNAR KPYSDIVGVIVLVYKPS -- YRLGKATPELSEN 50
 XX 11
 XX ID 10R KILCKKPTLPCKYINSHKVEEY NEWVITSLSSGIGDSSESSSESLVCKND 223
 XX 11
 XX QY 51 QVHAWDKATPEESVNRKLTSSSDIVGVIVLVYKPSKATPEELSVTEPKANFIMKGSK 110
 XX 11
 XX ID 231 E WSSGVEE KVRVTVVIVVIVVIVVIVVIVVIVVIVVIVVIVVIVVIVVIVVIVV 275
 XX 11
 XX QY 111 LVMQANRWQPLAVQESD 131
 XX 11
 XX ID 276 LTVANSLWEP EMIGQLK 296
 XX 11
 XX
 XX RESULT 14
 XX AAY29860
 XX ID AAY29860 standard; Protein: 263 AA
 XX
 XX AC AAY29860;
 XX
 XX 16 NOV 1999 (first entry)
 XX
 XX Vaccinia virus SPICE protein
 XX
 XX Vaccinia virus; smallpox inhibitor of complement enzymes; SPICE;
 XX fusion protein; hyperacute rejection; xenograft; inflammation;
 XX post ischemic reperfusion injury; malimmunity; autoimmune disease;
 XX immune system disorder; neurodegeneration; infection; gene therapy;
 XX blood additive; extracorporeal circulation system;
 XX
 XX Vaccinia virus
 XX
 XX Key Location/Attributes
 XX Note: EntrezGene 13
 XX Note: *encoded by v3A*
 XX
 XX W09944625.A1
 XX
 XX 10 SEP 1999
 XX
 XX 02 MAR 1999 99WO-US04645
 XX
 XX 03-MAR-1998; 98US-0076821

PR 03-MAR-1998; 98US-0076821
 XX
 XX (OYJO) UNIV J HNS HOPKINS;
 XX (OYPI-) UNIV PILLSBURGH;
 XX
 XX Rosendaar AM, Ahearn JM;
 XX WPI; 1999-56081/46;
 XX N P508; AAZ21090;
 XX
 XX New smallpox inhibitor of complement enzyme proteins, used to treat
 XX complement mediated disease, particularly hyperacute rejection
 XX
 XX claim 1; Fig 2; 88pp; English;
 XX
 XX The present sequence represents Vaccinia virus smallpox inhibitor of
 XX complement enzymes (SPICE) protein. SPICE is an inhibitor of complement
 XX activation, and so can be used to treat or prevent complement mediated
 XX disorders, especially hyperacute rejection, inflammation or post
 XX ischemic reperfusion injury, malimmunities, autoimmune diseases,
 XX immune system disorders, neurodegeneration and infections. Hyperacute
 XX rejection may also be prevented by treating the graft with SPICE before
 XX transplanting it or by using a xenograft that has been transformed to
 XX express SPICE from a gene therapy vector. SPICE is also useful as
 XX additive to blood, e.g. in an extracorporeal circulation system (coated
 XX on tubing) or in storage, also for studying complement activation.
 XX Transgenic animals that express SPICE are used as sources of xenografts
 XX
 XX Sequence 263 AA;
 XX
 XX Query Match 26.4%; Score 197.5; ID 20; Length 263;
 XX Best Local Similarity 29.9%; Fred. No. 9.5e 12;
 XX Matches 38; Conservative 20; Mismatches 58; Indels 11; Gaps 4;
 XX
 XX QY 2 LSKDPPPEVKNARPYYSPLVGVIVLVYKPSYKATPEELSVTEPKANFIMKAPPP 61
 XX 11
 XX ID 146 VKQLPPLPSLSNGKNGYNDPTTSGSVVTVYSNYSYSLGNSVLCSS-- GHSN PP 199
 XX 11
 XX QY 52 LELVAVP LSSVSTVAVSLMMP LKAPRSESEVSTPASE LMS LKLVV VAPRMW 121
 XX 11
 XX ID 200 TCGQ -- LVKQDGLITNXYLSSSG KKEYSYNVVDLCKYKYSLSSSSSDPSNFW 256
 XX 11
 XX QY 122 PTLAPVC 128
 XX 11
 XX ID 256 P-ELPK 261
 XX
 XX RESULT 20
 XX AAY29860
 XX ID AAY29860 standard; Protein: 263 AA
 XX
 XX AC AAY29860;
 XX
 XX 16 NOV 1999 (first entry)
 XX
 XX Mutated VCP giving SPICE protein sequence
 XX
 XX Vaccinia virus; smallpox inhibitor of complement enzymes; SPICE;
 XX fusion protein; hyperacute rejection; xenograft; inflammation;
 XX post ischemic reperfusion injury; malimmunity; autoimmune disease;
 XX immune system disorder; neurodegeneration; infection; gene therapy;
 XX blood additive; extracorporeal circulation system;
 XX
 XX Vaccinia virus
 XX
 XX Key Location/Attributes
 XX Note: EntrezGene 13
 XX Note: *encoded by v3A*
 XX
 XX W09944625.A1
 XX
 XX 10 SEP 1999
 XX
 XX 02 MAR 1999 99WO-US04645
 XX
 XX 03-MAR-1998; 98US-0076821

F1 duplication 83
 F1 Znote "See note a in comments below."
 F1 duplication 144
 F1 Znote "See note a in comments below."
 F1 duplication 202
 F1 Znote "See note a in comments below."
 XX USN249208.N
 XX 14 MAR 1989.
 XX 20 AUG 1989; BRUS (249208).
 XX 20 AUG 1989; BRUS (249208).
 XX (USSH) NAT INST OF HEALTH.
 XX K00941.0
 XX W011 1989 165431/22.
 XX N PSDB: AAN0113.
 XX New protein with anti complement activity
 F1 encoded by Vaccinia virus 98K gene
 XX Disclosure: Figure 2A; 20pp; English.
 XX C4b binding protein which specifically blocks human complement cascades.
 CC It is the deduced sequence of a 96kDa protein encoded by sequence 52-840
 CC of the 98K gene of vaccinia virus strain WR. Note a - these sites
 CC indicate the start of 60 amino acid tandem repeating units which have a
 CC consensus sequence. The signal peptide sequence is not found in purified
 CC 98K protein recovered from the medium of cells infected with vaccinia
 CC virus strain WR. A suggested use is to treat diseases due to abnormally
 CC high complement activity.
 CC (Note: Revised entry submitted to correct the patent number format of
 CC US Government owned NUS applications to prevent clashes with ongoing US
 CC granted patent numbers. For further information please visit the Derwent
 CC web site at www.derwent.com (patent details as 02/11)
 XX Sequence 263 AA;
 SQ
 Query Match 25.7%; Score 193.5; DB 10; Length 263;
 Best local Similarity 29.1%; Pred. No. 2.4e-11;
 Matches 47; Conservative 19; Mismatches 60; Indels 11; Gaps 4;
 QY 2 ISCHPPEVKNAPKPYSLPVTGGLVETSESYKELICRAKAFETSDNVAHAWKAPP 61
 DB 146 VKQSPFSTSNCHNGYEDFYTHGSSVVTYSNSGYSLGNSGVCSG - GEWSO PP 199
 QY 62 IESVANKIISCSNPVGGGFMNKSKEAFERFQVETKANEIKKSKITVWQANEMWG 121
 DB 200 IQV 1VKCHDTISNVTSSCHKEFSYGVNVAWVLEKQKQVETSSSSGSSPQNTWKE 255
 QY 122 PTALPW 128
 DB 256 P-ELPKC 261
 QY 123
 AAY29859
 ID AAY29859 standard; protein: 263 AA.
 XX AAY29859;
 XX 16 NOV 1999 (first entry)
 XX Vaccinia complement control protein sequence.
 XX Vaccinia virus; smallpox inhibitor of complement enzymes; SPICE;
 KW fusion protein; hyperacute rejection; xenograft; inflammation;
 KW post ischaemic reperfusion injury; malignancies; autoimmune disease;
 KW immune system disorder; neurodegeneration; infection; gene therapy;

KW blood additive; extracorporeal circulation system.
 XX Vaccinia virus.
 OS Synthetic.
 XX W09944425-A1.
 XX 10 SEP 1999.
 XX 02-MAR-1999; 9900 US04635.
 XX 03-MAR-1998; 9805-0076821.
 XX (OYJO) UNIV JOHNS HOPKINS.
 XX (OYPI-) UNIV PITTSBURGH.
 XX Rosemond AM, Alward JM;
 XX WPI: 1999-550981/46.
 XX N-PSDB: AAZ21091.
 XX New smallpox inhibitor of complement enzyme protein, used to treat
 XX complement-mediated disease, particularly hyperacute rejection
 XX Claim 5; Fig 1; 88pp; English.
 XX The present invention describes the Vaccinia virus smallpox inhibitor of
 XX complement enzymes (SPICE) protein. SPICE is an inhibitor of complement
 XX activation, and so can be used to treat or prevent complement mediated
 XX disorders, especially hyperacute rejection, inflammation or post-
 XX ischaemic reperfusion injury, malignancies, autoimmune diseases,
 XX immune system disorders, neurodegeneration and infections. Hyperacute
 XX rejection may also be prevented by treating the graft with SPICE before
 XX transplanting it or by using a xenograft that has been transfected to
 XX express SPICE from a gene therapy vector. SPICE is also useful as
 XX additive to blood, e.g. in an extracorporeal circulation system (coated
 XX on tubing) or in storage, also for studying complement activation.
 XX Transgenic animals that express SPICE are used as sources of xenografts.
 XX the present sequence is a vaccinia complement control protein
 XX (VCP) encoded by the specifically claimed mutated VCP nucleotide
 XX sequence, having a silent T to A transversion at nucleotide position
 XX number 267.
 XX Sequence 263 AA;
 SQ
 Query Match 25.7%; Score 193.5; DB 20; Length 263;
 Best local Similarity 29.1%; Pred. No. 2.4e-11;
 Matches 47; Conservative 19; Mismatches 60; Indels 11; Gaps 4;
 QY 2 ISCHPPEVKNAPKPYSLPVTGGLVETSESYKELICRAKAFETSDNVAHAWKAPP 61
 DB 146 VKQSPFSTSNCHNGYEDFYTHGSSVVTYSNSGYSLGNSGVCSG - GEWSO PP 199
 QY 62 IESVANKIISCSNPVGGGFMNKSKEAFERFQVETKANEIKKSKITVWQANEMWG 121
 DB 200 IQV 1VKCHDTISNVTSSCHKEFSYGVNVAWVLEKQKQVETSSSSGSSPQNTWKE 255
 QY 122 PTALPW 128
 DB 256 P-ELPKC 261
 RESULT 24
 AAB13014
 ID AAB13014 standard; protein: 263 AA.
 XX AAB13014;
 XX 11-DEC-2000 (first entry)
 XX Complement inhibitory protein VCP amino acid sequence.
 XX post ischaemic reperfusion injury; malignancies; autoimmune disease;
 KW immune system disorder; neurodegeneration; infection; gene therapy;

KW treatment; diagnosis; amyloid plaque.
 OS Vaccinia virus.
 XX W020004.027 AL.
 XX 27 JUL-2000.
 XX 19 JAN 2000; 2000W0 US011.5.
 XX 19 JAN 1999; 990S-0116428.
 XX (OVID) UNIV LOUISVILLE RES FOUND INC.
 PA (KOTW/) KOTWAL G J.
 PA (DAILY/) DAILY J.
 PL Kotwal GJ, Daily J;
 XX WPI: 2000 476187/41
 DR N US06; AAA72738.
 XX
 XX Treating Alzheimer's disease using a Vaccinia virus protein that blocks
 PT the complementation pathway
 XX
 PS Claim 1; Page 42-43; 96pp; English.
 XX
 CC This invention relates to a method for treating Alzheimer's disease. The
 CC method uses a composition comprising a Vaccinia virus complement control
 CC protein, which blocks the complement pathway by binding to complement
 CC components. The protein designated VCP, blocks complement activation and
 CC can bind to amyloid plaques in samples. The transmembrane domain and a
 CC portion of the c-terminus (Abeta) of the amyloid precursor protein (APP)
 CC form the nucleus of the amyloid plaque, the hallmark of Alzheimer's
 CC disease. The Abeta peptide activates the complement pathway. The VCP
 CC protein used in the method of the invention, down regulates the
 CC complement pathway activation caused by Abeta. The method and composition
 CC may be used for the treatment of Alzheimer's disease. The VCP protein
 CC also binds to amyloid plaques and may be labelled and used to detect the
 CC presence of amyloid plaques in pathological samples, and therefore
 CC diagnose Alzheimer's disease. The present sequence represents the
 CC Vaccinia virus VCP protein used in the method of the invention.
 XX
 XX Sequence: 264 AA;
 SQ
 Query Match: 25.7%; Score 193.5; DB 21; Length 263;
 Best Local Similarity 29.1%; Pred. No. 2.4e-11;
 Matches 37; Conservative 19; Mismatches 60; Indels 11; Gaps 4;
 QY 2 ISCHPPVKKAKKQVYSIPIVQIVLIVPIYISPSYRLIGLKAHFTISENIVHAIVKAPV 61
 DE 146 VKQSPPSISGRINGYEIYFTISVVTYSNSGYSLIGNSGLVQSA----GEWSH-PP 199
 QY 62 ICSYVNTKISGSDPIVPGIPGEMKSKAFPHIGDSVTFTCKANFTMKSGSKTWQGANEMWG 121
 DB 200 IQG--IVKCHPHTISMGYSSGHPKESYSYNNVQVDEKCKYGYNLSSSSSSISPGNTWK 255
 QY 122 FTALVVC 128
 DB 256 P ELPKC 261
 RESULT 25
 AAR15244
 ID AAR15244 standard; Protein: 424 AA.
 XX AAR15244;
 XX 17-MAR 1992 (first entry)
 XX CD46 from clone pm5.8
 XX SCF, short consensus repeats; transmembrane; cytoplasmic;
 KW membrane cofactor protein; MCP.

XX OS Homo sapiens.
 XX
 XX Key
 FT Peptide
 FT /label- sig_peptide
 FT 34..324
 FT /label- mat_protein
 FT 83
 FT Modified-site
 FT /label- N-glycosylation_site
 FT 114
 FT Modified-site
 FT /label- N-glycosylation_site
 FT 289..304
 FT Domain
 FT /label= hydrophobic_transmembrane_domain
 XX
 PN W05118097-A.
 XX
 XX 28-NOV-1991.
 XX
 XX 10-MAY-1991; 91WO-AU00199.
 XX
 XX 11-MAY-1990; 30AO-0000133.
 XX
 PA (UWME-) UNIV MELBOURNE.
 PL Purcell DEJ, Russell SM, McKenzie JF;
 XX WFI: 1991-09251/50.
 DR N-SPDR; AAQ14919.
 XX
 CC New CD46 membrane cofactor protein variants - useful as probes
 PT to identify CD46 isoforms and for diagnosing spontaneous
 PT abortion, inhibiting immuno:response and treating leukaemia
 XX
 PS D-sclosure: fig 1A and 3B; 77pp; English.
 XX
 CC The sequence of the pm5.8 clone is identical to the pm5.1 clone in
 CC the portion encoding the NH2 leader and four SCR regions. The
 CC sequence after nucleotide 890 was different, and results from
 CC reading through of the cDNA into an intron sequence after the
 CC fourth SCR. The protein encoded by this new sequence encodes
 CC a 16 amino acid hydrophobic region. Probably serving as a membrane
 CC spanning sequence. The putative cytoplasmic tail would also
 CC contain a high proportion of charged amino acids.
 CC See also AAQ14915-25, AAQ15211-12 and AAR15457-59.
 XX
 XX Sequence 324 AA;
 SQ
 Query Match: 25.2%; Score 180.5; DB 12; Length 424;
 Best Local Similarity 31.4%; Pred. No. 7.7e-11;
 Matches 43; Conservative 22; Mismatches 51; Indels 21; Gaps 7;
 QY 1 ELSCI-PPPEVKNARKPYYSLPV----PGTVLRYTSPS- YPLI-EKAIPIISENQ 51
 DB 159 KVIC-PPPKIKNCKHTPSEVVEFYLDVY- YSCDAVCHDPFSLIGESTLYC GDNS 214
 QY 52 VHAIVDKAPPICESVNTKISGSDPIVPGIPGEMKSKAFPHIGDSVTFTCKANFTMKSGSKT 111
 DB 215 V---WSRAAPEG---KVKPGCFPPVVEN-KJISGFGKSKYKATVMEETDKGYLLWSLT 247
 QY 112 VMCOANFMWGPALVVC 128
 DB 268 IVCDIN-TWDP-PVPKC 283
 RESULT 26
 AAR15232
 ID AAR15232 standard; Protein: 335 AA.
 XX AAR15232;
 XX 17-MAR-1992 (first entry)
 XX
 XX


```

DB 125 KVLCTPPPKIKKCKHFFSEVFEYLDVY---YSCDHPGDDPESLIGESTIYVC-GDNS 180
QV 52 VIATWCKAPPIESVKNKTSISDPIVPGGFMNKGSKAPPRHDSVTETCKANFTMKSGSKT 111
DB 181 V---WSRAAPEG---KVKKFFPPVVENCKQISGFGKKFYKATVMFECDKGFLDGSST 233
QV 112 VMCQANFMCPITALVCSDEP 128
DB 244 IVCDNSNSTWDP-PVPKCLVLP 254

RESULT 29
AAK10927
ID AAK10927 standard; Protein: 457 AA.
XX A*
XX 09 MAY 1991 (first entry)
XX Human membrane cofactor protein isoform with CYT1 C-terminus.
XX Mammalian membrane cofactor protein; complement activity;
XX inflammation; autoimmune diseases; tissue injury.
XX Key Location/Qualifiers
XX Region 1..251
XX /label= short consensus repeats (4)
XX Region 252..266
XX /label= serine-threonine rich region, STA
XX Region 267..281
XX /label= STB
XX Region 282..295
XX /label= STC
XX Region 296..309
XX /label= unknown region
XX Region 310..341
XX /label= hydrophobic region
XX Region 342..357
XX /label= CYT1 cytoplasmic region
XX W09102002 A.
XX 21 FEB 1991.
XX 20 JUL 1990; 90WO-0504107.
XX 19 APR 1990; 90OS-0510709.
XX 21 JUL 1989; 89OS-0484210.
XX (UNIV) UNIV OF WASHINGTON.
XX Atkinson JP;
XX WPI; 1991-074491/10.
XX New recombinant mammalian membrane cofactor protein - for
XX treating diseases with altered complement activity e.g.
XX inflammatory and autoimmune conditions
XX Disclosure; fig 8; 38pp; English.
XX This is a human isoform of a membrane cofactor protein (MCP).
XX Pharmaceutical compns. contg. the protein are useful in the
XX treatment of inflammatory and autoimmune diseases mediated by
XX excess or misdirection of complement activity, e.g. rheumatoid
XX arthritis or multiple sclerosis. Protection against tissue
XX injury caused by e.g. myocardial infarction or stroke may also
XX be provided. Antibodies raised against the MCP can be used in
XX autoimmune disease diagnosis to predict the probability of
XX recurrent miscarriages by testing for MCP levels in the placenta.
XX See also AAK10864-66.
XX Sequence 457 AA;
SQ

```

```

Query Match 25.2%; Score 189.5; DB 12; Length 457;
Best Local Similarity 30.2%; Pred. No. 8.7e-11; Indels 15; Gaps 6;
Matches 42; Conservative 23; Mismatches 59;
QV 1 FLSDDPPPKVKNARKPYYSIPIVPG-TVIRYTCSPS-----YRLIGKKAIFCISENOVHA 54
DB 125 KVLCTPPPKIKKCKHFFSEVFEYLDVYSCDHPGDDPESLIGESTIYVC-GDNSV-- 181
QV 55 TWDKAPPIESVKNKTSISDPIVPGGFMNKGSKAPPRHDSVTETCKANFTMKSGSKTWC 114
DB 182 -WSRAAPEG---KVKKFFPPVVENCKQISGFGKKFYKATVMFECDKGFLDGSSTIVC 246
QV 115 QANFMCPITALVCSDEP 133
DB 237 DSNSTWDP-PVPKCLVLP 254

RESULT 29
AAK15230
ID AAK15230 standard; Protein: 373 AA.
XX A*
XX AAK15230;
XX 17-MAR-1992 (first entry)
XX CD46 from clone pm5.6.
XX SCR: short consensus repeats; transmembrane; cytoplasmic;
XX membrane cofactor protein; MCP.
XX Homo sapiens.
XX Key Location/Qualifiers
XX Pept_de 1..34
XX /label= sig_peptide
XX Protein 34..373
XX /label= mat_protein
XX Modified-site 83
XX /label= N-glycosylation_site
XX Modified-site 114
XX /label= N-glycosylation_site
XX Modified-site 273
XX /label= N-glycosylation_site
XX Region 287..314
XX /note= "Ser/Thr rich region - O-linked
XX glycosylation sites"
XX Domain 329..339
XX /label= hydrophobic_transmembrane_domain
XX W09118097-A
XX 28-NOV-1991
XX 10-MAY-1991; 91WO-AU00199.
XX 11-MAY-1990; 90AU-0000133.
XX (UYNF) UNIV MELBOURNE.
XX Purcell DPJ, Russell SM, McKenzie JFC;
XX WPI 1991-363251/50.
XX N-PSDB; AAK14916.
XX New CD46 membrane co-factor protein variants - useful as probes
XX to identify CD46 isoforms and for diagnosing spontaneous
XX abortion, inhibiting immunoresponse and treating leukaemia
XX Disclosure; Fig 1B and 3A; 77pp; English.
XX The pm5.6 coding sequence corresponds to pm5.1, with the exception
XX that as for pm5.3, a 93 bp fragment is deleted from the fourth region
CC

```


of (AA046163) plus a stop codon both sequences contain 4 SCR regions of natural MCP primers (AA046165-66) and (AA046169-70) are used for amplification of the DNAs encoding these proteins.


```

Db 215 WSKAAAFEC KVKKRPVVVENCQKQNGCKKFKYYKATVMPFCKUKGPFYLLGSDITVQ 269
QY 115 QANEMWGPTALPVC 128
Db 270 DSNSTWDP FVPRC 282

RESULT 36
AAR93942
ID AAR93942 standard; Protein: 377 AA.
AC AAR93942;
DT 21 MAY 1996 (first entry)
DE CD46 construct subSCR2+3.
XX CD46; recombinant protein; short consensus repeat; SCR;
KW regulator of complement activation; transgenic animal; pig;
KW organ transplantation.
XX Synthetic.
XX WO9606937 A1.
XX PN 30 AUG 1995; 95WO-AU00553.
XX PP 07 MAR 1996.
XX PR 30 AUG 1994; 94AU-0007724.
XX PA (AUST-) AUSTIN RES INST.
XX PI Christiansen D, Loveland B, McKenzie IF, Milland J;
XX WO96160368/16.
XX DR N-PSDB; AAT17598.
XX PT Increasing prodn. of recombinant proteins, esp. CD46 - by reducing
PT the amt. of A and/or T in an A and/or T rich region of encoding gene
PT exon
XX Claim 12; Page 38 39; 60pp; English.
XX CD46 subSCR2+3 (AAR93942) is the product of a cDNA construct
CC (AAT17598) obtd. by splice overlap extension PCR of wild-type CD46
CC cDNA (AAT17595). The A/T contents of A-rich exons 3-5 of the
CC gene, encoding the short consensus repeats (SCR) 2 and 3 of
CC host cells, e.g. CHO-K1 and COS-7. CD46 subSCR2+3 is used to
CC prevent complement or inflammation-mediated tissue damage, to
CC improve immunity to tumours or viruses, to control fertilisation
CC and to prevent spontaneous abortion. Expression in transgenic
CC animals, esp. pigs, provides organs suitable for transplantation.
XX SQ Sequence 377 AA;
Query Match 25.1%; Score 188.5; DB 17; Length 377;
Host Local Similarity 30.6%; Pred. No. 1.2e-10;
Matches 41; Conservative 23; Mismatches 55; Indels 15; Gaps 6;
QY 1 EISCDPPPEVKNAKPPYSLPIVPG-TLVRYTSPS-----YELIGKATFCISENQVHA 54
Db 159 KVLCTPPPKIKNGKHTFSEVEFEYLLAVTYSCTPAAGPDPFSLIGESTIYC-GDNSV 215
QY 55 TWKAPPTCTSVNKTCTSCSPPIVGGCFMKNKGSKAFFHGLSVIFCTKANFMKSKIVWC 114
Db 216 WSKAAAFEC KVKKRPVVVENCQKQNGCKKFKYYKATVMPFCKUKGPFYLLGSDITVQ 270
QY 115 QANEMWGPTALPVC 128
Db 271 DSNSTWDP FVPRC 283

RESULT 36
AAR93942
ID AAR93942 standard; Protein: 377 AA.
AC AAR93942;
DT 21 MAY 1996 (first entry)
DE CD46 construct subSCR3.
XX CD46; recombinant protein; short consensus repeat; SCR;
KW regulator of complement activation; transgenic animal; pig;
KW organ transplantation.
XX Synthetic.
XX WO9606937 A1.
XX PN 30 AUG 1995; 95WO-AU00553.
XX PP 07 MAR 1996.
XX PR 30 AUG 1994; 94AU-0007724.
XX PA (AUST-) AUSTIN RES INST.
XX PI Christiansen D, Loveland B, McKenzie IF, Milland J;
XX WO96160368/16.
XX DR N-PSDB; AAT17597.
XX PT Increasing prodn. of recombinant proteins, esp. CD46 - by reducing
PT the amt. of A and/or T in an A and/or T rich region of encoding gene
PT exon
XX Claim 12; Page 36 37; 60pp; English.
XX CD46 subSCR3 (AAR93941) is the product of a cDNA construct
CC (AAT17597) obtd. by splice overlap extension PCR of wild-type CD46
CC cDNA (AAT17595). The A/T content of A-rich exon 5 of the CD46
CC gene, encoding the short consensus repeat 3 (SCR3) region of
CC host cells, e.g. CHO-K1 and COS-7. CD46 subSCR3 is used to prevent
CC complement- or inflammation-mediated tissue damage, to improve
CC immunity to tumours or viruses, to control fertilisation and to
CC prevent spontaneous abortion. Expression in transgenic animals,
CC esp. pigs, provides organs suitable for transplantation.
XX SQ Sequence 377 AA;
Query Match 25.1%; Score 188.5; DB 17; Length 477;
Host Local Similarity 30.6%; Pred. No. 1.2e-10;
Matches 41; Conservative 23; Mismatches 55; Indels 15; Gaps 6;
QY 1 EISCDPPPEVKNAKPPYSLPIVPG-TLVRYTSPS-----YELIGKATFCISENQVHA 54
Db 159 KVLCTPPPKIKNGKHTFSEVEFEYLLAVTYSCTPAAGPDPFSLIGESTIYC-GDNSV 215
QY 55 TWKAPPTCTSVNKTCTSCSPPIVGGCFMKNKGSKAFFHGLSVIFCTKANFMKSKIVWC 114
Db 216 WSKAAAFEC KVKKRPVVVENCQKQNGCKKFKYYKATVMPFCKUKGPFYLLGSDITVQ 270
QY 115 QANEMWGPTALPVC 128
Db 271 DSNSTWDP FVPRC 283

```


KW Inflammation; autoimmune diseases; tissue injury.

XX Key Location/Qualifiers
 XX Region 1..251
 XX /Label= short consensus repeats (4)
 XX Region 252..266
 XX /Label= serine threonine rich region, STB
 XX Region 267..280
 XX /Label= STC
 XX Region 281..294
 XX /Label= unknown region
 XX Region 295..326
 XX /Label= hydrophobic region
 XX Region 327..350
 XX /Label= Cyt2 cytoplasmic tail region

XX W09102002 A.

XX 21 FEB 1991.

XX 20 JUL 1990; 90WO-US04107.

XX 19 APR 1990; 90US-0510709.

XX 21 JUL 1989; 89US-0384210.

XX (UNIV) UNIV OF WASHINGTON.

XX Atkinson JP;

XX WPI; 1991 074491/10.

XX N-PSDB; AAG10864.

XX New recombinant mammalian membrane co-factor protein for
 XX treating diseases with altered complement activity e.g.
 XX inflammatory and autoimmune conditions

XX Disclosure; fig 1; 38pp; English.

XX This human isoform of a membrane cofactor protein (MCP) is useful
 XX in a pharmaceutical compo. for the treatment of inflammatory and
 XX autoimmune diseases mediated by excess or misdirection of comple-
 XX ment activity, e.g. rheumatoid arthritis or multiple sclerosis.
 XX protection against tissue injury caused by e.g. myocardial in-
 XX farction or stroke may also be provided. Antibodies raised
 XX against this MCP can be used in autoimmune disease diagnosis to
 XX predict the probability of recurrent miscarriages by testing for
 XX MCP levels in the placenta.
 XX See also AAG10865-66 and AAG10927.

XX Sequence 384 AA;

Query Match 25.1%; Score 188.5; DB 12; Length 384;
 Best Local Similarity 30.6%; Pred. No. 1,2a-10;
 Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 6;

QY 1 EIS:DFPEEVKNARKPYYSLEFIVE;-IVLRVTCSPS-----YRLIGDKAIFCISENOVHA 54

DB 159 KVLATTFPRFKRNKRIITFVIVFYLLDAVTSQDPAPDPDFSLIGESTIYC GDNVS- 215

QY 55 TWDKAPFICISVNKTIISGSDPIVVDGCPMKNKSKAPFPHGHSVFTCKANFTMKGSKIVWP 114

DB 216 WSRAPAEV- KVKVRFETVWVWCKGKISGEGKFKFYKAIVMPECDKGFYLDSDITIVC 270

QY 115 QANEMWGTALIVC 128

DB 271 DSNSTWDP-IVPKC 283

RESULT 41

AA866416

DB AA866416 standard; Protein: 384 AA.

XX

XX AA866416;

XX 15-APR-1995 (first entry)

XX Human CD46.

XX Terminal complement inhibitor protein, terminal CIP; CD59; CD46;
 XX transmembrane terminal CIP; TMICIP; 136 antigen; transmembrane
 XX organ transplantation; glycosyl-phosphatidy inositol; GPI.

XX Homo sapiens.

XX Key location/Qualifiers
 XX Peptide 1..34
 XX /Label= Sig_peptide

XX W09523512 A1.

XX 03-SEP-1995.

XX 01-MAR-1995; 95WO-US02944.

XX 03-MAR-1994; 94US-0205720.

XX (ALEX-) ALEXION PHARM INC.

XX Rollins S. Rether RP, Squinto SP;

XX WPI; 1995-320335/41.

XX N-PSDB; AAT03339.

XX Terminal complement inhibitor chimeric protein and nucleic acid
 XX esp. against human complement, useful for protecting cells from
 XX complement attack e.g. in organ transplantation

XX Disclosure; Page 66-68; 85pp; English.

XX A terminal complement inhibitor protein (CIP), is used in the
 XX construction of chimeric cDNA coding for transmembrane terminal
 XX CIP, pref. comprising amino acids 1-7 of CD59 fused to amino
 XX acids 270-350 (the transmembrane domain) of CD46 (AA866416). Such
 XX chimeric cDNA is incorporated into a retrovirus vector and used
 XX in the breeding of transgenic animals as a means of producing
 XX transgenic organs that are protected against human complement
 XX attack upon transplantation.

XX Sequence 384 AA;

Query Match 25.1%; Score 148.5; DB 16; Length 384;
 Best Local Similarity 30.6%; Pred. No. 1,2a-10;
 Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 6;

QY 1 EIS:DFPEEVKNARKPYYSLEFIVE;-IVLRVTCSPS-----YRLIGDKAIFCISENOVHA 54

DB 159 KVLATTFPRFKRNKRIITFVIVFYLLDAVTSQDPAPDPDFSLIGESTIYC GDNVS- 215

QY 55 TWDKAPFICISVNKTIISGSDPIVVDGCPMKNKSKAPFPHGHSVFTCKANFTMKGSKIVWP 114

DB 216 WSRAPAEV- KVKVRFETVWVWCKGKISGEGKFKFYKAIVMPECDKGFYLDSDITIVC 270

QY 115 QANEMWGTALIVC 128

DB 271 DSNSTWDP-IVPKC 283

RESULT 42

AA858394

DB AA858394 standard; Protein: 421 AA

XX

XX AA858394;

XX 14-MAR-2001 (first entry)

XX Lung cancer associated polypeptide sequence SEQ ID 732.

	ATOM	3737	C	LEU	C	45	62.664	85.961	-4.263	1.00	28.71	C
	ATOM	3738	O	LEU	C	45	63.094	86.894	-3.558	1.00	21.68	C
	ATOM	3739	N	CYS	C	46	61.410	85.547	-4.238	1.00	25.91	C
	ATOM	3740	CA	CYS	C	46	60.455	86.152	-3.343	1.00	26.90	C
5	ATOM	3741	C	CYS	C	46	60.610	85.392	-2.032	1.00	30.25	C
	ATOM	3742	O	CYS	C	46	60.448	84.173	-1.980	1.00	28.51	C
	ATOM	3743	CB	CYS	C	46	59.021	86.026	-3.908	1.00	28.02	C
	ATOM	3744	SG	CYS	C	46	57.741	86.546	-2.696	1.00	28.63	C
10	ATOM	3745	N	ILE	C	47	60.925	85.115	-0.971	1.00	21.11	C
	ATOM	3746	CA	ILE	C	47	61.120	85.484	-0.314	1.00	24.65	C
	ATOM	3747	CD	ILE	C	47	62.649	85.531	-0.722	1.00	32.62	C
	ATOM	3748	CG2	ILE	C	47	63.505	84.878	-0.358	1.00	27.06	C
	ATOM	3749	CG1	ILE	C	47	63.050	85.958	-0.959	1.00	25.64	C
	ATOM	3750	CD1	ILE	C	47	64.429	87.119	1.592	1.00	32.03	C
15	ATOM	3751	C	ILE	C	47	60.431	86.274	1.421	1.00	31.05	C
	ATOM	3752	O	ILE	C	47	59.931	87.399	1.226	1.00	22.58	C
	ATOM	3753	N	THR	C	48	60.421	85.669	2.596	1.00	27.58	C
	ATOM	3754	CA	THR	C	48	59.964	86.388	3.764	1.00	27.51	C
	ATOM	3755	CB	THR	C	48	58.584	85.987	4.273	1.00	28.85	C
	ATOM	3756	CG1	THR	C	48	59.383	86.770	5.120	1.00	25.10	C
	ATOM	3757	CG2	THR	C	48	58.490	84.526	4.619	1.00	26.50	C
	ATOM	3758	C	THR	C	48	61.001	86.164	4.839	1.00	29.22	C
	ATOM	3759	O	THR	C	48	61.455	85.845	5.089	1.00	29.41	C
20	ATOM	3760	N	LYS	C	49	61.445	87.243	5.463	1.00	27.29	C
	ATOM	3761	CA	LYS	C	49	62.425	87.112	6.533	1.00	31.22	C
	ATOM	3762	CB	LYS	C	49	63.478	88.220	6.427	1.00	26.53	C
	ATOM	3763	CG	LYS	C	49	64.429	88.239	5.134	1.00	33.41	C
	ATOM	3764	CD	LYS	C	49	65.703	88.351	5.346	1.00	40.12	C
	ATOM	3765	CE	LYS	C	49	66.262	87.134	6.055	1.00	42.32	C
30	ATOM	3766	NZ	LYS	C	49	67.729	87.262	6.166	1.00	46.64	C
	ATOM	3767	C	LYS	C	49	61.745	87.219	7.877	1.00	33.53	C
	ATOM	3768	O	LYS	C	49	62.249	86.692	8.856	1.00	30.36	C
	ATOM	3769	N	ASP	C	50	60.596	87.896	7.952	1.00	25.34	C
	ATOM	3770	CA	ASP	C	50	59.978	88.083	9.253	1.00	26.98	C
35	ATOM	3771	CB	ASP	C	50	59.961	89.579	9.597	1.00	25.16	C
	ATOM	3772	CG	ASP	C	50	59.154	90.397	8.607	1.00	27.41	C
	ATOM	3773	OD1	ASP	C	50	58.459	89.768	7.749	1.00	22.49	C
	ATOM	3774	OD2	ASP	C	50	59.207	91.664	8.693	1.00	26.37	C
	ATOM	3775	C	ASP	C	50	58.598	87.492	9.365	1.00	25.28	C
40	ATOM	3776	O	ASP	C	50	57.883	87.770	10.321	1.00	24.69	C
	ATOM	3777	N	LYS	C	51	58.247	86.664	8.386	1.00	26.19	C
	ATOM	3778	CA	LYS	C	51	56.948	86.006	8.319	1.00	23.97	C
	ATOM	3779	CB	LYS	C	51	56.717	85.091	9.526	1.00	31.09	C
	ATOM	3780	CG	LYS	C	51	57.749	84.021	9.749	1.00	32.84	C
45	ATOM	3781	CD	LYS	C	51	57.625	82.919	8.769	1.00	44.41	C
	ATOM	3782	CE	LYS	C	51	58.505	81.752	9.179	1.00	52.55	C
	ATOM	3783	NZ	LYS	C	51	58.266	81.397	10.605	1.00	51.40	C
	ATOM	3784	C	LYS	C	51	55.791	86.996	8.241	1.00	25.78	C
	ATOM	3785	O	LYS	C	51	54.660	86.628	8.510	1.00	25.03	C
50	ATOM	3786	N	VAL	C	52	56.048	88.252	7.896	1.00	25.78	C
	ATOM	3787	CA	VAL	C	52	54.937	89.195	7.758	1.00	23.31	C
	ATOM	3788	CB	VAL	C	52	54.976	90.286	8.894	1.00	30.82	C
	ATOM	3789	CG1	VAL	C	52	53.786	91.197	8.802	1.00	27.39	C
	ATOM	3790	CG2	VAL	C	52	54.946	89.611	10.264	1.00	33.79	C
55	ATOM	3791	C	VAL	C	52	55.085	89.832	6.376	1.00	29.16	C

AAW06882 standard; Protein: 577 AA.

XX AAW06882;

XX 18 MAR 1997 (first entry)

XX Membrane co-factor protein-decay accelerating factor hybrid.

XX Complement inhibitor; membrane co-factor protein; MCP;

XX decay accelerating factor; DAF; chimeric protein; glycosaminoglycan;

XX heparin; cell lysis; sepsis; adult respiratory distress syndrome;

XX reperfusion injury; cell damage.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Region 1..254

XX Region 255..577

XX Region 578..596

XX W09644965 A2.

XX 07 NOV 1996.

XX 03 MAY 1996; 96W0-US06401.

XX 05 MAY 1995; 95US-0445149.

XX (CHIR) CHIRON CORP.

XX Creasey AA, Innis MA, Zaror I;

XX WPI; 1996 596167/50.

XX N-PSDB; AAT46065.

XX Chimeric proteins for inhibiting complement-mediated cell lysis

XX comprise membrane co factor protein and decay accelerating factor

XX peptide sequences

XX Disclosure; Page 25-26; 34pp; English.

XX A hybrid protein (AAW06882) comprises portions (see also AAW06880-81) of the complement-inhibitors membrane co-factor protein (MCP) and decay accelerating factor (DAF). It can be used in novel chimeric proteins also incorporating a peptide (AAW06883-90) able to bind glycosaminoglycans (esp. heparin) present on cell surfaces. The constructs are encoded by overlapping PCR (see also AAT46066-72) using MCP-DAF hybrid DNA (AAT46065) as template, and can be expressed in e.g. insert cells. The chimeric proteins are directed to cell surfaces where they inhibit complement-mediated cell lysis. They are used to treat and prevent disease states in which complement plays a role, e.g. sepsis, adult respiratory distress syndrome, reperfusion injury and tissue damage.

XX Sequence 577 AA;

Query Match 25 18; Score 188.5; DB 17; Length 577;

Best Local Similarity 30.68; Pred. No. 2e-10;

Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 6;

QY 1 EISDPPPEVNKARKPYVSLPIVPG-TVRYTCSPS-----YRLIGKKAIFCIISNGVHA 54

DB 125 KVLCTPPPKIKNGKHITSEVEVEFYLLAVTYSCDPAGPDPFSLIGSTIYC-GDNSV-- 181

QY 55 TWKAPPIECESVNRKITSDDPIVPGFMNKGSKAPFRRGDSVITFCANFTMKGSKIVWC 114

DB 182 WSRAPPEP-----KVKRCPFFVVENKQISCFCKKFFYKATVMEFCUKYFIDCSDFIYC 236

QY 115 QANEMWGDTALPVC 128

DB 247 QSNSTWDDPFWIKC 249

RESULT 45

AAE12569

ID AAE12569 standard; Protein: 611 AA.

XX AAE12569;

XX 03-JAN-2002 (first entry)

XX CAB2 protein.

XX Expression vector; crippled selectable marker; neomycin resistance;

XX H.V. protein; human immunodeficiency virus; improved expression; CAB2;

XX CAB4; amplifiable selectable marker; dihydrofolate reductase; dhfr;

XX Transgene; continuous cell line preparation

XX Unidentified.

XX US2001024807-A1.

XX 27-SEP-2001

XX 22-DEC-2000; 2000US-0748061.

XX (1-NOV-1999; 99US-162930P.

XX 30-DEC-1999; 99US-0475460.

XX (CHIR) CHIRON CORP.

XX Innis M, Scott EM;

XX WPI; 2001 638503/73.

XX N-PSDB; AAD20355.

XX New expression vector, useful for improving expression of transgene or polypeptide, comprises 3 polynucleotides encoding crippled selectable marker, heterologous polypeptide or second amplifiable selectable marker

XX Example 2, Fig 1; 27pp; English.

XX The invention relates to a new expression vector comprising a first polynucleotide encoding a first, crippled selectable marker which include sequences encoding antibiotic (neomycin) resistance containing one or more crippling mutations; second polynucleotide encoding a heterologous polypeptide of interest which is viral protein (e.g., an HIV protein) or is CAB2 or CAB4; and a third polynucleotide encoding a second amplifiable selectable marker (e.g., dihydrofolate reductase (dhfr)). The expression vectors are useful for the efficient expression of desired polypeptides or improving expression of a transgene of interest. The transformed cells can be used in the preparation of continuous cell lines in which the cells are essentially immortal or for the preparation of established cell lines that have the potential to be subcultured in vitro. The present sequence is CAB2 protein.

XX Aberrant splicing of CAB2 DNA was corrected by removing donor and acceptor sites using overlapping PCR

XX Sequence 611 AA;

Query Match 25 18; Score 188.5; DB 22; Length 611;

Best Local Similarity 30.68; Pred. No. 2.1e-10;

Matches 41; Conservative 23; Mismatches 55; Indels 15; Gaps 6;

QY 1 EISDPPPEVNKARKPYVSLPIVPG-TVRYTCSPS-----YRLIGKKAIFCIISNGVHA 54

DB 159 KVLCTPPPKIKNGKHITSEVEVEFYLLAVTYSCDPAGPDPFSLIGSTIYC-GDNSV 215

QY 55 TWKAPPIECESVNRKITSDDPIVPGFMNKGSKAPFRRGDSVITFCANFTMKGSKIVWC 114

DB 216 WSRAPPEP-----KVKRCPFFVVENKQISCFCKKFFYKATVMEFCUKYFIDCSDFIYC 270

QY 115 QANEMWGDTALPVC 128

DE 211 USN:DWB EVRCS 203

Search completed: November 6, 2002, 16:06:41
Job time: 40 1004 sec

GenCore version 5.1.3
Copyright (c) 1994-2002 CompuGen Ltd.

OM protein protein search, using sw model

Run on: November 6, 2002, 16:04:59 : Search time 10.539 Seconds
(without alignments)
312.880 Million cell updates/sec

Title: US-09-834-309-6
Protein score: 752
Sequence: 1 ETSCHPEPEVKNRPHYSQ ANEMWGPTALPVCEDEPLE 135

Scoring table: BLOSUM62
Gapop 10.0, Capext 0.5

Searched: 231628 seqs, 24425594 residues

Total number of hits satisfying chosen parameters: 231628

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post processing: Minimum Match 0%
Maximum Match 100%
Listing first 100 summaries

Database : Issued Patents_AA: *
1: /cqn2_6/prodata/1/iaa/5A-COMB.pep.*
2: /cqn2_6/prodata/1/iaa/5B-COMB.pep.*
3: /cqn2_6/prodata/1/iaa/6A-COMB.pep.*
4: /cqn2_6/prodata/1/iaa/6B-COMB.pep.*
5: /cqn2_6/prodata/1/iaa/6C-COMB.pep.*
6: /cqn2_6/prodata/1/iaa/backfiles.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	220.5	29.3	1466	6	Patent No. 5256642
2	220.5	29.3	1466	6	Patent No. 5472939
3	220.5	29.3	1537	6	Patent No. 5256642
4	220.5	29.3	1537	6	Patent No. 5472939
5	220.5	29.3	1847	6	Patent No. 5256642
6	220.5	29.3	1847	6	Patent No. 5472939
7	220.5	29.3	2039	6	Patent No. 5256642
8	220.5	29.3	2039	6	Patent No. 5472939
9	199.5	26.5	463	4	Sequence 2, Appl 1
10	192.5	25.6	263	4	Sequence 2, Appl 1
11	190.5	25.3	384	4	Sequence 2, Appl 1
12	188.5	25.1	169	1	Sequence 16, Appl 1
13	188.5	25.1	169	2	Sequence 16, Appl 1
14	188.5	25.1	254	1	Sequence 13, Appl 1
15	188.5	25.1	254	2	Sequence 13, Appl 1
16	188.5	25.1	254	2	Sequence 13, Appl 1
17	188.5	25.1	293	1	Sequence 16, Appl 1
18	188.5	25.1	293	2	Sequence 16, Appl 1
19	188.5	25.1	424	2	Sequence 46, Appl 1
20	188.5	25.1	470	2	Sequence 42, Appl 1
21	188.5	25.1	473	2	Sequence 44, Appl 1
22	188.5	25.1	473	2	Sequence 44, Appl 1
23	188.5	25.1	484	6	Patent No. 5514787
24	188.5	25.1	577	2	Sequence 3, Appl 1
25	188.5	25.1	611	4	Sequence 3, Appl 1
26	178.5	23.7	133	2	Sequence 31, Appl 1
27	178.5	23.7	133	2	Sequence 31, Appl 1

28	178.5	23.7	254	2	US-08-356-61-29
29	178.5	23.7	254	2	US-08-769-667A-29
30	175.5	23.3	254	2	US-08-356-61-30
31	175.5	23.3	254	2	US-08-769-667A-30
32	163	21.7	86	6	5514582-41
33	153.5	20.4	124	6	5514582-38
34	153.5	20.4	265	2	US-08-177-109A-57
35	153.5	20.4	265	2	US-08-687-706-57
36	153.5	20.4	764	2	US-08-177-199A-2
37	153.5	20.4	764	2	US-08-687-706-2
38	150.5	20.0	126	6	5514582-35
39	145.5	19.3	126	6	5514582-43
40	144	19.1	197	2	US-08-356-61-27
41	144	19.1	197	2	US-08-769-667A-27
42	142	18.9	323	1	US-08-435-49-2
43	142	18.9	324	1	US-08-110-16A-14
44	142	18.9	324	1	US-08-888-71-14
45	139	18.5	610	1	US-08-365-470-3
46	139	18.5	610	3	US-08-209-668-19
47	139	18.5	610	4	US-08-209-668-89
48	139	18.5	610	6	5217870-2
49	130.5	17.4	274	2	US-08-177-109A-58
50	130.5	17.4	274	2	US-08-687-706-58
51	127.5	17.0	1019	1	US-08-296-04A-4
52	127.5	17.0	1019	2	US-08-596-405-4
53	127.5	17.0	1019	2	US-08-877-620-4
54	127.5	17.0	1083	1	US-08-296-04A-2
55	127.5	17.0	1083	2	US-08-596-405-2
56	127.5	17.0	1083	2	US-08-877-620-2
57	126.5	16.8	120	6	5514582-36
58	125.5	16.7	196	3	US-08-824-692-32
59	125.5	16.7	229	3	US-08-824-692-31
60	125.5	16.7	290	3	US-08-824-692-29
61	124	16.5	830	6	5378464-2
62	123.5	16.4	484	2	US-08-252-193-9
63	123.5	16.4	484	3	US-09-276-197-9
64	123.5	16.4	830	5	PCT-US91-05056-2
65	120	16.0	207	2	US-08-640-977-5
66	120	16.0	248	2	US-08-640-977-2
67	120	16.0	248	2	US-08-640-977-4
68	120	16.0	326	2	US-08-640-977-1
69	119	15.8	830	1	US-08-110-158-4
70	115.5	15.4	574	6	5378464-3
71	113	15.0	127	6	5514582-37
72	110.5	14.7	177	3	US-08-824-692-36
73	110	14.6	181	2	US-08-640-977-3
74	106	14.1	128	6	5514582-42
75	104	13.9	128	6	5514582-39
76	103	13.7	128	6	5514582-35
77	100.5	13.4	127	6	5514582-33
78	100.5	13.4	177	3	US-08-824-692-30
79	98	13.0	62	1	US-08-210-267A-13
80	98	13.0	62	1	US-08-688-677-13
81	98	13.0	62	3	US-08-477-860-13
82	96	12.8	240	3	US-08-824-692-23
83	95	12.6	216	3	US-08-824-692-24
84	94	12.5	84	4	US-08-793-416-6
85	93.5	12.4	933	5	US-08-313-200-1
86	93.5	12.4	933	5	PCT-US93-0387-1
87	93	12.4	62	1	US-08-210-267A-12
88	93	12.4	62	1	US-08-688-677-12
89	93	12.4	62	3	US-08-477-860-12
90	91	12.0	76	2	US-08-356-61-28
91	90.5	12.0	76	2	US-08-769-667A-28
92	90	12.0	17	4	US-08-602-996A-31
93	88.5	11.9	385	2	US-08-340-547A-2
94	88.5	11.9	385	2	US-08-461-543A-2
95	87.5	11.6	372	2	US-08-513-278-2
96	87.5	11.6	372	6	5514582-2
97	84.5	11.2	123	3	US-08-824-692-37
98	84.5	11.2	123	3	US-08-824-692-38
99	83	11.0	145	2	US-08-640-977-6
100	82.5	11.0	128	6	5514582-34

ALIGNMENTS

```

RESULT 1
5472949.5
? Patent No. 5472949
? APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WING,
? WINNIE W.; CARSON, GERALD R.; JUNG, INO, MICHAEL F.; LIP, STEPHEN
? H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
? TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
? PREPARED BY (OR) AND A THROMBOLYTIC AGENT, AND THE METHODS OF
? USE THEREOF
? NUMBER OF SEQUENCES: 40
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/148,825
? FILING DATE: 24 SEP 1993
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 412,745
? FILING DATE: 26 SEP 1989
? APPLICATION NUMBER: 332,865
? FILING DATE: 03 APR 1989
? APPLICATION NUMBER: 176,542
? FILING DATE: 01 APR 1988
? SEQ ID NO: 6
? LENGTH: 1466
? 5256642.6

Query Match: 29.48; Score: 220.5; DB: 6; Length: 1466;
Best Local Similarity: 36.08; Pred. No. 1,86; 16;
Matches: 49; Conservative: 18; Mismatches: 54; Indels: 15; Gaps: 6;

QY 2 ISDTPFEVKNAPLYYS---LPVFTVLVLTGSPS YRLGKAFICISENOV 52
DB 1015 ISCEPPTISNG--DFYNNRSTPHNGIVVYQHGHGQHQFELVGRSVYISKDQ 1072

QY 53 BATWKAFFTCESVKNKILTSSEFVPEEMNKSFAFEPDPSVETKANKEMSKIV 112
DB 1073 VCVWSSPPRCISLTK---CLAPVKAIRVPHRSTGTLTETIRGCTGTWVNSHIV 1129

QY 113 WQANEMMGCPALVVC 128
DB 1140 QQTNGRWGP-KLEPC 1144

? SEQ ID NO: 6
? LENGTH: 1466

```

```

RESULT 2
5472949.5
? Patent No. 5472949
? APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WING,
? WINNIE W.; CARSON, GERALD R.; JUNG, INO, MICHAEL F.; LIP, STEPHEN
? H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
? TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
? MEDIATED DISORDERS
? NUMBER OF SEQUENCES: 40
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/148,825
? FILING DATE: 24 SEP 1993
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 412,745
? FILING DATE: 26 SEP 1989
? APPLICATION NUMBER: 332,865
? FILING DATE: 03 APR 1989
? APPLICATION NUMBER: 176,542
? FILING DATE: 01 APR 1988
? SEQ ID NO: 6
? LENGTH: 1466
? 5472949.5

Query Match: 29.48; Score: 220.5; DB: 6; Length: 1466;
Best Local Similarity: 36.08; Pred. No. 1,86; 16;
Matches: 49; Conservative: 18; Mismatches: 54; Indels: 15; Gaps: 6;

```

```

Matches: 49; Conservative: 18; Mismatches: 54; Indels: 15; Gaps: 6;

QY 2 ISDTPFEVKNAPLYYS---LPVFTVLVLTGSPS YRLGKAFICISENOV 52
DB 1015 ISCEPPTISNG--DFYNNRSTPHNGIVVYQHGHGQHQFELVGRSVYISKDQ 1072

QY 53 BATWKAFFTCESVKNKILTSSEFVPEEMNKSFAFEPDPSVETKANKEMSKIV 112
DB 1073 VCVWSSPPRCISLTK---CLAPVKAIRVPHRSTGTLTETIRGCTGTWVNSHIV 1129

QY 113 WQANEMMGCPALVVC 128
DB 1140 QQTNGRWGP-KLEPC 1144

RESULT 3
5256642.5
? Patent No. 5256642
? APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WING,
? WINNIE W.; CARSON, GERALD R.; JUNG, INO, MICHAEL F.; LIP, STEPHEN
? H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
? TITLE OF INVENTION: COMPOSITIONS OF SOLUBLE COMPLEMENT
? PREPARED BY (OR) AND A THROMBOLYTIC AGENT, AND THE METHODS OF
? USE THEREOF
? NUMBER OF SEQUENCES: 40
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/188,128
? FILING DATE: 24 SEP 1990
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 412,745
? FILING DATE: 26 SEP 1989
? APPLICATION NUMBER: 332,865
? FILING DATE: 03 APR 1989
? APPLICATION NUMBER: 176,542
? FILING DATE: 01 APR 1988
? SEQ ID NO: 5
? LENGTH: 1547
? 5256642.5

Query Match: 29.48; Score: 220.5; DB: 6; Length: 1547;
Best Local Similarity: 36.08; Pred. No. 1,90; 15;
Matches: 49; Conservative: 18; Mismatches: 54; Indels: 15; Gaps: 5;

```

```

QY 2 ISDTPFEVKNAPLYYS---LPVFTVLVLTGSPS YRLGKAFICISENOV 52
DB 1015 ISCEPPTISNG--DFYNNRSTPHNGIVVYQHGHGQHQFELVGRSVYISKDQ 1072

QY 53 BATWKAFFTCESVKNKILTSSEFVPEEMNKSFAFEPDPSVETKANKEMSKIV 112
DB 1073 VCVWSSPPRCISLTK---CLAPVKAIRVPHRSTGTLTETIRGCTGTWVNSHIV 1129

QY 113 WQANEMMGCPALVVC 128
DB 1140 QQTNGRWGP-KLEPC 1144

RESULT 4
5472949.5
? Patent No. 5472949
? APPLICANT: FEARON, DOUGLAS T.; KLICKSTEIN, LLOYD B.; WING,
? WINNIE W.; CARSON, GERALD R.; JUNG, INO, MICHAEL F.; LIP, STEPHEN
? H.; MAKRIDES, SAVVAS; MARSH, HENRY C., JR.
? TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
? MEDIATED DISORDERS
? NUMBER OF SEQUENCES: 40
? CURRENT APPLICATION DATA:
? APPLICATION NUMBER: US/08/148,825
? FILING DATE: 24 SEP 1993
? PRIOR APPLICATION DATA:
? APPLICATION NUMBER: 412,745
? FILING DATE: 26 SEP 1989
? APPLICATION NUMBER: 332,865
? FILING DATE: 03 APR 1989
? APPLICATION NUMBER: 176,542
? FILING DATE: 01 APR 1988
? SEQ ID NO: 6
? LENGTH: 1466
? 5472949.5

Query Match: 29.48; Score: 220.5; DB: 6; Length: 1466;
Best Local Similarity: 36.08; Pred. No. 1,86; 16;
Matches: 49; Conservative: 18; Mismatches: 54; Indels: 15; Gaps: 6;

```


DB 1632 QVQINGRWD KLPHQ 1646

RESULT 8

54/2949 2

1 APPLICANT: FLAON, DOUGLAS L.; KICKSTEIN, LLOYD R.; WONG, WENLI W.; WARGON, GERALD R.; CONNING, MICHAEL F.; LIP, STEPHEN H.; MAKRIEIS, SAVVAS; MAKSI, DENNY C., JR.
2 TITLE OF INVENTION: METHOD OF TREATING COMPLEMENT
3 MEDIATED DISORDERS

4 NUMBER OF SEQUENCES: 40

5 CURRENT APPLICATION DATA:

6 APPLICATION NUMBER: US/08/138,825

7 FILING DATE: 19 OCT 1993

8 PRIOR APPLICATION DATA:

9 APPLICATION NUMBER: 508 128

10 FILING DATE: 24 SEP 1990

11 APPLICATION NUMBER: 412 745

12 FILING DATE: 26 SEP 1989

13 APPLICATION NUMBER: 332 865

14 FILING DATE: 03 APR 1989

15 APPLICATION NUMBER: 176 542

16 FILING DATE: 01 APR 1988

17 SEQ ID NO: 25

18 LENGTH: 2039

54/2949 2

Query Match 29.6%; Score 220.5; DB 6; Length 2039;

Best Local Similarity 46.0%; Pred. No. 2,86-152

Matches 49; Conservatives 18; Mismatches 54; Indels 15; Gaps 5;

QY 2 EISDPPPEVKNAR-----KPYSLPIVGVIVLYTSPS YRLDGEKALPCTISENV 52

DB 1517 ESEPEPEFNS DEVSNNPSPHNTVTVYQHTPTPESEALFELVGEISVTSKDDQ 1574

QY 54 HAUDKAPPEVKNKLSHIVAGGMNKSNAFPGDSVDFCHANIIMAGSKIV 112

DB 1636 VAWSSPPPTSTNK CTAFVENATKVTGRSFEFSLTEIRKQFGFVMVGSHTV 1631

QY 113 WQANEMMGFTALPVED 128

DB 1632 QVQINGRWD KLPHQ 1646

RESULT 9

US 08 981 2418 2

Sequence 2, Application US/080812418

Patent No. 6270997

GENERAL INFORMATION:

APPLICANT: KAYOMURA, KOJI

APPLICANT: MURAKAMI, HIROSHI

APPLICANT: SHIGEMURA, TAMOSU

TITLE OF INVENTION: DNA ENCODING A PORCINE COMPLEMENT

TITLE OF INVENTION: INHIBITOR

NUMBER OF SEQUENCES: 2

CORRESPONDENCE ADDRESS:

ADDRESSEE: BURCH, STEWART, KOLASCH & BURCH

STREET: PO BOX 747

CITY: FALLS CHURCH

STATE: VA

COUNTRY: USA

ZIP: 22040 0747

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS DOS

SOFTWARE: Patent in Release #1.0, Version #1.40

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/981,2418

FILING DATE: 12 DEC 1997

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: MURPHY JR, GERALD M.

REGISTRATION NUMBER: 28,977

REFERENCE/DOCKET NUMBER: 2520 111P

TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-205-8000

TELEFAX: 703-205-8050

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 463 amino acids

TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-981-2348-2

Query Match

Best Local Similarity 31.9%; Pred. No. 5,96-14;

Matches 45; Conservatives 21; Mismatches 52; Indels 23; Gaps 6;

QY 1 EISDPPPEVKNAR-----KPYSLPIVGVIVLYTSPS YRLDGEKALPCTISENV 50

DB 168 KILKPEGEIPNGKYTNSHKVEFY---NEWTVYSLSSTGPEESLVGESLPTLRD 224

QY 51 QVHATWVAPPTCPVKNKTISQSLPIVGVIVLYTSPS YRLDGEKALPCTISENV 116

DB 224 E-----WSSDPPPE-----KVKPSTVGVNCHIVAGGGMNKSNAFPGDSVDFCHANIIMAGSKIV 274

QY 111 WQANEMMGFTALPVED 141

DB 276 TIVGKANSTWEP-EMPGCIKD 295

RESULT 10

US-07-906-983-2

Sequence 2, Application US/07906983

Patent No. 5187268

GENERAL INFORMATION:

APPLICANT: Kotwal, Girish

APPLICANT: Moss, Bernard

TITLE OF INVENTION: Synthetic, Anti Complement Protein and

TITLE OF INVENTION: the Gene Encoding Same

NUMBER OF SEQUENCES: 3

CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend

STREET: One Market Plaza, Steuart Tower, Suite 2000

CITY: San Francisco

STATE: California

COUNTRY: USA

ZIP: 94105

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC DOS/MS-DOS

SOFTWARE: Patent in Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/07/906,983

FILING DATE: 19920701

CLASSIFICATION: 530

ATTORNEY/AGENT INFORMATION:

NAME: Weber, Kenneth A.

REGISTRATION NUMBER: 31,677

REFERENCE/DOCKET NUMBER: 15280-9

TELECOMMUNICATION INFORMATION:

TELEPHONE: 415-543-9600

TELEFAX: 415-543-5043

INFORMATION FOR SEQ ID NO: 2:

SEQUENCE CHARACTERISTICS:

LENGTH: 263 amino acids

TYPE: AMINO ACID

TOPOLOGY: linear

MOLECULE TYPE: protein

US-07-906-983-2

Query Match

25.6%; Score 192.5; DB 1; Length 263;

Sequence ID: Application US/08/888/171
 Patent No. 5891528
 GENERAL INFORMATION:

APPLICANT: Jone Long, Ko
 APPLICANT: Higgins, Paul J.
 APPLICANT: Yeh, C. Grace
 TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT
 TITLE OF INVENTION: ACTIVATION
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson, P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: MA
 COUNTRY: US

ZIP: 02110-2804
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: Windows
 SOFTWARE: FastSeq for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/888/171
 FILING DATE: 04 Jul 1997

REGISTRATION NUMBER: 29,096
 REFERENCE/DE/KF NUMBER: 06180/005002

TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617/542 8906
 TELEFAX: 617/542 8906

TELEX: 200154
 INFORMATION FOR SEQ ID NO: 18:

LENGTH: 169 amino acids
 TYPE: amino acid
 TOPOLOGY: Linear

MOLECULE TYPE: Protein
 US 08 888 171 18

Query Match: 25.1% Score 188.5; DB 2; Length 169;

Best Local Similarity: 40.6%; Pred. No. 6,56 14;

Matches: 41; Conservative: 24; Mismatches: 55; Indels: 15; Gaps: 6;

QY 1 FLGSGTTEVKRKAKYYSLEIVG IVLYVTS YRLGKALFQISENVHA 54

DB 1 KVLTPPEKIKNGKHTSEVEVEVLLAVTSCTAPGDPESLCTIY GNSV 57

QY 55 TWKAPPTESVNRKTSSTGIVGKMKNSKATPRGDSVTFCKANFHKKSKTVW 114

DB 58 WSRAPR KVKCRFPVVENCKVSGGKRYKAIWMEFDKGYLGGSTIVC 112

QY 115 CANEMMGCTALFV 128

DB 113 DSNSTWEP PVPRK 125

RESULT 14

US 08 810 416A 13

Sequence 13: Application US/08/810/416A

Patent No. 5891528

GENERAL INFORMATION:

APPLICANT: Jone Long, Ko et al.

TITLE OF INVENTION: CHEMOKE PROTEINS WHICH BLOCK

TITLE OF INVENTION: COMPLEMENT ACTIVATION

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: Massachusetts
 COUNTRY: U.S.A.
 ZIP: 02110-2804

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 COMPUTER: IBM PS/2 Model 502 or 55SX
 OPERATING SYSTEM: MS-DOS (Version 5.0)
 SOFTWARE: WordPerfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/810/416A
 FILING DATE: 22 Sep-1994

CLASSIFICATION: 4.35

ATTORNEY/AGENT INFORMATION:

NAME: Paul J. Clark

REGISTRATION NUMBER: 40,162

REFERENCE/DE/KF NUMBER: 06180/005001

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542 8906

TELEFAX: (617) 542 8906

TELEX: 200154

INFORMATION FOR SEQ ID NO: 13:

LENGTH: 254 amino acids

TYPE: amino acid

STRANDEDNESS: not relevant

TOPOLOGY: Linear

MOLECULE TYPE: Protein

US 08 810-416A 13

Query Match: 25.1% Score 188.5; DB 1; Length 254;

Best Local Similarity: 40.6%; Pred. No. 6,56 14;

Matches: 41; Conservative: 24; Mismatches: 55; Indels: 15; Gaps: 6;

QY 1 FLGSGTTEVKRKAKYYSLEIVG IVLYVTS YRLGKALFQISENVHA 54

DB 125 KVLTPPEKIKNGKHTSEVEVEVLLAVTSCTAPGDPESLCTIY GNSV 101

QY 55 TWKAPPTESVNRKTSSTGIVGKMKNSKATPRGDSVTFCKANFHKKSKTVW 114

DB 182 WSRAPR KVKCRFPVVENCKVSGGKRYKAIWMEFDKGYLGGSTIVC 236

QY 115 CANEMMGCTALFV 128

DB 247 DSNSTWEP PVPRK 249

RESULT 15

US-08-888-171-13

Sequence 13: Application US/08/888/171

Patent No. 5891528

GENERAL INFORMATION:

APPLICANT: Jone Long, Ko

APPLICANT: Higgins, Paul J.

APPLICANT: Yeh, C. Grace

TITLE OF INVENTION: METHODS OF INHIBITING COMPLEMENT

TITLE OF INVENTION: ACTIVATION

NUMBER OF SEQUENCES: 19

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson, P.C.

STREET: 225 Franklin Street

CITY: Boston

STATE: MA

COUNTRY: US

ZIP: 02110 2804

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows95

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/888,171

FILING DATE: 04-JUL-1997

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 09/410,416
FILING DATE: 22 SEP-1994
ATTORNEY/AGENT INFORMATION:
NAME: Freeman, John W.
REGISTRATION NUMBER: 29,066
REFERENCE/DOCKET NUMBER: 06180/005002
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617/542-507
TELEFAX: 617/542-890
TELEX: 200154

INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:
LENGTH: 254 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US 08 808 171-14

Query Match 25.1% Score 188.5; DB 2; Length 254;
Best Local Similarity 30.6%; Prod No. 5,9c-13;
Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 6;

QY 1 ELSURPEPEVNARKPPYSLSLIVPGTVRYTCSPS-----YRLIGEKATFCISENOVHA 54
DB 125 KVLCTPPKIKNGKHTFSEVFEVFLDAVYSCDPAPGDPFSLIGESTLYC-GDNVS-- 181
QY 55 TWKAPFICESVNKTISCSDFIVPGSEFMNKGSKAPFERBGLSVTPTCKANFTMKGSKTVWC 114
DB 142 WSKAAPE-----KVKCRFPVVENVKQISGSGKKFYKATVMEICLKGFLGSDTIVC 246
QY 115 QANIMWCPTALIVC 128
DB 247 DSNSTWCP-FVPRC 249

RESULT 16

US-08-435-149-1
Sequence 1, Application US/08435149
Patent No. 5466402
GENERAL INFORMATION:
APPLICANT: INNIS, MICHAEL A.
APPLICANT: ZAROK, ISABEL
APPLICANT: CREASEY, ANLA A.
TITLE OF INVENTION: CHIMERIC MCP AND DAF PROTEINS WITH CELL
SURFACE LOCALIZING DOMAIN
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: CHIRON CORPORATION
STREET: INTELLECTUAL PROPERTY - R440, P.O. BOX 8097
CITY: EMERYVILLE
STATE: CALIFORNIA
COUNTRY: U.S.A.
ZIP: 94662-8097
COMPUTER READABLE FORM
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,149
FILING DATE: 05 MAY-1995
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:
NAME: SAVEREIDE, PAUL B.
REGISTRATION NUMBER: 46,914
REFERENCE/DOCKET NUMBER: 0949-001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 601-2585
TELEFAX: (510) 655-3542
TELEX: N/A
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 254 amino acids

TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-435-149-1

Query Match 25.1% Score 188.5; DB 2; Length 254;

Best Local Similarity 30.6%; Prod No. 5,9c-13;
Matches 41; Conservative 23; Mismatches 55; Indels 15; Gaps 6;

QY 1 ELSCLPPPEVNARKPPYSLSLIVPGTVRYTCSPS-----YRLIGEKATFCISENOVHA 54
DB 125 KVLCTPPKIKNGKHTFSEVFEVFLDAVYSCDPAPGDPFSLIGESTLYC-GDNVS-- 181
QY 55 TWKAPFICESVNKTISCSDFIVPGSEFMNKGSKAPFERBGLSVTPTCKANFTMKGSKTVWC 114
DB 182 WSKAAPE-----KVKCRFPVVENVKQISGSGKKFYKATVMEICLKGFLGSDTIVC 246
QY 115 QANIMWCPTALIVC 128
DB 237 DSNSTWCP-FVPRC 249

RESULT 17

US-08-310-416A-16
Sequence 16, Application US/08310416A
Patent No. 5479546
GENERAL INFORMATION:
APPLICANT: Ione-Long Ko et al.
TITLE OF INVENTION: CHIMERIC PROTEINS WHICH BLOCK
TITLE OF INVENTION: COMPLEMENT ACTIVATION
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: Massachusetts
COUNTRY: U.S.A.
ZIP: 02110-2804
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM PS/2 Model 50Z or 50SX
OPERATING SYSTEM: MS-DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/310,416A
FILING DATE: 22-SEP-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Paul T. Clark
REGISTRATION NUMBER: 30,162
REFERENCE/DOCKET NUMBER: 06180/035001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 203 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-310-416A-16

Query Match 25.1% Score 88.5; DB 1; Length 294;

Best Local Similarity 30.6%; Prod No. 71c-14;
Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 5;

QY 1 ELSCLPPPEVNARKPPYSLSLIVPGTVRYTCSPS-----YRLIGEKATFCISENOVHA 54
DB 125 KVLCTPPKIKNGKHTFSEVFEVFLDAVYSCDPAPGDPFSLIGESTLYC-GDNVS-- 181

OPERATING SYSTEM: PC DOS/MS DOS
SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA

APPLICATION NUMBER: US/09/001,000

FILING DATE: CONCURRENTLY HERewith

PRIOR APPLICATION DATA

APPLICATION NUMBER: US/09/001,000

FILING DATE: 11 JAN 1994

PRIOR APPLICATION DATA

APPLICATION NUMBER: US/09/001,000

FILING DATE: 10 MAY 1991

PRIOR APPLICATION DATA

APPLICATION NUMBER: US/09/001,000

FILING DATE: 11 MAY 1990

ATTORNEY/AGENT INFORMATION

NAME: BENT, Stephen A.

REGISTRATION NUMBER: 29,768

REFERENCE/INVENTOR NUMBER: 17,217/112 (A5)

COMMUNICATION INFORMATION

TELEPHONE: (202)672-5000

TELEFAX: (202)672-5000

TELEX: 904196

INFORMATION FOR SEQ ID NO: 2

SEQUENCE CHARACTERISTICS

LENGTH: 677 amino acids

TYPE: amino acid

MOLECULE TYPE: Protein

US 09 834 309 6

Query Match: 25.1% Score: 188.5; DB: 2; Length: 677

Best local similarity: 30.6%; Pred. No.: 170; 121

Matches: 41; Conservative: 23; Mismatches: 55; Indels: 15; Gaps: 6

QY 1 EISCHPEPPVKARKYYSLEIVPG TVLRKTSNS - YRLIGKATPISENVVHA 54

DB 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 55 IWRKAPPTFESVNRKTSSTIVSEEMNFSSKAPFESGVHDFKANEEMSKIVW 114

DB 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

QY 159 KVLCTPPPKIKNGKHTESEVEVEYLDVAVTSQAPGPHFSLGSLTIC GNSV - 215

```

GENERAL INFORMATION:
APPLICANT: Scott, Elizabeth
APPLICANT: Innis, Michael
TITLE OF INVENTION: EXPRESSION VECTORS, TRANSCRIPTION SYSTEMS, AND METHOD OF
FILE REFERENCE: 1527-004
CURRENT FILING DATE: 1999-12-20
NUMBER OF SEQ ID NOS: 42
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO: 42
LENGTH: 611
TYPE: DPT
ORGANISM: CAB2
US 09/475,460A 42

Query Match      25.1% Score 188.5; DB 4; Length 611;
Best Local Similarity 40.6%; Pred. No. 1,80-12;
Matches 41; Conservative 24; Mismatches 55; Indels 15; Gaps 6;

QY 1 FLSCTPPPEVKNKPKYYSIPVPC-TVLRYTCSPS-----YRLIGKKAIFCISENVHIA 54
DB 159 KVLTPPKIKNGKITSEVEVEYLDVYSDPAPGPPDFSLIGESTIYC-GDHSV--- 215
QY 55 TWKRAPIICFVNKTISSDPIVGRKMKSKKAPPHRSDSVITCKANFTMKGSKITVWC 114
DB 216 WSKAAPKPKKVKPPPPVVENKQISGFKKKYKATVMEYTKGFLDGSQDTIVC 270
QY 115 QANENMGITALPVC 128
DB 271 DSNSTWDP PVKPS 283

RESULT 26
US 08/456,461 31
Sequence 31, Application US/08/456461
Patent No. 583989
GENERAL INFORMATION:
APPLICANT: Smith, Richard A.G.
APPLICANT: Dodd, Ian
APPLICANT: Mossakowski, Danuta E.L.
APPLICANT: Freeman, Mary A.
TITLE OF INVENTION: NO. 583989c1 Compounds
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: SmithKline Beecham Corporate Intellectual Property
STREET: P.O. Box 1509
CITY: King of Prussia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19406
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/456,461
FILING DATE: 03 Jul-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jarvis, Herbert H.
REGISTRATION NUMBER: 41,171
REFERENCE/DOCKET NUMBER: P30423
TELECOMMUNICATION INFORMATION:
TELEPHONE: (610) 270-5019
TELEFAX: (610) 270-5090
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 145 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide

```

```

FRAGMENT TYPE: internal
US-08-355-361-31

Query Match      23.7% Score 174.5; DB 2; Length 143;
Best Local Similarity 30.9%; Pred. No. 3,1e-12;
Matches 43; Conservative 20; Mismatches 55; Indels 21; Gaps 5;

QY 2 ISCDPPPEVKNK-----RKPYYSIPVPCIVRYTCSPS YRLIGKKAIFCISE 49
DB 3 IPCGLPPTITNGDFTSTNKRFHY-----GSVVIYFQNPQSGDRKVFELWHEPSVYCTSN 57
QY 50 NOVHATWDKAPPHICHSVNKTISSDPIVGRKMKSKKAPPHRSDSVITCKANFTMKGS 109
DB 58 DIQGVGTSWSDALQCLIPNK---CTTPNVNENIVSTENKSFSEINEVVEFEGDGFVWKGP 134
QY 110 KTVWCQANENMGITALPVC 128
DB 115 RRVKCOA-NKWF-P-ELPSC 132

RESULT 27
US-08-769-967A-31
Sequence 31, Application US/08769967A
Patent No. 5859223
GENERAL INFORMATION:
APPLICANT: Mossakowski, Danuta E.L.
APPLICANT: Smith, Richard A.G.
APPLICANT: Dodd, Ian
APPLICANT: Freeman, Anne Mary
TITLE OF INVENTION: Soluble CR1 derivatives
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: SmithKline Beecham Corporate Intellectual Property
STREET: P.O. Box 1539
CITY: King of Prussia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19406
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Ver. on #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/769,967A
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,569
FILING DATE: 15-May-1995
ATTORNEY/AGENT INFORMATION:
NAME: King, William T.
REGISTRATION NUMBER: 30,954
REFERENCE/DOCKET NUMBER: P30423C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (610) 270-5364
TELEFAX: (610) 270-5090
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 133 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: internal
US-08-769-967A-31

Query Match      23.7% Score 174.5; DB 2; Length 143;
Best Local Similarity 30.9%; Pred. No. 3,1e-12;
Matches 43; Conservative 20; Mismatches 55; Indels 21; Gaps 5;

QY 2 ISCDPPPEVKNK-----RKPYYSIPVPCIVRYTCSPS-----YRLIGKKAIFCISE 49
DB 3 IPCGLPPTITNGDFTSTNKRFHY-----GSVVIYFQNPQSGDRKVFELWHEPSVYCTSN 57

```


STREET: P.O. Box 1539
CITY: Kind of Prussia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19406
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/456,461
FILING DATE: 31-Jul-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: JETVIS, Robert H.
REGISTRATION NUMBER: 41,171
REFERENCE/DOCKET NUMBER: P40424
TELEPHONE: (610) 270-5619
TELEFAX: (610) 270-5090
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 254 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US 08 456-461-40

Query Match 23.3%; Score 175.5; DB 2; Length 254;
Best Local Similarity 30.9%; Pred. No. 1.5e-11;
Matches 43; Conservative 19; Mismatches 56; Indels 21; Gaps 5;

27 2 ISCDPPEVKNA-----RKPYSLPIVPGTIVRTSPS-----VRLGKKAIFQISE 49
124 LPGLPTITNGDFISTNNENPHY-----GSVVTYRNPSSGRKKVFLVGEFSIYCTSN 178
50 NOVHATWKAIPICSVNKTISCDPIVGGGNKRC:KAPFHGDSVTFCKANFTMKGS 109
179 DQVWISGAPQVTFPNK--CTPRVEN:ILVSEFSLF:INEVVEFCQGFVYMKGP 235
110 KTVWCOANEMWGPTALPVC 128
236 HRVKCOALNKWEP-ELPSC 253

RESULT 41
US 08 769-967A 40
Sequence 40, Application US/08769967A
Patent No. 5859224
GENERAL INFORMATION:
APPLICANT: Mossakowska, Danuta E.L.
APPLICANT: Smith, Richard A.G.
APPLICANT: Dodd, Ian
APPLICANT: Freeman, Anne Mary
TITLE OF INVENTION: Soluble "RI" Derivatives
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: SmithKline Beecham Corporate Intellectual Property
STREET: P.O. Box 1539
CITY: Kind of Prussia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19406
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/769,967A
FILING DATE:

CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,569
FILING DATE: 15-May-1995
ATTORNEY/AGENT INFORMATION:
NAME: King, William T.
REGISTRATION NUMBER: 30,954
REFERENCE/DOCKET NUMBER: P40424C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (610) 270-5364
TELEFAX: (610) 270-5090
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 254 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
FRAGMENT TYPE: N-terminal
US-08-769-967A-30

Query Match 23.3%; Score 175.5; DB 2; Length 254;
Best Local Similarity 30.9%; Pred. No. 1.5e-11;
Matches 43; Conservative 19; Mismatches 56; Indels 21; Gaps 5;

QY 2 ISCDPPEVKNA-----RKPYSLPIVPGTIVRTSPS-----VRLGKKAIFQISE 49
DB 124 LPGLPTITNGDFISTNNENPHY-----GSVVTYRNPSSGRKKVFLVGEFSIYCTSN 178
QY 50 NOVHATWKAIPICSVNKTISCDPIVGGGNKRC:KAPFHGDSVTFCKANFTMKGS 109
DB 179 DQVWISGAPQVTFPNK--CTPRVEN:ILVSEFSLF:INEVVEFCQGFVYMKGP 235
QY 110 KTVWCOANEMWGPTALPVC 128
DB 236 HRVKCOALNKWEP-ELPSC 253

RESULT 42
5514582-41
Patent No. 5514582
APPLICANT: CAPIN, DANIEL J.; LASKY, LAUREN E. A.
TITLE OF INVENTION: RECOMBINANT DNA ENCODING HYBRID
IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 43
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/185,670
FILING DATE: 21-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 986,931
FILING DATE: 08-DEC-1992
APPLICATION NUMBER: 808,122
FILING DATE: 16-DEC-1991
APPLICATION NUMBER: 440,625
FILING DATE: 22-NOV-1989
APPLICATION NUMBER: 315,015
FILING DATE: 23-FEB-1989
SEQ ID NO: 41:
LENGTH: 86
5514582 41

Query Match 21.7%; Score 163; DB 6; Length 86;
Best Local Similarity 32.6%; Pred. No. 4.4e-11;
Matches 29; Conservative 15; Mismatches 41; Indels 4; Gaps 1;

QY 32 CSPSYRLGKGA FCISENQVHAIWKAIPICSVNKTISCDPIVGGGNKRC:KAPFHGDSVTFCKANFTMKGS 120
DB 1 CDPFSLGLGHASICTVENETIGVWRPSPT:EK---ITCKKFGVSHGEMVSGRGPVYN 56
QY 92 HCDISVTFCKANFTMKGSKTVWCOANEMW 120
DB 57 YKDTIVFKCQCGEVIROSSVTHCDADSKW 85

```

RESULT 66
US 08 177-109A-57
PATENT NO. 5928492
APPLICANT: CAPN, DANIEL J. LASKY, LAURENCE A.
TITLE OF INVENTION: RECOMBINANT DNA ENCODING HYBRID
IMMUNOGLOBULINS
NUMBER OF SEQUENCES: 44
CURRENT APPLICATION DATA
  APPLICATION NUMBER: US/08/185,670
  FILING DATE: 21 JAN 1994
  PRIORITY APPLICATION DATA
    APPLICATION NUMBER: 986,941
    FILING DATE: 08 DEC 1992
    APPLICATION NUMBER: 808,122
    FILING DATE: 16 DEC 1994
    APPLICATION NUMBER: 440,625
    FILING DATE: 22 NOV 1999
    APPLICATION NUMBER: 415,016
    FILING DATE: 23 FEB 1999
SEQ ID NO: 66
LENGTH: 124

```

```

Query Match
Best Local Similarity 41.1%, Score 153.5, DB 6; Length 124;
Matches 42; Conservative 17; Mismatches 59; Indels 17; Gaps 6;

QY 2 ISCDPEPVNA---PKYYSLEPLVGVYDYSFPLGKAFGLSENQVHATWD 57
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 1 LHPEDHDENGEYWRSPYVW SDLSHFVYGVYLRSSANRTE---QVRCWS 57

QY 58 KAFPLTEVNR---KQYYSLEPLVGVYDYSFPLGKAFGLSENQVHATWD 117
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 54 GATAICD---NAGYCSNPGIPGTRKVGSG YRLEDSVTVH SRGILLRSGRRRLQCEG 108

QY 118 EMMDPITALVWESDF 142
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 109 GWSGTE PSQWSEF 122

```

```

RESULT 64
US 08 177-109A-57
Sequence 57, Application US/08/177109A
Patent No. 5928492
GENERAL INFORMATION:
  APPLICANT: Jeanis E. Bourcade and Teresa J. Oglesby
  TITLE OF INVENTION: MODIFIED COMPLEMENT PROTEASES
  NUMBER OF SEQUENCES: 62
  CORRESPONDENCE ADDRESS:
    ADDRESSEE: Patricia L. Pabst
    STREET: 2800 One Atlantic Center
    CITY: Atlanta
    STATE: Georgia
    ZIP: 30309-3450
  COMPUTER READABLE FORM:
    OPERATING SYSTEM: IBM PC compatible
    SOFTWARE: Patent In Release #1.0, Version #1.25
  CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/177,109A
    FILING DATE: 03 JAN 1994
    CLASSIFICATION: 514
  NAME: Pabst, Patricia L.
  REGISTRATION NUMBER: 41,284
  REFERENCE/BOOK NUMBER: WI 107 DIV
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: (404) 874-8794
    TELEFAX: (404) 874-8795
  INFORMATION FOR SEQ ID NO: 57:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 265 amino acids
      TYPE: amino acid
      TOPOLOGY: linear
      MOLECULE TYPE: protein
      HYDROTHERICAL: No
  US 08 177-109A-57

```

```

Query Match
Best Local Similarity 41.1%, Score 153.5, DB 2; Length 265;
Matches 42; Conservative 17; Mismatches 59; Indels 17; Gaps 6;

```

```

SEQUENCE CHARACTERISTICS:
  LENGTH: 265 amino acids
  TYPE: amino acid
  TOPOLOGY: linear
  MOLECULE TYPE: protein
  HYDROTHERICAL: No
US 08 177-109A-57

Query Match
Best Local Similarity 41.1%, Score 153.5, DB 2; Length 265;
Matches 42; Conservative 17; Mismatches 59; Indels 17; Gaps 6;

QY 2 ISCDPEPVNA---PKYYSLEPLVGVYDYSFPLGKAFGLSENQVHATWD 57
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 76 LHPEDHDENGEYWRSPYVW SDLSHFVYGVYLRSSANRTE---QVRCWS 127

QY 58 KAFPLTEVNR---KQYYSLEPLVGVYDYSFPLGKAFGLSENQVHATWD 117
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 128 GATAICD---NAGYCSNPGIPGTRKVGSG YRLEDSVTVH SRGILLRSGRRRLQCEG 184

QY 118 EMMDPITALVWESDF 142
  | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 184 GWSGTE PSQWSEF 197

```

```

RESULT 55
US 08 687-706-57
Sequence 57, Application US/08/687706
Patent No. 5928492
GENERAL INFORMATION:
  APPLICANT: Jeanis E. Bourcade and Teresa J. Oglesby
  TITLE OF INVENTION: MODIFIED COMPLEMENT PROTEASES
  NUMBER OF SEQUENCES: 62
  CORRESPONDENCE ADDRESS:
    ADDRESSEE: Patricia L. Pabst
    STREET: 2800 One Atlantic Center
    CITY: Atlanta
    STATE: Georgia
    ZIP: 30309-3450
  COMPUTER READABLE FORM:
    OPERATING SYSTEM: IBM PC compatible
    SOFTWARE: Patent In Release #1.0, Version #1.25
  CURRENT APPLICATION DATA:
    APPLICATION NUMBER: US/08/687,706
    FILING DATE: 26 JUL 1996
    CLASSIFICATION: 514
  PRIOR APPLICATION DATA:
    APPLICATION NUMBER: US 08/177,109
    FILING DATE: 03 JAN 1994
    CLASSIFICATION: 514
  ATTORNEY/AGENT INFORMATION:
    NAME: Pabst, Patricia L.
    REGISTRATION NUMBER: 41,284
    REFERENCE/BOOK NUMBER: WI 107 DIV
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (404) 874-8794
      TELEFAX: (404) 874-8795
    INFORMATION FOR SEQ ID NO: 57:
      SEQUENCE CHARACTERISTICS:
        LENGTH: 265 amino acids
        TYPE: amino acid
        TOPOLOGY: linear
        MOLECULE TYPE: protein
        HYDROTHERICAL: No
  US 08 687-706-57

```


COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/769,967A
 FILING DATE:
 CLASSIFICATION: 536
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/440,569
 FILING DATE: 15 May 1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Kind, William T.
 REGISTRATION NUMBER: 40,904
 REFERENCE/DOCKET NUMBER: P404,902
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (610) 270-5364
 TELEFAX: (610) 270-5090
 INFORMATION FOR SEQ ID NO: 27:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 197 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: polypeptide
 FRAGMENT TYPE: N terminal
 US-08 769 967A 27

Query Match 19 18; Score 144; DB 2; Length 197;
 Best Local Similarity 29.58; Pred. No. 3,10-08;
 Matches 41; Conservative 22; Mismatches 54; Indels 22; Gaps 9;
 QY 3 SCDDPPFYKNAKPYSLP--IVPGIVLRYTSPSYRIGKEKALFQISENQVHATWTKAPPI 62
 DB 63 SCRNPPHWPV MVIVIKGLQNGSGLKYSCTKGYRLGSSSATCLISGDT-VIWDNETPI 120
 QY 63 CSVNKLTISCSDP--IVGGMNKSADPRHGDVFTCKAN-----FTMKGSKIIVWC 114
 DB 121 CD--RHCGPLPTIN--DEIST-NENFIHGSVWTYRCNPGSGRKKVFLVGEPSIYC 175
 QY 116 QANE--MW GPTALPW 128
 DB 176 ISNDQVGLWSGDA PQG 192

RESULT 42
 US-08 435-149 2
 Sequence 2, Application US/08435149
 Patent No. 5865402
 GENERAL INFORMATION:
 APPLICANT: INNIS, MICHAEL A.
 APPLICANT: ZAROR, ISABEL
 APPLICANT: GREASEY, ANLA A.
 TITLE OF INVENTION: CHIMERIC MCP AND DAF PROTEINS WITH CELL
 SURFACE LOCALIZING DOMAIN
 NUMBER OF SEQUENCES: 26
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: CHIRON CORPORATION
 STREET: INTELLECTUAL PROPERTY - B440, P.O. BOX 8097
 CITY: EMERYVILLE
 STATE: CALIFORNIA
 COUNTRY: U.S.A.
 ZIP: 94662 8097
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC DOS/MS DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/435,149
 FILING DATE: 05 MAY 1995
 CLASSIFICATION: 530
 ATTORNEY/AGENT INFORMATION:

NAME: SAVEREIDE, PAUL B.
 REGISTRATION NUMBER: 36,914
 REFERENCE/DOCKET NUMBER: 0989,001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (510) 601-2585
 TELEFAX: (510) 655-3542
 TELEX: N/A
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 324 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-435-149-2
 Query Match 18.9%; Score 144; DB 2; Length 324;
 Best Local Similarity 29.98; Pred. No. 9,60-08;
 Matches 40; Conservative 24; Mismatches 50; Indels 20; Gaps 9;
 QY 3 SCDDPPFYKNAKPYSLP--IVPGIVLRYTSPSYRIGKEKALFQISENQVHATWTKA 59
 DB 128 SCPN-GEIRNGQ---IDVFGILFALINFSVIGYKLFSTISFELISSRSLV- WSEF 182
 QY 60 PPIC-SSVNTTISC-SDPIVPGCFMNMKSKAD-RRGDVFTCKANFTMKGSKIIVWCAN 117
 DB 183 LPEC----PEIYCPAPPDINDGLI-QGEEKHYGYRQSVTVACNKGFTMIGHSIYIVNN 247
 QY 118 ---EMKGPTALPVC 128
 DB 238 DCEWSSQDP PEC 249

RESULT 43
 US-08 310-416A-14
 Sequence 14, Application US/08310416A
 Patent No. 5673546
 GENERAL INFORMATION:
 APPLICANT: Jone-Long Ko et al.
 TITLE OF INVENTION: CHIMERIC PROTEINS WHICH BLOCK
 COMPLEMENT ACTIVATION
 NUMBER OF SEQUENCES: 19
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Fish & Richardson P.C.
 STREET: 225 Franklin Street
 CITY: Boston
 STATE: Massachusetts
 COUNTRY: U.S.A.
 ZIP: 02110 2804
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 4b
 COMPUTER: IBM PS/2 Model 502 or 35SX
 OPERATING SYSTEM: MS-DOS (Version 5.0)
 SOFTWARE: Wordperfect (Version 5.1)
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/310 416A
 FILING DATE: 22-SEP-1994
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Paul T. Clark
 REGISTRATION NUMBER: 30,162
 REFERENCE/DOCKET NUMBER: 0616/CC5001
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (617) 542-5070
 TELEFAX: (617) 542-8906
 TELEX: 200154
 INFORMATION FOR SEQ ID NO: 14:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 324 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: linear
 MOLECULE TYPE: protein

GenCure version 5.1.1.4
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein protein search, using sw model
Run on: November 6, 2002 16:04:59 : Search time 14.5539 Seconds
(without alignments)
891.311 Million cell updates/sec

Title: US 09-844-409 6
Perfect score: 76.2
Sequence: 1 E1SCDPPEVKNAKPYSL.....ANEMWGTPALPVQESDFPLE 145

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 283148 seqs, 96089344 residues

Total number of hits satisfying chosen parameters: 283148

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post processing: Minimum Match: 90%
Maximum Match: 100%
Listing first 100 summaries

Database: PIR_71.*

1: p1r1.*
2: p1r2.*
3: p1r3.*
4: p1r4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	75.2	100.0	1025	1 A43526	complement C3d/Eps
2	74.9	99.6	363	2 A45903	complement C3d/Eps
3	74.9	99.6	676	2 A45900	complement C3b rec
4	466.5	62.0	1091	1 PLO009	complement C3d/Eps
5	242	40.9	597	1 S53711	C4BP alpha chain p
6	225.5	30.0	597	1 NHH044	C4b-binding protei
7	222	29.5	469	1 NHH054	C4b-binding protei
8	221.5	29.5	2014	2 136946	complement recepto
9	221.5	29.5	2489	2 173012	complement C3b/C4b
10	215	28.6	579	2 A56740	sperm-eqg recognit
11	208.5	27.7	558	2 S57953	C4BP protein alpha
12	200	26.6	610	1 146001	C4b-binding protei
13	197.5	26.3	263	1 C36838	complement control
14	197.5	26.3	263	1 C36838	hypothetical prote
15	196.5	26.0	263	2 B72152	B181 protein var
16	194.5	25.7	263	1 WNVZSP	apolipoprotein h
17	188.5	25.1	449	2 G02013	sperm C4b - human
18	188.5	25.1	469	2 157908	membrane cofactor
19	188.5	25.1	477	2 154479	membrane cofactor
20	188.5	25.1	484	2 S01R96	membrane cofactor
21	181.5	24.1	462	2 J05194	membrane cofactor
22	181.5	24.1	469	2 J05194	membrane cofactor
23	176	24.4	1234	1 NEMSH	complement factor
24	172.5	22.9	497	2 352954	complement regulat
25	168	22.4	808	2 D45049	complement factor
26	167	22.2	440	2 A44516	complement recepto
27	164.5	21.9	482	2 A34948	complement C3b/C4b
28	157.5	20.9	669	2 S65551	factor II - bovine
29	156.5	20.8	252	2 A4877	C4b-binding protei

complement factor
X/Y protein - mod
complement factor
endothelial leuko
complement factor
P-selectin precurs
secretory comple
membrane bound com
decay-accelerating
E-selectin - becin
apolipoprotein H p
complement control
E-selectin precurs
seizure-related pr
coagulation factor
coagulation factor
apolipoprotein H p
C4BP protein, beta
E-selectin precurs
scavenger receptor
complement C2 prec
complement factor
coagulation factor
decay-accelerating
P-selectin - rat
apolipoprotein H p
complement factor
complement factor
P-selectin precurs
apolipoprotein H p
E-selectin - pig
apolipoprotein H p
hypothetical prote
hypothetical prote
apolipoprotein H p
hypothetical prote
P-selectin precurs
intequinary muc
C4b-binding protei
classical comple
complement factor
complement factor
complement C7 prec
apolipoprotein H p
B6R protein precurs
hypothetical prote
probable complem
ps/hr protein - va
complement factor
complement C6 prec
ASP protein - var
hypothetical prote
hypothetical prote
H7P protein - vari
B7R protein - vari
hypothetical prote
complement factor
FEV ap2, ps/hr pro
iodide peroxidase
iodide peroxidase
E-selectin precurs
complement factor
iodide peroxidase
E-selectin precurs
hypothetical prote
hypothetical prote
iodide peroxidase
C4BP beta chain
E-selectin precurs
haptoglobin precurs

ALIGNMENTS

RESULT 1
A4526
complement C3d/Epstein Barr virus receptor precursor mouse
N:Active names: complement receptor type 2
C:Species: Mus musculus (house mouse)
C:Date: 10 Sep 1999 #sequence revision 10 Sep 1999 #text change 10 Sep 1999
C:Accession: A4526; A4548; A4549; A4560; B42215
R:Function: J.D.
J:Immunol: 144, 4458-4467, 1999
A:Title: Comparative structure and evolution of murine CR2, the homolog of the human C3d
A:Reference number: A4526; MIMD:9022976
A:Accession: A4526
A:Molecule type: mRNA
A:Residues: 1 1025
A:Cross references: GB:M6684; EMBL:304154; NID:q192687; PIDD:AAA47448.1; PIDD:q192688
R:Immunol: 144, 2974-2984, 1999
A:Title: A molecular and immunological characterization of mouse CR2. Evidence for a si
A:Reference number: A4548; MIMD:9101089
A:Accession: A4548
A:Molecule type: mRNA
A:Residues: 12 405; 13 407-519; A4521 1025; MIMD:
A:Cross references: GB:M6112; NID:q192692; PIDD:AAA45295.1; PIDD:q192694
R:Immunol: J.D.; hemolysis; M.A.; Levy; D.N.; Strominger; J.H.
Proc. Natl. Acad. Sci. U.S.A. 86, 242-246, 1989
A:Title: Cloning and characterization of murine complement receptor type 2.
A:Reference number: A4549; MIMD:8909880
A:Accession: A4549
A:Molecule type: mRNA
A:Residues: 43 401-591; 1025; F.2
A:Cross references: GB:304154
R:Immunol: J.B.; Paul; M.S.; Asperger; M.; Weiss; J.H.
J. Immunol. 144, 2058-2067, 1990
A:Title: Murine complement receptor gene family. Identification and characterization of
A:Reference number: A4560; MIMD:8948140
A:Accession: A4560
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: F.100 181-292; 961-964 1025; K08
A:Cross references: GB:M29281; NID:q192686; PIDD:AAA47447.1; PIDD:q192693
A:Note: the authors failed to translate GGA for residue 421 as GLY, and CCA for residue
A:Note: the authors translated the codon CAC for residue 727 as Asn
C:Superfamily: complement C3d/Epstein Barr virus receptor; complement factor 1 repeat ho
C:Key words: alternative splicing; duplication; glycoprotein; receptor; transmembrane pro
F.1 112/anti: signal sequence; status predicted: 553
F.12 1025/product: complement C3d/Epstein Barr virus receptor 2 (15-repeat form) #status
F.13 975/domain: extracellular #status predicted: EX1
F.14 776/domain: complement factor H repeat homology #PH01
F.16 136/domain: complement factor H repeat homology #PH02
F.146 207/domain: complement factor H repeat homology #PH03
F.207 264/domain: complement factor H repeat homology #PH04
F.264 334/domain: complement factor H repeat homology #PH05
F.334 399/domain: complement factor H repeat homology #PH06
F.399 459/domain: complement factor H repeat homology #PH07
F.459 519/domain: complement factor H repeat homology #PH08
F.519 562/domain: complement factor H repeat homology #PH09
F.562 644/domain: complement factor H repeat homology #PH10
F.644 709/domain: complement factor H repeat homology #PH12
F.709 769/domain: complement factor H repeat homology #PH13
F.769 834/domain: complement factor H repeat homology #PH14
F.834 899/domain: complement factor H repeat homology #PH15
F.899 959/domain: complement factor H repeat homology #PH16
F.959 989/domain: transmembrane #status predicted: TM
F.989 1025/domain: intracellular #status predicted: CINF

Query Match 100.0% Score 762; DB 1; Length 1025;
Best Local Similarity 100.0% Freq. No. 6, 96 64;
Matches 105; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1 F1ESDPPPEVKNARKPYSLPVLVPTVLSYRLEKKAIPQSENQVHAHWKAP 60

DB 11 F1ESDPPPEVKNARKPYSLPVLVPTVLSYRLEKKAIPQSENQVHAHWKAP 70
QY 61 F1CESVNTTISQPIVPSPTMNRSSKATPPTSVTTTAKRTMKSEKTVKQJASEQW 120
14 71 F1CESVNTTISQPIVPSPTMNRSSKATPPTSVTTTAKRTMKSEKTVKQJASEQW 140
QY 121 GP1ALPVCESDPTPE 145
DB 141 GP1ALPVCESDPTPE 145

RESULT 2
B45900
complement C3d/Epstein Barr virus receptor precursor alternative splice form mouse
C:Species: Mus musculus (house mouse)
C:Date: 30 Sep 1999 #sequence revision 30 Sep 1999 #text change 16 Jul 1999
C:Accession: B45900; C45900
R:Kurtz; C.H.; O'Toole; E.; Christensen; S.M.; Weiss; J.H.
J. Immunol. 144, 3581-3591, 1990
A:Title: The murine complement receptor gene family. IV. Alternative splicing of C1Z
A:Reference number: A45900; MIMD:9022976
A:Accession: B45900
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual
A:Molecule type: mRNA
A:Residues: 1-36; K08
A:Accession: C45900
A:Status: preliminary; nucleic acid sequence not shown; not compared with conceptual
A:Molecule type: mRNA
A:Residues: 1-19; F.1 84 363; K02
C:Superfamily: complement C3d/Epstein Barr virus receptor; complement factor H repeat
F.23 81/domain: complement factor H repeat homology #PH1
F.186 145/domain: complement factor H repeat homology #PH2
F.154 210/domain: complement factor H repeat homology #PH3
F.218 274/domain: complement factor H repeat homology #PH4
F.274 335/domain: complement factor H repeat homology #PH5

Query Match 99.68; Score 749; DB 2; Length 363;
Best Local Similarity 99.38; Freq. No. 4, 96 64;
Matches 134; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 F1ESDPPPEVKNARKPYSLPVLVPTVLSYRLEKKAIPQSENQVHAHWKAP 60
DB 83 Q1SCDPPPEVKNARKPYSLPVLVPTVLSYRLEKKAIPQSENQVHAHWKAP 142
QY 61 F1CESVNTTISQPIVPSPTMNRSSKATPPTSVTTTAKRTMKSEKTVKQJASEQW 120
14 143 F1CESVNTTISQPIVPSPTMNRSSKATPPTSVTTTAKRTMKSEKTVKQJASEQW 202
QY 121 GP1ALPVCESDPTPE 145
DB 201 GP1ALPVCESDPTPE 217

RESULT 3
A45900
complement C3b receptor type 2 long form precursor mouse (transmem)
C:Species: Mus musculus (house mouse)
C:Date: 30 Sep 1999 #sequence revision 30 Sep 1999 #text change 16 Jul 1999
C:Accession: A45900; I48406
R:Kurtz; C.H.; O'Toole; E.; Christensen; S.M.; Weiss; J.H.
J. Immunol. 144, 3581-3591, 1990
A:Title: The murine complement receptor gene family. IV. Alternative splicing of C1Z
A:Reference number: A45900; MIMD:9022976
A:Accession: A45900
A:Status: preliminary
A:Molecule type: mRNA
A:Residues: 1 676; K08
A:Cross references: GB:M46470
A:Experimental source: clone 31-1
R:Kup; Y.D.; Kimshita; T.; Molina; B.; Houdoude; D.; Soyak; T.; Warner; L.M.; Bolers,
J. Exp. Med. 181, 151-159, 1995
A:Title: Mouse complement regulatory protein Crry/p65 uses the spectral mechanisms of

A:Reference number: 148406; MUID:95105691

A:Accession: 148406

A>Status: preliminary; translated from GH/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 21467 RES.

A:Cross references: EMBL:U7128; MID:9595980; FIDN:AAA78471.1; PID:9595982

C:Genetics:

A:Gene: CR2

A:Features: 803, 1142, 1427, 2743, 33471

C:Superfamily: complement factor H repeat homology

F:22-78/Domain: complement factor H repeat homology <PH02>

F:83-140/Domain: complement factor H repeat homology <PH03>

F:145-271/Domain: complement factor H repeat homology <PH03>

F:217-272/Domain: complement factor H repeat homology <PH04>

F:276-331/Domain: complement factor H repeat homology <PH05>

F:336-394/Domain: complement factor H repeat homology <PH06>

F:399-458/Domain: complement factor H repeat homology <PH07>

F:463-523/Domain: complement factor H repeat homology <PH08>

F:531-607/Domain: complement factor H repeat homology <PH09>

F:592-648/Domain: complement factor H repeat homology <PH10>

Query Match 99.68; Score 749; DB 2; Length 676;

Best Local Similarity 99.38; Pred. No. 8,76-64; Indels 0; Gaps 6;

Matches 144; Conservative 1; Mismatches 0; Gaps 6;

QY 1 FTSITPPFVNAPKPYSLPIVPTVITPYTSPSPYLIGEKATFVISENCHVATWKPAP 60

DB 1 FTSITPPFVNAPKPYSLPIVPTVITPYTSPSPYLIGEKATFVISENCHVATWKPAP 60

QY 396 QLSCTPPFVNAPKPYSLPIVPTVITPYTSPSPYLIGEKATFVISENCHVATWKPAP 455

DB 396 QLSCTPPFVNAPKPYSLPIVPTVITPYTSPSPYLIGEKATFVISENCHVATWKPAP 455

QY 61 PTCSEVNTISSTGIVPVSQPMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 120

DB 61 PTCSEVNTISSTGIVPVSQPMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 120

QY 456 PTCSEVNTISSTGIVPVSQPMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 515

DB 456 PTCSEVNTISSTGIVPVSQPMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 515

QY 121 QPTALPVCESDPFPLE 135

DB 121 QPTALPVCESDPFPLE 135

QY 516 QPTALPVCESDPFPLE 540

DB 516 QPTALPVCESDPFPLE 540

RESULT 4

PI0009

complement C3d/Epstein-Barr virus receptor precursor human

N:Alternate names: complement receptor 2; CR2/CD21

C:Species: Homo sapiens (man)

C:Date: 30 Jun 1992; frequency revision: 07-Jul-1995; #text_change 22-Jun-1999

C:Accession: J10928; A3958; A2336; A24319; B24319; C24319; D24319; F24319; P10

W:Weis, J.J.; Tonhak, L.E.; Smith, J.A.; Weis, J.H.; Fearon, D.T.

J. Exp. Med. 167, 1047-1066, 1988

A:Title: Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus

A:Reference number: J10928; MUID:88171282

A:Accession: J10928

A:Molecule type: mRNA

A:Residues: 1-1091; WEL

A:Note: nucleotide 1566-1625 are missing from Figure 1; therefore, residues 522-542 have

been removed; Moore, M.D.; Cooper, N.R.; Tack, B.F.; Nemerow, G.R.

Proc. Natl. Acad. Sci. U.S.A. 84, 9194-9198, 1987

A:Title: Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (com

A:Reference number: A3958; MUID:88097454

A:Accession: A3958

A:Molecule type: mRNA

A:Residues: 1456; G; 457-644; E; 646-669; R; 671-816; N; 817-840; L; 841-844

A:Cross references: 38-104665; NID-0191919; PIFN-AAA46784.1; PID:0181920

R:Fujiwara, A.; Barley, J.B.; Frank, M.B.; Gruner, B.A.; Frazier, B.; Hollers, V.M.

J. Biol. Chem. 264, 2118-2125, 1989

A:Title: Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus recep

A:Reference number: A32036; MUID:89124277

A:Accession: A32036

A:Molecule type: mRNA

A:Residues: 1456; G; 457-658; 718-1050; T; 1052-1060; E; 1062-1091 <PDU>

A:Cross references: 38-104464

R:Weis, J.J.; Fearon, D.T.; Hlickstein, L.H.; Wong, W.W.; Richards, S.A.; De Fruyn Kops,

Proc. Natl. Acad. Sci. U.S.A. 85, 5643-5648, 1988

A:Title: Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor

of complement

A:Reference number: A94114; MUID:86287311

A:Accession: A24319

A:Molecule type: protein

A:Residues: 226-240; X110; 257-267; 332-343; 583-591; G; 593; T; 595-596; 728-735; W12-

A:Experimental source: B-lymphoblastoid cell lines SB and Raji

C:Genetics:

A:Gene: GDB:CR2

A:Cross references: GDB:119802; OMIM:120650

A:Major position: 119, 1332

C:Superfamily: complement C3d/Epstein-Barr virus receptor; complement factor H repeat

C:Keywords: alternative splicing; duplication; glycoprotein; transmembrane protein

F:1-20/Domain: signal sequence #status predicted <SIG>

F:21-1091/Product: complement receptor 2 (16 repeat form) #status predicted <MAT1>

F:21-658-718-1091/Product: complement receptor 2 (21 repeat form) #status predicted <

F:23-82/Domain: complement factor H repeat homology <PH01>

F:91-146/Domain: complement factor H repeat homology <PH02>

F:154-230/Domain: complement factor H repeat homology <PH03>

F:215-271/Domain: complement factor H repeat homology <PH04>

F:276-342/Domain: complement factor H repeat homology <PH05>

F:351-406/Domain: complement factor H repeat homology <PH06>

F:410-465/Domain: complement factor H repeat homology <PH07>

F:470-523/Domain: complement factor H repeat homology <PH08>

F:526-594/Domain: complement factor H repeat homology <PH09>

F:601-656/Domain: complement factor H repeat homology <PH10>

F:660-716/Domain: complement factor H repeat homology <PH11>

F:720-772/Domain: complement factor H repeat homology <PH12>

F:777-837/Domain: complement factor H repeat homology <PH13>

F:846-907/Domain: complement factor H repeat homology <PH14>

F:909-965/Domain: complement factor H repeat homology <PH15>

F:970-1026/Domain: complement factor H repeat homology <PH16>

F:1034-1056/Domain: transmembrane #status predicted <TM>

F:1057-1091/Domain: intracellular #status predicted <INT>

F:121, 129, 234, 372, 472, 698, 858, 881, 919/Binding site: carbohydrate (Asn)

Query Match 62.08; Score 46.5; DB 1; Length 1091;

Best Local Similarity 61.28; Pred. No. 1,46-46;

Matches 82; Conservative 18; Mismatches 43; Indels 1; Gaps 1;

QY 2 ISCDPPSVNARKPYSLPIVPGIVIRYICSPSRIGEKATFVISENCHVATWKPAP 61

DB 2 ISCDPPSVNARKPYSLPIVPGIVIRYICSPSRIGEKATFVISENCHVATWKPAP 61

QY 62 ICESVYKTKISCDPIVPGCGFMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 121

DB 62 ICESVYKTKISCDPIVPGCGFMNKGKAPFHPQSVTFTTKANFTMKSKIVWQANEMW 121

QY 8 KCLAYNKSSGCEIFIVPGYKINGS IYVNCUSVFAFAKRLI SMNKNKSVWQANEMW 149

DB 8 KCLAYNKSSGCEIFIVPGYKINGS IYVNCUSVFAFAKRLI SMNKNKSVWQANEMW 149

QY 122 PTALPVCESDPFPLE 135

DB 122 PTALPVCESDPFPLE 135

QY 140 PTRLPTCYSVFPLE 153

DB 140 PTRLPTCYSVFPLE 153

RESULT 5

S53711

C4BP alpha chain precursor - rabbit

C:Species: Oryctolagus cuniculus (domestic rabbit)

C:Date: 10-Sep-1999; frequency revision 10-Sep-1999; #text_change 10-Sep-1999

C:Accession: S53711

A:Reference number: S53711; MUID:95226458

A:Accession: S53711

A>Status: preliminary; nucleic acid sequence not shown

A:Molecule type: mRNA

A:Residues: 1537; STOP

A:Cross references: EMBL:235490

C:Superfamily: C4b-binding protein alpha chain; complement factor H repeat homology

F:50-107/Domain: complement factor H repeat homology <PH1>

F:112-169/Domain: complement factor H repeat homology <PH2>

F:174-233/Domain: complement factor H repeat homology <PH3>

F:239-296/Domain: complement factor H repeat homology <PH4>

F:299-360/Domain: complement factor H repeat homology <PH5>

F:364-422/Domain: complement factor H repeat homology <PH6>

F:268 498/bosamin: von Willebrand factor type A repeat homology - VFA.
 E:482 752/bosamin: tryptsin homology #status: atypical - TR.
 E:17 76 12 98 103 145 131 198 165 205 191 218 478 596 511 527 599 616 656 682 695 725/03
 E:122 112 295 076/bosamin: site: carbohydrate (ASN) (conservative) #status: experimental
 E:259 220/266/bosamin: site: Arg 135 (complement factor D) #status: experimental
 E:126 256 600/Act: site: His 45p. See #status: experimental

Query Match
 best local similarity 31.1% Score 158.5; DB 1; Length 764;
 Matches 42; Conservative 17; Mismatches 59; Indels 17; Gaps 6;

25 123 DFFPEVNA EFVYSLFVIVGLVLYVTSVSPVLEKALFVLSKQVIAHW 67
 131 11113 11113 11111 11111 11111 11111 11111 11111 11111
 10 101 TRFPHPEFENFYWRSYVYV SUEISFVYVGLVLE SANPVS QVNPQS 157
 111 111 111 111 111 111 111 111 111 111
 25 50 KAPVPEVVKILTSVDFIVVQEMKSGKAFKRRHGVVFIFKAFV MKSGSKIVWQAN 117
 111 111 111 111 111 111 111 111 111 111
 10 153 GQVATCD NGAYVSNPGLPGLTRKVGSG YRLISVYVHSRGLTRGSRRTQGS 208
 111 111 111 111 111 111 111 111 111 111
 25 110 EHWGFTALVWESDF 157
 111 111 111 111 111 111 111 111 111 111
 10 200 GSWSEDF PSQVSEF 272
 111 111 111 111 111 111 111 111 111 111

RESULT 3
 159/75

X/Y protein: mouse (fragment)
 #Species: Mus musculus (house mouse)
 #Date: 26 Jul 1996 #Sequence revision 26 Jul 1996 #Text change 05 Nov 1999
 #Accession: U56975
 #Accession Show: M3 Cde: J.L.; E1114 cde: L.B.; Wnt: W.W.; Pear: P.T.; Lally: P.A.
 #Imm: 130; 5480-5494; 1367

A:Title: Expansion of the complement receptor gene family: Identification in the mouse C
 A:Reference number: U56975; M3 Cde/196475
 A:Accession: U56975
 A:Status: preliminary; translated from GR/EMD/24901
 A:Molecule type: mRNA
 A:Residues: 1 540 RES.

A:Cross references: GR/M3/192; NID:020127; PID:AAA10574.1; PID:0202428
 #Supernat: Y; complement factor H repeat homology
 E:6 72/bosamin: complement factor H repeat homology - PH
 E:186 244/bosamin: complement factor H repeat homology - PH2
 E:149 502/bosamin: complement factor H repeat homology - PH3

Query Match
 best local similarity 28.2% Score 150; DB 2; Length 440;
 Matches 47; Conservative 22; Mismatches 50; Indels 22; Gaps 6;

25 4 DFFPEVNA EKPYSSEIVMTVIRVTSVSRVLTGEKAFVISEKQVIAHWK 56
 111 111 111 111 111 111 111 111 111 111
 10 35 DFFPVVYVNAVMLSEKSLFSE RQVVERCHVGEIMKQASVWQSLNK----WEP 87
 111 111 111 111 111 111 111 111 111 111
 25 50 APTVTSVKILTSVSPVIVVQEM NKSQAFRRHDSVVFVFKANFIMKSGK 112
 111 111 111 111 111 111 111 111 111 111
 10 90 ELPSEF EKAVLPQPMQVQEMQMKREYVYGVENVLEFQVYTLRESSTASAVL 144
 111 111 111 111 111 111 111 111 111 111
 25 13 WQANFMWQV 123
 111 111 111 111 111 111 111 111 111 111
 10 115 WQVGFANST 155
 111 111 111 111 111 111 111 111 111 111

RESULT 6
 N0000

complement factor H precursor, long splice form [validated] human
 #Species: homo sapiens (man)
 #Date: 01 Dec 1994 #Sequence revision 31 Dec 1994 #Text change 08 Dec 2000
 #Accession: S00254; A02260; A42262; A61565; A26305; 172634; S66298
 #Accession Show: J.L.; Day: A.J.; Harris: L.J.R.; Sim: R.B.
 #Imm: 1 239; 554 602; 1988

A:Title: The complete amino acid sequence of human complement factor H.
 A:Reference number: S00254; M3 Cde/04059
 A:Accession: S00254
 A:Molecule type: mRNA

A:Residues: 1 1241 RRP.
 A:Cross references: EMBL:Y00716; NID:031964; PID:CAA6704.1; PID:041965
 A:Note: 402 Pyl was also found
 A:Note: parts of this sequence, including the amino and carboxy ends of the mature p
 ReStaller, C.; Schwaebler, W.; Dietrich, M.; Weiss, E.H
 Eur. J. Immunol. 21, 799 802, 1991
 A:Title: Human complement factor H: Two factor H proteins are derived from alternative
 A:Reference number: A60238; M3 Cde/91164292
 A:Accession: A60238
 A:Status: not compared with conceptual translation
 A:Molecule type: mRNA
 A:Residues: 1 56:1177 1241 EST.
 A:Note: only portions of this 4.3 kilobase mRNA were sequenced
 E:Day: A.J.; Eppel: J.; Lynch: A.; Melnick: R.; Harris: L.J.R.; Sim: R.B.
 Biophys. Rep. 7, 201-207, 1987
 A:Title: Sequence analysis of a cDNA clone encoding the C-terminal end of human comp
 A:Reference number: A54726; M3 Cde/00025472
 A:Accession: A54726
 A:Status: not compared with conceptual translation
 A:Molecule type: mRNA
 A:Residues: 1 579 1231 cDAY.
 A:Cross references: GR/M3/157; NID:040497; PID:AAA62076.1; PID:040498
 A:Note: parts of this sequence were determined by protein sequencing
 B:Kapoche, J.; Day, A.J.; Willis, A.C.; Bell, K.L.; Campbell, R.D.; Sim, R.B.
 Biophys. Rep. 6, 65-72, 1986
 A:Title: Partial characterization of human complement factor H by protein and cDNA se
 A:Reference number: A61565; M3 Cde/86184124
 A:Accession: A61565
 A:Status: not compared with conceptual translation
 A:Molecule type: mRNA
 A:Residues: MET:PHILNAK11050 1157; Y:1079 1102 R12.
 B:Sim, R.B.; D'Silva, R.G.
 Biochem. J. 205, 285-293, 1982
 A:Title: Purification and structural studies on the complement system control protein
 A:Reference number: A26305; M3 Cde/0404213
 A:Accession: A26305
 A:Molecule type: protein
 A:Residues: 19 205 22 29; V:41-44; Q:735 cSIM.
 B:Barlow, P.N.; Norman, D.G.; Steinkasserer, A.; Horne, J.; Foster, J.; Briscoe, P.
 Biochemistry 31, 4626-4634, 1992
 A:Title: Soluble structure of the fifth repeat of factor H: A second example of the
 A:Reference number: A45511; M3 Cde/92242649
 A:Accession: A45511; NMR structure determination, residues 927-965
 B:Staller, C.; Kristensen, V.; Schwachble, W.; Dietrich, M.; Weiss, E.H
 J. Immunol. 146, 4190-4196, 1991
 A:Title: Cloning of the 1.4-kb mRNA species of human complement factor H reveals a no
 A:Reference number: 156100; M3 Cde/91201892
 A:Accession: 172634
 A:Status: translated from GR/EM32/0DB1
 A:Molecule type: mRNA
 A:Residues: 1047-1241 RES.
 A:Cross references: GR/M3/5294; NID:0418766; PID:AAA65443.1; PID:0418767
 B:Carroll, J.A.; Bates, R.C.; Smith, A.L.; Lotoz, L.; Arellano, A.; Jordan, D.L.; Burn
 Biochim. Biophys. Acta 1289, 305-311, 1996
 A:Title: Factor H co-purifies with thrombospondin isolated from platelet secretate.
 A:Reference number: S66298; M3 Cde/96205465
 A:Accession: S66298
 A:Status: preliminary
 A:Molecule type: protein
 A:Residues: 411-419; 574-578, 580-582 cAR.
 #Comment: Factor H has also been found bound to cell membranes in an unknown manner.
 #Comment: Alternative transcripts of 4.3, 1.8, and 1.4 kilobases are expressed in liv
 #Genetics: SHP1
 A:Gene: GHR:HP1; HF
 A:Cross references: GHR:120041; OMIM:134470
 A:Map position: 2342 1q42
 #Genetics: cHF2.

Genome version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 6, 2002, 16:04:58 : Search time 8.5316 Seconds
(without alignments)
612.680 Million cell updates/sec

Title: US 09-834-309-6

Perfect score: 752

Sequence: 1 EISCDPPPEVKNARKYYSLS.....ANEMGPTALPVCEDFPLE 135

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 105224 seqs, 4870550 residues

Total number of hits satisfying chosen parameters: 105224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post processing: Minimum Match 100

Maximum Match 100%

Listing first 100 summaries

Database : SwissProt_40.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query %	Match	Length	DB ID	Description
1	752	100.0	1025	1	C62_MOUSE	P19070 mus musculus
2	466.5	62.0	1033	1	C62_HUMAN	P30023 homo sapiens
3	225.5	40.0	597	1	C4BP_HUMAN	P04003 homo sapiens
4	222	29.5	469	1	C4BP_MOUSE	P08607 mus musculus
5	220.5	29.3	2039	1	C1L_HUMAN	P17927 homo sapiens
6	208.5	27.7	558	1	C4BP_RAT	Q63514 rattus norvegicus
7	200	26.6	610	1	C4BP_BOVIN	P28065 bos taurus
8	193.5	25.7	263	1	VCP_VACCV	P10998 vaccinia virus
9	188.5	25.1	477	1	MP_HUMAN	P15529 homo sapiens
10	176	23.4	1234	1	CFAH_MOUSE	P06909 mus musculus
11	157.5	20.9	585	1	CFAH_BOVIN	Q28085 bos taurus
12	156.5	20.8	252	1	C4BP_HUMAN	P29851 homo sapiens
13	153.5	20.4	407	1	DAF2_MOUSE	Q61476 mus musculus
14	153.5	20.4	764	1	C7AB_HUMAN	P06751 homo sapiens
15	149	19.8	1241	1	C7AB_HUMAN	P08603 homo sapiens
16	146.5	19.7	551	1	LEM2_EBIBT	P27113 oryctolagus
17	148	19.7	390	1	DAF1_MOUSE	Q61475 mus musculus
18	144.5	19.2	151	1	CFAH_PIG	Q03710 sus scrofa
19	143.5	19.1	768	1	LEM3_MOUSE	Q01102 mus musculus
20	142.5	18.9	360	1	C7P1_HSVSA	Q01016 herpesvirus
21	142	18.9	381	1	DAF_HUMAN	P08174 homo sapiens
22	142	18.9	485	1	LEM2_BOVIN	P98107 bos taurus
23	140	18.6	549	1	LEM2_RAT	P98105 rattus norvegicus
24	139	18.5	610	1	LEM2_HUMAN	P16581 homo sapiens
25	137	18.2	561	1	FL3B_HUMAN	P05160 homo sapiens
26	135	18.0	668	1	FL3B_MOUSE	Q07968 mus musculus
27	134	17.8	297	1	APDH_RAT	P26644 rattus norvegicus
28	133.5	17.8	258	1	C4BB_RAT	Q63515 rattus norvegicus
29	131.5	17.5	612	1	LEM2_MOUSE	Q00690 mus musculus
30	130.5	17.4	752	1	C62_HUMAN	P06681 homo sapiens
31	130.5	17.4	763	1	CFAH_MOUSE	P04186 mus musculus
32	130.5	17.4	1019	1	LPC_TACTR	P28175 tachypleus
33	130	17.3	340	1	DAF_PONPY	P49457 pongo pygmaeus

P94106 rattus norvegicus
P43240 canis familiaris
P94109 oryctolagus
Q24222 oryctolagus
P17690 bos taurus
Q04591 homo sapiens
P42201 bos taurus
Q01339 mus musculus
P98110 sus scrofa
P43703 canis familiaris
Q60401 cavia porcellus
P02749 homo sapiens
P16109 homo sapiens
Q09101 drosophila
Q04472 sus scrofa
P21180 mus musculus
P46480 homo sapiens
P10443 homo sapiens
Q11227 canis familiaris
Q62965 homo sapiens
P24084 vaccinia virus
P13671 homo sapiens
P21115 vaccinia virus
Q63769 rattus norvegicus
P61475 gallus gallus
Q92496 homo sapiens
P79539 homo sapiens
P45419 mus musculus
P44650 rattus norvegicus
P40846 rattus norvegicus
P07202 homo sapiens
Q51198 macaca mulatta
Q28768 papio hamadryas
P09933 sus scrofa
Q62802 canis familiaris
Q28066 bos taurus
P98141 bos taurus
P14151 homo sapiens
Q45247 pan troglodytes
Q45245 pongo pygmaeus
Q62558 mus saxatilis
Q00147 homo sapiens
P31530 mus musculus
P98394 mus musculus
P41640 felis silvestris
P06846 rattus norvegicus
P18347 mus musculus
P48740 h. c. sapiens
Q60610 homo sapiens
Q13219 homo sapiens
P01589 homo sapiens
P00736 homo sapiens
P55067 rattus norvegicus
P40417 atelapha zeyheri
Q05996 homo sapiens
Q99018 mus musculus
Q98458 homo sapiens
Q97004 rattus norvegicus
Q08808 mus musculus
P82957 didelphis marsupialis
P81282 bos taurus
Q58452 metatheropithecus
P98089 rattus norvegicus
P48829 oryctolagus
Q77293 macaca mulatta
P80109 bos taurus

ALIGNMENTS

RESULT 1

entities requires a license agreement (See <http://www.isb-sib.org> or send an email to license@isb-sib.org).

QY	1	EISGDPPEVKNARKKPYSLPIVPQTIVLYETCTSYRILGRKAIFCISENQVHATWDKAP	60
DD	11	EISCDPPEVKNARKKPYSLPIVPQTIVLYETCTSYRILGEKAIFCISENQVHATWDKAP	70
QY	61	PICSEVNKTLSISDPTVPCEFNKKSKAFPRHGDSVFTECKANFTMKGSKTVMQCANEHW	120
DD	71	PICSEVNKLISCSLDPVTGCFPNKKSSKAFPRHGDSVFTECKANFTMKGSKTVMQCANEHW	130
QY	121	GPTALPWCESTFPLE 145	
DD	131	GPTALPWCESTFPLE 145	

RESULT 2

ID	CR2 HUMAN	STANDARD:	PRT: 1033 AA.
AD	P20024;		
DI	01-FEB-1991 (Ref. 17, Created)		
DI	01-FEB-1991 (Ref. 17, Last sequence update)		
DI	16-OCT-2001 (Ref. 40, Last annotation update)		
DE	Complement receptor type 2 precursor (cr2) (Complement C3d receptor) (Epstein-Barr virus receptor) (EBV receptor) (CD21 antigen).		
GN	CR2 OR C3dR.		
SUS	Homo sapiens (Human).		
CUS	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
COX	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
RN	Nr_01_TaxID=9606;		
[1]			
SEQUENCE FROM N.A.			
MDLINE=89121277; PubMed=2563370;			
Fujisaku A., Harley J.B., Frank M.H., Gruner B.A., Frazier B.,			
Hollers V.M.;			
"Genomic organization and polymorphisms of the human Cd/Epstein-Barr			
virus receptor";			
J. Biol. Chem. 264:2118-2125(1989).			
[2]			
SEQUENCE OF 226-233; 256-257; 332-341; 667-677 AND 898-908.			
MDLINE=B6287311; PubMed=3016712;			
Weiss J.J., Fearon D.T., Klickstein L.B., Wong W.W., Richards S.A.,			
de Bruyn Kops A., Smith J.A., Weiss J.H.;			
"Identification of a partial cDNA clone for the C3d/Epstein-Barr			
virus receptor of human B lymphocytes: homology with the receptor for			
fragments C3d and C4b of the third and fourth components of			
complement";			
Proc. Natl. Acad. Sci. U.S.A. 83:5649-5643(1986).			
[3]			
SEQUENCE OF 492-556 FROM N.A. (SHORT ISOFORM).			
MDLINE=91294286; PubMed=B490543;			
Staba S.K., Todd S.C., Hedrick J.A., Speiser C.L., Lambiris J.D.,			
Tsoukas C.D.;			
"Characterization of the EBV/Cd receptor on the human Jurkat T cell			
line: evidence for a novel transcript.";			
J. Immunol. 150:5311-5320(1993).			
[4]			
FUNCTION: RECEPTOR FOR COMPLEMENT C3d AND FOR THE EPSTEIN-BARR			
VIRUS ON HUMAN B CELLS AND T-CELLS. PARTICIPATES IN B LYMPHOCYTES			
ACTIVATION.			
[5]			
SUBCELLULAR LOCATION: Type I membrane protein.			
[6]			
ALTERNATIVE PRODUCTS: 2 ISOFORMS: A LONG FORM (SHOWN HERE) AND A			
SHORT FORM; ARE PRODUCED BY ALTERNATIVE SPLICING.			
[7]			
TISSUE SPECIFICITY: MAJORE B LYMPHOCYTES, T LYMPHOCYTES AND			
POLLICULAR DENDRITIC CELLS OF THE SPLEEN.			
[8]			
SIMILARITY: TO MOUSE CR2. CD21 IS A MEMBER OF THE REGULATORS OF			
COMPLEMENT ACTIVATION (RCA) FAMILY.			
[9]			
SIMILARITY: CONTAINS 15 SUSHI (SCR) DOMAINS.			
[10]			
DATABASE: NCBI-PROW; NOTE=Cd quide cd21 entry;			
WWW="http://www.ncbi.nlm.nih.gov/prow/cd/cd21.htm".			

This SWISS-prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on use by non profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial purposes without prior written permission is prohibited.

F1 DLSLEFID 685 714 BY SIMILARITY.
 F1 LLSLEFID 719 762 BY SIMILARITY.
 F1 LLSLEFID 739 779 BY SIMILARITY.
 F1 LLSLEFID 788 840 BY SIMILARITY.
 F1 LLSLEFID 816 843 BY SIMILARITY.
 F1 LLSLEFID 851 894 BY SIMILARITY.
 F1 LLSLEFID 860 907 BY SIMILARITY.
 F1 LLSLEFID 912 905 BY SIMILARITY.
 F1 LLSLEFID 941 968 BY SIMILARITY.
 F1 CARBOHYD 121 121 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 127 127 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 294 294 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 372 372 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 492 492 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 624 624 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 682 682 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 800 800 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 824 824 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 861 861 N LINKED (GLCNAC) () (POTENTIAL).
 F1 CARBOHYD 911 911 N LINKED (GLCNAC) () (POTENTIAL).
 F1 VARSPLIC 499 524 MISSING (IN SHORT ISOFORM).
 F1 VARSPLIC 525 556 LTPDPLVLYNCHAGSSLEDPYGVTVTVIC -- NHLP
 F1 LTPDPLVLYNCHAGSSLEDPYGVTVTVIC (IN SHORT ISOFORM).
 F1 VARSPLIC 667 667 Q - D (IN REF. 2).
 F1 VARSPLIC 902 902 Q - G (IN REF. 2).
 F1 VARSPLIC 906 906 B - L (IN REF. 2).
 SQ SEQUENCE 1033 AA: 1129-13 MW: 174908407847ADA PR664:
 Query Match 62.0%; Score 466.9; DB 1; Length 1033;
 Identical Similarity 61.2%; Pos. No. 49-99; 1; Gaps 1;
 Matches 82; Conservative 18; Mismatches 64; Indels 1; Gaps 1;
 QY 2 LSCDPPKVNARKPYSLPVLIVIVRYVNSPYKVLGKKAIFCISENQVHAIWKAAP 61
 ID 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 QY 21 LSCDPPKVNARKPYSLPVLIVIVRYVNSPYKVLGKKAIFCISENQVHAIWKAAP 80
 ID 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 QY 62 LSCDPPKVNARKPYSLPVLIVIVRYVNSPYKVLGKKAIFCISENQVHAIWKAAP 121
 ID 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 QY 61 KQYVKNYSNCPFLVAGYKRNCS LYSKNGSVFAK/NFSMNKNSVW/QANNMWG 139
 ID 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 QY 122 LTPDPLVLYNCHAGSSLEDPYGVTVTVIC -- NHLP
 ID 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11
 ID 140 LTPDPLVLYNCHAGSSLEDPYGVTVTVIC -- NHLP
 RP3011 3
 240P HUMAN STANDARD: PRT; 597 AA.
 A' 104000;
 D1 25-02-1996 (Ref. 2); (Created)
 D1 01-01-1994 (Ref. 2); (Last sequence update)
 D1 01-01-2001 (Ref. 40); (Last annotation update)
 DE C4b binding protein alpha chain precursor (C4bp) (Proline rich
 DE protein) (PRP).
 GN C4BA OR C4BP.
 OS Homo sapiens (human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 RX NCBI TaxID=7606;
 RP 111
 RP 3840EN-E FROM N.A.
 RC 11500; Laver;
 RX MEDLINE=9007499; PubMed 2562215;
 RA Matsunaga T., Okamura S., Aso T., Sata T., Nihio Y.;
 RI "Molecular cloning of the cDNA coding for proline-rich protein (PRP):
 RI identity of PRP as C4b binding protein.";
 RL Biochem. Biophys. Res. Commun. 165:148-144 (1989).
 RN 121
 RP SEQUENCE FROM N.A.
 RX MEDLINE=91113199; PubMed 1069602;
 RA Aso T., Okamura S., Matsunaga T., Sakamoto N., Sata T., Nihio Y.;
 RI "Genomic organization of the alpha chain of the human C4b binding

protein gene.";
 RL Biochem. Biophys. Res. Commun. 174:222-227 (1991).
 RN 141
 RP SEQUENCE OF 9-81 FROM N.A.
 RX MEDLINE=88242821; PubMed 3478624;
 RA Lintin S.J., Lewin A.R., Reid K.B.M.;
 RI "Derivation of the sequence of the signal peptide in human
 RI C4b-binding protein and interspecies cross hybridisation of the c4bp
 RI cDNA sequence.";
 RL FEBS Lett. 232:328-332 (1988).
 RN 141
 RP SEQUENCE OF 203-288 FROM N.A.
 RX MEDLINE=86401119; PubMed-3017751;
 RA Lintin S.J., Reid K.B.M.;
 RI "Studies on the structure of the human C4b binding protein gene.";
 RL FEBS Lett. 204:77-81 (1986).
 RN 151
 RP SEQUENCE OF 80-597 FROM N.A.
 RX MEDLINE=86025405; PubMed-4840370;
 RA Chung L.P., Bentley D.R., Reid K.B.M.;
 RI "Molecular cloning and characterization of the cDNA coding for C4b
 RI binding protein, a regulatory protein of the classical pathway of the
 RI human complement system.";
 RL Biochem. J. 240:133-141 (1985).
 RN 161
 RP SEQUENCE OF 49-88;
 RX MEDLINE=85296301; PubMed-403666;
 RA Chung L.P., Gadhon J., Reid K.B.M.;
 RI "Amino acid sequence studies of human C4b-binding protein: N terminal
 RI sequence analysis and alignment of the fragments produced by limited
 RI proteolysis with chymotrypsin and the peptides produced by cyanogen
 RI bromide treatment.";
 RL Mol. Immunol. 22:427-435 (1985).
 RN 171
 RP ELECTRON MICROSCOPY, 3D-STRUCTURE, AND LEGEND BINDING.
 RX MEDLINE=9222145; PubMed-4222461;
 RA Ehlback B., Smith C.A., Mueller, Bernhard H.J.;
 RI "Visualization of human C4b-binding protein and its complexes with
 RI vitamin K-dependent protein S and complement protein C4b.";
 RL PROC. NATL. ACAD. SCI. U.S.A. 80:4451-4455 (1983).
 CC -1- FUNCTION: C4BP CONTROLS THE CLASSICAL PATHWAY OF COMPLEMENT
 CC ACTIVATION. IT BINDS AS A COFACTOR TO C3b/C4b INACTIVATOR
 CC (C3bINA), WHICH THEN HYDROLYZES THE COMPLEMENT FRAGMENT C4b. IT
 CC ALSO ACCELERATES THE DEGRADATION OF THE C4bC2a COMPLEX (C4
 CC CONVERTASE) BY DISSOCIATING THE COMPLEMENT FRAGMENT C2a ALPHA
 CC CHAIN FROM C4b. IT INTERACTS ALSO WITH ANTI-COAGULANT PROTEIN S
 CC AND WITH SERUM AMYLASE P COMPONENT.
 CC -1- SUBUNIT: DISULFIDE-LINKED COMPLEX OF 7 ALPHA CHAINS AND 3
 CC OF 3 POSSIBLE ISOPTS. A 570 KDa COMPLEX OF ALPHA CHAINS OR A 500 KDa
 CC BETA CHAIN. A 540 KDa HOMOPOLYMER OF ALPHA CHAINS. THE CENTRAL BODY OF
 CC COMPLEX OF 6 ALPHA CHAINS AND 1 BETA CHAIN. EACH WITH THE
 CC THE ALPHA CHAIN HOMOPOLYMER SUPPORTS TENTACLES. EACH WITH THE
 CC BINDING SITE FOR C4b AT THE END.
 CC -1- TISSUE SPECIFICITY: CHYLOMICRONS IN THE PLASMA.
 CC -1- SIMILARITY: CONTAINS 8 SUSHI (SHR) DOMAINS.
 CC -1- SIMILARITY: TO C4BP BETA CHAIN AND TO FIG APO-LIP-PROTEIN R.
 CC -1- CAUTION: IT IS UNCERTAIN WHETHER MET 1 OR MET 17 IS THE INITIATOR.
 CC -----
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb.ch/chemcom/>
 CC or send an email to license@isb-stb.ch).
 CC -----
 DR EMBL; M31452; AAA36507.1; -;
 DR EMBL; M62486; AAA36506.1; -;
 DR EMBL; M62475; AAA36506.1; JOINED.
 DR EMBL; M62476; AAA36506.1; JOINED.
 DR EMBL; M62477; AAA36506.1; JOINED.
 DR EMBL; M62478; AAA36506.1; JOINED.
 DR EMBL; M62479; AAA36506.1; JOINED.

A* p10998.
 DT 01 JUL 1989 (Rel. 11, Created)
 DT 01 JUL 1989 (Rel. 11, Last sequence update)
 DT 16 OCT 2001 (Rel. 40, Last annotation update)
 DE Complement control protein precursor (CCP) (Secretory protein 35)
 DE (Protein C3) (28 kDa protein).
 GN C3L.
 OS Vaccinia virus (strain WR), and
 OS Vaccinia virus (strain Copenhagen).
 OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
 OC Orthopoxvirus.
 OX NEB_TaxID=10254, 10249;
 RN [1]
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 20-37.
 RC STRAIN-WR.
 RX MEDLINE-BH418974; PubMed-4412473;
 RA Kotwal G.J., Moss B.;
 RT "Vaccinia virus encodes a secretory polypeptide structurally related
 RL to complement control proteins.";
 RL Nature 345:176-178(1988)
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN-WR.
 RX MEDLINE-B9074756; PubMed-2849248;
 RA Kotwal G.J., Moss B.;
 RT "Analysis of a large cluster of nonessential genes deleted from a
 RL vaccinia virus terminal transposition mutant.";
 RL Virology 167:524-547(1988).
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN-COPENHAGEN;
 RX MEDLINE-Q1021027; PubMed-2219722;
 RA Goebel S.J., Johnson G.P., Perkins M.F., Davis S.W., Winslow J.P.,
 RA Paolletti E.;
 RT "The complete DNA sequence of vaccinia virus.";
 RL Virology 179:247-266(1990).
 RN [4]
 RP COMPLETE GENOME.
 RC STRAIN-COPENHAGEN.
 RA Goebel S.J., Johnson G.P., Perkins M.E., Davis S.W., Winslow J.P.,
 RA Paolletti E.;
 RT "Appendix to 'The complete DNA sequence of vaccinia virus'.";
 RL Virology 179:517-563(1990).
 RN [5]
 RP FUNCTION.
 RX MEDLINE-Q2115714; PubMed-1731333;
 RA Isaacs S.N., Kotwal G.J., Moss B.;
 RT "Vaccinia virus complement control protein prevents
 RL antibody-dependent complement-enhanced neutralization of infectivity
 RL and contributes to virulence.";
 RL Proc. Natl. Acad. Sci. U.S.A. 89:628-632(1992).
 RN [6]
 RP STRUCTURE BY NMR OF 146-264.
 RX MEDLINE-Q7446168; PubMed-9299452;
 RA Willes A.P., Shaw G., Bright J., Petrezel A., Campbell I.D.,
 RA Barlow P.N.;
 RT "NMR studies of a viral protein that mimics the regulators of
 RL complement activation.";
 RL J. Mol. Biol. 272:253-265(1997).
 CC 1 FUNCTION: SERVES TO PREVENT THE VIRUS AGAINST COMPLEMENT ATTACK BY
 CC INHIBITING BOTH CLASSICAL AND ALTERNATIVE PATHWAYS OF COMPLEMENT
 CC ACTIVATION. BINDS C3B AND C4B.
 CC 1 SIMILARITY: BELONGS TO THE SUPERFAMILY OF THE REGULATORS OF
 CC COMPLEMENT ACTIVATION (SCCA).
 CC 1 SIMILARITY: CONTAINS 4 SUSHI (SCR) DOMAINS.
 CC
 CC THIS SWISS prot entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/)
 CC or send an email to license@isb-sib.ch).

CC EMBL: X13156; CAA31564.1; -
 DR EMBL: M22812; AAA69605.1; -
 DR EMBL: M35027; AAA47997.1; -
 DE E.C.F.: A31003; WWVZSP.
 DR PDB: 1VVC; 02-DEC-97.
 DR PDB: 1VVD; 02-DEC-97.
 DR PDB: 1VVE; 02-DEC-97.
 DR InterPro: IPR000436; Sushi_SCR_CCP
 DR Pfam: PF00384; sushi; 4.
 DR SMART: SMO10.2; CCP; 4.
 KW Signal; Repeat; Sushi; 3D-structure.
 FT SIGNAL: 1 19
 FT CHAIN: 20 263 COMPLEMENT CONTROL PROTEIN.
 FT DOMAIN: 20 82 SUSHI 1.
 FT DOMAIN: 85 144 SUSHI 2.
 FT DOMAIN: 147 202 SUSHI 3.
 FT DOMAIN: 205 262 SUSHI 4.
 FT DISULFID: 21 70 HY SIMILARITY.
 FT DISULFID: 54 81 HY SIMILARITY.
 FT DISULFID: 86 126 BY SIMILARITY.
 FT DISULFID: 112 143 BY SIMILARITY.
 FT DISULFID: 148 190 BY SIMILARITY.
 FT DISULFID: 176 201 HY SIMILARITY.
 FT DISULFID: 206 248 HY SIMILARITY.
 FT DISULFID: 234 261 HY SIMILARITY.
 SQ SEQUENCE 263 AA; 28629 MW; E4325C9A6EE8997 CRC64;
 Query Match 25.78; Score 19.5; EB 1; Length 263;
 Pct local Similarity 29.18; Pct. NC 2.24 12;
 Matches 37; Conservative 19; Mismatches 60; Indels 11; Gaps 4.
 QY 2 ISCTDPPEVFNAPKPYSLPIVPTVTPYVWCSYPLIRKKAIPQISENVAHATWKAAPP 61
 Db 146 VKQSPFSLNCRKNGSYEDFYDGSVVYTSNGYSLNNGVLSG ---GEWSD-PP 199
 QY 62 ICESYNNKVISCSDDPIVCGPMNKGSKAPF-RHCLSVTFICRANFTMKSKTVWQANPMWG 121
 Db 200 TQQ-----VKPHPTISNGYSLSSGPKRSYSYNNVDFRKYGYKLSGSSSSTSPENTWR 255
 QY 122 PTALPVC 128
 Db 256 P-ELPKC 261
 RESULT 9
 MCP_HUMAN
 ID MCP_HUMAN STANDARD; PRT; 277 AA.
 AC P15529;
 DT 01-APR-1990 (Rel. 14, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Membrane cofactor protein precursor (CD46 antigen) (Tropoelastin
 DE Leucocyte common antigen) (LILX).
 GN MCP.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 1-58.
 RX MEDLINE-B8285080; PubMed-3260937;
 RA Lublin D.P., Liszewski M.K., Post T.W., Arce M.A., Le Beau M.M.,
 RA Reibel M.B., Lemons R.S., Seya T., Atkinson J.P.;
 RT "Molecular cloning and chromosomal localization of human membrane
 RT cofactor protein (MCP). Evidence for inclusion in the multiprotein
 RT family of complement-regulatory proteins.";
 RL J. Exp. Med. 168:181-194(1988).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC TISSUE-Testis;
 RX MEDLINE-Q3114658; PubMed-8418811;
 RA Cervoni F., Benichou P., Akhoundi S., Hsi B.L., Rossi H.;

FT DOMAIN 22 77 SUSHI 1.
 FT DOMAIN 80 135 SUSHI 2.
 FT DOMAIN 138 192 SUSHI 4.
 FT DISULFID 23 63 BY SIMILARITY.
 FT DISULFID 49 76 BY SIMILARITY.
 FT DISULFID 81 121 BY SIMILARITY.
 FT DISULFID 107 134 BY SIMILARITY.
 FT DISULFID 139 179 BY SIMILARITY.
 FT DISULFID 165 191 BY SIMILARITY.
 FT DISULFID 202 202 INTERCHAIN (WITH ALPHA CHAIN) (POTENTIAL).
 FT DISULFID 216 216 INTERCHAIN (WITH ALPHA CHAIN) (POTENTIAL).
 FT CARBOHYD 64 64 N-LINKED (GLCNAC:) (POTENTIAL).
 FT CARBOHYD 71 71 N-LINKED (GLCNAC:) (POTENTIAL).
 FT CARBOHYD 98 98 N-LINKED (GLCNAC:) (POTENTIAL).
 FT CARBOHYD 117 117 N-LINKED (GLCNAC:) (POTENTIAL).
 FT CARBOHYD 154 154 N-LINKED (GLCNAC:) (POTENTIAL).
 FT VARIANT 198 198 P -> S (IN DHSNP:1803226).
 FT /FTID-VAR:012049.
 SQ SEQUENCE 2% AA: 28457 MW: 616664067052E7 CRC64;
 Query Match 20.8%; Score 156.5; DB 1; Length 252;
 Best Local Similarity 28.9%; Pred. No. 11e-08;
 Matches 47; Conservative 19; Mismatches 57; Indels 15; Gaps 6;
 QY 4 CDPPEVKNARKPYSLPVTGL RYTGSPSYRLIGKAIKFCISENQVHATWDKAPPI 62
 DB 23 CPELPVINS---IFVAKEVEQILGTVGCIKGHYLVKKTLFCNASKE---WDNTTTE 75
 QY 63 CYSVKNKTSICSDPIVGGFMNKKAPRHGDSVTFCTKANTKMGSKTVWCQANEMWGP 122
 DB 76 C---RLGHCPOPVLVNGEFS--SSQPVNSDKITFMENHYILKGSNESQCLEHTWAP 129
 QY 123 TALPQVES 130
 DB 130 -PPICRS 136
 RESULT 14
 DAF2_MOUSE STANDARD; PRT; 407 AA.
 AC Q51476;
 DT 01-NOV-1997 (rel. 35, Created)
 DT 01-NOV-1997 (rel. 35, Last sequence update)
 DT 01-NOV-1997 (rel. 35, Last annotation update)
 DE Complement decay-accelerating factor, Transmembrane precursor (DAF-TM).
 GN DAF2.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RP 111
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=93404982; PubMed=745711;
 RA Spicer A.P., Seldin M.F., Gendler S.J.;
 RT *Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes, duplicated genes encode glycosylphosphatidylinositol anchored and transmembrane forms.*;
 RL J. Immunol. 155: 3079-3091 (1995).
 CC FUNCTION: PROTECTION OF CELLS FROM COMPLEMENT-MEDIATED DAMAGE (BY SIMILARITY)
 CC SUBCELLULAR LOCATION Type I membrane protein (Potential).
 CC TISSUE SPECIFICITY TESTES, SPLEEN AND LYMPH NODE.
 CC DOMAIN: THE FIRST SUSHI DOMAIN (SCR1) IS NOT NECESSARY FOR FUNCTION. SCR2 AND SCR4 PROVIDE THE PROPER CONFORMATION FOR THE ACTIVE SITE ON SCR4 (BY SIMILARITY).
 CC SIMILARITY: CONTAINS 4 SUSHI (SCR) DOMAINS.
 CC SIMILARITY: BELONGS TO THE RECEPTORS OF COMPLEMENT ACTIVATION (RCA) FAMILY.
 CC

CC This SWISS-PROT entry is copyright, it is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation at the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed, usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/academic/> or send an email to license@isb-sib.ch).
 CC
 DR EMBL: L41365; AB00092.1; -
 DR ISSP: P08603; IHCC.
 DR MGD: MGI:104849; Dnf2.
 DR In-Pro: IPR000436; Sushi_SCR_Ccp.
 DR Pfam: PF00084; sushi; 4.
 DR SMART: SM00332; CCP; 4.
 KW Complement pathway; Glycoprotein; Repeat; Signal; Sushi;
 KW Transmembrane
 FT SIGNAL 1 39 POTENTIAL.
 FT CHAIN 40 407 COMPLEMENT DECA-ACCELERATING FACTOR, TRANSMEMBRANE, EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 40 368 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 369 389 POTENTIAL.
 FT DOMAIN 407 407 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 40 100 SUSHI 1.
 FT DOMAIN 102 164 SUSHI 2.
 FT DOMAIN 167 226 SUSHI 3.
 FT DOMAIN 229 290 SUSHI 4.
 FT DOMAIN 291 363 SER/THR RICH (BY SIMILARITY).
 FT DISULFID 70 99 BY SIMILARITY.
 FT DISULFID 133 150 BY SIMILARITY.
 FT DISULFID 134 163 BY SIMILARITY.
 FT DISULFID 158 209 BY SIMILARITY.
 FT DISULFID 145 225 BY SIMILARITY.
 FT DISULFID 230 272 BY SIMILARITY.
 FT DISULFID 258 289 BY SIMILARITY.
 FT CARBOHYD 132 192 N-LINKED GLCNAC: (POTENTIAL).
 FT CARBOHYD 267 267 N-LINKED GLCNAC: (POTENTIAL).
 SQ SEQUENCE 407 AA: 44469 MW: 608824372C6A40 CRC64;
 Query Match 20.4%; Score 153.5; DB 1; Length 407;
 Best Local Similarity 27.5%; Pred. No. 3.7e-08;
 Matches 39; Conservative 31; Mismatches 53; Indels 19; Gaps 8;
 QY 3 CDPPEVKNARKPYSLP--IVPCTVIRYFGSYRLIGKAIKFCISENQVHATWDK 59
 DB 157 SCNPKNKDLNG---HINPTGLGFGSEINSONGYRLGHTSILCTITGNV--LWIDE 221
 QY 50 PPICESVKNKTSICSDPIVGGFMNKKAPRHGDSVTFCTKANTKMGSKTVWCQANE 118
 DB 222 FVCTHP-----FCDPPKINDGIMRGSISYK--QGVITSCDKGFIIFGNSIIVCSKS 277
 QY 119 ---MWKPTALPVC--ESDFPLE 135
 DB 278 DVGQW3-SPPQCIEESKVPK 298
 RESULT 14
 CFAE_HUMAN STANDARD; PRT; 764 AA
 ID CTAB_HUMAN
 AC P00751; O130(6); Q29944; Q9BTF5; Q9EX92;
 DT 2-JUL-1985 (rel. 01, Created)
 DT 0-OCT-1994 (rel. 30, Last sequence update)
 DT 16-OCT-2001 (rel. 40, Last annotation update)
 DE Complement factor B precursor (EC 3.4.21.47) (C3/C5 convertase) (properdin factor B) (glycine-rich beta glycoprotein) (G3G) (FBF2).
 GN BF.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 NCBI_TaxID=9606;
 RN 111
 RP S-SEQUENCE FROM N.A. (ALLELES S; FA AND FB).
 RX MEDLINE=91365702; PubMed=2249879;
 RA Davrinche C., Abbal M., Clere A.;

- Proc. Natl. Acad. Sci. U.S.A. 79:661-665(1982).
- [12]
- SEQUENCE OF 16-259 FROM N.A.
MEDLINE=84158924; PubMed=6424161;
Morley R.J.; Campbell R.D.;
*Internal homologues of the Bb fragment from human complement
Component Factor B, a class III MHC antigen.;
EMBL J. 3:153-157(1984).
[13]
SEQUENCE OF 1-99 FROM N.A.
TISSUE=Blood;
MEDLINE=87102880; PubMed=4644061;
Wu L.C.; Morley R.J.; Campbell R.D.;
*Cell-specific expression of the human complement protein factor B
gene: evidence for the role of two distinct 5' flanking elements.;
Cell 48:331-342(1987).
[14]
GLYCATION IN POSITION 291.
RX MEDLINE=91174758; PubMed=20069411;
Niemann M.A.; Brown A.S.; Muller E.J.;
*The principal site of glycation of human complement factor B.;
Biochem. J. 274:473-480(1991).
CC -1- FUNCTION: FACTOR B WHICH IS PART OF THE ALTERNATE PATHWAY OF THE
COMPLEMENT SYSTEM IS CLEAVED BY FACTOR D INTO 2 FRAGMENTS: BA AND
BB. BB, A SERINE PROTEASE, THEN COMBINES WITH COMPLEMENT FACTOR D
TO GENERATE THE C3 OR C5 CONVERTASE. IT HAS ALSO BEEN IMPLICATED
IN PROLIFERATION AND DIFFERENTIATION OF PREACTIVATED B
LYMPHOCYTES, RAPID SPREADING OF PERIPHERAL BLOOD MONOCYTES,
STIMULATION OF LYMPHOCYTE RECEPTORS AND LYSIS OF ERYTHROCYTES.
BA INHIBITS THE PROLIFERATION OF PREACTIVATED B LYMPHOCYTES.
-1- CATALYTIC ACTIVITY: cleaves C3 in the alpha chain to yield C3a and
C3b. Cleaves C5 in the alpha chain to yield C5a and C5b. Both
cleavages take place at the C-terminal of an arginine residue.
-1- SUBUNIT: MONOMER.
-1- ALTERNATIVE PRODUCTS: 2 isoforms: 1 (shown here) and 2; are
produced by alternative splicing.
-1- POLYPEPTIDISM: TWO MAJOR VARIANTS, 1 AND 2, AND 2 MINOR VARIANTS.
AS WELL AS AT LEAST 14 VERY RARE VARIANTS, HAVE BEEN IDENTIFIED.
-1- MISCELLANEOUS: FACTOR B IS A MAJOR HISTOCOMPATIBILITY COMPLEX
CLASS-III PROTEIN.
-1- SIMILARITY: WITH COMPLEMENT C2.
-1- SIMILARITY: CONTAINS 4 SUBIT (SIB) REMAINS.
-1- SIMILARITY: CONTAINS 1 WFA DOMAIN.
-1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
TRYPSIN FAMILY.
This SWISS-Prot entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation
at the European Bioinformatics Institute. There are no restrictions on the
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed, usage by and for commercial
entities requires a license agreement (see <http://www.ssi.unizh.ch/seq/>)
or send an email to license@sib-switzerland.ch.
- EMBL: X72875; CAA51489.1;
EMBL: S67410; AAD13489.1;
EMBL: U15702; AAA16620.1;
EMBL: X00284; CAA25077.1;
EMBL: AF019414; AAB67977.1;
EMBL: BC004144; AAB04144.1;
EMBL: AF349679; AAK40167.1;
EMBL: K01566; AAA36225.2;
EMBL: J00125; NOT_ANNOTATED; CUR.
EMBL: J00126; AAA36226.1;
EMBL: J00185; AAA36219.1; ALT_SEQ.
EMBL: J00186; AAA36220.1;
EMBL: M15082; AAA59625.1;
PIR: A00948; BBHD.
PIR: S14339; S14339.
PIR: S34075; S34075.
HSSP: P30744; 2HNT.
SWISS-2DPA3E; P00751; HUMAN.

- 51 "Molecular characterization of human complement factor B subtypes.^{1,2}
 52 Immunogenetics 32:309-312(1990).
 53 121
 54
 55 SEQUENCE FROM N.A. (ALLELE S).
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561


```

DR      Siera 2DPAGE: P00751;
DR      MW: 148470;
DR      InterPro: IPR001314; Chymotrypsin.
DR      InterPro: IPR000446; Sushi_SCR_CSP.
DR      InterPro: IPR001254; Trypsin.
DR      InterPro: IPR002035; VWFA.
DR      Pfam: PF00084; sushi1_1.
DR      Pfam: PF00089; trypsin1_1.
DR      Pfam: PF00094; vwa1_1.
DR      PRINTS: PR00722; CHYMOTRYPSIN.
DR      PRINTS: PR00453; VWFADOMAIN.
DR      SMART: SM00012; CCP_3.
DR      SMART: SM00020; TRYPSIN_1.
DR      SMART: SM00427; VWA_1.
DR      PROSITE: PS0240; TRYPSIN_DOM_1.
DR      PROSITE: PS00144; TRYPSIN_HIS_1.
DR      PROSITE: PS00145; TRYPSIN_SER_1.
DR      PROSITE: PS0234; VWFA_1.
DR      Complement alternate pathway: Plasma: Serine protease;
KW      glycoprotein; Repeat; Sushi; Signal; Polymorphism; Zymogen;
KW      Alternative splicing.
FT      SIGNAL      1 25
FT      CHAIN       26 764
FT      CHAIN       26 259
FT      CHAIN       260 764
FT      DOMAIN      36 99
FT      DOMAIN      102 159
FT      DOMAIN      164 219
FT      DOMAIN      270 469
FT      DOMAIN      482 764
FT      ACT_SITE    526 526
FT      ACT_SITE    576 576
FT      ACT_SITE    699 699
FT      DISULFID     37 76
FT      DISULFID     62 98
FT      DISULFID     104 145
FT      DISULFID     181 158
FT      DISULFID     165 205

Query Match      20.4%; Score 153.5; DB 1; Length 764;
Best local Similarity 41.1%; Ident. No. 7.4e-08;
Matches 42; Conservative 17; Mismatches 59; Indels 17; Gaps 6;

QY      2 ISCTPPPEVKNA---RKPPYSLIPVPTVLRYTCSPSYRLIGEKALFCSNQVIATWD 57
DQ      1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
DQ      101 TPTPTPTDFEFCFVWPSPPYV ---SDLSFHCYDGYTLRGSAKTC---QVNGRWS 152
QY      58 KAPPICESVNTISCSPIVIGFPMKSGKAPPHGDSVFTCKANFTMKGSKTVVWQAN 117
DQ      1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
DQ      153 QGTALCD---NAGCSNNGIFIGTKKVSQ -YRLDSVYHCISRGTLRGSSRRTCQEG 208
QY      118 PMWGPTALPVCSDF 142
DQ      1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
DQ      209 GSWSCTE-PSGQDSF 272

RESULT 15
CPAH_HUMAN STANDARD; PRI: 1241 AA.
AC P08603; Q14570; P78435; Q0N086;
DT 01 AUG 1988 (Ref. 10). Created.
DT 01 JAN 1990 (Ref. 13, Last sequence update)
DI 16-OCT-2001 (Ref. 40, Last annotation update)
DE Complement factor H precursor (H factor 1).
GN HFI OR HF OR CFH.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN 11
RS SEQUENCE FROM N.A. (ISOFORMS 1 AND 2), AND VARIANT Y-402.
RC TISSUE=Liver.
CC MEDLINE=88134059; PubMed=2964625;

```

```

RA Ripoche J., Day A.J., Harris T.J.R., Sim R.B.;
RT "The complete amino acid sequence of human complement factor H.";
RL Biochem. J. 249:593-602(1988).
RN 12
RX SEQUENCE OF 53-445 FROM N.A.
RX MEDLINE=87(54207; PubMed=2946589;
RA Schulz T.F., Schwaebler W., Stanley K.F., Weiss E., Dierich M.P.;
RT "Human complement factor H: isolation of cDNA clones and partial cDNA
sequence of the 38-kDa tryptic fragment containing the binding site
for C3b.";
RL Eur. J. Immunol. 16:1351-1355(1986).
RN 13
RX SEQUENCE OF 226-449 FROM N.A.; AND PARTIAL SEQUENCE.
RX MEDLINE=8616701; PubMed=2937845;
RA Kristensen E., Wetzel R.A., Tack B.F.;
RT "Structural analysis of human complement protein H: homology with C3b
binding protein, beta 2-glycoprotein 1 and the Ha fragment of H2.";
RL J. Immunol. 136:3407-3411(1986).
RN 14
RX SEQUENCE FROM N.A. (ISOFORM 2).
RA Hird C.;
RL Submitted (JAN-2000) to the EMBL/GenBank/TrEMBL databases.
RN 15
RX SEQUENCE OF 1047-1231 FROM N.A.
RX MEDLINE=91201892; PubMed=1826708;
RA Esteller C., Kojonen V., Schwaebler W., Dierich M.P., Weiss E.H.;
RT "Cloning of the 1.4-kb mRNA species of human complement factor H
reveals a novel member of the short consensus repeat family related
to the carboxy terminal of the classical 150 kDa molecule.";
RL J. Immunol. 146:3190-3196(1991).
RN 16
RX SEQUENCE OF 19-35.
RX MEDLINE=83048213; PubMed=6215918;
RA Sim R.H., Discipio R.G.;
RT "Purification and structural studies of the complement system control
protein beta 2H (Factor H)";
RL Biochem. J. 205:285-293(1982).
RN 17
RX SEQUENCE OF 1-19 FROM N.A.
RA Vik D.P., Williams S.A.;
RL Submitted (APR-1996) to the EMBL/GenBank/TrEMBL databases.
RN 18
RX SEQUENCE OF 1-9 FROM N.A.
RA Dominguez O.;
RL thesis (1993), Hospital Trias i Pujol, Spain.
RN 19
RX STRUCTURE BY NMR OF 927-985 (SUSHI 16).
RX MEDLINE=91278097; PubMed=1826116;
RA Norman D.G., Barlow P.N., Baron M., Day A.T., Sim R., Campbell I.D.;
RT "Three-dimensional structure of a complement control protein module
in solution";
RL J. Mol. Biol. 219:717-725(1991).
RN 110
RX STRUCTURE BY NMR OF 264-322 (SUSHI 5).
RX MEDLINE=92232649; PubMed=1533152;
RA Barlow P.N., Norman D.G., Steinkasserer A., Jarne T.J., Pearce J.;
RT "Solution structure of the fifth repeat of factor H: a second example
of the complement control protein module";
RL Biochemistry 31:3626-3634(1992).
RN 111
RX STRUCTURE BY NMR OF 866-985 (SUSHI 15 AND 16).
RX MEDLINE=94333119; PubMed=8331663;
RA Barlow P.N., Steinkasserer A., Norman D.G., Kieffer R., Wiles A.P.;
RT "Solution structure of a pair of complement modules by nuclear
magnetic resonance";
RL J. Mol. Biol. 242:268-284(1993).
CC 1- FUNCTION: FACTOR H FUNCTIONS AS A COFACTOR IN THE INACTIVATION OF THE
C3b BY FACTOR I AND ALSO INCREASES THE RATE OF DISSOCIATION OF THE
C3HbB COMPLEX (C3 CONVERTASE) AND OF THE (C3b)HbB COMPLEX (C5
CONVERTASE) IN THE ALTERNATIVE COMPLEMENT PATHWAY.
CC 1- ALTERNATIVE PRODUCTS: 2 ISOFORMS; (SHOWN HERE) AND 2; ARE

```


SEQUENCE FROM N.A.
 TISSUE=Heart;
 MEDLINE=92189729; PubMed=1472169;
 RA Lariqun J.D., Tsang T.C., Rumberger J.M., Burns D.K.;
 RT "Characterization of cDNA and genomic sequences encoding rabbit
 ELAM 1: conservation of structure and functional interactions with
 leukocytes.";
 RL DNA Cell Biol. 11:149-162(1992).
 CC -1 FUNCTION: EXPRESSED ON CYTOKINE INDUCED ENDOTHELIAL CELLS AND
 MEDIATES THEIR BINDING TO LEUKOCYTES. THE LIGAND RECOGNIZED BY
 ELAM 1 IS STALKY LEWIS X (ALPHA(1-3)FUCOSYLATED DERIVATIVES OF
 POLYLACTOSAMINE THAT ARE FOUND AT THE NONREDUCING TERMINI OF
 GLYCOSLIPIDS)
 CC -1 SUBCELLULAR LOCATION: Type 1 membrane protein.
 CC -1 INDUCTION: BY CYTOKINES.
 CC -1 SIMILARITY: TO OTHER SELECTINS/LECAMS
 CC -1 SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
 CC -1 SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN
 CC -1 SIMILARITY: CONTAINS 5 SUSHI (SCR) DOMAINS.
 CC
 CC This SWISS PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation
 the European Bioinformatics Institute. There are no restrictions on its
 use by non profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 or send an email to license@sib.sib.ch).
 CC
 EMBL: M91004; AAA1243.1;
 DR EMBL: M91005; AAA1244.1;
 DR BSSP: P16581; IKA7.
 DR InterPro: IPR000561; EGF-like.
 DR InterPro: IPR002396; Selectin.
 DR InterPro: IPR000436; Sushi_SCR_NCP.
 DR InterPro: IPR001404; Lectin_C.
 DR Pfam: PF00008; EGF_1.
 DR Pfam: PF00059; Lectin_C_1.
 DR Pfam: PF00084; Sushi_5.
 DR PRINTS: PR00343; SELECTIN.
 DR SMART: SM00042; CYP_5.
 DR SMART: SM00044; CLECT_1.
 DR SMART: SM00181; EGF_1.
 DR PROSITE: PS00022; EGF_1; 1.
 DR PROSITE: PS01186; EGF_2; 1.
 DR PROSITE: PS00615; C-TYPE_LECTIN_1; 1.
 DR PROSITE: PS50047; C-TYPE_LECTIN_2; 1.
 KW Cell adhesion; Transmembrane; Glycoprotein; EGF-like domain; Lectin;
 FT SIGNAL 1 24
 FT CHAIN 24 551 E-SELECTIN.
 FT DOMAIN 24 495 EXTRACELLULAR (POTENTIAL).
 FT TRANSMEM 496 517 POTENTIAL.
 FT DOMAIN 518 551 CYTOPLASMIC (POTENTIAL).
 FT DOMAIN 40 140 C-TYPE LECTIN (SHORT FORM).
 FT DOMAIN 141 177 EGF-LIKE.
 FT DOMAIN 181 240 SUSHI_1.
 FT DOMAIN 243 302 SUSHI_2.
 FT DOMAIN 305 365 SUSHI_3.
 FT DOMAIN 368 428 SUSHI_4.
 FT DOMAIN 431 487 SUSHI_5.
 FT DISULFID 42 140 HY SIMILARITY.
 FT DISULFID 114 132 HY SIMILARITY.
 FT DISULFID 145 156 HY SIMILARITY.
 FT DISULFID 150 165 HY SIMILARITY.
 FT DISULFID 167 176 HY SIMILARITY.
 FT DISULFID 182 229 HY SIMILARITY.
 FT DISULFID 212 239 HY SIMILARITY.
 FT DISULFID 244 288 HY SIMILARITY.
 FT DISULFID 274 301 HY SIMILARITY.
 FT DISULFID 306 351 HY SIMILARITY.
 FT DISULFID 337 364 HY SIMILARITY.
 FT DISULFID 369 414 HY SIMILARITY.
 FT DISULFID 400 427 HY SIMILARITY.

FT DISULFID 432 473 BY SIMILARITY.
 FT DISULFID 459 486 BY SIMILARITY.
 FT CARBOHYD 32 32 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 45 45 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 162 162 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 194 194 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 201 201 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 205 205 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 267 267 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 314 314 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 321 321 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 334 334 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 442 442 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 466 466 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CONFLICT 308 308 T > A (IN REF. 1; AAA1244).
 FT CONFLICT 328 328 T > A (IN REF. 1; AAA1244).
 FT CONFLICT 491 491 A > V (IN REF. 1; AAA1244).
 SQ SEQUENCE 551 AA; 60346 MW; 23B78A33B24240E GR064;
 Query Match 19.7%; Score 143.5; DB 1; Length 551;
 Best Local Similarity 25.9%; Pred. No. 1.66-17;
 Matches 36, Conservative 20, Mismatches 48, Indels 35, Gaps 6;
 QY 1 ETSQDPEVKNRKPYSLPVPGTVLRYTSPSYELIGKEAIPGISENQVHATWKAQ 40
 DB 254 DVKCS-----SGSSAPW-----NTCTDCEEGFTLLAKSLQTS-----GSMENEK 298
 QY 61 PICES-----NKTISQSDPIVPGCFMKNKSKAHPHGHGVSVPCKANFTMKSK 111
 DB 259 FTCKAVSLTIHMPONGSVSGSN-----SSGKTFPRSSCNFTCEENLLRGAQ 448
 QY 112 VMCQANEMWGTALPVCE 130
 DB 349 VECTAGLWFOQA-PVCHA 366
 RESULT 17
 DAPL_MOUSE
 ID DAPL_MOUSE STANDARD; PRP; 390 AA.
 AC Q61475, Q61357, P97732.
 DT 01-NOV-1997 (Ref. 35, Created)
 DT 01-NOV-1997 (Ref. 35, Last sequence update)
 DT 15-JUL-1994 (Ref. 38, Last annotation update)
 DE Complement decay-accelerating factor, 391 anchored precursor
 DE (DAF-GPI).
 GN DAP1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Scleroqithi; Muridae; Murinae; Mus.
 OC NCBI_TaxID=1:690;
 RN 111
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Testis;
 RX MEDLINE=95104982; PubMed=7545711;
 RA Spicer A.P., Seldin M.F., Gendler S.J.;
 RT "Molecular cloning and chromosomal localization of the mouse decay
 accelerating factor genes. duplicated genes encode
 glycosylphosphatidylinositol-anchored and transmembrane forms.";
 RT J. Immunol. 155:3079-3091(1995).
 RL J. Immunol. 155:3079-3091(1995).
 RN 121
 RP SEQUENCE OF 7-390 FROM N.A.
 RC STRAIN=BALB/c; TISSUE=Spleen;
 RX MEDLINE=96162213; PubMed=8671624;
 RA Fukuda Y., Yasui A., Okada H.;
 RT "Molecular cloning of murine decay accelerating factor by
 immunoscreening.";
 RL Int. Immunol. 8:379-385(1996).
 CC -1 FUNCTION: PROTECTION OF CELLS FROM COMPLEMENT-MEDIATED DAMAGE (BY
 SIMILARITY).
 CC -1 SUBCELLULAR LOCATION: Attached to the membrane by a GPI-anchor.
 CC -1 TISSUE SPECIFICITY: BRAIN, SPLEEN, EPITHELIA, SKELETAL MUSCLE,
 CC LIVER, TESTES, THYMUS, SPLEEN AND LYMPH NODE.
 CC -1 DOMAIN: THE FIRST SUSHI DOMAIN (S381) IS NOT NECESSARY FOR

FUNCTION, SCR2 AND SCR4 PROVIDE THE PROPER CONFORMATION FOR THE
ACTIVE SITE ON SCR1 (BY SIMILARITY).
SIMILARITY: CONTAINS 4 SUSHI (SCR) DOMAINS
SIMILARITY: BELONGS TO THE RECEPTORS OF COMPLEMENT ACTIVATION
(CR) FAMILY.

THIS SWISS-PROT ENTRY IS COPYRIGHTED. IT IS PRODUCED THROUGH A COLLABORATION
BETWEEN THE SWISS INSTITUTE OF BIOINFORMATICS AND THE EMBL OUTSTATION
AT DESK. BIOINFORMATICS INSTITUTE. THERE ARE NO RESTRICTIONS ON ITS
USE BY NON-PROFIT INSTITUTIONS AS LONG AS ITS CONTENT IS IN NO WAY
MODIFIED AND THIS STATEMENT IS NOT REMOVED. USARE BY AND FOR COMMERCIAL
ENTITIES REQUIRES A LICENSE AGREEMENT (SEE <http://www.isb.ch/submit.htm>)
OR SEND AN EMAIL TO LICENSE@ISB.SIB.CH.

EMBL: L41666; AAC00094.1;
EMBL: U66670; BAA09840.1;
EMBL: P06003; A000;
MOL: M0104860; D011;
InterPro: IPR000436; Sushi_SCR_CCP;
SMART: SM00042; sush1; 4;
KW Complement pathway; glycoprotein; Membrane; Repeat; GPI anchor;
KW Signal; Sushi;
FT SIGNAL 1 34 POTENTIAL
FT MAIN 45 601 COMPLEMENT DEACT ACTIVATING FACTOR,
GPI ANCHORED,
REMOVED IN MATURE FORM (BY SIMILARITY).
FT TR-REP 662 900
FT DOMAIN 95 96 SUSHI 1;
FT DOMAIN 97 150 SUSHI 2;
FT DOMAIN 162 224 SUSHI 3;
FT DOMAIN 224 285 SUSHI 4;
FT DOMAIN 288 661 SCR/SCR REPTL
FT DISULFID 65 94 BY SIMILARITY
FT DISULFID 98 145 BY SIMILARITY
FT DISULFID 129 158 BY SIMILARITY
FT DISULFID 163 204 BY SIMILARITY
FT DISULFID 190 220 BY SIMILARITY
FT DISULFID 225 267 BY SIMILARITY
FT DISULFID 254 294 BY SIMILARITY
FT CARBOHYD 187 187 N LINKED (GLNAC...) (POTENTIAL);
FT DISULFID 262 262 N LINKED (GLNAC...) (POTENTIAL);
FT DISULFID 361 361 GPI ANCHOR (BY SIMILARITY).
FT CONFLICT 7 7 P - A (1N REF, 2);
FT CONFLICT 9 9 E - G (1N REF, 2);
FT CONFLICT 84 84 E - G (1N REF, 2);
FT CONFLICT 91 91 E - G (1N REF, 2);
FT CONFLICT 135 145 E - K (1N REF, 2);
FT CONFLICT 174 174 H - L (1N REF, 2);
FT CONFLICT 180 180 L - I (1N REF, 2);
SQ SEQUENCE 490 AA; 42618 MW; 44187210FF47FEE7 CRC64;

Query Match 19.2%; Score 148; DB 1; Length 600;
Best local similarity 25.2%; Pred. No. 1; 6-07;
Matches 40 Conservative 42 Mismatches 45 Indels 12 Gaps 5;

QY CSDHDFVKKARAYVSEIP LVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
DB 16 SCFNPMLNNG RLVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
QY CSDHDFVKKARAYVSEIP LVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
DB 16 SCFNPMLNNG RLVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59

QY CSDHDFVKKARAYVSEIP LVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
DB 16 SCFNPMLNNG RLVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
QY CSDHDFVKKARAYVSEIP LVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59
DB 16 SCFNPMLNNG RLVNIVLVKPTSPSVRLGKAKPTSPENAVHATWKA 59

GN Sus serofa (Pig).
OS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus
OX NCBI_TaxID=9823;
RN 111
RP MEDLINE 91472856; PubMed 1680099;
PA Poolman T J, van de Weth A P, Coppioeters W P, van Zeeven A J,
Bouquet Y H;
RT Cloning and sequencing of the porcine complement factor B.
RL Immunobiology 34:332-35(1991).
CC 1- FUNCTION: FACTOR B WHICH IS PART OF THE ALTERNATIVE PATHWAY OF THE
COMPLEMENT SYSTEM IS CLEAVED BY FACTOR D INTO 2 FRAGMENTS: BA AND
BB. RB, A SERINE PROTEASE, THEN COMBINES WITH COMPLEMENT FACTOR D
TO GENERATE THE C3 OR C5 CONVERTASE.
CC 1- CATALYTIC ACTIVITY: cleaves C3 in the alpha chain to yield eta and
C4b, cleaves C5 in the alpha chain to yield eta and C5b. Both
cleavages take place at the C-terminal of an arginine residue.
CC 1- SUBUNIT: MONOMER.
CC 1- MISCELLANEOUS: FACTOR B IS A MAJOR HISTOCOMPLEMENT COMPLEX
CLASS-III PROTEIN.
CC 1- SIMILARITY: WITH COMPLEMENT C2.
CC 1- SIMILARITY: CONTAINS 3 SUSHI (SCR) DOMAINS (BY SIMILARITY).
CC 1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1. AS KNOWN AS THE
TRYPSIN FAMILY.

THIS SWISS-PROT ENTRY IS COPYRIGHTED. IT IS PRODUCED THROUGH A COLLABORATION
BETWEEN THE SWISS INSTITUTE OF BIOINFORMATICS AND THE EMBL OUTSTATION
AT DESK. BIOINFORMATICS INSTITUTE. THERE ARE NO RESTRICTIONS ON ITS
USE BY NON-PROFIT INSTITUTIONS AS LONG AS ITS CONTENT IS IN NO WAY
MODIFIED AND THIS STATEMENT IS NOT REMOVED. USARE BY AND FOR COMMERCIAL
ENTITIES REQUIRES A LICENSE AGREEMENT (SEE <http://www.isb.ch/submit.htm>)
OR SEND AN EMAIL TO LICENSE@ISB.SIB.CH.

EMBL: M59240; AAA11021.1;
EMBL: P02749; LOUH;
InterPro: IPR000436; Sushi_SCR_CCP;
InterPro: IPR001254; Trypsin;
DR PLAM: PF00084; sush1; 2;
DR SMART: SM00042; CCP; 2;
DR PROSITE: PS00240; TRYPSIN_DOM; PARTIAL;
DR PROSITE: PS00134; TRYPSIN_HIS; PARTIAL;
DR PROSITE: PS00145; TRYPSIN_SER; PARTIAL;
KW Complement alternative pathway; Plasma; Hydrolase; Serine protease;
KW Glycoprotein; Repeat; Sushi;
FT DOMAIN 1 1 NON_TER
FT DOMAIN 1 58 SUSHI 2;
FT DOMAIN 63 118 SUSHI 3;
FT DISULFID 4 46 BY SIMILARITY;
FT DISULFID 42 59 BY SIMILARITY;
FT DISULFID 66 106 BY SIMILARITY;
FT DISULFID 92 119 BY SIMILARITY;
FT CARBOHYD 24 24 N LINKED (GLNAC...) (POTENTIAL);
FT CARBOHYD 44 44 N LINKED (GLNAC...) (POTENTIAL);
FT NON_TER 151 151
SQ SEQUENCE 151 AA; 16765 MW; BE247E7947E517F CRC64;

Query Match 19.2%; Score 144; DB 1; Length 151;
Best local similarity 30.4%; Pred. No. 1; 07;
Matches 41 Conservative 17 Mismatches 60 Indels 17 Gaps 6;

QY 2 ISVWQPEVKNA---KPIYSLPIVPGVLPVLTSPSVRLGKAKPTSPENAVHATW 57
DB 2 IRLRGRHDFENGEYWRAPVYND---SDEISLPDGLTLEGSANGK QALRWD 59
QY 5P KAPDPTESVVKNTTSTSPVIVPQPMNKSKAPPRHDSVPTKANTMKGSKTVWQANE 117
DB 54 GQTALCD--DGAGYCNPGPIPTGRKVGQTQ YRLDSVTVYVCTRGTLRSGQPTQEG 109
QY 118 EMMQPTALVPCSDP 142
DB 110 GSWSTHEFSCQDSF 124

```

RESULT 19
LEM3 MOUSE
ID LEM3_MOUSE STANDARD: PRT: 768 AA.
AC G01102:
DT 01 APR 1993 (Rel. 25, Created)
DT 01 APR 1994 (Rel. 25, Last sequence update)
DT 16 OCT 2001 (Rel. 40, Last annotation update)
DE P-selectin precursor (Granule membrane protein 140) (GMP-140) (PADGEM)
DE (CD62P) (Leukocyte-endothelial cell adhesion molecule 5) (LECAM3).
OS Selp or GMP.
OS Mus musculus (Mouse)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
OX NCBI TaxID=10090.
RN [1]
RN SEQUENCE FROM N.A.
RA MEDLINE=92340571; PubMed=1478846;
RA Weller A., Isenmann S., Vestweber D.;
RT "Cloning of the mouse endothelial selectins. Expression of both E-
RT and P-selectin is inducible by tumor necrosis factor alpha.";
RL J. Biol. Chem. 267:15176-15183(1992).
RN [2]
RN SEQUENCE FROM N.A.
RA MEDLINE=92345617; PubMed=1479089;
RA Sanders W.F. Jr.; Wilson P.W.; Ballantyne C.M.; Beaudet A.L.;
RT "Molecular cloning and analysis of in vivo expression of murine P-
RT selectin.";
RL Blood 80:795-800(1992).
CC 1. FUNCTION: CA(2+)-DEPENDENT RECEPTOR FOR MYELOID CELLS THAT BINDS
CC 2. TO CARBOHYDRATES ON NEUTROPHILS AND MONOCYTES. MEDIATES THE
CC 3. INTERACTION OF ACTIVATED ENDOTHELIAL CELLS OR PLATELETS WITH
CC 4. LEUKOCYTES. THE LIGAND RECOGNIZED IS SIALLYL-LEWIS X.
CC 5. 1 SUBCELLULAR LOCATION: TYPE I membrane protein.
CC 6. 1 TISSUE SPECIFICITY: STORED IN THE ALPHA-GRANULES OF PLATELETS
CC 7. AND WEIBEL PALADE BODIES OF ENDOTHELIAL CELLS. UPON CELL
CC 8. ACTIVATION BY AGONISTS, P-SELECTIN IS TRANSPORTED RAPIDLY TO
CC 9. THE CELL SURFACE.
CC 10. INDUCTION: BY TNF-ALPHA.
CC 11. SIMILARITY: TO OTHER SELECTINS/LECAMS.
CC 12. SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
CC 13. SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
CC 14. SIMILARITY: CONTAINS 8 SUSHI (SCR) DOMAINS; MOUSE P-LECTIN LACKS
CC 15. THE HUMAN SUSHI-2 EQUIVALENT.
CC
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announcement/
CC or send an email to license@isb.sib.ch).
CC
DR DR PROSITE; PS00615; C-TYPE LECTIN.1; 1.
DR DR PROSITE; PS00641; C-TYPE LECTIN.2; 1.
KW Cell adhesion; Transmembrane; Glycoprotein; EGF-like domain; Lectin;
KW Selectin; Signal; Sushi; Repeat; Lipoprotein; Palmitate.
FT SIGNAL 1 41 POTENTIAL.
FT CHAIN 42 768 P-SLECTIN.
FT D-MAIN 42 709 EXTRACELLULAR (POTENTIAL).
FT T-ANSMEM 710 733 POTENTIAL.
FT D-MAIN 734 768 CYTOPLASMIC (POTENTIAL).
FT D-MAIN 58 158 C-TYPE LECTIN (SHORT FORM).
FT D-MAIN 59 195 EGF-LIKE.
FT D-MAIN 199 258 SUSHI 1.
FT D-MAIN 261 320 SUSHI 2.
FT D-MAIN 323 382 SUSHI 3.
FT D-MAIN 385 444 SUSHI 4.
FT D-MAIN 447 506 SUSHI 5.
FT D-MAIN 509 568 SUSHI 6.
FT D-MAIN 579 638 SUSHI 7.
FT D-MAIN 641 700 SUSHI 8.
FT D-SULFID 60 158 HY SIMILARITY.
FT D-SULFID 131 150 BY SIMILARITY.
FT D-SULFID 163 174 BY SIMILARITY.
FT D-SULFID 168 183 BY SIMILARITY.
FT D-SULFID 185 194 BY SIMILARITY.
FT D-SULFID 200 244 BY SIMILARITY.
FT D-SULFID 230 257 BY SIMILARITY.
FT D-SULFID 262 306 BY SIMILARITY.
FT D-SULFID 292 319 BY SIMILARITY.
FT D-SULFID 324 368 BY SIMILARITY.
FT D-SULFID 354 381 BY SIMILARITY.
FT D-SULFID 386 430 BY SIMILARITY.
FT D-SULFID 416 443 BY SIMILARITY.
FT D-SULFID 448 492 BY SIMILARITY.
FT D-SULFID 478 505 BY SIMILARITY.
FT D-SULFID 510 554 BY SIMILARITY.
FT D-SULFID 540 567 BY SIMILARITY.
FT D-SULFID 580 624 BY SIMILARITY.
FT D-SULFID 510 637 BY SIMILARITY.
FT D-SULFID 542 686 BY SIMILARITY.
FT D-SULFID 572 699 BY SIMILARITY.
FT CARBOHYD 398 398 N-LINKED (GLCNAc...) (POTENTIAL).
FT CARBOHYD 503 603 N-LINKED (GLCNAc...) (POTENTIAL).
FT CARBOHYD 554 654 N-LINKED (GLCNAc...) (POTENTIAL).
FT CARBOHYD 561 661 N-LINKED (GLCNAc...) (POTENTIAL).
FT CARBOHYD 579 679 N-LINKED (GLCNAc...) (POTENTIAL).
FT LIPID 745 745 PALMITATE (BY SIMILARITY).
FT SITE 756 759 FNDCYTGQIS SIGNAL (PROBABLE).
FT CONFLICT 724 724 A > E; N REF. 2).
SQ SEQUENCE 758 AA; 83098 MW; 45740402P6658 CROM44;
Query Match 19.1%; Score 143.5; ID 1; Length 768;
Best Local Similarity 29.5%; Pred. No. 7.5e 07;
Matches 33; Conservative 15; Mismatches 49; Indels 15; Gaps 5;
OY 29 RYTCSPSYRGLGKKAIFCISENVHATWIKAFVLCISVKNLISCSQIVVGGFMKKS 86
DB 289 KFETLGYRAFGSNTLPTGSCQ----WSEPLPTCEA--IAEPETIDHSGMCGVPS 40
OY 87 KAPFFHGDSVTFCKKAKFTMKSKTKVGCANLWNGPTALPWCS--DFEL 134
DB 341 TGTCPCYNSSTFICACFGVIAKNDIAQCASDSQWTAFA PFCIALQTPPPV 391
RESULT 20
CCPH_BSVSA
ID CCPH_BSVSA STANDARD: PRT: 160 AA.
AC C01016:
DT 01-APR-1993 (Rel. 25, Created)
DT 01-APR-1993 (Rel. 25, Last sequence update)
DT 15-JUL-1998 (Rel. 36, Last annotation update)
DE Complement control protein homolog p-19 (ccp1)
DE 4 OR CCPH
OS Herpesvirus saimiri (strain 11).

```

Virusen, bakterielle Viren, die RNA-Struktur Herpesviridae, Gammaherpesviridae, Kapsidproteine.

№ 111-112/1998

ANNALS

MELVILLE, 440,000; POLYMER, 142,000;

Vibrecht L. C., Nicholas J., Biller D., Cameron K.R., Kinsinger B.,

NEWMAN C., WITTMANN S., CLAXTON M.A., COLEMAN H., FLECK

1911

"I'll illustrate the effect of the logarithmic

1 Virel. 46:5047

APPENDIX I

MELB. INF. 4260674;

Abrecht, L. v., Hockenstein B.

CC POLYLACTAMINE THAT ARE FOUND AT THE NONREDUCING TERMINI OF
CC GLYCOPOLIPIDS)
CC 1 SUBCELLULAR LOCATION: Type I membrane protein.
CC 1 SIMILARITY: TO OTHER SELECTINS/LECTINS
CC 1 SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
CC 1 SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
CC 1 SIMILARITY: CONTAINS 5 SUSHI (SCR) DOMAINS.
CC
CC THIS SWISS PROT entry is copyright © It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announcce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: L25627; AAA11113.1;
CC HSSP: P16581; 1KJA.
CC InterPro: IPR000461; EGF-like.
CC InterPro: IPR000466; Sushi SCR cnp.
CC InterPro: IPR001404; Lectin_C.
CC Pfam: PF00008; EGF; 1.
CC Pfam: PF00059; Lectin_C; 1.
CC Pfam: PF00084; Sushi; 5.
CC SMART: SM00042; CCP; 5.
CC SMART: SM00044; CUEP; 1
CC SMART: SM00101; EGF; 1.
CC PROSITE: PS00222; EGF_1; 1.
CC PROSITE: PS01106; EGF_2; 1.
CC PROSITE: PS06615; C-TYPE LECTIN_1; 1.
CC PROSITE: PS56041; C-TYPE LECTIN_2; 1.
CC Cell adhesion; Transmembrane; Glycoprotein; EGF-like domain; Lectin;
KW Selectin; Signal; Sushi; Repeat.
FT SIGNAL 1 21 POTENTIAL.
FT CHAIN 22 549 E-SELECTIN.
FT DOMAIN 22 494 EXTRACELLULAR (POTENTIAL).
FT TRANSMEM 495 516 POTENTIAL.
FT DOMAIN 517 549 CYTOPLASMIC (POTENTIAL).
FT DOMAIN 38 148 EGF-LIKE.
FT DOMAIN 149 175 SUSHI 1.
FT DOMAIN 179 249 SUSHI 2.
FT DOMAIN 242 301 SUSHI 3.
FT DOMAIN 304 364 SUSHI 4.
FT DOMAIN 367 427 SUSHI 5.
FT DOMAIN 430 486 SUSHI 6.
FT DISULFID 40 148 HY SIMILARITY.
FT DISULFID 111 140 HY SIMILARITY.
FT DISULFID 143 154 HY SIMILARITY.
FT DISULFID 148 163 HY SIMILARITY.
FT DISULFID 165 174 HY SIMILARITY.
FT DISULFID 180 225 HY SIMILARITY.
FT DISULFID 210 248 HY SIMILARITY.
FT DISULFID 243 287 HY SIMILARITY.
FT DISULFID 273 300 HY SIMILARITY.
FT DISULFID 305 350 HY SIMILARITY.
FT DISULFID 336 363 HY SIMILARITY.
FT DISULFID 368 413 HY SIMILARITY.
FT DISULFID 499 426 HY SIMILARITY.
FT DISULFID 431 472 HY SIMILARITY.
FT DISULFID 458 485 HY SIMILARITY.
FT CARBOHYD 25 25 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 60 60 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 145 145 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 192 192 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 203 203 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 266 266 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 313 313 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 320 320 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 333 333 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 343 343 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 441 441 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 445 465 N-LINKED (GLCNAC...) (POTENTIAL).
SQ SEQUENCE 549 AA; 60079 MW; 85CFEEDB7B0144CB CRC64;

Query Match 18.6%; Score 140; DH 1; Length 549;
Best local Similarity 29.6%; Pred. No 1.2e-06;
Matches 34; Conservative 13; Mismatches 58; Indels 10; Gaps 4;
QY 16 PYSLDIPVGVLTVCSPSTRLIGERAKRISINQVIAIWDKAPPCSVNKTISQSDP 76
DB 583 PSASAPFGSGSKPFGDEFGELKGRRLQCSYAGE... WDSKPPVAGV... QCSH 444
QY 76 IYVGGIMKFKSKAPFHGDSVTFCKANFMKSKTVMQANEMWGPITALPVTES 130
DB 435 DLFGK MMSUSGPAVFGIVAEFTLPEGWILNLSILLDAIGWS AMLPTEA 487
RESULT 24
LEM2 HUMAN STANDARD; PRT: 510 AA.
AC P.6581; P16111;
DT 01-APR-1993 (Ref. 14, Created)
DT 01-AUG-1993 (Ref. 15, last sequence update)
DT 16-OCT-2001 (Ref. 40, last annotation update)
DE E-selectin precursor (Endothelial leukocyte adhesion molecule 1)
DE (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2)
DE (CD62E).
GN Spleen or ELAMC.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Gracilata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
OX NCBI_TaxID:9606;
RN 111
RP SEQUENCE FROM N.A.
RX MEDLINE:9017359; PubMed:1689848;
RA Hession C., Osborn L., Goff D., Chappas C., Vassallo C.,
RA Paisek M., Piliack C., Tizard R., Goff S., McCarthy K., Hopple S.,
RA Lobb R.;
RT "Endothelial leukocyte adhesion molecule 1: direct expression cloning
RT and functional interactions.";
RL Proc. Natl. Acad. Sci. U.S.A. 87:1677-1677(1990).
RN 121
RP SEQUENCE FROM N.A.
RX MEDLINE-86162047; PubMed:2466335;
RA Bevilacqua M.P., Stegeman S., Giribone M.A. Jr., Seed B.;
RT "Endothelial leukocyte adhesion molecule 1: an inducible receptor for
RT neutrophils related to complement regulatory proteins and lectins.";
RL Science 243:1150-1155(1989).
RN 131
RP SEQUENCE FROM N.A.
RX MEDLINE-91115870; PubMed:1703529;
RA Collins T., Williams A., Johnston G., Kim J., Eddy R., Shows L.;
RA Gombone M.A. Jr., Bevilacqua M.P.;
RT "Structure and chromosomal location of the gene for endothelial-
RT leukocyte adhesion molecule 1.";
RL J. Biol. Chem. 266:2466-2473(1991).
RN 141
RP LIGAND.
RX MEDLINE-9068005; PubMed:1701274;
RA Phillips M.L., Nudelman E., Gaeta F.C., Perez M., Singhal A.K.;
RA Lakomori S., Paulson J.C.;
RT "ELAM 1 mediates cell adhesion by recognition of a carbohydrate
RT ligand, sialyl-Lex.";
RL Science 240:1130-1132(1990).
RN 151
RP 3D-STRUCTURE MODELING OF LECTIN DOMAIN.
RX MEDLINE-94262575; PubMed:7681016;
RA Mills A.;
RT "Modelling the carbohydrate recognition domain of human E-selectin.";
RL FEBS Lett. 319:5-11(1993).
RN 161
RX X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 22 178.
RX MEDLINE-94130646; PubMed:7509040;
RA Graves B.J., Crowther R.L., Chandran S., Rumberger J.M., Li S.,
RA Huang K.-S., Presky D.H., Familletti P.G., Weliczky R.A., Burns D.K.;
RT "Insight into E-selectin/ligand interaction from the crystal
RT structure and mutagenesis of the lectin domain.";

61 Nature 367:532-538(1994).
 62 [1]
 63 VARIANT ARG 149.
 64 MEDLINE-95194107; PubMed-544025;
 65 Wenzel K., Felix S., Klier F.X., Bruchard R., Menke T., Sebhatlike S.,
 66 Schutte K., Glaser C., Rohde K., Baumann G., Speer A.:
 67 "p-selectin polymorphism and atherosclerosis: an association study.";
 68 Hum. Mol. Genet. 3:1905-1913(1994).
 69 [18]
 70 VARIANT ARG 149.
 71 MEDLINE-99144508; PubMed-9933748;
 72 Ye S.Q., Ishii D., Virsik D., Zhang L.Q., Yoshim S.E., Gupta R.:
 73 "A p-selectin polymorphism affects the mutation of serine 128 to arginine in
 74 the EGF gene: a risk factor for coronary artery disease.";
 75 J. Biomed. Sci. 6:18-21(1999).
 76 FUNCTION: EXPRESSION OF CYTOKINE-INDUCED ENDOTHelial CELLS AND
 77 MEDIATES THEIR BINDING TO LEUKOCYTES. THE LIGAND RECOGNIZED BY
 78 PLAM-1 IS STALKY LEWIS X (ALPHA(1-3)FUCOSYLATED DERIVATIVES OF
 79 POLYGLYCOSAMINE THAT ARE FOUND AT THE NONREDUCING TERMINI OF
 80 GLYCOPROTEINS).
 81 SUBCELLULAR LOCATION: Type I membrane protein.
 82 POLYMORPHISM: A POLYMORPHISM IN POSITION 149 IS ASSOCIATED WITH A
 83 HIGHER RISK OF CORONARY ARTERY DISEASE (CAD). A SIGNIFICANTLY
 84 HIGHER MUTATION FREQUENCY (ARG 149) IS OBSERVED IN PATIENTS WITH
 85 ANGIOGRAPHICALLY PROVEN SEVERE ATHEROSCLEROSIS COMPARED WITH AN
 86 UNSELECTED POPULATION (SER 149).
 87 SIMILARITY: TO OTHER SELECTINS/LEWIS.
 88 SIMILARITY: CONTAINS 1 C- TYPE LECTIN FAMILY DOMAIN.
 89 SIMILARITY: CONTAINS 1 EGF LIKE DOMAIN.
 90 SIMILARITY: CONTAINS 6 SUSHI (SCR) DOMAINS.
 91 DATABASE: NAME: PRO6; NOTE: CD-antigen CD62E entry;
 92 WWW: <http://www.ncbi.nlm.nih.gov/seq/efg/efg.htm>
 93
 94 THIS SWISS PROT entry is copyrighted. It is produced through a collaboration
 95 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 96 the European Bioinformatics Institute. There are no restrictions on its
 97 use by non-profit institutions as long as its content is in no way
 98 modified and this statement is not removed. Usage by and for commercial
 99 entities requires a license agreement (See <http://www.isdb.ch/bankinfo.htm>
 100 or send an email to license@isb.stg.ch).
 101
 102 EMBL: M30340; AAA52337.1;
 103 EMBL: M61893; AAA52337.1; JOINED.
 104 EMBL: M61895; AAA52337.1; JOINED.
 105 EMBL: M61897; AAA52337.1; JOINED.
 106 EMBL: M61898; AAA52337.1; JOINED.
 107 EMBL: M61899; AAA52337.1; JOINED.
 108 EMBL: M61900; AAA52337.1; JOINED.
 109 EMBL: M61892; AAA52337.1; JOINED.
 110 EMBL: M24736; AAA52337.1; JOINED.
 111 FIC: A32606; A32606.
 112 FIC: A50406; A50406.
 113 FIC: A06150; A06150.
 114 FIC: TEST; 31 AUG 94.
 115 FIC: 18JA; 03 APR 96.
 116 MIM: 131210;
 117 InterPro: IPR000561; EGF Like.
 118 InterPro: IPR002396; Selectin.
 119 InterPro: IPR004367; Sushi SCR CDP.
 120 InterPro: IPR001307; Lectin C1.
 121 FIC: PF00006; EGF 1.
 122 FIC: PF00059; Lectin C1.
 123 FIC: PF00004; Sushi 6.
 124 PRINTS: PR00044; SELECTIN
 125 SMART: SM00042; C1P1 6
 126 SMART: SM00044; C1P1 1
 127 SMART: SM00181; EGF 1
 128 PROSITE: PS00022; EGF 1 1
 129 PROSITE: PS01186; EGF 2 1
 130 PROSITE: PS00615; C- TYPE LECTIN 1 1
 131 PROSITE: PS00041; C- TYPE LECTIN 2 1
 132 C11 adhesion; Transmembrane; Glycoprotein; EGF like domain; Lectin;
 133 Selectin; Signal; Sushi; Repeat; Polymorphism; 3D-structure.

FT SIGNAL 1 21
 FT CHAIN 22 610
 FT DOMAIN 22 556
 FT TRANSMEM 557 578
 FT DOMAIN 579 610
 FT DOMAIN 48 148
 FT DOMAIN 139 175
 FT DOMAIN 179 248
 FT DOMAIN 241 400
 FT DOMAIN 404 464
 FT DOMAIN 365 426
 FT DOMAIN 429 489
 FT DOMAIN 492 548
 FT DISULFID 40 148
 FT DISULFID 111 140
 FT DISULFID 144 164
 FT DISULFID 148 164
 FT DISULFID 165 174
 FT DISULFID 180 224
 FT DISULFID 210 247
 FT DISULFID 242 286
 FT DISULFID 272 299
 FT DISULFID 404 489
 FT DISULFID 345 362
 FT DISULFID 367 412
 FT DISULFID 398 425
 FT DISULFID 430 475
 FT DISULFID 461 488
 FT DISULFID 494 544
 FT DISULFID 520 547
 FT CARBOHYD 25 25
 FT CARBOHYD 149 149
 FT CARBOHYD 160 160
 FT CARBOHYD 179 179
 FT CARBOHYD 199 199
 FT CARBOHYD 204 204
 FT CARBOHYD 265 265
 FT CARBOHYD 312 312
 FT CARBOHYD 342 342
 FT CARBOHYD 504 504
 FT CARBOHYD 527 527
 FT VARIANT 140 140
 FT VARIANT 149 149
 FT VARIANT 295 295
 FT VARIANT 421 421
 FT VARIANT 468 468
 FT VARIANT 575 575
 FT VARIANT 610 610
 FT SEQUENCE 610 AA; 66655 MW; 7043830012292269664 S; K (ASSOCIATED WITH A RISK FACTOR FOR CAD).
 FTID-VAR 004191.
 E - K (IN HGSNP:5464).
 FTID-VAR 011791.
 E - Q (IN HGSNP:5369).
 FTID-VAR 011792.
 H - Y (IN HGSNP:5369).
 FTID-VAR 011793.
 L - T (IN HGSNP:5464).
 FTID-VAR 011794.
 Query Match 18.5%; Score 149; DB 1; Length 610;
 Best Local Similarity 31.5%; Pred. No. 139; 06;
 Matches 44; Conservative 18; Mismatches 46; Indels 20; Gaps 6;
 QY 40 YDPSSTRGIGKATFTISENVHAIWKAPFCHSVKNTLSSGTCVQVGRMN KISK 67
 111 111 111 111 111 111 111 111 111 111
 DB 333 FTCEGFMLGQVAVVECTTQGV---WUQIVVCAVQV T ALSNP ERYGMN LPSAS 485
 111 111 111 111 111 111 111 111 111 111
 QY 88 APFHGIVTFTKANTMKSGKTYWCANEMWHTA LIVES 140
 111 111 111 111 111 111 111 111 111 111
 DB 486 GSEFVGSSEFSCGEGVFKGSKRIQ* - GDVGEWNIKEPTFA 427
 111 111 111 111 111 111 111 111 111 111
 RESULT 25
 FTID_HUMAN
 ID FT38 HUMAN
 AC P05160; STANDARD; 181; 661 AA.

DT 14 AUG-1987 (rel. 05, created)
 DT 01 AUG-1990 (rel. 15, last sequence update)
 DT 16 OCT-2001 (rel. 40, last annotation update)
 DE Coagulation factor XIII B chain precursor (EC 2.3.2.13) (protein-
 DE glutamine gamma-glutamyltransferase B chain) (Transglutaminase B
 DE chain).
 GN F13B.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 OX NCBI_TaxID:9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 PX MEDLINE-91105154; PubMed-2271707;
 RA Bottemus R.E., Ichinose A., Davie E.W.;
 RT "Nucleotide sequence of the gene for the b subunit of human factor
 RT XIII.";
 RL Biochemistry 29:11195-11209(1990).
 RN [2]
 RP SEQUENCE OF 2 661 FROM N.A.
 PX MEDLINE-87026535; PubMed-4021194;
 RA Ichinose A., McMillen H.A., Fujikawa K., Davie E.W.;
 RT "Amino acid sequence of the b subunit of human factor XIII, a protein
 RT composed of ten repetitive segments.";
 RL Biochemistry 25:4633-4638(1986).
 RN [3]
 RP REVISIONS.
 RA Ichinose A.;
 RL Submitted (FEB-1987) to the EMBL/GenBank/DBJ databases.
 RN [4]
 RP SEQUENCE OF 1-20 FROM N.A.
 RX MEDLINE-90251467; PubMed-2339367;
 RA Grundmann U., Nerlich C., Rein T., Zettlmeissl G.;
 RT "Complete cDNA sequence encoding the b subunit of human factor XIII.";
 RL Nucleic Acids Res. 18:2817-2817(1990).
 RN [5]
 RP VARIANT PHE 450.
 RX MEDLINE-94414189; PubMed-8324218;
 RA Bashiguchi T., Saito M., Morishita E., Matsuda T., Ichinose A.;
 RT "Two genetic defects in a patient with complete deficiency of the b-
 RT subunit for coagulation factor XIII.";
 RL Blood 82:145-150(1993).
 CC 1 FUNCTION: THE B CHAIN OF FACTOR XIII IS NOT CATALYTICALLY ACTIVE,
 CC BUT IS THOUGHT TO STABILIZE THE A SUBUNITS AND REGULATE THE RATE
 CC OF TRANSGLUTAMINASE FORMATION BY THROMBIN.
 CC 1 SUBUNIT: TETRAMER OF TWO A CHAINS AND TWO B CHAINS.
 CC 1 DISEASE: A DEFICIENCY IN F13B CAN RESULT IN A LIFE-LONG BLEEDING
 CC TENDENCY, DEFECTIVE WOUND HEALING, AND HABITUAL ABORTION.
 CC 1 SIMILARITY: CONTAINS 10 SUSHI (SCR) DOMAINS.
 CC
 CC THIS SWISS-PROT entry is copyright . It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL: M64554; AAA51821.1; ALT_SEQ.
 DR EMBL: M14057; AAA88042.1;
 DR EMBL: X51823; CAA6123.1;
 DR PIR: A23840; A23840.
 DR PIR: A36397; A36397.
 DR PIR: S09480; S09480.
 DR ISSP: P06603; IHE1.
 DR MIM: 144580;
 DR InterPro: IPR000436; Sushi_SCR_CCP.
 DR Pfam: PF00084; sushi; 8.
 DR SMART: SM0002; CCP; 8.
 KW Transferrase; Plasma; Blood coagulation; Repeat; Glycoprotein; Signal;
 KW Sushi; Disease mutation.
 FT SIGNAL 1 20

FT CHAIN 21 661
 FT DOMAIN 24 88
 FT SUSHI 1.
 FT SUSHI 2.
 FT SUSHI 3.
 FT SUSHI 4.
 FT SUSHI 5.
 FT SUSHI 6.
 FT SUSHI 7.
 FT SUSHI 8.
 FT SUSHI 9.
 FT SUSHI 10.
 FT SUSHI 11.
 FT SUSHI 12.
 FT SUSHI 13.
 FT SUSHI 14.
 FT SUSHI 15.
 FT SUSHI 16.
 FT SUSHI 17.
 FT SUSHI 18.
 FT SUSHI 19.
 FT SUSHI 20.
 FT SUSHI 21.
 FT SUSHI 22.
 FT SUSHI 23.
 FT SUSHI 24.
 FT SUSHI 25.
 FT SUSHI 26.
 FT SUSHI 27.
 FT SUSHI 28.
 FT SUSHI 29.
 FT SUSHI 30.
 FT SUSHI 31.
 FT SUSHI 32.
 FT SUSHI 33.
 FT SUSHI 34.
 FT SUSHI 35.
 FT SUSHI 36.
 FT SUSHI 37.
 FT SUSHI 38.
 FT SUSHI 39.
 FT SUSHI 40.
 FT SUSHI 41.
 FT SUSHI 42.
 FT SUSHI 43.
 FT SUSHI 44.
 FT SUSHI 45.
 FT SUSHI 46.
 FT SUSHI 47.
 FT SUSHI 48.
 FT SUSHI 49.
 FT SUSHI 50.
 FT SUSHI 51.
 FT SUSHI 52.
 FT SUSHI 53.
 FT SUSHI 54.
 FT SUSHI 55.
 FT SUSHI 56.
 FT SUSHI 57.
 FT SUSHI 58.
 FT SUSHI 59.
 FT SUSHI 60.
 FT SUSHI 61.
 FT SUSHI 62.
 FT SUSHI 63.
 FT SUSHI 64.
 FT SUSHI 65.
 FT SUSHI 66.
 FT SUSHI 67.
 FT SUSHI 68.
 FT SUSHI 69.
 FT SUSHI 70.
 FT SUSHI 71.
 FT SUSHI 72.
 FT SUSHI 73.
 FT SUSHI 74.
 FT SUSHI 75.
 FT SUSHI 76.
 FT SUSHI 77.
 FT SUSHI 78.
 FT SUSHI 79.
 FT SUSHI 80.
 FT SUSHI 81.
 FT SUSHI 82.
 FT SUSHI 83.
 FT SUSHI 84.
 FT SUSHI 85.
 FT SUSHI 86.
 FT SUSHI 87.
 FT SUSHI 88.
 FT SUSHI 89.
 FT SUSHI 90.
 FT SUSHI 91.
 FT SUSHI 92.
 FT SUSHI 93.
 FT SUSHI 94.
 FT SUSHI 95.
 FT SUSHI 96.
 FT SUSHI 97.
 FT SUSHI 98.
 FT SUSHI 99.
 FT SUSHI 100.
 FT SUSHI 101.
 FT SUSHI 102.
 FT SUSHI 103.
 FT SUSHI 104.
 FT SUSHI 105.
 FT SUSHI 106.
 FT SUSHI 107.
 FT SUSHI 108.
 FT SUSHI 109.
 FT SUSHI 110.
 FT SUSHI 111.
 FT SUSHI 112.
 FT SUSHI 113.
 FT SUSHI 114.
 FT SUSHI 115.
 FT SUSHI 116.
 FT SUSHI 117.
 FT SUSHI 118.
 FT SUSHI 119.
 FT SUSHI 120.
 FT SUSHI 121.
 FT SUSHI 122.
 FT SUSHI 123.
 FT SUSHI 124.
 FT SUSHI 125.
 FT SUSHI 126.
 FT SUSHI 127.
 FT SUSHI 128.
 FT SUSHI 129.
 FT SUSHI 130.
 FT SUSHI 131.
 FT SUSHI 132.
 FT SUSHI 133.
 FT SUSHI 134.
 FT SUSHI 135.
 FT SUSHI 136.
 FT SUSHI 137.
 FT SUSHI 138.
 FT SUSHI 139.
 FT SUSHI 140.
 FT SUSHI 141.
 FT SUSHI 142.
 FT SUSHI 143.
 FT SUSHI 144.
 FT SUSHI 145.
 FT SUSHI 146.
 FT SUSHI 147.
 FT SUSHI 148.
 FT SUSHI 149.
 FT SUSHI 150.
 FT SUSHI 151.
 FT SUSHI 152.
 FT SUSHI 153.
 FT SUSHI 154.
 FT SUSHI 155.
 FT SUSHI 156.
 FT SUSHI 157.
 FT SUSHI 158.
 FT SUSHI 159.
 FT SUSHI 160.
 FT SUSHI 161.
 FT SUSHI 162.
 FT SUSHI 163.
 FT SUSHI 164.
 FT SUSHI 165.
 FT SUSHI 166.
 FT SUSHI 167.
 FT SUSHI 168.
 FT SUSHI 169.
 FT SUSHI 170.
 FT SUSHI 171.
 FT SUSHI 172.
 FT SUSHI 173.
 FT SUSHI 174.
 FT SUSHI 175.
 FT SUSHI 176.
 FT SUSHI 177.
 FT SUSHI 178.
 FT SUSHI 179.
 FT SUSHI 180.
 FT SUSHI 181.
 FT SUSHI 182.
 FT SUSHI 183.
 FT SUSHI 184.
 FT SUSHI 185.
 FT SUSHI 186.
 FT SUSHI 187.
 FT SUSHI 188.
 FT SUSHI 189.
 FT SUSHI 190.
 FT SUSHI 191.
 FT SUSHI 192.
 FT SUSHI 193.
 FT SUSHI 194.
 FT SUSHI 195.
 FT SUSHI 196.
 FT SUSHI 197.
 FT SUSHI 198.
 FT SUSHI 199.
 FT SUSHI 200.
 FT SUSHI 201.
 FT SUSHI 202.
 FT SUSHI 203.
 FT SUSHI 204.
 FT SUSHI 205.
 FT SUSHI 206.
 FT SUSHI 207.
 FT SUSHI 208.
 FT SUSHI 209.
 FT SUSHI 210.
 FT SUSHI 211.
 FT SUSHI 212.
 FT SUSHI 213.
 FT SUSHI 214.
 FT SUSHI 215.
 FT SUSHI 216.
 FT SUSHI 217.
 FT SUSHI 218.
 FT SUSHI 219.
 FT SUSHI 220.
 FT SUSHI 221.
 FT SUSHI 222.
 FT SUSHI 223.
 FT SUSHI 224.
 FT SUSHI 225.
 FT SUSHI 226.
 FT SUSHI 227.
 FT SUSHI 228.
 FT SUSHI 229.
 FT SUSHI 230.
 FT SUSHI 231.
 FT SUSHI 232.
 FT SUSHI 233.
 FT SUSHI 234.
 FT SUSHI 235.
 FT SUSHI 236.
 FT SUSHI 237.
 FT SUSHI 238.
 FT SUSHI 239.
 FT SUSHI 240.
 FT SUSHI 241.
 FT SUSHI 242.
 FT SUSHI 243.
 FT SUSHI 244.
 FT SUSHI 245.
 FT SUSHI 246.
 FT SUSHI 247.
 FT SUSHI 248.
 FT SUSHI 249.
 FT SUSHI 250.
 FT SUSHI 251.
 FT SUSHI 252.
 FT SUSHI 253.
 FT SUSHI 254.
 FT SUSHI 255.
 FT SUSHI 256.
 FT SUSHI 257.
 FT SUSHI 258.
 FT SUSHI 259.
 FT SUSHI 260.
 FT SUSHI 261.
 FT SUSHI 262.
 FT SUSHI 263.
 FT SUSHI 264.
 FT SUSHI 265.
 FT SUSHI 266.
 FT SUSHI 267.
 FT SUSHI 268.
 FT SUSHI 269.
 FT SUSHI 270.
 FT SUSHI 271.
 FT SUSHI 272.
 FT SUSHI 273.
 FT SUSHI 274.
 FT SUSHI 275.
 FT SUSHI 276.
 FT SUSHI 277.
 FT SUSHI 278.
 FT SUSHI 279.
 FT SUSHI 280.
 FT SUSHI 281.
 FT SUSHI 282.
 FT SUSHI 283.
 FT SUSHI 284.
 FT SUSHI 285.
 FT SUSHI 286.
 FT SUSHI 287.
 FT SUSHI 288.
 FT SUSHI 289.
 FT SUSHI 290.
 FT SUSHI 291.
 FT SUSHI 292.
 FT SUSHI 293.
 FT SUSHI 294.
 FT SUSHI 295.
 FT SUSHI 296.
 FT SUSHI 297.
 FT SUSHI 298.
 FT SUSHI 299.
 FT SUSHI 300.
 FT SUSHI 301.
 FT SUSHI 302.
 FT SUSHI 303.
 FT SUSHI 304.
 FT SUSHI 305.
 FT SUSHI 306.
 FT SUSHI 307.
 FT SUSHI 308.
 FT SUSHI 309.
 FT SUSHI 310.
 FT SUSHI 311.
 FT SUSHI 312.
 FT SUSHI 313.
 FT SUSHI 314.
 FT SUSHI 315.
 FT SUSHI 316.
 FT SUSHI 317.
 FT SUSHI 318.
 FT SUSHI 319.
 FT SUSHI 320.
 FT SUSHI 321.
 FT SUSHI 322.
 FT SUSHI 323.
 FT SUSHI 324.
 FT SUSHI 325.
 FT SUSHI 326.
 FT SUSHI 327.
 FT SUSHI 328.
 FT SUSHI 329.
 FT SUSHI 330.
 FT SUSHI 331.
 FT SUSHI 332.
 FT SUSHI 333.
 FT SUSHI 334.
 FT SUSHI 335.
 FT SUSHI 336.
 FT SUSHI 337.
 FT SUSHI 338.
 FT SUSHI 339.
 FT SUSHI 340.
 FT SUSHI 341.
 FT SUSHI 342.
 FT SUSHI 343.
 FT SUSHI 344.
 FT SUSHI 345.
 FT SUSHI 346.
 FT SUSHI 347.
 FT SUSHI 348.
 FT SUSHI 349.
 FT SUSHI 350.
 FT SUSHI 351.
 FT SUSHI 352.
 FT SUSHI 353.
 FT SUSHI 354.
 FT SUSHI 355.
 FT SUSHI 356.
 FT SUSHI 357.
 FT SUSHI 358.
 FT SUSHI 359.
 FT SUSHI 360.
 FT SUSHI 361.
 FT SUSHI 362.
 FT SUSHI 363.
 FT SUSHI 364.
 FT SUSHI 365.
 FT SUSHI 366.
 FT SUSHI 367.
 FT SUSHI 368.
 FT SUSHI 369.
 FT SUSHI 370.
 FT SUSHI 371.
 FT SUSHI 372.
 FT SUSHI 373.
 FT SUSHI 374.
 FT SUSHI 375.
 FT SUSHI 376.
 FT SUSHI 377.
 FT SUSHI 378.
 FT SUSHI 379.
 FT SUSHI 380.
 FT SUSHI 381.
 FT SUSHI 382.
 FT SUSHI 383.
 FT SUSHI 384.
 FT SUSHI 385.
 FT SUSHI 386.
 FT SUSHI 387.
 FT SUSHI 388.
 FT SUSHI 389.
 FT SUSHI 390.
 FT SUSHI 391.
 FT SUSHI 392.
 FT SUSHI 393.
 FT SUSHI 394.
 FT SUSHI 395.
 FT SUSHI 396.
 FT SUSHI 397.
 FT SUSHI 398.
 FT SUSHI 399.
 FT SUSHI 400.
 FT SUSHI 401.
 FT SUSHI 402.
 FT SUSHI 403.
 FT SUSHI 404.
 FT SUSHI 405.
 FT SUSHI 406.
 FT SUSHI 407.
 FT SUSHI 408.
 FT SUSHI 409.
 FT SUSHI 410.
 FT SUSHI 411.
 FT SUSHI 412.
 FT SUSHI 413.
 FT SUSHI 414.
 FT SUSHI 415.
 FT SUSHI 416.
 FT SUSHI 417.
 FT SUSHI 418.
 FT SUSHI 419.
 FT SUSHI 420.
 FT SUSHI 421.
 FT SUSHI 422.
 FT SUSHI 423.
 FT SUSHI 424.
 FT SUSHI 425.
 FT SUSHI 426.
 FT SUSHI 427.
 FT SUSHI 428.
 FT SUSHI 429.
 FT SUSHI 430.
 FT SUSHI 431.
 FT SUSHI 432.
 FT SUSHI 433.
 FT SUSHI 434.
 FT SUSHI 435.
 FT SUSHI 436.
 FT SUSHI 437.
 FT SUSHI 438.
 FT SUSHI 439.
 FT SUSHI 440.
 FT SUSHI 441.
 FT SUSHI 442.
 FT SUSHI 443.
 FT SUSHI 444.
 FT SUSHI 445.
 FT SUSHI 446.
 FT SUSHI 447.
 FT SUSHI 448.
 FT SUSHI 449.
 FT SUSHI 450.
 FT SUSHI 451.
 FT SUSHI 452.
 FT SUSHI 453.
 FT SUSHI 454.
 FT SUSHI 455.
 FT SUSHI 456.
 FT SUSHI 457.
 FT SUSHI 458.
 FT SUSHI 459.
 FT SUSHI 460.
 FT SUSHI 461.
 FT SUSHI 462.
 FT SUSHI 463.
 FT SUSHI 464.
 FT SUSHI 465.
 FT SUSHI 466.
 FT SUSHI 467.
 FT SUSHI 468.
 FT SUSHI 469.
 FT SUSHI 470.
 FT SUSHI 471.
 FT SUSHI 472.
 FT SUSHI 473.
 FT SUSHI 474.
 FT SUSHI 475.
 FT SUSHI 476.
 FT SUSHI 477.
 FT SUSHI 478.
 FT SUSHI 479.
 FT SUSHI 480.
 FT SUSHI 481.
 FT SUSHI 482.
 FT SUSHI 483.
 FT SUSHI 484.
 FT SUSHI 485.
 FT SUSHI 486.
 FT SUSHI 487.
 FT SUSHI 488.
 FT SUSHI 489.
 FT SUSHI 490.
 FT SUSHI 491.
 FT SUSHI 492.
 FT SUSHI 493.
 FT SUSHI 494.
 FT SUSHI 495.
 FT SUSHI 496.
 FT SUSHI 497.
 FT SUSHI 498.
 FT SUSHI 499.
 FT SUSHI 500.
 FT SUSHI 501.
 FT SUSHI 502.
 FT SUSHI 503.
 FT SUSHI 504.
 FT SUSHI 505.
 FT SUSHI 506.
 FT SUSHI 507.
 FT SUSHI 508.
 FT SUSHI 509.
 FT SUSHI 510.
 FT SUSHI 511.
 FT SUSHI 512.
 FT SUSHI 513.
 FT SUSHI 514.
 FT SUSHI 515.
 FT SUSHI 516.
 FT SUSHI 517.
 FT SUSHI 518.
 FT SUSHI 519.
 FT SUSHI 520.
 FT SUSHI 521.
 FT SUSHI 522.
 FT SUSHI 523.
 FT SUSHI 524.
 FT SUSHI 525.
 FT SUSHI 526.
 FT SUSHI 527.
 FT SUSHI 528.
 FT SUSHI 529.
 FT SUSHI 530.
 FT SUSHI 531.
 FT SUSHI 532.
 FT SUSHI 533.
 FT SUSHI 534.
 FT SUSHI 535.
 FT SUSHI 536.
 FT SUSHI 537.
 FT SUSHI 538.
 FT SUSHI 539.
 FT SUSHI 540.
 FT SUSHI 541.
 FT SUSHI 542.
 FT SUSHI 543.
 FT SUSHI 544.
 FT SUSHI 545.
 FT SUSHI 546.
 FT SUSHI 547.
 FT SUSHI 548.
 FT SUSHI 549.
 FT SUSHI 550.
 FT SUSHI 551.
 FT SUSHI 552.
 FT SUSHI 553.
 FT SUSHI 554.
 FT SUSHI 555.
 FT SUSHI 556.
 FT SUSHI 557.
 FT SUSHI 558.
 FT SUSHI 559.
 FT SUSHI 560.
 FT SUSHI 561.
 FT SUSHI 562.
 FT SUSHI 563.
 FT SUSHI 564.
 FT SUSHI 565.
 FT SUSHI 566.
 FT SUSHI 567.
 FT SUSHI 568.
 FT SUSHI 569.
 FT SUSHI 570.
 FT SUSHI 571.
 FT SUSHI 572.
 FT SUSHI 573.
 FT SUSHI 574.
 FT SUSHI 575.
 FT SUSHI 576.
 FT SUSHI 577.
 FT SUSHI 578.
 FT SUSHI 579.
 FT SUSHI 580.
 FT SUSHI 581.
 FT SUSHI 582.
 FT SUSHI 583.
 FT SUSHI 584.
 FT SUSHI 585.
 FT SUSHI 586.
 FT SUSHI 587.
 FT SUSHI 588.
 FT SUSHI 589.
 FT SUSHI 590.
 FT SUSHI 591.
 FT SUSHI 592.
 FT SUSHI 593.
 FT SUSHI 594.
 FT SUSHI 595.
 FT SUSHI 596.
 FT SUSHI 597.
 FT SUSHI 598.
 FT SUSHI 599.
 FT SUSHI 600.
 FT SUSHI 601.
 FT SUSHI 602.
 FT SUSHI 603.
 FT SUSHI 604.
 FT SUSHI 605.
 FT SUSHI 606.
 FT SUSHI 607.
 FT SUSHI 608.
 FT SUSHI 609.
 FT SUSHI 610.
 FT SUSHI 611.
 FT SUSHI 612.
 FT SUSHI 613.
 FT SUSHI 614.
 FT SUSHI 615.
 FT SUSHI 616.
 FT SUSHI 617.
 FT SUSHI 618.
 FT SUSHI 619.
 FT SUSHI 620.
 FT SUSHI 621.
 FT SUSHI 622.
 FT SUSHI 623.
 FT SUSHI 624.
 FT SUSHI 625.
 FT SUSHI 626.
 FT SUSHI 627.
 FT SUSHI 628.
 FT SUSHI 629.
 FT SUSHI 630.
 FT SUSHI 631.
 FT SUSHI 632.
 FT SUSHI 633.
 FT SUSHI 634.
 FT SUSHI 635.
 FT SUSHI 636.
 FT SUSHI 637.
 FT SUSHI 638.
 FT SUSHI 639.
 FT SUSHI 640.
 FT SUSHI 641.
 FT SUSHI 642.
 FT SUSHI 643.
 FT SUSHI 644.
 FT SUSHI 645.
 FT SUSHI 646.
 FT SUSHI 647.
 FT SUSHI 648.
 FT SUSHI 649.
 FT SUSHI 650.
 FT SUSHI 651.
 FT SUSHI 652.
 FT SUSHI 653.
 FT SUSHI 654.
 FT SUSHI 655.
 FT SUSHI 656.
 FT SUSHI 657.
 FT SUSHI 658.
 FT SUSHI 659.
 FT SUSHI 660.
 FT SUSHI 661.
 FT SUSHI 662.
 FT SUSHI 663.
 FT SUSHI 664.
 FT SUSHI 665.
 FT SUSHI 666.
 FT SUSHI 667.
 FT SUSHI 668.
 FT SUSHI 669.
 FT SUSHI 670.
 FT SUSHI 671.
 FT SUSHI 672.
 FT SUSHI 673.
 FT SUSHI 674.
 FT SUSHI 675.
 FT SUSHI 676.
 FT SUSHI 677.
 FT SUSHI 678.
 FT SUSHI 679.
 FT SUSHI 680.
 FT SUSHI 681.
 FT SUSHI 682.
 FT SUSHI 683.
 FT SUSHI 684.
 FT SUSHI 685.
 FT SUSHI 686.
 FT SUSHI 687.
 FT SUSHI 688.
 FT SUSHI 689.
 FT SUSHI 690.
 FT SUSHI 691.
 FT SUSHI 692.
 FT SUSHI 693.
 FT SUSHI 694.
 FT SUSHI 695.
 FT SUSHI 696.
 FT SUSHI 697.
 FT SUSHI 698.
 FT SUSHI 699.
 FT SUSHI 700.
 FT SUSHI 701.
 FT SUSHI 702.
 FT SUSHI 703.
 FT SUSHI 704.
 FT SUSHI 705.
 FT SUSHI 706.
 FT SUSHI 707.
 FT SUSHI 708.
 FT SUSHI 709.
 FT SUSHI 710.
 FT SUSHI 711.
 FT SUSHI 712.
 FT SUSHI 713.
 FT SUSHI 714.
 FT SUSHI 715.
 FT SUSHI 716.
 FT SUSHI 717.
 FT SUSHI 718.
 FT SUSHI 719.
 FT SUSHI 720.
 FT SUSHI 721.
 FT SUSHI 722.
 FT SUSHI 723.
 FT SUSHI 724.
 FT SUSHI 725.
 FT SUSHI 726.
 FT SUSHI 727.
 FT SUSHI 728.
 FT SUSHI 729.
 FT SUSHI 730.
 FT SUSHI 731.
 FT SUSHI 732.
 FT SUSHI 733.
 FT SUSHI 734.
 FT SUSHI 735.
 FT SUSHI 736.
 FT SUSHI 737.
 FT SUSHI 738.
 FT SUSHI 739.
 FT SUSHI 740.
 FT SUSHI 741.
 FT SUSHI 742.
 FT SUSHI 743.
 FT SUSHI 744.
 FT SUSHI 745.
 FT SUSHI 746.
 FT SUSHI 747.
 FT SUSHI 748.
 FT SUSHI 749.
 FT SUSHI 750.
 FT SUSHI 751.
 FT SUSHI 752.
 FT SUSHI 753.
 FT SUSHI 754.
 FT SUSHI 755.
 FT SUSHI 756.
 FT SUSHI 757.
 FT SUSHI 758.
 FT SUSHI 759.
 FT SUSHI 760.
 FT SUSHI 761.
 FT SUSHI 762.
 FT SUSHI 763.
 FT SUSHI 764.
 FT SUSHI 765.
 FT SUSHI 766.
 FT SUSHI 767.
 FT SUSHI 768.
 FT SUSHI 769.
 FT SUSHI 770.
 FT SUSHI 771.
 FT SUSHI 772.
 FT SUSHI 773.
 FT SUSHI 774.
 FT SUSHI 775.
 FT SUSHI 776.
 FT SUSHI 777.
 FT SUSHI 778.
 FT SUSHI 779.
 FT SUSHI 780.
 FT SUSHI 781.
 FT SUSHI 782.
 FT SUSHI 783.
 FT SUSHI 784.
 FT SUSHI 785.
 FT SUSHI 786.
 FT SUSHI 787.
 FT SUSHI 788.
 FT SUSHI 789.
 FT SUSHI 790.
 FT SUSHI 791.
 FT SUSHI 792.
 FT SUSHI 793.
 FT SUSHI 794.
 FT SUSHI 795.
 FT SUSHI 796.
 FT SUSHI 797.
 FT SUSHI 798.
 FT SUSHI 799.
 FT SUSHI 800.
 FT SUSHI 801.
 FT SUSHI 802.
 FT SUSHI 803.
 FT SUSHI 804.
 FT SUSHI 805.
 FT SUSHI 806.
 FT SUSHI 807.
 FT SUSHI 808.
 FT SUSHI 809.
 FT SUSHI 810.
 FT SUSHI 811.
 FT SUSHI 812.
 FT SUSHI 813.
 FT SUSHI 814.
 FT SUSHI 815.
 FT SUSHI 816.
 FT SUSHI 817.
 FT SUSHI 818.
 FT SUSHI 819.
 FT SUSHI 820.
 FT SUSHI 821.
 FT SUSHI 822.
 FT SUSHI 823.
 FT SUSHI 824.
 FT SUSHI 825.
 FT SUSHI 826.
 FT SUSHI 827.
 FT SUSHI 828.
 FT SUSHI 829.
 FT SUSHI 830.
 FT SUSHI 831.
 FT SUSHI 832.<

FT CARBOHYD 145 145 N LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 205 205 N LINKED (GLCNAC...) (POTENTIAL).
 EQ SEQUENCE 297 AA; 33197 MW; 911209DA6C119D59 CRC64;

 Query Match 17.88; Score 134; DB 1; Length 297;
 Best Local Similarity 26.68; Pred. No. 2.4e-06;
 Matches 37; Conservative 19; Mismatches 65; Indels 18; Gaps 6;

 QY 2 SCDEPPFVKNARKPYSLP... VGLVLRVTCSPYRLGKKAIFCISENQVHATW 56
 DB 92 HCPPIPPKFAALKEYTSCVNSFFQDIIVFKCLPHFAMFGNDIVTCTA-----HCNW 146
 QY 57 DKAPPICSVNKTISCSDPIVPGFPMNKGSKAPRHGNSVTFCKANFTMKSKIVWQA 115
 DB 147 TOLPCKRE-----VKCPFSRDNCFENVYDAKPVLSYKDKAVFCCHTYKLDGPERVECT 201
 QY 116 ANEMMGCTALPVCSDFPL 134
 DB 292 KTGHW SALLFSKASCKL 218

 RESULT 28
 C400 RAT
 ID C400_RAT STANDARD; PRT; 258 AA.
 AC Q64515;
 DT 01 NOV 1997 (rel. 45, last sequence update)
 DE 15 JUL 1998 (rel. 46, last annotation update)
 DE C4B binding protein beta chain precursor.
 GN C400P.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Rattus.
 OX NCBI_TaxID:10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN: SPRAGUE DAWLEY; TISSUE: Liver;
 RX MEDLINE-97166082; PubMed-9011975;
 RA Hillarp A., Wiklund H., Thern A., Dahlback B.;
 RT "Molecular cloning of rat C4B binding protein alpha- and beta-chains;
 RT structural and functional relationships among human, bovine, rabbit,
 RT mouse, and rat proteins.";
 RL J. Immunol. 158:1415-1423(1997).
 CC - FUNCTION: C4BP CONTROLS THE CLASSICAL PATHWAY OF COMPLEMENT
 CC ACTIVATION. IT BINDS AS A COFACTOR TO C3B/C4B INACTIVATOR
 CC (CHINA). WHICH THEN HYDROLYZES THE COMPLEMENT FRAGMENT C4B. IT
 CC ALSO ACCELERATES THE DEGRADATION OF THE C4BC2A COMPLEX (C3
 CC CONVERTASE) BY DISSOCIATING THE COMPLEMENT FRAGMENT C2A. IT
 CC INTERACTS ALSO WITH ANTICOGULANT PROTEIN S AND WITH SERUM AMYLOID
 CC P COMPLEMENT
 CC - SUBUNIT: DISULFIDE-LINKED COMPLEX OF C4BP ALPHA AND BETA CHAINS.
 CC - SIMILARITY: TO C4BP ALPHA CHAIN AND TO PIG APOLIPOPROTEIN R.
 CC - SIMILARITY: CONTAINS 3 SUSHI (SCR) DOMAINS.

 This SWISS PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (see <http://www.isb-sib.ch/announcements/>
 or send an email to license@isb-sib.ch).

 EMBL: Z50052; CAA90192.1;
 DDB: J01998; U000;
 DDB: InterPro: IPR000436; SUSHI_SCR_CYP.
 DDB: Pfam: PF00084; SUSHI: 3.
 DDB: SMART: SM00042; CYP: 3.
 KW Complement pathway; Plasma; glycoprotein; Repeat; Sushi; Signal.
 FT SIGNAL 1 15 BY SIMILARITY.
 FT CHAIN 16 258 C4B BINDING PROTEIN BETA CHAIN.
 FT DOMAIN 19 74 SUSHI 1 (ATYPICAL; LACK A CYS).
 FT DOMAIN 77 132 SUSHI 2.
 FT DOMAIN 145 189 SUSHI 3.

FT DISULFID 46 73 BY SIMILARITY.
 FT DISULFID 78 118 BY SIMILARITY.
 FT DISULFID 136 176 BY SIMILARITY.
 FT DISULFID 162 188 BY SIMILARITY.
 FT DISULFID 217 217 INTERHA 4 (WITH ALPHA CHAIN)
 FT CARBOHYD 27 27 (POTENTIAL).
 FT CARBOHYD 67 67 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 89 89 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 95 95 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 114 114 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 218 218 N-LINKED (GLCNAC...) (POTENTIAL).
 SQ SEQUENCE 258 AA; 28641 MW; 6363999J8A850K1C CRC64;

 Query Match 17.88; Score 133.5; DB 1; Length 258;
 Best Local Similarity 26.18; Pred. No. 2.3e-06;
 Matches 35; Conservative 17; Mismatches 57; Indels 25; Gaps 5;

 QY 3 SCDEPPFVKNARKPYSLPVGIVLR-----VVGKFTEDQ 115
 DB 19 SCSEPPPVNNS-----VVGKFTEDQ 115
 QY 57 DKAPPICSVNKTISCSDPIVPGFPMNKGSKAPRHGNSVTFCKANFTMKSKIVWQA 116
 DB 67 NSTPELCILGH---CPDPVLENGKIN--SSDP7NISGRIMFEGNIGYILKSNWSQCLE 120
 QY 117 NEMMGCTALPVCS 130
 DB 121 DHTWAP-DLPICRS 133

 RESULT 29
 LEM2_MOUSE
 ID LEM2_MOUSE STANDARD; PRT; 6.2 AA.
 AC Q60690;
 DT 01-APR-1999 (rel. 25, Created)
 DT 01-APR-1999 (rel. 25, last sequence update)
 DE E-selectin precursor (Endothelial leukocyte adhesion molecule 1)
 DE (E-AM-1) (leukocyte-endothelial cell adhesion molecule 2) (LECAM2)
 DE (CD62E).
 GN SELE OR ELAM-1.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_TaxID:10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE-92283265; PubMed-1375914;
 RA Decker-Andre M., van Halbeek H. Losberger C., Whelan J.,
 RA De Amater J.F.;
 RT "Murine endothelial leukocyte adhesion molecule 1 is a close
 RT structural and functional homologue of the human protein.";
 RL Eur. J. Biochem. 206:401-411(1992)
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE-92240571; PubMed-1378846;
 RA Weier A., Isenmann S., Vestweber D.;
 RT "Cloning of the mouse endothelial selectin Expression of both E-
 RT and P-selectin is inducible by tumor necrosis factor alpha.";
 RL J. Biol. Chem. 267:15176-15183(1992).
 CC - FUNCTION: EXPRESSED ON CYTOKINE INDUCED ENDOTHELIAL CELLS AND
 CC MEDIATES THEIR BINDING TO LEUKOCYTES. THE LIGAND RECOGNIZED BY
 CC E-AM-1 IS SIALYL-LEWIS X (ALPHA(1-3)FUCOSYLATED DERIVATIVES OF
 CC POLYLACTOSAMINE THAT ARE FOUND AT THE NONREDUCING TERMINI OF
 CC GLYCOPROTEINS).
 CC - SUBCELLULAR LOCATION: Type I membrane protein.
 CC - SIMILARITY: TO OTHER SELECTINS/LECAMs.
 CC - SIMILARITY: CONTAINS 1 C-TYPE-LECTIN FAMILY DOMAIN.
 CC - SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
 CC - SIMILARITY: CONTAINS 6 SUSHI (SCR) DOMAINS.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration

group. ?

RL Biochem. J. 213:201-209(1984).

[8]

RN VARIANT C2B DEF-209 AND APO-464

RX MEDLINE-96215049; PubMed-8621452;

RA Wetzel R.A., Kallies J., Lakk M.I., Kiepiela P., Akama H.,

RA Johnson C.A., Benson P., Gollan H.P.;

RT "Type II human complement C2 deficiency. Allele specific amino acid

RT substitutions (Ser189 -> Phe; Gly444 -> Arg) cause impaired C2

RT secretion. ?

RL J. Biol. Chem. 271:5824-5831(1996).

[9]

RN VARIANT C2D TYR-131.

RX MEDLINE-98344005; PubMed-9670940;

RA Zhu Z.B., Atkinson T.P., Volanakis J.E.;

RT "A novel type II complement C2 deficiency allele in an African-

RT American family. ?

RL J. Immunol. 161:578-584(1998).

[10]

CC -1 FUNCTION: COMPONENT C2 WHICH IS PART OF THE CLASSICAL PATHWAY OF

CC THE COMPLEMENT SYSTEM IS CLEAVED BY ACTIVATED FACTOR C1 INTO TWO

CC FRAGMENTS: C2B AND C2A. C2A, A SERINE PROTEASE, THEN COMBINES WITH

CC COMPLEMENT FACTOR 4B TO GENERATE THE C3 OR C5 CONVERTASE

CC -1 CATALYTIC ACTIVITY: CLEAVES C3 IN THE ALPHA-CHAIN TO YIELD C3A AND

CC C3B. CLEAVES C5 IN THE ALPHA-CHAIN TO YIELD C5A AND C5B. BOTH

CC CLEAVAGES TAKE PLACE AT THE C-TERMINAL OF AN ARGININE RESIDUE.

CC -1 DISEASE: DEFECTS IN C2 ARE THE CAUSE OF C2 DEFICIENCY (C2D). THIS

CC IS AN AUTOSOMAL RECESSIVE DISEASE. DEFICIENT INDIVIDUALS HAVE AN

CC INCREASED INCIDENCE OF SLE AND SLE-LIKE SYNDROMES,

CC GLOMERULONEPHRITIS, VASCULITIS AND PYOGENIC INFECTIONS. TYPE I C2D

CC IS CHARACTERIZED BY COMPLETE LOSS OF THE PROTEIN WHILE TYPE II C2D

CC IS CHARACTERIZED BY A SELECTIVE BLOCK IN C2 SECRETION

CC -1 MISCELLANEOUS: C2 IS A MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-III

CC PROTEIN.

CC -1 SIMILARITY: WITH COMPLEMENT FACTOR H.

CC -1 SIMILARITY: CONTAINS 3 SUSHI (SCR) DOMAINS.

CC -1 SIMILARITY: CONTAINS 1 VWFA DOMAIN.

CC -1 SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE

CC TRYPSIN FAMILY.

CC

CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC

DR EMBL: M15082; AAA59624.1; ?

DR EMBL: L09708; AAB97607.1; ?

DR EMBL: L09706; AAB97607.1; JOINED.

DR EMBL: L09707; AAB97607.1; JOINED.

DR EMBL: AF019411; AAB67975.1; ?

DR EMBL: X04481; CAA28169.1; ?

DR PIR: A25290; C2HU.

DR PIR: A05289; A05289.

DR HSSP: P00734; 1VR1.

DR MEROPS: S01.194; ?

DR MIM: 217000; ?

DR InterPro: IPR001314; Chymotrypsin.

DR InterPro: IPR000436; Sushi_SCR_CCP.

DR InterPro: IPR001254; Trypsin.

DR InterPro: IPR002035; VWFA.

DR Pfam: PF00084; sushi; 3.

DR Pfam: PF00089; trypsin; 2.

DR Pfam: PF00092; vwa; 1.

DR PRINTS: PR00722; CHYMOTRYPSIN.

DR SMART: SM00042; CCP; 4.

DR SMART: SM00020; Tryp_Spc; 1.

DR SMART: SM00427; VWA; 1.

DR PROSITE: PS00240; TRYPSIN_DOM; 1.

DR PROSITE: PS00146; TRYPSIN_HIS; 1.

DR PROSITE: PS00145; TRYPSIN_SER; 1.

DR PROSITE: PS00744; VWFA; 1

KW Complement pathway; Plasma; Glycoprotein; Hydrolase; Serine protease;

KW Signal; Repeat, Sushi, Disease mutation; Polymorphism.

FT SIGNAL 1 20

FT CHAIN 21 752 COMPLEMENT C2.

FT CHAIN 21 243 COMPLEMENT C2B FRAGMENT.

FT CHAIN 214 752 COMPLEMENT C2A FRAGMENT.

FT DOMAIN 23 85 SUSHI 1.

FT DOMAIN 88 145 SUSHI 2.

FT DOMAIN 150 205 SUSHI 3.

FT DOMAIN 254 452 VWFA.

FT DOMAIN 456 752 SERINE PROTEASE.

FT ACT_SITE 507 507 CHARGE RELAY SYSTEM (BY SIMILARITY).

FT ACT_SITE 561 561 CHARGE RELAY SYSTEM (BY SIMILARITY).

FT ACT_SITE 679 679 CHARGE RELAY SYSTEM (BY SIMILARITY).

FT DISULFID 24 64 BY SIMILARITY.

FT DISULFID 51 84 BY SIMILARITY.

FT DISULFID 89 131 BY SIMILARITY.

FT DISULFID 117 144 BY SIMILARITY.

FT DISULFID 151 191 BY SIMILARITY.

FT DISULFID 177 204 BY SIMILARITY.

FT CARBOHYD 29 29 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 112 112 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 290 290 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 333 333 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 467 467 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 471 471 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 621 621 N-LINKED GLCNAC. (POTENTIAL).

FT CARBOHYD 651 651 N-LINKED GLCNAC. (POTENTIAL).

FT VARIANT 131 131 C -> V; N C2D, TYPE II).

FT VARIANT 209 209 /FTID-VAR-008544.

FT VARIANT 454 464 /FTID-VAR-008545.

FT VARIANT 533 533 G -> R; N C2D, TYPE II).

FT VARIANT 533 533 /FTID-VAR-008546.

FT VARIANT 533 533 F -> L; N DHSRI:1042664.

FT SEQUENCE 752 AA; 83267 MW; 5A9AAL3700CF444 CRC64;

Query Match 17.48; Score 140.5; DR 1; Length 752;

Best Local Similarity 27.08; Pred. No 1.5e 05;

Matches 38; Conservative 19; Mismatches 61; Indels 24; Gaps 8;

QY 2 ISCDPPEVKVNRKPYV-----SLPIVPGVVLRYTCSPSYRLIGEKAIFTSISNQVHATW 56

DB 87 VCAIPIVSPFENG---YIPRIIGSYV--GNVAVSFECHXGILRGSPVRCQ---RNDQW 137

QY 57 DRAPPICHSVAKTISCSDPIVPGGFMMKSGKAP--RHGDSVTFCTKANKFMKSGSKI VMTQA 116

DB 138 DGEITAVCD--NCAVGHFNPGISLCAVAVTSPF---GHRQKVPYPRSSNIVLTSSSEPEFG 143

QY 1-7 NPMWGHFALPVCRS-----DPP 133

DB 194 NGVWSCTPR-PICRQPPSYDEP 213

RESULT 11

CFAR_MOUSE STANDARD; PRT; 761 AA

AC P04186;

DT 20-MAR-1987 (Rel. 04, Created)

DT 01-AUG-1991 (Rel. 19, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

GN Complement factor B precursor (pC3.4.41.47); (C3/C5 convertase).

GN HF OR H2-HF.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Graciosa; Vertebrata; Euteleostomi;

OC Mammalia; Euteleia; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

OX NCBI_TaxID-10390;

RN 11

RP SEQUENCE FROM N.A.

RX MEDLINE-91035130; PubMed-2229060;

RA Ishikawa N., Nonaka M., Wetzel R.A. (often H.R.);

RT "Murine complement C2 and factor B gene and cDNA cloning reveals

RN SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
 RX MEDLINE-91177916; PubMed-2007602;
 RA Mol-4 T., Miyata T., Misumi Y., Tokunaga F., Nakamura T., Toh Y.,
 RA Ikohara Y., Iwawata S.;
 RI "Limulus factor C: An endotoxin sensitive serine protease zymogen
 RI with a mosaic structure of complement-like, epidermal growth
 RI factor-like, and lectin-like domains.";
 RL J. Biol. Chem. 266:6554-6561(1991).
 CC 1 FUNCTION: THIS ENZYME IS CLOSELY ASSOCIATED WITH AN ENDOTOXIN-
 CC SENSITIVE HEMOLYMPH COAGULATION SYSTEM WHICH MAY PLAY IMPORTANT
 CC ROLES IN BOTH HEMOSTASIS AND HOST DEFENSE MECHANISMS. ITS ACTIVE
 CC FORM CATALYZES THE ACTIVATION OF FACTOR B.
 CC 2 CATALYTIC ACTIVITY: Selective cleavage of 103-Arg-1-Ser-104 and
 CC 124 Ile-111e 125 bonds in Limulus clotting factor B to form
 CC activated factor B. Cleavage of Pro-Arg-1 Xaa bonds in synthetic
 CC substrates.
 CC 3 ENZYME REGULATION: ACTIVATED BY GRAM-NEGATIVE BACTERIAL
 CC LIPOLYSACCHARIDES AND CHYMOTRYPSIN.
 CC 4 SUBUNIT: HETERODIMER OF A LIGHT CHAIN AND A HEAVY CHAIN LINKED
 CC BY A DISULFIDE BOND.
 CC 5 SIMILARITY: CONTAINS 5 SUSHI (SCR) DOMAINS.
 CC 6 SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
 CC 7 SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
 CC 8 SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY.
 CC
 CC This SWISS PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL-outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC
 DR PM01: D90271; BAA1415.1;
 DR PM02: D90272; BAA1416.1;
 DR PM03: A98748; A98748;
 DR PM04: B48748; B48748;
 DR BSSP: P00744; 1UW0.
 DR MISC05: S01259;
 DR InterPro: IP0001414; chymotrypsin.
 DR InterPro: IP0000561; EGF-like.
 DR InterPro: IP0004043; LECT.
 DR InterPro: IP0000436; Sushi_SCR_GCP.
 DR InterPro: IP001254; Trypsin.
 DR InterPro: IP001404; lectin_C.
 DR Pfam: PF00059; lectin_C; 1.
 DR Pfam: PF00084; sushi; 5.
 DR Pfam: PF00089; trypsin; 1.
 DR PRINTS: PR00722; CHYMOTRYPSIN.
 DR SMART: SM00042; GCP; 5.
 DR SMART: SM00044; GLEP; 1.
 DR SMART: SM00181; EGF; 1.
 DR SMART: SM00020; TRYP-SPE; 1.
 DR PROSITE: PS00615; C-TYPE_LECTIN_1; FALSE_NEG.
 DR PROSITE: PS00941; C-TYPE_LECTIN_2; 1.
 DR PROSITE: PS00922; EGF_1; 1.
 DR PROSITE: PS01186; EGF_2; FALSE_NEG.
 DR PROSITE: PS01186; EGF_2; 1.
 DR PROSITE: PS00240; TRYPSIN_DOM; 1.
 DR PROSITE: PS00144; TRYPSIN_HIS; 1.
 DR PROSITE: PS00145; TRYPSIN_SER; 1.
 DR PROSITE: PS00145; TRYPSIN_SER; 1.
 KW Hydrolase; Serine protease; Signal; Alternative splicing; Lectin;
 KW hemolymph clotting; Glycoprotein; Cell adhesion; EGF-like domain;
 KW Sushii; Repeat.
 FI SIGNAL 1 25
 FI CHAIN 26 1019 LIMULUS CLOTTING FACTOR C.
 FI CHAIN 26 690 LIMULUS CLOTTING FACTOR C, HEAVY CHAIN.
 FI CHAIN 691 1019 LIMULUS CLOTTING FACTOR C, LIGHT CHAIN.
 FI CHAIN 691 762 LIMULUS CLOTTING FACTOR C, A CHAIN.
 FI CHAIN 763 1019 LIMULUS CLOTTING FACTOR C, B CHAIN.

FT DOMAIN 102 137 EGF-LIKE.
 FT DOMAIN 142 195 SUSHI.
 FT DOMAIN 200 254 SUSHI.
 FT DOMAIN 260 321 SUSHI.
 FT DOMAIN 325 421 LECT.
 FT DOMAIN 436 568 C-TYPE LECTIN.
 FT DOMAIN 576 634 SUSHI.
 FT DOMAIN 685 748 SUSHI.
 FT DOMAIN 763 1019 SERINE PR TEASE.
 FT ACT_SITE 809 809 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT ACT_SITE 865 865 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT BINDING 966 966 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT DOMAIN 643 689 SUBSTRATE (BY SIMILARITY).
 FT DISULFID 106 118 PRO-RICH.
 FT DISULFID 122 125 BY SIMILARITY.
 FT DISULFID 127 136 BY SIMILARITY.
 FT DISULFID 436 447 BY SIMILARITY.
 FT DISULFID 464 564 BY SIMILARITY.
 FT DISULFID 548 556 BY SIMILARITY.
 FT DISULFID 794 810 BY SIMILARITY.
 FT DISULFID 942 951 BY SIMILARITY.
 FT DISULFID 962 996 BY SIMILARITY.
 FT CARBOHYD 523 523 N-LINKED GLCNAC... (POTENTIAL).
 FT CARBOHYD 534 534 N-LINKED GLCNAC... (POTENTIAL).
 FT CARBOHYD 624 624 N-LINKED GLCNAC... (POTENTIAL).
 FT CARBOHYD 740 740 N-LINKED GLCNAC... (POTENTIAL).
 FT CARBOHYD 757 767 N-LINKED GLCNAC... (POTENTIAL).
 FT CARBOHYD 912 912 N-LINKED GLCNAC... (POTENTIAL).
 FT VAPSPIC 492 498 LITWIS - TDRVAT (IN SHORT ISOFORM).
 FT VAPSPIC 499 1019 MISSING (IN SHORT ISOFORM).
 SQ SEQUENCE 1019 AA; 112346 MW; 58281406711289H CRC64;
 Query Match 17.4%; Score 180.5; Db 1; Length 1019;
 Best Local Similarity 26.6%; Pred. No. 2.1e+05;
 Matches 42; Conservative 22; Mismatches 57; Indels 47; Gaps 9;
 QY 2 ISCHP-----PP-----EVNARKPY- - SLFTVGVIVRYTCSYSYRIJDEKAI 44
 DB 180 ISCHPQWS-PPPKTPKAKVSPPHBYVM-SNRMFGALIFESDSPPYLLDQETL 249
 QY 45 FCISENOVHAIWKAPPICESVKNITICS DP----VQGFPMKKGSKAIPRHDSV 96
 DB 240 TC-----QNGQWSGQIPQCK---KLIVFCHIDP/NHAFHVKICVQKYQFP--QGLV 290
 QY 97 TETCRANITMGSKTIVQCANEMWG---PTALPVCESD 141
 DB 291 TYTCSONYFLMGFNTLKNPDGWSGSGQPS-VLADRF 248
 RESULT 33
 DAF_PONY STANDARD; PRT; (10 AA).
 AC P49457;
 DT 01-FEB-1994 (rel. 33, Created)
 DT 01-FEB-1994 (rel. 33, Last sequence update)
 DE 01-NOV-1995 (rel. 35, Last annotation update)
 DE Complement decay-accelerating factor (CD55) (Fragment).
 DAF OR CD55.
 OS Pendo pygmaeus (Orangutan).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Primates; Catarrhi; Hominoidea; Pongidae.
 OX NCBI_TaxID:9600;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE-9110622; PubMed-7506743;
 RA Nickells M W, Alvarez J L, Lublin D M, Atkinson J P;
 RI "Characterization of DAF-2, a high molecular weight form of decay
 RI accelerating factor (DAF; CD55), as a covalently cross linked dimer
 RI of DAF-1."
 RL J. Immunol 152:676-685(1994).
 CC 1- FUNCTION: THIS PROTEIN RECOGNIZES 54H AAV C4B FRAGMENTS THAT
 CC CONDENSE WITH CELL-SURFACE HYDROXYL OR AMINO GROUPS WHEN NASTENI

CD4 AND CD8 ARE LOCALLY GENERATED DURING C4 AND C3 ACTIVATION. INTERACTION OF DAF WITH CELL ASSOCIATED CD4 AND CD8 POLYPEPTIDES INTERFERES WITH THEIR ABILITY TO CATALYZE THE CONVERSION OF C2 AND FACTOR B TO ENZYMICALLY ACTIVE C3A AND Bb AND THEREBY PREVENTS THE FORMATION OF C4bA AND C4bB. THE AMPLIFICATION CONVERTASES OF THE COMPLEMENT CASCADE (BY SIMILARITY).

CD5 SUBUNIT MEMBER (MAJOR FORM) AND NON DISULFIDE-LINKED, COVALENT DIMER (MINOR FORM).

CD6 SUBCELLULAR LOCATION: Attached to the membrane by a GPI anchor. ALTERNATIVE PRODUCTS: TWO FORMS OF DAF (DAF 2, SHOWN HERE, AND DAF 1) ARE PRODUCED BY ALTERNATIVE SPLICING OF THE SAME GENE. DAF 1 IS THE FIRST SUSHI DOMAIN (SUSHI) IS NOT NECESSARY FOR FUNCTION. SUSHI 2 AND SUSHI 3 PROVIDE THE PROPER CONFORMATION FOR THE ACTIVE SITE ON SUSHI 4 (BY SIMILARITY).

CD7 ACTIVE SITE ON SUSHI 4 (BY SIMILARITY).

CD8 TIME THE SER/THR RICH DOMAIN IS HEAVILY O GLYCOSYLATED.

CD9 SIMILARITY: CONTAINS 4 SUSHI (SUSHI) DOMAINS.

CD10 SIMILARITY: BELONGS TO THE RECEPTORS OF COMPLEMENT ACTIVATION (C3A) FAMILY.

THIS SWISS PROT ENTRY IS COPYRIGHT. IT IS PRODUCED THROUGH A COLLABORATION BETWEEN THE SWISS INSTITUTE OF BIOINFORMATICS AND THE EMBL OUTSTATION AT THE EUROPEAN BIOINFORMATICS INSTITUTE. THERE ARE NO RESTRICTIONS ON ITS USE BY NON-PROFIT INSTITUTIONS AS LONG AS ITS CONTENT IS IN NO WAY MODIFIED AND THIS STATEMENT IS NOT REMOVED. USAGE BY AND FOR COMMERCIAL ENTITIES REQUIRES A LICENSE AGREEMENT (SEE <http://www.ebi.ac.uk/infocentre> or send an email to license@ebi.ac.uk).

EMBL: S62779; AA060609.1; BSSP: P16109; LFSR.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

InterPro: IPR000436; SUSHI SCR CDP.

LEMB3 KAI STANDARD: DR1: 768 AA. P98106.

01 FEB 1996 (Ref: 35, Created)

01 FEB 1996 (Ref: 35, Last sequence update)

01 MAR 2002 (Ref: 41, Last annotation update)

P-selectin precursor (Granule membrane protein 14b) (PM 14b) (PADIEM) (PADIEM) (leukocyte endothelial cell adhesion molecule 3) (LECAM3).

CD1 Rattus norvegicus (Rat).

CD2 Eukaryota; Metazoa; Chordata; Clariata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurosticti; Muridae; Murinae; Rattus; NCBI TaxID: 10116.

CD3 SEQUENCE FROM N.A.

CD4 TISSUE-Locus:

CD5 MEDLINE: 94 43817; PubMed: 7520013; Auchampach J.A., Oliver M.G., Anderson J.C., Manning A.M., "Cloning, sequence comparison and in vivo expression of the gene encoding rat P-selectin."

CD6 FUNCTION: CA(2+)-DEPENDENT RECEPTOR FOR MYELOID CELLS THAT BINDS TO CARBOHYDRATES ON NEUTROPHILS AND MONOCYTES. MEDIATES THE INTERACTION OF ACTIVATED ENDOTHELIAL CELLS OR PLATELETS WITH LEUKOCYTES. THE LIGAND RECOGNIZED IS SIALYL LEWIS X.

CD7 SUBCELLULAR LOCATION: Type I membrane protein.

CD8 TISSUE SPECIFICITY: EXPRESSED IN ALL TISSUES EXAMINED: SPLEEN, LUNG, BRAIN, LIVER, HEART, KIDNEY, THYMUS, SMALL INTESTINE.

CD9 INDUCTION: BY ACUTE INFLAMMATION (PROBABLE).

CD10 SIMILARITY: TO OTHER SELECTINS/LECTINS.

CD11 SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.

CD12 SIMILARITY: CONTAINS 1 EGF LIKE DOMAIN.

CD13 SIMILARITY: CONTAINS 8 SUSHI (SUSHI) DOMAINS; KAI P-LETTIN LACKS THE HUMAN SUSHI-2 EQUIVALENT.

THIS SWISS PROT ENTRY IS COPYRIGHT. IT IS PRODUCED THROUGH A COLLABORATION BETWEEN THE SWISS INSTITUTE OF BIOINFORMATICS AND THE EMBL OUTSTATION AT THE EUROPEAN BIOINFORMATICS INSTITUTE. THERE ARE NO RESTRICTIONS ON ITS USE BY NON-PROFIT INSTITUTIONS AS LONG AS ITS CONTENT IS IN NO WAY MODIFIED AND THIS STATEMENT IS NOT REMOVED. USAGE BY AND FOR COMMERCIAL ENTITIES REQUIRES A LICENSE AGREEMENT (SEE <http://www.ebi.ac.uk/infocentre> or send an email to license@ebi.ac.uk).

EMBL: J23088; AAA60325.1; BSSP: P16109; LFSR.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

InterPro: IPR000561; EGF-like.

01 MAR 2002 (rel. 41, Last annotation update)
 DE Limulus clotting factor C precursor (P03421.04) (P03421.04)
 OS Cariniscorpius rotundicauda (Southeast Asian horseshoe crab).
 CC Eukaryota; Metazoa; Arthropoda; Chelicerata; Merostomata; Xiphosura;
 CC Limulidae; Cariniscorpius.
 XX NBI TaxID=6048;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX LIMULUS-Blood;
 RA Medline=952648506; PubMed=7548401;
 RI Ding J.L., Navas M.A., III, Ho B.;
 RI "Molecular cloning and sequence analysis of factor C cDNA from the
 RI Singapore horseshoe crab, Cariniscorpius rotundicauda.";
 RI Mol. Biol. Biotechnol. 4:90-104(1995).
 CC 1. FUNCTION: THIS ENZYME IS CLOSELY ASSOCIATED WITH AN ENDOTOXIN-
 CC SENSITIVE HEMOLYMPH COAGULATION SYSTEM WHICH MAY PLAY IMPORTANT
 CC ROLES IN BOTH HEMOSTASIS AND HOST DEFENSE MECHANISMS. ITS ACTIVE
 CC FORM CATALYZES THE ACTIVATION OF FACTOR B
 CC CATALYTIC ACTIVITY: Selective cleavage of 103-Arg-1-Ser-104 and
 CC 124 Ile-1-Ile 125 bonds in Limulus clotting factor B to form
 CC activated factor B. Cleavage of Pro-Arg-1-Xaa bonds in synthetic
 CC substrates.
 CC 2. ENZYME REGULATION: ACTIVATED BY GRAM-NEGATIVE BACTERIAL
 CC LIPOLYSACCHARIDES AND CHYMOTRYPSIN (BY SIMILARITY).
 CC 3. SUBUNIT: HETERODIMER OF A LIGHT CHAIN AND A HEAVY CHAIN LINKED
 CC BY A DISULFIDE BOND (BY SIMILARITY).
 CC 4. SIMILARITY: CONTAINS 5 SUSHI (SCR) DOMAINS.
 CC 5. SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN.
 CC 6. SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
 CC 7. SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS THE
 CC TRYPSIN FAMILY.

THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (see [http://www.isb-sib.ch/announcements/](http://www.isb-sib.ch/announcements)
 or send an email to license@isb-sib.ch).

EMBL: S7063; AAB34361.1;
 BSSP: P0074; J000.
 MEROFS: S01219;
 InterPro: IP0001314; Chymotrypsin.
 InterPro: IP0000961; EGF-like
 InterPro: IP0004043; LcCL.
 InterPro: IP000436; Sushi_SCR_CCP.
 InterPro: IP001254; Trypsin.
 InterPro: IP001304; Lectin_C.
 Pfam: PF00054; Lectin_C; 1.
 Pfam: PF00084; Sushi; 5.
 Pfam: PF00084; Trypsin; 1.
 PRINTS: PR00722; CHYMOTRYPSIN.
 SMART: SM00042; CCP; 5.
 SMART: SM00044; CLECT; 1.
 SMART: SM00181; EGF; 1.
 SMART: SM00020; Tryp_Spc; 1.
 PROSITE: PS00615; C-TYPE_LECTIN_1; FALSE_NEG.
 PROSITE: PS00041; C-TYPE_LECTIN_2; 1.
 PROSITE: PS00022; EGF_1; 1.
 PROSITE: PS01186; EGF_2; FALSE_NEG.
 PROSITE: PS00820; LcCL; 1.
 PROSITE: PS00240; TRYPSIN_DOM; 1.
 PROSITE: PS00134; TRYPSIN_HIS; 1.
 PROSITE: PS00135; TRYPSIN_SER; 1.
 Hydrolase; Serine protease; Signal;
 KW Glycoprotein; Cell adhesion; EGF-like domain; Sushi; Repeat.
 FT SIGNAL 1 25 BY SIMILARITY.
 FT CHAIN 26 1019 LIMULUS CLOTTING FACTOR C.
 FT CHAIN 26 690 LIMULUS CLOTTING FACTOR C, HEAVY CHAIN.
 FT CHAIN 691 1019 LIMULUS CLOTTING FACTOR C, LIGHT CHAIN.
 FT CHAIN 691 762 LIMULUS CLOTTING FACTOR C, A CHAIN.

FT CHAIN 763 1019 LIMULUS CLOTTING FACTOR C, E CHAIN.
 FT DOMAIN 102 137 EGF-LIKE.
 FT DOMAIN 142 195 SUSHI 1.
 FT DOMAIN 200 254 SUSHI 2.
 FT DOMAIN 260 321 SUSHI 3.
 FT DOMAIN 325 421 LcCL.
 FT DOMAIN 436 568 C-TYPE LECTIN
 FT DOMAIN 576 634 SUSHI 4.
 FT DOMAIN 685 748 SUSHI 5.
 FT DOMAIN 763 1019 SERINE PROTEASE.
 FT ACT_SITE 809 809 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT ACT_SITE 865 865 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT ACT_SITE 966 966 CHARGE RELAY SYSTEM (BY SIMILARITY).
 FT BINDING 960 960 SUBSTRATE (BY SIMILARITY).
 FT DOMAIN 643 689 PRO-RCH.
 FT DISULFID 106 118 BY SIMILARITY.
 FT DISULFID 112 125 BY SIMILARITY.
 FT DISULFID 127 136 BY SIMILARITY.
 FT DISULFID 436 447 BY SIMILARITY.
 FT DISULFID 464 564 BY SIMILARITY.
 FT DISULFID 538 556 BY SIMILARITY.
 FT DISULFID 794 810 BY SIMILARITY.
 FT DISULFID 932 951 BY SIMILARITY.
 FT DISULFID 962 996 BY SIMILARITY.
 FT CARBOHYD 523 523 N-LINKED (GLNAC; ...) (POTENTIAL).
 FT CARBOHYD 534 534 N-LINKED (GLNAC; ...) (POTENTIAL).
 FT CARBOHYD 624 624 N-LINKED (GLNAC; ...) (POTENTIAL).
 FT CARBOHYD 740 740 N-LINKED (GLNAC; ...) (POTENTIAL).
 FT CARBOHYD 767 767 N-LINKED (GLNAC; ...) (POTENTIAL).
 FT CARBOHYD 912 912 N-LINKED (GLNAC; ...) (POTENTIAL).
 SQ SEQUENCE 1019 AA; 112429 MW; 5187 ED8B17B6C3 CRC64;
 Query Match 17.08; Score 12.15; BB 1; Length 1019;
 Best Local Similarity 24.78; Pred NC 4.1e 05;
 Matches 39; Conservative 28; M-Smarches 54; Indels 47; Gaps 8;
 QY 2 ISCDF-----PPEV-----KNARFAYSLPVPPTVLTITCSPSYKLIGKAL 44
 DE LRO ISLNGQWSNFPKCIIECAVSSPFGKVNALSCDIECATIRFSCHSPYVLTIGETL 219
 QY 45 FCISLHNOVHATWDKAPPIESVNTISCS-DPI---VPGCFMKKSKAFPHCDVS 96
 DE 240 TC---QSNQWNGIPOCKNL---VFGPDLQVNHAEHKVIGVEKYGQFP--GTEV 240
 QY 97 TPTCFANFTMGSKTVWCQANMWC---ETALVCESD 131
 DE 291 TVTSCGNVFLMGFDLTKCNPIGWSWSQ-SQKQVADSE 328
 RESULT 38
 APOL_HOVIN
 ID A_09H_HOVIN STANDARD; PRT; 145 AA
 AC I17690; Q38052;
 DT 01-AUG-1990 (Rel. 15, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 15-OCT-2001 (Rel. 40, Last annotation update)
 DE Beta-2-glycoprotein I precursor (Apolipoprotein H) (Apo H) (H2GPI)
 DE (Beta(2)GPI).
 GN APOL.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae.
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxID=5913;
 RN 1
 PP SEQUENCE FROM N.A.
 RC TISSUE=Liver.
 RA Gao B., Virnaci M., Pomm E., Lazar W., Sley E., Sakauchi K.,
 RA Appella E., Kunos G., Takacs E.;
 RI Submitted (Aug-1992) to the EMBL/Genbank/DBJ databases
 RF [2]
 RE SEQUENCE 38 145 FROM N.A., PARTIAL SEQUENCE. AND DISULFIDE BONDS.
 RC TISSUE=Liver;


```

RN [6]
RP REVIEW
RX MEDLINE=94226679; PubMed 8172644;
RA Ziptel P.F., Skerka C.;
RT "Complement factor H and related proteins: an expanding family of
RL complement-regulatory proteins?";
RL Immunol. Today 15:121-126(1994).
CC -! FUNCTION: MIGHT BE INVOLVED IN COMPLEMENT REGULATION. CAN
CC ASSOCIATE WITH LIPIDPROTEINS AND MAY PLAY A ROLE IN LIPID
CC METABOLISM.
CC -! SUBCELLULAR LOCATION: Extracellular.
CC -! TISSUE SPECIFICITY: LIVER.
CC -! PTM: N-GLYCOSYLATED. TWO FORMS ARE OBSERVED; ONE WITH A SINGLE
CC SIDE CHAIN AND THE OTHER WITH TWO.
CC -! SIMILARITY: CONTAINS 5 SUSHI (SCR) DOMAINS.
CC -! SIMILARITY: STRONG, TO FACTOR H.
CC
CC This SWISS PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed, usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL: M65292; AAA35946.1;
DR EMBL: M65293; AAA35947.1;
DR EMBL: A1049741; CA93064.1;
DR EMBL: X56209; CA93066.1;
DR FIC: A40455; A40455;
DR FIC: S14604; S14604;
DR ISSP: F10998; 1VDV.
DR MIM: 144371;
DR InterPro: IP000436; Sushi_SCR_CCP.
DR Pfam: PF00084; sush1; 5.
DR SMART: SM00042; CCP; 5.
KW Repeat: Glycoprotein; Sushi; Signal; Polymorphism.
FT SIGNAL 1 18
FT CHAIN 19 440
FT DOMAIN 22 84
FT DOMAIN 86 141
FT DOMAIN 146 202
FT DOMAIN 207 264
FT DOMAIN 265 328
FT CARBOHYD 126 126
FT CARBOHYD 194 194
FT VARIANT 157 157
FT VARIANT 159 159
FT VARIANT 175 175
FT VARIANT 175 175
FT VARIANT 71 71
FT VARIANT 71 71
FT CONFLICT 71 71
FT SEQUENCE 440 AA; 37661 MW; 8DC0D4F92A85E035 CRC64;
GCuty Match 16.7%; Score 125.5; DB:1; Length 430;
Best Local Similarity 26.5%; Pred. No. 1,9e-05;
Matches 45; Conservative 25; Mismatches 59; Indels 13; Gaps 7;
UY 1 ELSVTPPEVKNARKPYSLFIVP GTVLRVTCSPSVRLIGERAKFQISENQVHATWDKA 59
DE 144 DTSQVNPPTVGNAYIVSRQMSKYISGEVRYQCRSPYEMFGDEEVMGLNGN-----WTE- 197
UY 60 PPHCSVAKRTICSS DPTIVGDFPMNKISKAPFRHGDSDVFTCKANFTMKSKIVVWCOANE 118
DE 198 PPQKC DSTCKGCPPPHIDNQTITSEPLSVYAPASSVVEYQCNLYQLEGNKRITCR-NG 254
UY 119 MMS PTALPG 128
DE 255 QWSEPPKCHPC 266
RESULT 40

```

```

LEM3_BOVIN
ID LEM3_BOVIN STANDARD; PRT: 646 AA.
AC P42201;
DT 01-NOV-1995 (rel. 32, last sequence update)
DT 01-NOV-1995 (rel. 32, last sequence update)
DT 15-JUL-1999 (rel. 38, last annotation update)
DE P-selectin precursor (Granule membrane protein 140) (GMP-140) (PAI-SEM)
DE (CD62P) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3).
GN S-IP.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Crariata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Luminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN 111
RP SEQUENCE FROM N.A.
RC TISSUE=Capillary endothelium;
RX MEDLINE=93243994; PubMed-7683458;
RA Strubel N.A., Nguyen M., Kansas G.J., Tedder T.F., Fischell J.;
RT "Isolation and characterization of a bovine cDNA encoding a
RT functional homolog of human p-selectin";
RL Biochem. Biophys. Res. Commun. 192:335-344(1993).
CC -! FUNCTION: CA(2+)-DEPENDENT RECEPTOR FOR MYELOID CELLS THAT BINDS
CC TO CARBOHYDRATES ON NEUTROPHILS AND MONOCYTES. MEDIATES THE
CC INTERACTION OF ACTIVATED ENDOTHELIAL CELLS OR PLATELETS WITH
CC LEUKOCYTES. THE LIGAND RECOGNIZED IS SIALYL-LEWIS X.
CC -! SUBCELLULAR LOCATION: TYPE I membrane protein.
CC -! TISSUE SPECIFICITY: STORED IN ALPHA-GRANULES OF PLATELETS
CC AND WEIBEL PALADE BODIES OF ENDOTHELIAL CELLS. UPON CELL
CC ACTIVATION BY AGONISTS, P-SELECTIN IS TRANSPORTED RAPIDLY TO
CC THE CELL SURFACE.
CC -! SIMILARITY TO OTHER SELECTINS/LECAMS.
CC -! SIMILARITY: CONTAINS 1 C-TYPE LIX IN FAMILY DOMAIN.
CC -! SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
CC -! SIMILARITY: CONTAINS 6 SUSHI (SCR) DOMAINS; BOVINE P-LECTIN LACKS
CC THE HUMAN SUSHI-3, -4 AND -7 EQUIVALENTS.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed, usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/
CC or send an email to license@isb-sib.ch).
CC
DR EMBL: U1241; AAA30743.1;
DR HSP: P16109; IPSH.
DR InterPro: IP000561; EGF-Like.
DR InterPro: IP0002396; Selectin.
DR InterPro: IP000436; Sushi_SCR_CCP.
DR InterPro: IP001304; lectin_C.
DR Pfam: PF00084; EGF; 1.
DR Pfam: PF00084; lectin_C; 1.
DR Pfam: PF00084; sush1; 6.
DR PRINTS: PF00343; SELECTIN.
DR SMART: SM00042; CCP; 6.
DR SMART: SM00042; CLECT; 1.
DR SMART: SM00341; EGF; 1.
DR PROSITE: PS02022; EGF_1; 1.
DR PROSITE: PS01186; EGF_2; 1.
DR PROSITE: PS03615; C-TYPE-LECTIN_1;
DR PROSITE: PS03041; C-TYPE-LECTIN_2;
KW Cell adhesion; Transmembrane; Glycoprotein; EGF-like domain; Lectin;
FT SIGNAL 1 41
FT CHAIN 42 646
FT DOMAIN 42 587
FT TRANSMEM 588 611
FT DOMAIN 612 646
FT DOMAIN 58 158
FT DOMAIN 159 195
FT DOMAIN 199 258
FT DOMAIN 261 320

```



```

DR 250 KGTW--SFLPTCRESKL 266
RESULT 42
LEM2_PIG
ID LEM2_PIG STANDARD: PRT: 484 AA.
AC P08110;
DI 01-FEB-1996 (Rel. 33, Created)
DI 01-FEB-1996 (Rel. 33, last sequence update)
DI 15-JUL-1998 (Rel. 36, last annotation update)
DE E-selectin precursor (Endothelial leukocyte adhesion molecule 1)
DE (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2)
DE (CD62E).
EN SELE.
OS Sus scrofa (Pig).
OC Eukaryota; Metazoa; Chordata; Gliata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OX NCBI_TaxID=9923;
RN [1]
RP SEQUENCE FROM N.A.
RX TISSUE-Aortic endothelium;
RX MEDLINE=95071192; PubMed=7526854;
RA Rollins S.A., Evans M.J., Johnson K.K., Elliot E.A., Squinto S.P.,
RA Matlis L.A., Roth R.P.;
RT "Molecular and functional analysis of porcine E-selectin reveals a
RT potential role in xenograft rejection.";
RL Biochem. Biophys. Res. Commun. 204:763-771(1994).
RN [2]
RP SEQUENCE FROM N.A.
RX TISSUE-Aortic endothelium;
RX MEDLINE=94271236; PubMed=7516159;
RA Isang V.T.M., Haskard D.O., Robinson M.K.;
RT "Cloning and expression kinetics of porcine vascular cell adhesion
RT molecule.";
RL Biochem. Biophys. Res. Commun. 201:805-805(1994).
CC 1 FUNCTION: EXPRESSED ON CYTOKINE INDUCED ENDOTHELIAL CELLS AND
CC MEDIATES THEIR BINDING TO LEUKOCYTES. THE LIGAND RECOGNIZED BY
CC ELAM-1 IS STAYL-LIPWIS X (ALPHA(1->3)FUCOSYLATED DERIVATIVES OF
CC POLYLACTOSAMINE THAT ARE FOUND AT THE NONREDUCING TERMINI OF
CC GLYCOLIPIDS).
CC 1 FUNCTION: PLAYS AN IMPORTANT ROLE IN ACUTE CELLULAR ALLOGRAFT
CC REJECTION AND PROBABLY ALSO IN XENOGRAFT REJECTION.
CC 1 SUBCELLULAR LOCATION: Type 1 membrane protein.
CC 1 SIMILARITY: TO OTHER SELECTINS/LECAMs.
CC 1 SIMILARITY: CONTAINS 1 C-TYPE LECTIN FAMILY DOMAIN
CC 1 SIMILARITY: CONTAINS 4 SUSHI (SCR) DOMAINS.
CC 1 SIMILARITY: CONTAINS 1 EGF-LIKE DOMAIN.
CC 1 THE HUMAN SUSHI-1 AND -4 EQUIVALENTS.
CC
CC THIS SWISS-PROT entry is copyrighted. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb.sib.ch/announce/
CC or send an email to license@isb.sib.ch).
CC
DR EMBL: L39076; AAA61545.1;
DR EMBL: 008450; AAA21541.1;
DR HSSP: P16581; IESL.
DR InterPro: IPR000561; EGF-like.
DR InterPro: IPR002196; Selectin.
DR InterPro: IPR000436; Sush1_SCR_CCP.
DR InterPro: IPR001304; lectin_C.
DR Pfam: PF00009; EGF; 1.
DR Pfam: PF00084; Sush1; 4.
DR PRINTS: PR00343; SELECTIN.
DR SMART: SM00042; CCP; 4.
DR SMART: SM00044; CLECT; 1.
DR SMART: SM00181; EGF; 1.
DR PROSITE: PS00022; EGF_1; 1.
DR PROSITE: PS01186; EGF_2; 1.
DR PROSITE: PS00615; C-TYPE LECTIN_1; 1.
DR PROSITE: PS50041; C-TYPE LECTIN_2; 1.
KW Cell adhesion, Transmembrane, Glycoprotein, EGF-like domain, Lectin.
FT Selectin, Signal, Sush1, Repeat.
FT SIGNAL 1 22 POTENTIAL..
FT CHAIN 23 484 E-SELECTIN.
FT DOMAIN 23 429 EXTRA-CELLULAR (POTENTIAL)..
FT TRANSMEM 430 451 POTENTIAL..
FT DOMAIN 452 484 CYTOPLASMIC (POTENTIAL)..
FT DOMAIN 39 139 C-TYPE LECTIN (SHORT FORM)..
FT DOMAIN 140 176 EGF-LIKE.
FT DOMAIN 180 236 SUSHI 1.
FT DOMAIN 239 299 SUSHI 2.
FT DOMAIN 302 362 SUSHI 3.
FT DOMAIN 365 421 SUSHI 4.
FT DISULFID 41 139 HY SIMILARITY.
FT DISULFID 112 131 HY SIMILARITY.
FT DISULFID 144 155 BY SIMILARITY.
FT DISULFID 149 164 BY SIMILARITY.
FT DISULFID 166 175 BY SIMILARITY.
FT DISULFID 181 222 BY SIMILARITY.
FT DISULFID 208 235 HY SIMILARITY.
FT DISULFID 240 285 BY SIMILARITY.
FT DISULFID 271 298 BY SIMILARITY.
FT DISULFID 303 348 BY SIMILARITY.
FT DISULFID 334 361 HY SIMILARITY.
FT DISULFID 366 407 HY SIMILARITY.
FT DISULFID 393 420 HY SIMILARITY.
FT CARBOHYD 61 61 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 65 65 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 79 79 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 160 160 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 201 201 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 254 254 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 376 376 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CARBOHYD 400 400 N-LINKED (GLNA.. ) (POTENTIAL)..
FT CONFLICT 253 253 C->Y (IN REF. 2).
FT CONFLICT 313 313 L->I (IN REF. 2).
FT CONFLICT 321 321 T->N (IN REF. 2).
FT CONFLICT 327 327 K->N (IN REF. 2).
FT CONFLICT 363 363 V->A (IN REF. 2).
FT CONFLICT 384 384 V->S (IN REF. 2).
FT CONFLICT 461 484 KEVSSSSSELDQPNSSSYQMPSDLI ->
NLFPAAPAFNPMIDPTKCIIT (IN REF. 2).
SQ SEQUENCE 484 AA; 52567 MW; APPFAF25CIEFD013 CRG64;
Query Match 16.48; Score 124.5; DB 1; Length 484;
Best Local Similarity 23.84; Pred. No. 4.6e-05;
Matches 34; Conservative 18; Mismatches 62; Indels 29; Gaps 5;
QY 2 ISCDP-IP-VKNARKPYSLPIVP-----GIVLYTCISYSLICERKAIICISNVHVAIW 56
Db 1/3 LQCEVWECDALENPVNVCVVICPSLPNNTTCACECKEFGELIGPEILQCTSS-----SSW 228
QY 57 KRAPPCISV-----NKTISCDPPIVHGIPMNGSKAPFRHIGDSVFTTUKANFTMK 107
Db 229 DCKKPKPCAVICQIVGHQPNQIWSC-----NHSSGEPAYKSYCHFTCAEGECIQ 278
QY 108 GSKTVNCLANEMWGPTALPVCEs 130
Db 279 GPAQ13CIAQSGWTQQA-PVCKA 300
RESULT 43
APOE_CANFA
ID APOILCANFA STANDARD: PRT: 345 AA.
AC P33703;
DI 01-FEB-1994 (Rel. 28, Created)
DI 01-FEB-1994 (Rel. 28, last sequence update)
DI 16-OCT-2001 (Rel. 40, last annotation update)
DE Beta-2-glycoprotein I precursor (Apolipoprotein II) (Apo-II) (B23PI)
DE (Beta(2)GPI).

```

GN CUBIC LAMINARIS (dead);
 CC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis;
 CC NCBI_LINID: 9616;
 GN [1]
 GN SEQUENCE FROM N.A.
 RP STRAIN-BEAGLE; TISSUE Liver;
 RX MEDLINE: 94221500; PubMed: 7682067;
 RA Sellar G.A., Krone J., Mohd H., Peoples M.E., Browne N.,
 RA Whitehead A.S.;
 RI "Characterization and acute phase modulation of canine apolipoprotein
 B (beta 2 glycoprotein 1)";
 RI Biochem. Biophys. Res. Commun. 191:1288-1294(1993).
 CC FUNCTION: BINDS TO VARIOUS KINDS OF NEGATIVELY CHARGED SUBSTANCES
 CC SUCH AS HEPARIN, PHOSPHOLIPIDS, AND DEXTRAN SULFATE. MAY PREVENT
 CC ACTIVATION OF THE INTRINSIC BLOOD COAGULATION CASCADE BY BINDING
 CC TO PHOSPHOLIPIDS ON THE SURFACE OF DAMAGED CELLS.
 CC 1. TISSUE SPECIFICITY: PLASMA.
 CC 1. SIMILARITY: CONTAINS 4 SUSHI (SUSHI) DOMAINS.
 CC THIS SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/sequence/>
 CC or send an email to license@isb-sib.ch).
 CC EMBL: X72933; CAA51448.1;
 DR PIR: JN0465; JN0465;
 DR RESID: P02490; 1012;
 DR Information: P02490; SUSHI STR exp.
 DR PIR: P02490; SUSHI: 4;
 DR SMART: SMO0042; Exp: 4;
 KW Report in binding: glycoprotein; Plasma; Repeat; SUSHI; Signal;
 FT SIGNAL 1 19
 FT CHAIN 20 445
 FT CHAIN 22 80
 FT CHAIN 84 146
 FT CHAIN 141 203
 FT CHAIN 204 293
 FT CHAIN 264 445
 FT DISULFID 24 66
 FT DISULFID 51 79
 FT DISULFID 84 124
 FT DISULFID 110 147
 FT DISULFID 142 188
 FT DISULFID 174 200
 FT DISULFID 205 248
 FT DISULFID 244 260
 FT DISULFID 264 315
 FT DISULFID 300 325
 FT DISULFID 407 445
 FT CARBOHYD 117 117
 FT CARBOHYD 162 162
 FT CARBOHYD 184 184
 FT CARBOHYD 194 194
 FT CARBOHYD 253 253
 FT CARBOHYD 445 445
 SQ SEQUENCE 445 AA; 66403 MW; 6082624879B74FEA CRC64;
 Query Match 16.4%; Score 124; DB 1; Length 445;
 Best local similarity: 26.1%; Pctd No. 4,600,0%;
 Matches 46; Conservative 18; Mismatches 68; Indels 16; Gaps 5;
 2Y 2 LSDFPEVKNAR KAVSLFIVGIVLYRTCSPSYRLIGKAIETSENQVHATW 57
 140 VPDPSPVKEALLSVKELATNNSLYGNKAVEGLPHYAMGNDTITCTA --HGWT 195
 58 KAPITLSEVKNKFLSDSPVIFGLPMKSKKAPFRRGDSVFTCKANFIMAGSLVWQA 116
 190 TLPEKE VKPFPSPGFGVGVNFAKGLIYKDKAMYGCHDTITLDRPEVVEKN 250

QY 117 NEMWGPIALPWCSEDEPL 134
 DB 251 PCNW SACSCHASCKL 266
 RESULT 44
 DAF_CAVPO
 ID DAF_CAVPO STANDARD; PRT: 507 AA;
 AC 060401; 060402; 060403; 060404; 060405; 060406; 060407; 060408;
 AC 060409; 060410; 060411; 060412; 060413; 060414; 060415; 060416;
 AC 060417; 060418; 060419; 060420; 060421; 060422; 060423; 060424;
 AC 060425; 060426; 060427; 060428; 060429; 060430; 060431; 060432;
 AC 060433; 060434; 060435; 060436; 060437; 060438; 060439; 060440;
 AC 060441; 060442; 060443; 060444; 060445; 060446; 060447; 060448;
 AC 060449; 060450; 060451; 060452; 060453; 060454; 060455; 060456;
 AC 060457; 060458; 060459; 060460; 060461; 060462; 060463; 060464;
 AC 060465; 060466; 060467; 060468; 060469; 060470; 060471; 060472;
 AC 060473; 060474; 060475; 060476; 060477; 060478; 060479; 060480;
 AC 060481; 060482; 060483; 060484; 060485; 060486; 060487; 060488;
 AC 060489; 060490; 060491; 060492; 060493; 060494; 060495; 060496;
 AC 060497; 060498; 060499; 060500; 060501; 060502; 060503; 060504;
 AC 060505; 060506; 060507; 060508; 060509; 060510; 060511; 060512;
 AC 060513; 060514; 060515; 060516; 060517; 060518; 060519; 060520;
 AC 060521; 060522; 060523; 060524; 060525; 060526; 060527; 060528;
 AC 060529; 060530; 060531; 060532; 060533; 060534; 060535; 060536;
 AC 060537; 060538; 060539; 060540; 060541; 060542; 060543; 060544;
 AC 060545; 060546; 060547; 060548; 060549; 060550; 060551; 060552;
 AC 060553; 060554; 060555; 060556; 060557; 060558; 060559; 060560;
 AC 060561; 060562; 060563; 060564; 060565; 060566; 060567; 060568;
 AC 060569; 060570; 060571; 060572; 060573; 060574; 060575; 060576;
 AC 060577; 060578; 060579; 060580; 060581; 060582; 060583; 060584;
 AC 060585; 060586; 060587; 060588; 060589; 060590; 060591; 060592;
 AC 060593; 060594; 060595; 060596; 060597; 060598; 060599; 060600;
 AC 060601; 060602; 060603; 060604; 060605; 060606; 060607; 060608;
 AC 060609; 060610; 060611; 060612; 060613; 060614; 060615; 060616;
 AC 060617; 060618; 060619; 060620; 060621; 060622; 060623; 060624;
 AC 060625; 060626; 060627; 060628; 060629; 060630; 060631; 060632;
 AC 060633; 060634; 060635; 060636; 060637; 060638; 060639; 060640;
 AC 060641; 060642; 060643; 060644; 060645; 060646; 060647; 060648;
 AC 060649; 060650; 060651; 060652; 060653; 060654; 060655; 060656;
 AC 060657; 060658; 060659; 060660; 060661; 060662; 060663; 060664;
 AC 060665; 060666; 060667; 060668; 060669; 060670; 060671; 060672;
 AC 060673; 060674; 060675; 060676; 060677; 060678; 060679; 060680;
 AC 060681; 060682; 060683; 060684; 060685; 060686; 060687; 060688;
 AC 060689; 060690; 060691; 060692; 060693; 060694; 060695; 060696;
 AC 060697; 060698; 060699; 060700; 060701; 060702; 060703; 060704;
 AC 060705; 060706; 060707; 060708; 060709; 060710; 060711; 060712;
 AC 060713; 060714; 060715; 060716; 060717; 060718; 060719; 060720;
 AC 060721; 060722; 060723; 060724; 060725; 060726; 060727; 060728;
 AC 060729; 060730; 060731; 060732; 060733; 060734; 060735; 060736;
 AC 060737; 060738; 060739; 060740; 060741; 060742; 060743; 060744;
 AC 060745; 060746; 060747; 060748; 060749; 060750; 060751; 060752;
 AC 060753; 060754; 060755; 060756; 060757; 060758; 060759; 060760;
 AC 060761; 060762; 060763; 060764; 060765; 060766; 060767; 060768;
 AC 060769; 060770; 060771; 060772; 060773; 060774; 060775; 060776;
 AC 060777; 060778; 060779; 060780; 060781; 060782; 060783; 060784;
 AC 060785; 060786; 060787; 060788; 060789; 060790; 060791; 060792;
 AC 060793; 060794; 060795; 060796; 060797; 060798; 060799; 060800;
 AC 060801; 060802; 060803; 060804; 060805; 060806; 060807; 060808;
 AC 060809; 060810; 060811; 060812; 060813; 060814; 060815; 060816;
 AC 060817; 060818; 060819; 060820; 060821; 060822; 060823; 060824;
 AC 060825; 060826; 060827; 060828; 060829; 060830; 060831; 060832;
 AC 060833; 060834; 060835; 060836; 060837; 060838; 060839; 060840;
 AC 060841; 060842; 060843; 060844; 060845; 060846; 060847; 060848;
 AC 060849; 060850; 060851; 060852; 060853; 060854; 060855; 060856;
 AC 060857; 060858; 060859; 060860; 060861; 060862; 060863; 060864;
 AC 060865; 060866; 060867; 060868; 060869; 060870; 060871; 060872;
 AC 060873; 060874; 060875; 060876; 060877; 060878; 060879; 060880;
 AC 060881; 060882; 060883; 060884; 060885; 060886; 060887; 060888;
 AC 060889; 060890; 060891; 060892; 060893; 060894; 060895; 060896;
 AC 060897; 060898; 060899; 060900; 060901; 060902; 060903; 060904;
 AC 060905; 060906; 060907; 060908; 060909; 060910; 060911; 060912;
 AC 060913; 060914; 060915; 060916; 060917; 060918; 060919; 060920;
 AC 060921; 060922; 060923; 060924; 060925; 060926; 060927; 060928;
 AC 060929; 060930; 060931; 060932; 060933; 060934; 060935; 060936;
 AC 060937; 060938; 060939; 060940; 060941; 060942; 060943; 060944;
 AC 060945; 060946; 060947; 060948; 060949; 060950; 060951; 060952;
 AC 060953; 060954; 060955; 060956; 060957; 060958; 060959; 060960;
 AC 060961; 060962; 060963; 060964; 060965; 060966; 060967; 060968;
 AC 060969; 060970; 060971; 060972; 060973; 060974; 060975; 060976;
 AC 060977; 060978; 060979; 060980; 060981; 060982; 060983; 060984;
 AC 060985; 060986; 060987; 060988; 060989; 060990; 060991; 060992;
 AC 060993; 060994; 060995; 060996; 060997; 060998; 060999; 061000;
 AC 061001; 061002; 061003; 061004; 061005; 061006; 061007; 061008;
 AC 061009; 061010; 061011; 061012; 061013; 061014; 061015; 061016;
 AC 061017; 061018; 061019; 061020; 061021; 061022; 061023; 061024;
 AC 061025; 061026; 061027; 061028; 061029; 061030; 061031; 061032;
 AC 061033; 061034; 061035; 061036; 061037; 061038; 061039; 061040;
 AC 061041; 061042; 061043; 061044; 061045; 061046; 061047; 061048;
 AC 061049; 061050; 061051; 061052; 061053; 061054; 061055; 061056;
 AC 061057; 061058; 061059; 061060; 061061; 061062; 061063; 061064;
 AC 061065; 061066; 061067; 061068; 061069; 061070; 061071; 061072;
 AC 061073; 061074; 061075; 061076; 061077; 061078; 061079; 061080;
 AC 061081; 061082; 061083; 061084; 061085; 061086; 061087; 061088;
 AC 061089; 061090; 061091; 061092; 061093; 061094; 061095; 061096;
 AC 061097; 061098; 061099; 061100; 061101; 061102; 061103; 061104;
 AC 061105; 061106; 061107; 061108; 061109; 061110; 061111; 061112;
 AC 061113; 061114; 061115; 061116; 061117; 061118; 061119; 061120;
 AC 061121; 061122; 061123; 061124; 061125; 061126; 061127; 061128;
 AC 061129; 061130; 061131; 061132; 061133; 061134; 061135; 061136;
 AC 061137; 061138; 061139; 061140; 061141; 061142; 061143; 061144;
 AC 061145; 061146; 061147; 061148; 061149; 061150; 061151; 061152;
 AC 061153; 061154; 061155; 061156; 061157; 061158; 061159; 061160;
 AC 061161; 061162; 061163; 061164; 061165; 061166; 061167; 061168;
 AC 061169; 061170; 061171; 061172; 061173; 061174; 061175; 061176;
 AC 061177; 061178; 061179; 061180; 061181; 061182; 061183; 061184;
 AC 061185; 061186; 061187; 061188; 061189; 061190; 061191; 061192;
 AC 061193; 061194; 061195; 061196; 061197; 061198; 061199; 061200;
 AC 061201; 061202; 061203; 061204; 061205; 061206; 061207; 061208;
 AC 061209; 061210; 061211; 061212; 061213; 061214; 061215; 061216;
 AC 061217; 061218; 061219; 061220; 061221; 061222; 061223; 061224;
 AC 061225; 061226; 061227; 061228; 061229; 061230; 061231; 061232;
 AC 061233; 061234; 061235; 061236; 061237; 061238; 061239; 061240;
 AC 061241; 061242; 061243; 061244; 061245; 061246; 061247; 061248;
 AC 061249; 061250; 061251; 061252; 061253; 061254; 061255; 061256;
 AC 061257; 061258; 061259; 061260; 061261; 061262; 061263; 061264;
 AC 061265; 061266; 061267; 061268; 061269; 061270; 061271; 061272;
 AC 061273; 061274; 061275; 061276; 061277; 061278; 061279; 061280;
 AC 061281; 061282; 061283; 061284; 061285; 061286; 061287; 061288;
 AC 061289; 061290; 061291; 061292; 061293; 061294; 061295; 061296;
 AC 061297; 061298; 061299; 061300; 061301; 061302; 061303; 061304;
 AC 061305; 061306; 061307; 061308; 061309; 061310; 061311; 061312;
 AC 061313; 061314; 061315; 061316; 061317; 061318; 061319; 061320;
 AC 061321; 061322; 061323; 061324; 061325; 061326; 061327; 061328;
 AC 061329; 061330; 061331; 061332; 061333; 061334; 061335; 061336;
 AC 061337; 061338; 061339; 061340; 061341; 061342; 061343; 061344;
 AC 061345; 061346; 061347; 061348; 061349; 061350; 061351; 061352;
 AC 061353; 061354; 061355; 061356; 061357; 061358; 061359; 061360;
 AC 061361; 061362; 061363; 061364; 061365; 061366; 061367; 061368;
 AC 061369; 061370; 061371; 061372; 061373; 061374; 061375; 061376;
 AC 061377; 061378; 061379; 061380; 061381; 061382; 061383; 061384;
 AC 061385; 061386; 061387; 061388; 061389; 061390; 061391; 061392;
 AC 061393; 061394; 061395; 061396; 061397; 061398; 061399; 061400;
 AC 061401; 061402; 061403; 061404; 061405; 061406; 061407; 061408;
 AC 061409; 061410; 061411; 061412; 061413; 061414; 061415; 061416;
 AC 061417; 061418; 061419; 061420; 061421; 061422; 061423; 061424;
 AC 061425; 061426; 061427; 061428; 061429; 061430; 061431; 061432;
 AC 061433; 061434; 061435; 061436; 061437; 061438; 061439; 061440;
 AC 061441; 061442; 061443; 061444; 061445; 061446; 061447; 061448;
 AC 061449; 061450; 061451; 061452; 061453; 061454; 061455; 061456;
 AC 061457; 061458; 061459; 061460; 061461; 061462; 061463; 061464;
 AC 061465; 061466; 061467; 061468; 061469; 061470; 061471; 061472;
 AC 061473; 061474; 061475; 061476; 061477; 061478; 061479; 061480;
 AC 061481; 061482; 061483; 061484; 061485; 061486; 061487; 061488;
 AC 061489; 061490; 061491; 061492; 061493; 061494; 061495; 061496;
 AC 061497; 061498; 061499; 061500; 061501; 061502; 061503; 061504;
 AC 061505; 061506; 061507; 061508; 061509; 061510; 061511; 061512;
 AC 061513; 061514; 061515; 061516; 061517; 061518; 061519; 061520;
 AC 061521; 061522; 061523; 061524; 061525; 061526; 061527; 061528;
 AC 061529; 061530; 061531; 061532; 061533; 061534; 061535; 061536;
 AC 061537; 061538; 061539; 061540; 061541; 061542; 061543; 061544;
 AC 061545; 061546; 061547; 061548; 061549; 061550; 061551; 061552;
 AC 061553; 061554; 061555; 061556; 061557; 061558; 061559; 061560;
 AC 061561; 061562; 061563; 061564; 061565; 061566; 061567; 061568;
 AC 061569; 061570; 061571; 061572; 061573; 061574; 061575; 061576;
 AC 061577; 061578; 061579; 061580; 061581; 061582; 061583; 061584;
 AC 061585; 061586; 061587; 061588; 061589; 061590; 061591; 061592;
 AC 061593; 061594; 061595; 061596; 061597; 061598; 061599; 061600;
 AC 061601; 061602; 061603; 061604; 061605; 061606; 061607; 061608;
 AC 061609; 061610; 061611; 061612; 061613; 061614; 061615; 061616;
 AC 061617; 061618; 061619; 061620; 061621; 061622; 061623; 061624;
 AC 061625; 061626; 061627; 061628; 061629; 061630; 061631; 061632;
 AC 061633; 061634; 061635; 061636; 061637; 061638; 061639; 061640;

Genature version 5.1.3

Copyright (c) 1993 - 2002 CompuGen Ltd.

OM protein protein search, using sw model

Run on: November 6, 2002, 14:06:00 : Search time 21.5799 Seconds
(without alignments)
1042.224 Million cell updates/sec

File: OS 09-834-309-6

Perfect score: 752

Sequence: 1 EISCDPPEVKNAKPKYYSI ANEMWPTALPWCSEDFPLE 145

Scoring table: BL0SUM62

Gapop 10.0, Gapext 0.5

Searched: 562222 seqs, 172994929 residues

Total number of hits satisfying chosen parameters: 562222

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post processing: Minimum Match 0%

Maximum Match 100%

Listing first 100 summaries

Database:

SPTFEMBL_100*

1: sp.archaea*

2: sp.bacteria*

3: sp.fungi*

4: sp.human*

5: sp.invertebrate*

6: sp.mammal*

7: sp.mhc*

8: sp.orquelella*

9: sp.phage*

10: sp.plant*

11: sp.todent*

12: sp.virus*

13: sp.vertebrate*

14: sp.unclassified*

15: sp.virus*

16: sp.bacterioph*

17: sp.archae*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB ID	Description
1	752	100.0	1042	11 Q99833	Q99833 mus musculus
2	749	99.6	679	11 Q99254	Q99254 mus musculus
3	499	66.4	1045	6 Q46545	Q46545 ovis aries
4	466.5	62.0	1042	4 Q14866	Q14866 homo sapien
5	466.5	62.0	1047	4 Q14212	Q14212 homo sapien
6	241.5	40.8	1411	4 Q25628	Q25628 papio hamad
7	224	29.8	533	11 Q08569	Q08569 cavia porce
8	222	29.5	469	11 Q91848	Q91848 mus musculus
9	221.5	29.5	2014	6 Q29540	Q29540 pan troglod
10	221.5	29.5	2039	4 Q16745	Q16745 homo sapien
11	221.5	29.5	2489	4 Q16744	Q16744 homo sapien
12	220.5	29.3	132	4 Q9H099	Q9H099 homo sapien
13	220.5	29.3	132	4 Q9H098	Q9H098 homo sapien
14	219.5	29.2	132	4 Q9H055	Q9H055 homo sapien
15	215.5	28.7	132	4 Q9H054	Q9H054 homo sapien
16	215	28.6	579	11 Q60736	Q60736 mus musculus

SUMMARIES

17	214	28.5	555	11 Q997A1	Q997A1 cavia porce
18	199.5	26.5	363	6 Q02839	Q02839 sus scrofa
19	198.5	26.4	300	11 Q980R2	Q980R2 mus musculus
20	198.5	26.4	365	11 Q88174	Q88174 mus musculus
21	197.5	26.3	263	12 Q89859	Q89859 variola vir
22	197.5	26.3	263	12 Q07033	Q07033 variola vir
23	195.5	26.0	263	12 Q89074	Q89074 variola vir
24	195.5	26.0	263	12 Q89061	Q89061 variola vir
25	193.5	25.7	259	12 Q87613	Q87613 capox viru
26	188.5	25.1	349	4 Q15429	Q15429 homo sapien
27	185.5	24.7	645	12 Q9W802	Q9W802 cavia mola
28	184.5	24.5	285	6 Q19121	Q19121 papio hamad
29	184.5	24.5	1901	4 Q9Y2E1	Q9Y2E1 homo sapien
30	183.5	24.4	661	6 Q29531	Q29531 pan troglod
31	182.5	24.3	315	6 Q28770	Q28770 papio cynoe
32	181.5	24.1	285	6 Q19126	Q19126 macaca fasc
33	181.5	24.1	285	6 Q19127	Q19127 macaca mola
34	181.5	24.1	369	6 P79138	P79138 corysophila
35	178.5	23.7	559	4 Q9H0V2	Q9H0V2 homo sapien
36	177	23.5	451	13 Q9DEG0	Q9DEG0 gallus gall
37	175.5	23.3	222	6 Q19120	Q19120 adus trivi
38	175.5	23.3	222	6 Q19125	Q19125 salicaria sci
39	175.5	23.3	346	6 Q62834	Q62834 salicaria sci
40	174	23.1	355	11 Q920M4	Q920M4 rattus norv
41	173	23.0	3567	11 Q9ES77	Q9ES77 mus musculus
42	172.5	22.9	417	11 Q35520	Q35520 rattus norv
43	172.5	22.9	497	11 Q63612	Q63612 rattus norv
44	172.5	22.9	559	11 Q63131	Q63131 rattus norv
45	172	22.9	1236	11 Q91Y86	Q91Y86 rattus norv
46	171.5	22.8	550	12 P88903	P88903 kaposi's sa
47	170.5	22.7	222	6 Q19122	Q19122 salicaria q
48	170	22.6	395	12 Q972M6	Q972M6 macaca mola
49	168.5	22.4	222	6 Q19124	Q19124 salicaria ny
50	168.5	22.4	314	6 Q62835	Q62835 salicaria ny
51	168.5	22.4	377	6 Q62836	Q62836 salicaria ny
52	168.5	22.4	378	6 Q62837	Q62837 salicaria ny
53	168	22.3	808	11 Q614C4	Q614C4 mus musculus
54	167.5	22.3	222	6 Q1912F	Q1912F salicaria pi
55	167.5	22.3	225	12 Q91MM3	Q91MM3 lung's sht
56	167.5	22.3	550	12 Q40912	Q40912 kaposi's sa
57	167	22.2	483	11 Q64735	Q64735 mus musculus
58	166.5	22.1	522	6 Q28769	Q28769 papio cynoe
59	164.5	21.9	267	11 P97919	P97919 cavia porce
60	164.5	21.9	267	12 Q9DH93	Q9DH93 yata like d
61	164.5	21.9	337	11 P97263	P97263 cavia porce
62	164.5	21.9	339	11 P97261	P97261 cavia porce
63	164.5	21.9	379	11 P70105	P70105 cavia porce
64	164.5	21.9	1653	5 Q9V109	Q9V109 dtrosophila
65	163.5	21.7	522	6 Q28797	Q28797 pan troglod
66	162.5	21.6	300	12 Q908F9	Q908F9 myxoma viru
67	162	21.5	711	4 Q9N015	Q9N015 homo sapien
68	162	21.5	716	4 Q95917	Q95917 homo sapien
69	161	21.4	777	4 Q9N013	Q9N013 homo sapien
70	161	21.4	787	4 Q9N014	Q9N014 homo sapien
71	161	21.4	792	4 Q9Y3J6	Q9Y3J6 homo sapien
72	161	21.4	1024	4 Q9BYH1	Q9BYH1 homo sapien
73	157.5	20.9	669	6 Q28085	Q28085 bras taurus
74	157	20.9	268	12 Q90AX5	Q90AX5 yata monkey
75	156.5	20.8	251	4 Q9ES25	Q9ES25 homo sapien
76	155.5	20.7	222	6 Q19123	Q19123 salicaria
77	155	20.6	3564	11 Q92313	Q92313 mus musculus
78	153.5	20.4	754	13 Q98215	Q98215 cypus mus cu
79	153.5	20.4	754	4 Q98215	Q98215 homo sapien
80	153	20.3	569	4 Q9H8K6	Q9H8K6 mus musculus
81	151	20.1	923	11 Q91X64	Q91X64 mus musculus
82	150	19.9	340	11 Q62479	Q62479 mus musculus
83	150	19.9	359	13 Q73756	Q73756 brachydanio
84	149.5	19.9	194	11 Q9Q7C8	Q9Q7C8 rattus norv
85	149	19.8	390	11 Q92130	Q92130 mus musculus
86	149	19.8	657	4 Q14006	Q14006 homo sapien
87	149	19.8	809	4 Q9H82	Q9H82 homo sapien
88	149	19.8	840	4 Q9H045	Q9H045 homo sapien
89	149	19.8	853	4 Q9H047	Q9H047 homo sapien


```

OX NCBI_TaxID=9548;
RN [1]
RP SEQUENCE FROM N.A.
EX MEDLINE=94292799; PubMed 8021505;
RA Birmingham D.J., Shen X.F., Bourcade D., Nickells M.W., Atkinson J.P.;
RT "Primary sequence of an alternatively spliced form of c-Kit. Candidate
for the 75,000 M(r) complement receptor expressed on chimpanzee
erythrocytes."
EL J. Immunol. 153:691-700(1994).
DR EMBL: L24920; AAA51438.1;
DR HSSP: P08603; IHFI
DR InterPro: IPR001424; SOD_CU_ZN.
DR InterPro: IPR000834; Zn_carboxypept.
DR Pfam: PF00084; sushi; 30.
DR SMART: SM00042; CCP; 30.
DR PROSITE: PS00143; CAPBOXYPEPT_ZN_2; UNKNOWN_2.
DR PROSITE: PS00087; SOD_CU_ZN_1; UNKNOWN_1.
KW Receptor.
FT NON_TER 2014 2014
SQ SEQUENCE 2014 AA; 221281 MW; 6D6C3A74D81F1DB9 CRC64.

Query Match 29.5%; Score 221.5; DB 6; Length 2014.
Best local Similarity 36.8%; Pred. No. 4.9e-16;
Matches 50; Conservative 17; Mismatches 54; Indels 15; Gaps 5;

QY 2 ISCDPPEVKNAKRPYS LPVPGTVLPGFNMKSGKAPFHGDSVTFCKANFTMKSGKIV 52
DB 1492 ISCEPPPTISNG--DFYSNNKTSFNGTIVTYQCHTGDKHQIFELVGRKSTVCTSKDDQ 1549
QY 53 HATWKAAPTCESVKNKFTISCDPVPVPGFNMKSGKAPFHGDSVTFCKANFTMKSGKIV 112
DB 1550 VGVWSSPPRCISTNK---CTAPEVENAIRVPGNRSEFSLTEIVRRCQPSFVWVSHIV 1506
QY 113 WCUANEMWCPITALPVC 128
DB 1607 CCQTNGRWCP-KLPHC 1621

RESULT 10
Q16745 PRELIMINARY; PRT; 2039 AA.
AC Q16745;
DT 01-Nov-1996 (TrEMBLrel. 01, Created)
DT 01-Nov-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE COMPLEMENT RECEPTOR 1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
EX MEDLINE=94065175; PubMed-8245463;
RA Vik D.P., Wong W.W.;
RT "Structure of the gene for the F allele of complement receptor type 1
and sequence of the coding region unique to the S allele."
EL J. Immunol. 151:6214-6224(1993).
DR EMBL: L17418; AAB60694.1; JOINED.
DR EMBL: L17390; AAB60694.1; JOINED.
DR EMBL: L17409; AAB60694.1; JOINED.
DR EMBL: L17419; AAB60694.1; JOINED.
DR EMBL: L17420; AAB60694.1; JOINED.
DR EMBL: L17421; AAB60694.1; JOINED.
DR EMBL: L17422; AAB60694.1; JOINED.
DR EMBL: L17423; AAB60694.1; JOINED.
DR EMBL: L17391; AAB60694.1; JOINED.

```

```

DR EMBL: L17392; AAB60694.1; JOINED.
DR EMBL: L17393; AAB60694.1; JOINED.
DR EMBL: L17394; AAB60694.1; JOINED.
DR EMBL: L17395; AAB60694.1; JOINED.
DR EMBL: L17396; AAB60694.1; JOINED.
DR EMBL: L17397; AAB60694.1; JOINED.
DR EMBL: L17398; AAB60694.1; JOINED.
DR EMBL: L17400; AAB60694.1; JOINED.
DR EMBL: L17401; AAB60694.1; JOINED.
DR EMBL: L17402; AAB60694.1; JOINED.
DR EMBL: L17403; AAB60694.1; JOINED.
DR EMBL: L17404; AAB60694.1; JOINED.
DR EMBL: L17405; AAB60694.1; JOINED.
DR EMBL: L17406; AAB60694.1; JOINED.
DR EMBL: L17407; AAB60694.1; JOINED.
DR EMBL: L17408; AAB60694.1; JOINED.
DR EMBL: L17410; AAB60694.1; JOINED.
DR EMBL: L17411; AAB60694.1; JOINED.
DR EMBL: L17412; AAB60694.1; JOINED.
DR EMBL: L17413; AAB60694.1; JOINED.
DR EMBL: L17414; AAB60694.1; JOINED.
DR EMBL: L17415; AAB60694.1; JOINED.
DR EMBL: L17416; AAB60694.1; JOINED.
DR HSSP: P08603; IHFI.
DR InterPro: IPR001424; SOD_CU_ZN.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR InterPro: IPR000834; Zn_carboxypept.
DR Pfam: PF00084; sushi; 30.
DR SMART: SM00042; CCP; 30.
DR PROSITE: PS00133; CAPBOXYPEPT_ZN_2; UNKNOWN_2.
DR PROSITE: PS00087; SOD_CU_ZN_1; UNKNOWN_1.
KW Receptor.
SQ SEQUENCE 2039 AA; 223633 MW; B2FE0311C6316635 CRC64;

Query Match 29.5%; Score 22.5; DB 4; Length 2039.
Best local Similarity 36.8%; Pred. No. 4.9e-16;
Matches 50; Conservative 17; Mismatches 54; Indels 15; Gaps 5;

QY 2 ISCDPPEVKNAKRPYS--LPVPGTVLPGFNMKSGKAPFHGDSVTFCKANFTMKSGKIV 52
DB 1517 ISCEPPPTISNG--DFYSNNKTSFNGTIVTYQCHTGDKHQIFELVGRKSTVCTSKDDQ 1574
QY 53 HATWKAAPTCESVKNKFTISCDPVPVPGFNMKSGKAPFHGDSVTFCKANFTMKSGKIV 112
DB 1575 VGVWSSPPRCISTNK---CTAPEVENAIRVPGNRSEFSLTEIVRRCQPSFVWVSHIV 1631
QY 113 WCUANEMWCPITALPVC 128
DB 1632 CCQTNGRWCP-KLPHC 1646

RESULT 11
Q16744 PRELIMINARY; PRT; 2439 AA.
AC Q16744;
DT 01-Nov-1996 (TrEMBLrel. 01, Created)
DT 01-Nov-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)
DE COMPLEMENT RECEPTOR 1.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
EX MEDLINE=94065175; PubMed-8245463;
RA Vik D.P., Wong W.W.;
RT "Structure of the gene for the F allele of complement receptor type 1
and sequence of the coding region unique to the S allele."
EL J. Immunol. 151:6214-6224(1993).
DR EMBL: L17418; AAB60694.1; JOINED.
DR EMBL: L17390; AAB60694.1; JOINED.
DR EMBL: L17409; AAB60694.1; JOINED.
DR EMBL: L17419; AAB60694.1; JOINED.
DR EMBL: L17420; AAB60694.1; JOINED.
DR EMBL: L17421; AAB60694.1; JOINED.
DR EMBL: L17422; AAB60694.1; JOINED.
DR EMBL: L17423; AAB60694.1; JOINED.
DR EMBL: L17391; AAB60694.1; JOINED.

```



```

DB 282 SANNSEWP-STPKC 294
II I I I I I
RESULT 20
ID 08H174 PRELIMINARY; PRT: 365 AA.
AC 08H174;
DT 01 NOV 1998 (TRENBLREL, 08, Created)
DT 01 NOV 1998 (TRENBLREL, 08, Last sequence update)
DT 01 JUN 2001 (TRENBLREL, 17, Last annotation update)
DE MEMBRANE COFACTOR PROTEIN (CD46).
GN MFP.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Eumetazoa; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID:10090;
RN 111
RP SEQUENCE FROM N.A.
RA Tsujimura A., Kitamura M., Seya T.;
RT "Molecular cloning of a murine homologue of membrane cofactor protein
(CD46): preferential expression in testicular germ cells.";
RL Thesis (1997).
RL Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
RN 121
RP SEQUENCE FROM N.A.
RA MEDLINE-98129724; PubMed-9461505;
RA Tsujimura A., Shida K., Kitamura M., Nomura M., Tanaka H.,
RA Matsumoto M., Matsumiya K., Okayama A., Nishimura Y., Okabe M.,
RA Seya T.;
RT "Molecular cloning of a murine homologue of membrane cofactor protein
(CD46): preferential expression in testicular germ cells.";
RL Biochem. J. 340:163-168(1998).
RN 141
RP SEQUENCE FROM N.A.
RA STRAIN-C57BL/6; TISSUE-TESTIS;
RA MEDLINE-96016109; PubMed-9799132;
RA Miwa T., Nonaka M., Okada N., Wakana S., Shiroishi T., Okada H.;
RT "Molecular cloning of rat and mouse membrane cofactor protein (MCP,
CD46): preferential expression in testis and close linkage between the
mouse Mcp and Cr2 genes on distal chromosome 1.";
RL Immunogenetics 48:463-471(1998).
RN 141
RP SEQUENCE FROM N.A.
RA STRAIN-C57BL/6; TISSUE-TESTIS;
RA MEDLINE-21085660; PubMed-11217861;
RA Kawai J., Shinadawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
RA Arakawa T., Hara A., Fukunishi Y., Konno H., Adachi J., Fukuda S.,
RA Aizawa K., Iwata M., Nishi K., Kiyosawa H., Kondo S., Yamanaka I.,
RA Saito T., Okazaki Y., Gajjarji T., Aono H., Kasuawa T., Saito K.,
RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
RA Fleischnann W., Gausterland T., Gissi C., King B., Kuchiwa H.,
RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
RA Schriml L.M., Staubli F., Suzuki K., Tomita M., Wagner L., Washio T.,
RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Harsh G.,
RA Blake K., Boffelli D., Bolunda N., Carninci P., de Bonaldo M.P.,
RA Brownstein M.J., Bull C., Fletcher C., Fujita M., Gariboldi M.,
RA Gustafson S., Hill D., Haimann M., Hume D.A., Kamiya M., Lee N.H.,
RA Lyons P., Marchionni L., Mashima J., Mazzarelli J., Mombaerts P.,
RA Nordone P., Kind H., Ringwald M., Rodriguez I., Sakamoto N.,
RA Sasaki H., Sato K., Schaubach C., Seya T., Shibata Y., Storch K.-F.,
RA Suzuki H., Toyooka K., Waeber K.H., Weitz G., Whitaker G., Wilming L.,
RA Wyshaw-Boris A., Yoshida K., Hasegawa Y., Kawaji H., Kohsaki S.,
RA Hayashizaki Y.;
RT "Functional annotation of a full-length mouse cDNA collection.";
RL Nature 409:685-690(2001).
DR EMBL: AB001566; HAA11859.1;
DR EMBL: AB010919; HAA34810.1;
DR EMBL: AK006642; BAB24682.1;
DR HSSP: pl0998; IVVD.
DR MGI: 1204290; Mcp.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR Pfam: PF00084; sushi; 4.

```

```

DR SMART: SM00032; CCP; 4.
KW Membrane, Signal.
SQ SEQUENCE 365 AA; 40881 MW; 84AA7A63E165C729 CRC64;
Query Match 26.4%; Score 196.5; DB 11; Length 465;
Best Local Similarity 31.3%; Pred. No 2.7e 4;
Matches 42; Conservative 22; Mismatches 55; Gaps 5;
QY 1 ELSCTDPFPPVANARKPPYSILPIVP-GTVLYRTPS - -YPIISKKAIECTSENQVHA 4
DB 170 YIICLPPIKIKNGTHITLDINFKYHEAVSYSCPTPKPKESILVISMIFWAS - IIN 225
QY 55 IWKAIPTCESVKNKTIISCDPIVIGGFMNKSAPFKHGSVIFGKANKIMAGSKIVW 114
DB 236 IWSNSPPK-----KVKKPFNVLNGRLSLKAGLIFSYKQIVMELELQHYMSSSSWY 281
QY 115 QANEMMGHTALPVC 128
DB 292 SANNSEWP-STPKC 294
RESULT 21
Q89859 PRELIMINARY; PRT: 253 AA.
AC Q89859;
DT 01-NOV-1996 (TRENBLREL, 01, Created)
DT 01-NOV-1996 (TRENBLREL, 01, Last sequence update)
DT 01-JUN-2001 (TRENBLREL, 17, Last annotation update)
DE HOMOLOGY OF VACCINIA VIRUS CDS C3L.
GN D151.
OS Variola virus.
OC Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
OC Orthopoxvirus.
OX NCBI_TaxID:10255;
RN 111
RP SEQUENCE FROM N.A.
RA STRAIN-HANGLADESH-1975;
RA MEDLINE-94088747; PubMed-8264798;
RA Masungu R.J., Esposito J.J., Liu L.I., Qi J., Utterback T.K.,
RA Knight J.C., Aubin L., Yuran T.E., Parsons T.M., Loparev V.N.;
RT "Potential virulence determinants in terminal regions of variola
smallpox virus genome.";
RL Nature 366:748-751(1993).
RN 121
RP SEQUENCE FROM N.A.
RA STRAIN-SOMALIA-1977;
RA Masungu R.J., Loparev V.N., Knight J.C., Chichikov V.E., Parsons T.M.,
RA Totmenin A.V., Shchelkunov S.N., Esposito J.J.;
RT Submitted (JUL-1995) to the EMBL/GenBank/DBJ databases.
DR EMBL: 122579; AAA60760.1;
DR EMBL: U18340; AAA69423.1;
DR HSSP: P10948; IVVD.
DR InterPro: IPR000436; Sushi_SCR_CCP.
DR Pfam: PF00184; sushi; 4.
DR SMART: SM01032; CCP; 4.
SQ SEQUENCE 253 AA; 28816 MW; 04650C303027C4220 CRC64;
Query Match 26.3%; Score 197.5; DB 12; Length 263;
Best Local Similarity 29.9%; Pred. No 2.4e 14;
Matches 38; Conservative 20; Mismatches 58; Gaps 4;
QY 2 ISCDPPIVKNARKPPYSILPIVIGVLYAY-GS-SYKIDKKAIECTSENQVHAIVKAP 61
DB 146 VKCQLPPI-INSGRINGYNDFTDGSVTVYCNSSYSLSINSGVLCSG-----GWSN 199
QY 62 ICESVKNKTIISCDPIVPGGFMNKSAPFKHGC-SVITFQANKFMKSGKIVWQANIMW 121
DB 200 TCG-----IVKCPHPPIINGYLSSGFKRSYSYN-NVDFTCKYGYKLSOSSSSSTSGNHW 255
QY 122 FTALPVC 128
DB 256 P-ELPKC 261

```


RESULT 42

Q63520 PRELIMINARY; PRI: 417 AA.
 AC Q63520;
 DT 01 JAN 1998 (TREMBLrel. 01, Created)
 DT 01 JAN 1998 (TREMBLrel. 01, Last sequence update)
 DE 512 ANTIGEN (FRAGMENT).
 DE 512 ANTIGEN (FRAGMENT).
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RA Dohi N., Sakurada C., Nonaka M., Okada N., Okada H.,
 "Novel isoform of rat complement regulatory protein, rat crry.";
 RL Submitted (Nov 1994) to the EMBL/GenBank/DBJ databases.
 DB EMBL: D42116; BAA22549.1;
 DB HSSP: P10998; 1VVD.
 DB TrnPro: IPR000436; Sushi_SCR_CCP.
 DB Pfam: PF00084; Sushi; 6.
 DB SMART: SM00042; CCP; 6.
 FT NON TER 417 417.
 SQ SEQUENCE 417 AA: 45951 MW: 042036600989BDB GRG64;

Query Match 22.9%; Score 172.5; DB 11; Length 417;
 Best Local Similarity 30.2%; Pred. No. 3,94-11;
 Matches 42; Conservative 21; Mismatches 55; Indels 21; Gaps 5;
 QY 2 ISCDPPPEVKNA-----RKPYSLPIVPGIVLRTCTSPS-----YRLIGEKALFVISE 49
 DB 159 IPCEIPPSTENGDFSPNKEFH-----GMVVYQCNTIARGKKLENVCEPSIHCTSI 75
 QY 50 NOVHATWIKAPICSVNKTISCSDPIVPGIIPVGGFMNKGSKAPRHHGUSVTFCKANFTMKGS 109
 DB 214 DGGGVWMSGFPQCTELNK---CTPHVENAVIVSKKSLFSLRWVFRQCGFMKKGD 132
 QY 110 KTVWCQANMGMGPTALPVC 128
 DB 271 SSVYCRSLNRWEP-QLPSC 150

RESULT 43

Q63612 PRELIMINARY; PRI: 497 AA.
 AC Q63612;
 DT 01 NOV 1996 (TREMBLrel. 01, Created)
 DT 01 NOV 1996 (TREMBLrel. 01, Last sequence update)
 DE 512 ANTIGEN (FRAGMENT).
 DE 512 ANTIGEN (FRAGMENT).
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RA Sakurada C., Seno H., Dohi N., Takizawa H., Nonaka M., Okada N.,
 Okada H.,
 "Molecular cloning of the rat complement regulatory protein, 512 antigen.";
 RL Biochem. Biophys. Res. Commun. 198;819-826(1994).
 DB EMBL: D42114; BAA07698.1;
 DB HSSP: P10998; 1VVD.
 DB TrnPro: IPR000436; Sushi_SCR_CCP.
 DB Pfam: PF00084; Sushi; 6.
 DB SMART: SM00042; CCP; 6.
 FT SIGNAL 1 46 POTENTIAL.
 FT CHAIN 37 497 512 ANTIGEN.
 SQ SEQUENCE 497 AA: 54786 MW: 177AC11EE0FADIC GRG64;

Query Match 22.9%; Score 172.5; DB 11; Length 497;
 Best Local Similarity 30.2%; Pred. No. 3,94-11;
 Matches 42; Conservative 21; Mismatches 55; Indels 21; Gaps 5;
 QY 2 ISCDPPPEVKNA-----RKPYSLPIVPGIVLRTCTSPS-----YRLIGEKALFVISE 49
 DB 159 IPCEIPPSTENGDFSPNKEFH-----GMVVYQCNTIARGKKLENVCEPSIHCTSI 214
 QY 50 NOVHATWIKAPICSVNKTISCSDPIVPGIIPVGGFMNKGSKAPRHHGUSVTFCKANFTMKGS 109
 DB 214 DGGGVWMSGFPQCTELNK---CTPHVENAVIVSKKSLFSLRWVFRQCGFMKKGD 271
 QY 110 KTVWCQANMGMGPTALPVC 128
 DB 271 SSVYCRSLNRWEP-QLPSC 288

RESULT 44

Q63135 PRELIMINARY; PRI: 554 AA.
 AC Q63135;
 DT 01-NOV-1996 (TREMBLrel. 01, Created)
 DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)
 DE COMPLEMENT REGULATORY PROTEIN.
 GN CRRY.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=SPRACU-DAWLEY;
 RX MEDLINE=96006570. PubMed=7590969;
 RA Guica R.J., Le C.F., Alexander J.J., Stred A.E., Moxley G. III;
 FT "Molecular characterization of rat crry with spread distribution of two alternative forms of crry mRNA.";
 RL Immunogenetics 42:362-367(1995).
 RN 2;
 RP SEQUENCE FROM N.A.
 RC TISSUE=LIVER;
 RA Dohi N., Sakurada C., Nonaka M., Okada N., Okada H.,
 RL Submitted (Oct 1997) to the EMBL/GenBank/DBJ databases.
 DB EMB: 136532; BAA91821.1;
 DB EMB: 142115; BAA22548.1;
 DB HSS: P10998; 1VVD.
 DB TrnPro: IPR000436; Sushi_SCR_CCP.
 DB Pfam: PF00084; Sushi; 7.
 DB SMART: SM00042; CCP; 7.
 SQ SEQUENCE 559 AA: 61680 MW: 29E10F6A21DB9BEE GRG64;

Query Match 22.9%; Score 172.5; DB 11; Length 559;
 Best Local Similarity 30.2%; Pred. No. 3,94-11;
 Matches 42; Conservative 21; Mismatches 55; Indels 21; Gaps 5;
 QY 2 ISCDPPPEVKNA-----RKPYSLPIVPGIVLRTCTSPS-----YRLIGEKALFVISE 49
 DB 159 IPCEIPPSTENGDFSPNKEFH-----GMVVYQCNTIARGKKLENVCEPSIHCTSI 214
 QY 50 NOVHATWIKAPICSVNKTISCSDPIVPGIIPVGGFMNKGSKAPRHHGUSVTFCKANFTMKGS 109
 DB 214 DGGGVWMSGFPQCTELNK---CTPHVENAVIVSKKSLFSLRWVFRQCGFMKKGD 271
 QY 110 KTVWCQANMGMGPTALPVC 128
 DB 271 SSVYCRSLNRWEP-QLPSC 288

RESULT 45

Q91YB6 PRELIMINARY; PRI: 1236 AA.
 ID Q91YB6
 AC Q91YB6;

